[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQGz-ELlMe2UGN_F43h0tCj8jKBXKYfEjfboa9cTd4F8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":86,"rows":93},"Sanofi Pasteur, a Sanofi Company",[4],374,false,15,142,2162897,31,20,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Influenza",94,{"name":18,"count":19},"Diphtheria",56,{"name":21,"count":22},"Pertussis",51,{"name":24,"count":25},"Tetanus",50,{"name":27,"count":28},"Meningitis",39,{"name":30,"count":31},"Poliomyelitis",27,{"name":33,"count":34},"Healthy Volunteers",26,{"name":36,"count":34},"Hepatitis B",[38,43,47,52,57,62,67,72,76,81],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05011123","Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia","2022-05-23","Yellow fever vaccine",{"nctId":44,"briefTitle":45,"date":46,"intervention":42},"NCT04942210","Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA","2022-06-24",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04936685","Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and\u002For 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers","2023-03-09","Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06744205","A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older","2026-04-16","Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT06838000","Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents","2026-12-01","PCV21",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT06686654","Study of a Human Metapneumovirus\u002FRespiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older","2027-01-18","Investigational hMPV\u002FRSV vaccine",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06736041","Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","2027-05-17","PCV21 vaccine",{"nctId":73,"briefTitle":74,"date":70,"intervention":75},"NCT06647407","Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","Pentavalent Meningococcal ABCYW vaccine",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT04843111","Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)","2028-05-18","Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06316297","Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne","2028-11-30","Acne mRNA vaccine",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,144,176,194,212,230,248,266,284,306,324,395,426,537,621,681,741,801,823,849,867,885,903,921,939,957,975,993,1011,1029,1130,1155,1252,1352,1400,1437,1469,1502,1538,1570,1605,1623,1646,1671,1689,1714,1732,1750,1775,1793,1811,1836,1861,1884,1907,1931,1954,1980,1998,2022,2047,2065,2083,2106,2131,2149,2167,2185,2207,2231,2249,2274,2292,2316,2334,2358,2383,2401,2423,2441,2464,2488,2506,2528,2551,2575,2593,2616,2637,2660,2683,2701,2719,2741,2759,2782,2806,2830,2848,2872,2897,2915,2938,2962,2985,3008,3026,3044,3067,3091,3114,3135,3158,3283,3342,3409,3467,3514,3575,3601,3651,3690,3722,3748,3784,3828,3861,3887,3924,3957,3998,4029,4059,4093,4115,4137,4159,4181,4203,4234,4261,4283,4305,4335,4357,4379,4401,4433,4468,4490,4517,4550,4583,4611,4629,4652,4670,4693,4711,4738,4756,4774,4792,4810,4836,4854,4872,4895,4913,4931,4949,4967,4985,5009,5027,5045,5063,5081,5103,5121,5139,5157,5179,5203,5221,5239,5266,5292,5310,5328,5352,5376,5394,5419,5437,5455,5473,5491,5509,5533,5551,5569,5587,5605,5623,5641,5659,5677,5695,5713,5731,5749,5767,5785,5803,5821,5839,5857,5875,5901,5926,5944,5962,5980,5998,6016,6040,6064,6088,6106,6124,6142,6160,6183,6201,6225,6248,6266,6290,6314,6332,6350,6374,6392,6410,6428,6446,6464,6482,6500,6518,6536,6554,6572,6597,6615,6633,6656,6674,6692,6710,6728,6746,6764,6782,6800,6818,6841,6859,6882,6900,6918,6936,6954,6981,6999,7017,7035,7058,7076,7099,7117,7141,7159,7177,7201,7219,7243,7261,7283,7301,7324,7342,7360,7382,7407,7434,7452,7470,7494,7512,7538,7556,7581,7604,7638,7656,7674,7692,7710,7728,7746,7764,7782,7800,7818,7843,7861,7879,7897,7915,7933,7957,7975,7993,8016,8034,8052,8070,8088,8110,8128,8146,8170,8188,8206,8224,8242,8260,8278,8305,8323,8341,8364,8382,8407,8431,8449,8471,8494,8512,8536,8554,8577,8595,8613,8636,8654,8672,8694,8719,8737,8762,8780,8803,8821,8839,8882,8908,8934,8964,8994,9024,9054,9076,9107,9135,9170,9192,9219,9246,9264,9282,9300,9318,9339,9361,9379,9404,9422,9447,9465,9486,9504,9526,9551,9569,9587,9605,9628,9646,9670,9688,9706,9724,9750,9768,9786,9804,9831,9849,9867,9892,9910,9928,9950,9968,9986,10004,10029,10047,10071,10089,10107,10125,10143,10161,10179,10197,10215,10233,10251,10269,10296,10314,10332,10357,10375,10398,10416,10434,10456,10474,10497,10515,10533,10559,10577,10595,10613,10631,10655,10677,10698,10716,10738,10765,10783,10801,10819,10845,10863,10881,10904,10922,10947,10965,10988,11006,11024,11046,11071,11089,11111,11129,11147,11173,11191,11209,11227,11245,11267,11285,11303,11321,11339,11360,11381,11410,11428,11446,11464,11482,11500,11518,11540,11579,11601,11623,11649,11667,11705,11723,11741,11759,11777,11795,11813,11831,11849,11867,11885,11903,11921,11944,11962,11980,11998,12019,12037,12055,12073,12103,12121,12139,12157,12175,12199,12224,12242,12260,12287,12305,12323,12341,12359,12377,12395,12413,12440,12458,12476,12494,12516,12534,12552,12577,12595,12619,12637,12655,12681,12699,12717,12735,12762,12780,12798,12816,12834,12865,12883,12901,12919,12937,12955,12973,12995,13013,13038,13056,13074,13147,13185,13223,13253,13282,13304,13336,13365,13389,13407,13429,13452,13475,13500,13518,13542,13566,13588,13611,13629],{"intervention":95,"totalTrials":96,"cells":97},"RotaTeq",2,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":140,"NA":142},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":139,"soonestReadout":70},[107,120],{"nctId":68,"briefTitle":69,"status":108,"phases":109,"primaryCompletion":70,"completion":70,"start":110,"enrollment":111,"conditions":112,"interventions":114},"ACTIVE_NOT_RECRUITING",[90],"2024-12-18",1714,[113],"Pneumococcal Immunization",[71,115,116,95,117,118,119],"Prevnar 20 vaccine","M-M-R II vaccine","Vaxelis vaccine","Varivax","Hexaxim Vaccine",{"nctId":121,"briefTitle":122,"status":123,"phases":124,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":133},"NCT01839175","Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination","COMPLETED",[90],"2014-07","2015-02","2013-04",350,[130,131,132],"Neisseria Meningitidis","Bacterial Infections","Virus Diseases",[134,135,136,95,137,138],"Hexavalent vaccine","NeisVac-C","Prevenar 13","Nimenrix","M-M-RVAXPRO",1,{"trials":141,"activeCount":100},[],{"trials":143,"activeCount":100},[],{"intervention":51,"totalTrials":96,"cells":145},{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":172,"NA":174},{"trials":147,"activeCount":100},[],{"trials":149,"activeCount":100},[],{"trials":151,"activeCount":100},[],{"trials":153,"activeCount":139,"soonestReadout":50},[154,164],{"nctId":155,"briefTitle":156,"status":123,"phases":157,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":163},"NCT06228586","Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam",[90],"2024-03-31","2024-01-18",447,[162,33],"Meningococcal Infection",[51],{"nctId":48,"briefTitle":49,"status":108,"phases":165,"primaryCompletion":50,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":171},[90],"2027-12-26","2022-08-23",209,[170,33],"Meningococcal Immunisation",[51],{"trials":173,"activeCount":100},[],{"trials":175,"activeCount":100},[],{"intervention":71,"totalTrials":139,"cells":177},{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":190,"NA":192},{"trials":179,"activeCount":100},[],{"trials":181,"activeCount":100},[],{"trials":183,"activeCount":100},[],{"trials":185,"activeCount":139,"soonestReadout":70},[186],{"nctId":68,"briefTitle":69,"status":108,"phases":187,"primaryCompletion":70,"completion":70,"start":110,"enrollment":111,"conditions":188,"interventions":189},[90],[113],[71,115,116,95,117,118,119],{"trials":191,"activeCount":100},[],{"trials":193,"activeCount":100},[],{"intervention":115,"totalTrials":139,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":208,"NA":210},{"trials":197,"activeCount":100},[],{"trials":199,"activeCount":100},[],{"trials":201,"activeCount":100},[],{"trials":203,"activeCount":139,"soonestReadout":70},[204],{"nctId":68,"briefTitle":69,"status":108,"phases":205,"primaryCompletion":70,"completion":70,"start":110,"enrollment":111,"conditions":206,"interventions":207},[90],[113],[71,115,116,95,117,118,119],{"trials":209,"activeCount":100},[],{"trials":211,"activeCount":100},[],{"intervention":116,"totalTrials":139,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":226,"NA":228},{"trials":215,"activeCount":100},[],{"trials":217,"activeCount":100},[],{"trials":219,"activeCount":100},[],{"trials":221,"activeCount":139,"soonestReadout":70},[222],{"nctId":68,"briefTitle":69,"status":108,"phases":223,"primaryCompletion":70,"completion":70,"start":110,"enrollment":111,"conditions":224,"interventions":225},[90],[113],[71,115,116,95,117,118,119],{"trials":227,"activeCount":100},[],{"trials":229,"activeCount":100},[],{"intervention":117,"totalTrials":139,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":244,"NA":246},{"trials":233,"activeCount":100},[],{"trials":235,"activeCount":100},[],{"trials":237,"activeCount":100},[],{"trials":239,"activeCount":139,"soonestReadout":70},[240],{"nctId":68,"briefTitle":69,"status":108,"phases":241,"primaryCompletion":70,"completion":70,"start":110,"enrollment":111,"conditions":242,"interventions":243},[90],[113],[71,115,116,95,117,118,119],{"trials":245,"activeCount":100},[],{"trials":247,"activeCount":100},[],{"intervention":118,"totalTrials":139,"cells":249},{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":256,"PHASE4":262,"NA":264},{"trials":251,"activeCount":100},[],{"trials":253,"activeCount":100},[],{"trials":255,"activeCount":100},[],{"trials":257,"activeCount":139,"soonestReadout":70},[258],{"nctId":68,"briefTitle":69,"status":108,"phases":259,"primaryCompletion":70,"completion":70,"start":110,"enrollment":111,"conditions":260,"interventions":261},[90],[113],[71,115,116,95,117,118,119],{"trials":263,"activeCount":100},[],{"trials":265,"activeCount":100},[],{"intervention":119,"totalTrials":139,"cells":267},{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":274,"PHASE4":280,"NA":282},{"trials":269,"activeCount":100},[],{"trials":271,"activeCount":100},[],{"trials":273,"activeCount":100},[],{"trials":275,"activeCount":139,"soonestReadout":70},[276],{"nctId":68,"briefTitle":69,"status":108,"phases":277,"primaryCompletion":70,"completion":70,"start":110,"enrollment":111,"conditions":278,"interventions":279},[90],[113],[71,115,116,95,117,118,119],{"trials":281,"activeCount":100},[],{"trials":283,"activeCount":100},[],{"intervention":61,"totalTrials":139,"cells":285},{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":292,"PHASE4":302,"NA":304},{"trials":287,"activeCount":100},[],{"trials":289,"activeCount":100},[],{"trials":291,"activeCount":100},[],{"trials":293,"activeCount":139,"soonestReadout":60},[294],{"nctId":58,"briefTitle":59,"status":108,"phases":295,"primaryCompletion":60,"completion":60,"start":296,"enrollment":297,"conditions":298,"interventions":300},[90],"2025-02-28",1268,[299],"Pneumococcal Infections",[61,301],"20vPCV",{"trials":303,"activeCount":100},[],{"trials":305,"activeCount":100},[],{"intervention":301,"totalTrials":139,"cells":307},{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":320,"NA":322},{"trials":309,"activeCount":100},[],{"trials":311,"activeCount":100},[],{"trials":313,"activeCount":100},[],{"trials":315,"activeCount":139,"soonestReadout":60},[316],{"nctId":58,"briefTitle":59,"status":108,"phases":317,"primaryCompletion":60,"completion":60,"start":296,"enrollment":297,"conditions":318,"interventions":319},[90],[299],[61,301],{"trials":321,"activeCount":100},[],{"trials":323,"activeCount":100},[],{"intervention":42,"totalTrials":325,"cells":326},5,{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":344,"PHASE3":361,"PHASE4":391,"NA":393},{"trials":328,"activeCount":100},[],{"trials":330,"activeCount":100},[331],{"nctId":332,"briefTitle":333,"status":123,"phases":334,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":338,"interventions":340},"NCT04142086","Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults",[88],"2021-06-24","2020-01-15",73,[339],"Yellow Fever (Healthy Volunteers)",[341,342,343,42],"Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine","Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine","Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine",{"trials":345,"activeCount":96,"soonestReadout":41},[346,354],{"nctId":44,"briefTitle":45,"status":108,"phases":347,"primaryCompletion":46,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":353},[89],"2027-06-29","2021-07-01",568,[352,33],"Yellow Fever",[42,42],{"nctId":39,"briefTitle":40,"status":108,"phases":355,"primaryCompletion":41,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":360},[89],"2027-04-23","2021-10-07",690,[352],[42,42],{"trials":362,"activeCount":100},[363,382],{"nctId":364,"briefTitle":365,"status":123,"phases":366,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":374},"NCT01436396","Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers",[90],"2013-09","2013-09-02","2011-09-07",792,[372,373,352],"Dengue","Dengue Hemorrhagic Fever",[375,42,376,377,378,379,375,380,381,377,379,378],"Live, attenuated dengue serotype 1, 2, 3, and 4 virus","Measles, mumps, and rubella (MMR) vaccine","Pneumococcal Conjugated Vaccine","Hepatitis A Pediatric Vaccine","Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine","Yellow Fever Vaccine","Measles, mumps, and rubella vaccine",{"nctId":383,"briefTitle":384,"status":123,"phases":385,"primaryCompletion":386,"completion":386,"start":387,"enrollment":388,"conditions":389,"interventions":390},"NCT07222059","Phase 3 Single Arm, Open Study on vYF in Adults",[90],"2025-12-25","2025-10-23",254,[352],[42],{"trials":392,"activeCount":100},[],{"trials":394,"activeCount":100},[],{"intervention":85,"totalTrials":96,"cells":396},{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":420,"PHASE4":422,"NA":424},{"trials":398,"activeCount":100},[],{"trials":400,"activeCount":100},[],{"trials":402,"activeCount":96,"soonestReadout":84},[403,414],{"nctId":404,"briefTitle":405,"status":406,"phases":407,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":413},"NCT07013747","Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne","RECRUITING",[88,89],"2029-06-19","2025-07-03",120,[412],"Acne",[85],{"nctId":82,"briefTitle":83,"status":406,"phases":415,"primaryCompletion":84,"completion":84,"start":416,"enrollment":417,"conditions":418,"interventions":419},[88,89],"2024-04-05",800,[412],[85],{"trials":421,"activeCount":100},[],{"trials":423,"activeCount":100},[],{"trials":425,"activeCount":100},[],{"intervention":427,"totalTrials":428,"cells":429},"MenACYW conjugate vaccine",8,{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":458,"PHASE4":524,"NA":535},{"trials":431,"activeCount":100},[],{"trials":433,"activeCount":100},[],{"trials":435,"activeCount":139,"soonestReadout":70},[436,448],{"nctId":73,"briefTitle":74,"status":108,"phases":437,"primaryCompletion":70,"completion":70,"start":438,"enrollment":439,"conditions":440,"interventions":442},[88,89],"2024-11-05",750,[441,33],"Meningococcal Immunization",[75,427,427,443,444,445,445,445,446,447],"Meningococcal group B vaccine","Paracetamol","DTap-HepB-IPV-Hib vaccine","Rotavirus vaccine","Pneumococcal 13-valent conjugate vaccine",{"nctId":449,"briefTitle":450,"status":123,"phases":451,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":455,"interventions":456},"NCT06128733","Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents",[88,89],"2025-08-27","2023-10-31",1215,[170,33],[75,427,443,443,443,427,457],"MenABCYW conjugate vaccine",{"trials":459,"activeCount":100},[460,470,487,501,515],{"nctId":461,"briefTitle":462,"status":123,"phases":463,"primaryCompletion":464,"completion":464,"start":465,"enrollment":466,"conditions":467,"interventions":469},"NCT03476135","Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children",[90],"2018-09-10","2018-02-27",91,[468],"Meningococcal Infections",[427],{"nctId":471,"briefTitle":472,"status":123,"phases":473,"primaryCompletion":474,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":479},"NCT03537508","Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US",[90],"2023-09-22","2018-04-25",2627,[478],"Healthy Volunteers (Meningococcal Infection)",[427,480,481,447,482,483,484,485,486],"MenACYW-135 conjugate vaccine","DTaP-IPV\u002F\u002FHib vaccine","Pentavalent rotavirus vaccine","Hepatitis B vaccine","Measles, mumps, rubella (MMR) vaccine","Varicella vaccine","Hepatitis A vaccine",{"nctId":488,"briefTitle":489,"status":123,"phases":490,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":496},"NCT03547271","Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe",[90],"2023-05-17","2023-05-24","2018-12-14",1660,[468],[427,497,498,499,499,500],"Meningococcal group A, C, W-135, and Y conjugate vaccine","DTaP-IPV-HB-Hib vaccine","Pneumococcal vaccine","MMR vaccine",{"nctId":502,"briefTitle":503,"status":123,"phases":504,"primaryCompletion":505,"completion":505,"start":506,"enrollment":507,"conditions":508,"interventions":510},"NCT03205371","Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers",[90],"2018-07-19","2016-11-07",1183,[509],"Meningitis, Meningococcal",[427,511,512,513,514],"MMR","Varicella","DTaP-IPV-HB-Hib","PCV13",{"nctId":516,"briefTitle":517,"status":123,"phases":518,"primaryCompletion":519,"completion":519,"start":520,"enrollment":521,"conditions":522,"interventions":523},"NCT06284915","Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers",[90],"2025-11-14","2024-03-19",840,[170,33],[427,427],{"trials":525,"activeCount":100},[526],{"nctId":527,"briefTitle":528,"status":123,"phases":529,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":534},"NCT05929651","Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy",[91],"2024-09-09","2023-09-07",71,[170,33],[427],{"trials":536,"activeCount":100},[],{"intervention":538,"totalTrials":539,"cells":540},"Pneumococcal 13-valent Conjugate Vaccine",6,{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":567,"PHASE4":617,"NA":619},{"trials":542,"activeCount":100},[],{"trials":544,"activeCount":100},[],{"trials":546,"activeCount":139,"soonestReadout":70},[547,563],{"nctId":548,"briefTitle":549,"status":123,"phases":550,"primaryCompletion":551,"completion":551,"start":552,"enrollment":553,"conditions":554,"interventions":555},"NCT01049035","A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers",[89],"2012-02-13","2009-12-16",580,[27,162],[556,557,558,559,560,538,561,562],"Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate","Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate","M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live","Varicella Virus Vaccine Live","Pneumococcal 7-valent Conjugate Vaccine","Rotavirus Vaccine","Hepatitis B Vaccine",{"nctId":73,"briefTitle":74,"status":108,"phases":564,"primaryCompletion":70,"completion":70,"start":438,"enrollment":439,"conditions":565,"interventions":566},[88,89],[441,33],[75,427,427,443,444,445,445,445,446,447],{"trials":568,"activeCount":100},[569,573,588,602],{"nctId":471,"briefTitle":472,"status":123,"phases":570,"primaryCompletion":474,"completion":474,"start":475,"enrollment":476,"conditions":571,"interventions":572},[90],[478],[427,480,481,447,482,483,484,485,486],{"nctId":574,"briefTitle":575,"status":123,"phases":576,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":581},"NCT03630705","Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico",[90],"2022-02-18","2018-10-17",525,[478],[582,583,584,538,585,562,586,587],"Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine","Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine","Measles, Mumps, and Rubella Virus Vaccine Live","Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine","Rotavirus Vaccine, Live, Pentavalent","Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine",{"nctId":589,"briefTitle":590,"status":123,"phases":591,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":595,"interventions":596},"NCT03673462","Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers",[90],"2023-03-16","2018-09-17",2797,[478],[597,598,599,538,561,562,600,601],"Meningococcal polysaccharide","Meningococcal","Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine","Measles, Mumps, and Rubella Virus Vaccine","Varicella Virus Vaccine",{"nctId":603,"briefTitle":604,"status":123,"phases":605,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":609,"interventions":610},"NCT03691610","Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers",[90],"2023-10-20","2018-10-04",950,[478],[611,583,612,613,614,615,538,616,562,584,559],"Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine","Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine","Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine","Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine","Haemophilus b Conjugate Vaccine","Rotavirus Vaccine, Live, Oral, Pentavalent",{"trials":618,"activeCount":100},[],{"trials":620,"activeCount":100},[],{"intervention":446,"totalTrials":325,"cells":622},{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":627,"PHASE3":637,"PHASE4":677,"NA":679},{"trials":624,"activeCount":100},[],{"trials":626,"activeCount":100},[],{"trials":628,"activeCount":139,"soonestReadout":70},[629,633],{"nctId":548,"briefTitle":549,"status":123,"phases":630,"primaryCompletion":551,"completion":551,"start":552,"enrollment":553,"conditions":631,"interventions":632},[89],[27,162],[556,557,558,559,560,538,561,562],{"nctId":73,"briefTitle":74,"status":108,"phases":634,"primaryCompletion":70,"completion":70,"start":438,"enrollment":439,"conditions":635,"interventions":636},[88,89],[441,33],[75,427,427,443,444,445,445,445,446,447],{"trials":638,"activeCount":100},[639,643,659],{"nctId":589,"briefTitle":590,"status":123,"phases":640,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":641,"interventions":642},[90],[478],[597,598,599,538,561,562,600,601],{"nctId":644,"briefTitle":645,"status":646,"phases":647,"primaryCompletion":648,"completion":648,"start":649,"enrollment":650,"conditions":651,"interventions":653},"NCT06397768","Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","TERMINATED",[90],"2025-09-18","2024-05-13",2226,[652],"RSV Immunization",[654,655,656,483,657,446,381,658],"RSVt vaccine","Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine","Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine","Streptococcus pneumoniae vaccine","Varicella virus vaccine",{"nctId":660,"briefTitle":661,"status":123,"phases":662,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":666,"interventions":667},"NCT05794230","Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa",[90],"2025-11-15","2023-03-27",1528,[170,33],[582,668,669,670,671,672,673,486,446,674,675,676,676,671,486],"Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine","Oral bivalent types 1 and 3; Poliomyelitis Vaccine","Pneumoccocal Vaccine","Measles, Mumps, and Rubella Vaccine live","DTwP-HepB-Hib-IPV vaccine","DTaP-IPV-Hib-HepB vaccine","Typhoid conjugate vaccine","Measles vaccine","Varicella vaccine live",{"trials":678,"activeCount":100},[],{"trials":680,"activeCount":100},[],{"intervention":443,"totalTrials":325,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":700,"PHASE3":710,"PHASE4":737,"NA":739},{"trials":684,"activeCount":100},[],{"trials":686,"activeCount":100},[687],{"nctId":688,"briefTitle":689,"status":646,"phases":690,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":695},"NCT04825223","Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants",[88],"2022-07-22","2021-03-29",576,[170,33],[696,697,698,699],"Multicomponent Meningococcal B Vaccine","Meningococcal Group B Vaccine MenB","Meningococcal Group B Vaccine","Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine",{"trials":701,"activeCount":139,"soonestReadout":70},[702,706],{"nctId":73,"briefTitle":74,"status":108,"phases":703,"primaryCompletion":70,"completion":70,"start":438,"enrollment":439,"conditions":704,"interventions":705},[88,89],[441,33],[75,427,427,443,444,445,445,445,446,447],{"nctId":449,"briefTitle":450,"status":123,"phases":707,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":708,"interventions":709},[88,89],[170,33],[75,427,443,443,443,427,457],{"trials":711,"activeCount":100},[712,725],{"nctId":713,"briefTitle":714,"status":123,"phases":715,"primaryCompletion":716,"completion":716,"start":717,"enrollment":718,"conditions":719,"interventions":720},"NCT03632720","Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom",[90],"2022-12-05","2018-10-10",788,[478],[721,443,722,723,724],"Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine","Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine","Human rotavirus RIX4414 strain vaccine","Pneumococcal 13-valent polysaccharide conjugate vaccine",{"nctId":726,"briefTitle":727,"status":123,"phases":728,"primaryCompletion":729,"completion":729,"start":730,"enrollment":731,"conditions":732,"interventions":734},"NCT04084769","Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)",[90],"2020-09-14","2019-09-03",570,[733],"Meningococcal Immunisation (Healthy Volunteers)",[735,736,443],"Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine","Meningococcal Group B vaccine",{"trials":738,"activeCount":100},[],{"trials":740,"activeCount":100},[],{"intervention":742,"totalTrials":743,"cells":744},"Quadrivalent Influenza Standard Dose Vaccine",4,{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":795,"PHASE4":797,"NA":799},{"trials":746,"activeCount":100},[],{"trials":748,"activeCount":100},[],{"trials":750,"activeCount":139,"soonestReadout":55},[751,764,773,783],{"nctId":752,"briefTitle":753,"status":123,"phases":754,"primaryCompletion":755,"completion":755,"start":756,"enrollment":757,"conditions":758,"interventions":760},"NCT05650554","Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older",[88,89],"2024-04-02","2022-12-12",682,[759],"Influenza Immunization",[761,762,742,763],"Quadrivalent Influenza mRNA Vaccine MRT5413","Quadrivalent Recombinant Influenza Vaccine","Quadrivalent Influenza High-Dose Vaccine",{"nctId":53,"briefTitle":54,"status":108,"phases":765,"primaryCompletion":55,"completion":55,"start":766,"enrollment":767,"conditions":768,"interventions":769},[88,89],"2025-01-06",1162,[15,33],[56,770,771,742,772],"TIV mRNA-neuraminidase","TIV mRNA-HA Vaccine 2","Quadrivalent Influenza Vaccine High Dose",{"nctId":774,"briefTitle":775,"status":123,"phases":776,"primaryCompletion":777,"completion":777,"start":778,"enrollment":779,"conditions":780,"interventions":781},"NCT05553301","Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older",[88,89],"2024-01-19","2022-10-03",560,[759],[782,762,742,763],"Quadrivalent Influenza mRNA Vaccine MRT5407",{"nctId":784,"briefTitle":785,"status":123,"phases":786,"primaryCompletion":787,"completion":787,"start":788,"enrollment":789,"conditions":790,"interventions":791},"NCT06361875","A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above",[88,89],"2025-06-09","2024-04-01",910,[759],[792,793,794,742,763,762],"Quadrivalent Influenza mRNA Vaccine MRT5421","Quadrivalent Influenza mRNA Vaccine MRT5424","Quadrivalent Influenza mRNA Vaccine MRT5429",{"trials":796,"activeCount":100},[],{"trials":798,"activeCount":100},[],{"trials":800,"activeCount":100},[],{"intervention":75,"totalTrials":96,"cells":802},{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":817,"PHASE4":819,"NA":821},{"trials":804,"activeCount":100},[],{"trials":806,"activeCount":100},[],{"trials":808,"activeCount":139,"soonestReadout":70},[809,813],{"nctId":73,"briefTitle":74,"status":108,"phases":810,"primaryCompletion":70,"completion":70,"start":438,"enrollment":439,"conditions":811,"interventions":812},[88,89],[441,33],[75,427,427,443,444,445,445,445,446,447],{"nctId":449,"briefTitle":450,"status":123,"phases":814,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":815,"interventions":816},[88,89],[170,33],[75,427,443,443,443,427,457],{"trials":818,"activeCount":100},[],{"trials":820,"activeCount":100},[],{"trials":822,"activeCount":100},[],{"intervention":66,"totalTrials":139,"cells":824},{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":843,"PHASE4":845,"NA":847},{"trials":826,"activeCount":100},[],{"trials":828,"activeCount":100},[],{"trials":830,"activeCount":139,"soonestReadout":65},[831],{"nctId":63,"briefTitle":64,"status":108,"phases":832,"primaryCompletion":65,"completion":65,"start":833,"enrollment":834,"conditions":835,"interventions":838},[88,89],"2024-11-11",1530,[836,837],"Human Metapneumovirus Immunization","Respiratory Syncytial Virus Immunization",[66,839,840,841,842],"Investigational hMPV vaccine","Investigational RSV vaccine","Licensed RSV Vaccine","Investigational RSV+hMPV vaccine",{"trials":844,"activeCount":100},[],{"trials":846,"activeCount":100},[],{"trials":848,"activeCount":100},[],{"intervention":839,"totalTrials":139,"cells":850},{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":855,"PHASE3":861,"PHASE4":863,"NA":865},{"trials":852,"activeCount":100},[],{"trials":854,"activeCount":100},[],{"trials":856,"activeCount":139,"soonestReadout":65},[857],{"nctId":63,"briefTitle":64,"status":108,"phases":858,"primaryCompletion":65,"completion":65,"start":833,"enrollment":834,"conditions":859,"interventions":860},[88,89],[836,837],[66,839,840,841,842],{"trials":862,"activeCount":100},[],{"trials":864,"activeCount":100},[],{"trials":866,"activeCount":100},[],{"intervention":840,"totalTrials":139,"cells":868},{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":879,"PHASE4":881,"NA":883},{"trials":870,"activeCount":100},[],{"trials":872,"activeCount":100},[],{"trials":874,"activeCount":139,"soonestReadout":65},[875],{"nctId":63,"briefTitle":64,"status":108,"phases":876,"primaryCompletion":65,"completion":65,"start":833,"enrollment":834,"conditions":877,"interventions":878},[88,89],[836,837],[66,839,840,841,842],{"trials":880,"activeCount":100},[],{"trials":882,"activeCount":100},[],{"trials":884,"activeCount":100},[],{"intervention":841,"totalTrials":139,"cells":886},{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":891,"PHASE3":897,"PHASE4":899,"NA":901},{"trials":888,"activeCount":100},[],{"trials":890,"activeCount":100},[],{"trials":892,"activeCount":139,"soonestReadout":65},[893],{"nctId":63,"briefTitle":64,"status":108,"phases":894,"primaryCompletion":65,"completion":65,"start":833,"enrollment":834,"conditions":895,"interventions":896},[88,89],[836,837],[66,839,840,841,842],{"trials":898,"activeCount":100},[],{"trials":900,"activeCount":100},[],{"trials":902,"activeCount":100},[],{"intervention":842,"totalTrials":139,"cells":904},{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":915,"PHASE4":917,"NA":919},{"trials":906,"activeCount":100},[],{"trials":908,"activeCount":100},[],{"trials":910,"activeCount":139,"soonestReadout":65},[911],{"nctId":63,"briefTitle":64,"status":108,"phases":912,"primaryCompletion":65,"completion":65,"start":833,"enrollment":834,"conditions":913,"interventions":914},[88,89],[836,837],[66,839,840,841,842],{"trials":916,"activeCount":100},[],{"trials":918,"activeCount":100},[],{"trials":920,"activeCount":100},[],{"intervention":56,"totalTrials":139,"cells":922},{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":927,"PHASE3":933,"PHASE4":935,"NA":937},{"trials":924,"activeCount":100},[],{"trials":926,"activeCount":100},[],{"trials":928,"activeCount":139,"soonestReadout":55},[929],{"nctId":53,"briefTitle":54,"status":108,"phases":930,"primaryCompletion":55,"completion":55,"start":766,"enrollment":767,"conditions":931,"interventions":932},[88,89],[15,33],[56,770,771,742,772],{"trials":934,"activeCount":100},[],{"trials":936,"activeCount":100},[],{"trials":938,"activeCount":100},[],{"intervention":770,"totalTrials":139,"cells":940},{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":951,"PHASE4":953,"NA":955},{"trials":942,"activeCount":100},[],{"trials":944,"activeCount":100},[],{"trials":946,"activeCount":139,"soonestReadout":55},[947],{"nctId":53,"briefTitle":54,"status":108,"phases":948,"primaryCompletion":55,"completion":55,"start":766,"enrollment":767,"conditions":949,"interventions":950},[88,89],[15,33],[56,770,771,742,772],{"trials":952,"activeCount":100},[],{"trials":954,"activeCount":100},[],{"trials":956,"activeCount":100},[],{"intervention":771,"totalTrials":139,"cells":958},{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":969,"PHASE4":971,"NA":973},{"trials":960,"activeCount":100},[],{"trials":962,"activeCount":100},[],{"trials":964,"activeCount":139,"soonestReadout":55},[965],{"nctId":53,"briefTitle":54,"status":108,"phases":966,"primaryCompletion":55,"completion":55,"start":766,"enrollment":767,"conditions":967,"interventions":968},[88,89],[15,33],[56,770,771,742,772],{"trials":970,"activeCount":100},[],{"trials":972,"activeCount":100},[],{"trials":974,"activeCount":100},[],{"intervention":772,"totalTrials":139,"cells":976},{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":987,"PHASE4":989,"NA":991},{"trials":978,"activeCount":100},[],{"trials":980,"activeCount":100},[],{"trials":982,"activeCount":139,"soonestReadout":55},[983],{"nctId":53,"briefTitle":54,"status":108,"phases":984,"primaryCompletion":55,"completion":55,"start":766,"enrollment":767,"conditions":985,"interventions":986},[88,89],[15,33],[56,770,771,742,772],{"trials":988,"activeCount":100},[],{"trials":990,"activeCount":100},[],{"trials":992,"activeCount":100},[],{"intervention":444,"totalTrials":139,"cells":994},{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":999,"PHASE3":1005,"PHASE4":1007,"NA":1009},{"trials":996,"activeCount":100},[],{"trials":998,"activeCount":100},[],{"trials":1000,"activeCount":139,"soonestReadout":70},[1001],{"nctId":73,"briefTitle":74,"status":108,"phases":1002,"primaryCompletion":70,"completion":70,"start":438,"enrollment":439,"conditions":1003,"interventions":1004},[88,89],[441,33],[75,427,427,443,444,445,445,445,446,447],{"trials":1006,"activeCount":100},[],{"trials":1008,"activeCount":100},[],{"trials":1010,"activeCount":100},[],{"intervention":445,"totalTrials":139,"cells":1012},{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1023,"PHASE4":1025,"NA":1027},{"trials":1014,"activeCount":100},[],{"trials":1016,"activeCount":100},[],{"trials":1018,"activeCount":139,"soonestReadout":70},[1019],{"nctId":73,"briefTitle":74,"status":108,"phases":1020,"primaryCompletion":70,"completion":70,"start":438,"enrollment":439,"conditions":1021,"interventions":1022},[88,89],[441,33],[75,427,427,443,444,445,445,445,446,447],{"trials":1024,"activeCount":100},[],{"trials":1026,"activeCount":100},[],{"trials":1028,"activeCount":100},[],{"intervention":582,"totalTrials":1030,"cells":1031},10,{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1049,"PHASE4":1121,"NA":1123},{"trials":1033,"activeCount":100},[],{"trials":1035,"activeCount":100},[],{"trials":1037,"activeCount":100},[1038],{"nctId":1039,"briefTitle":1040,"status":123,"phases":1041,"primaryCompletion":1042,"completion":1042,"start":1043,"enrollment":1044,"conditions":1045,"interventions":1047},"NCT03205358","Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers",[89],"2015-08-19","2015-03-31",188,[27,1046,468],"Meningococcal Meningitis",[582,1048],"Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine",{"trials":1050,"activeCount":100},[1051,1063,1067,1079,1089,1099,1103,1112],{"nctId":1052,"briefTitle":1053,"status":123,"phases":1054,"primaryCompletion":1055,"completion":1055,"start":1056,"enrollment":1057,"conditions":1058,"interventions":1059},"NCT03890367","Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers",[90],"2020-10-14","2019-09-12",707,[733],[1060,1061,1062],"Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine","Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine","Meningococcal group C polysaccharide Conjugate vaccine adsorbed",{"nctId":574,"briefTitle":575,"status":123,"phases":1064,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":1065,"interventions":1066},[90],[478],[582,583,584,538,585,562,586,587],{"nctId":1068,"briefTitle":1069,"status":123,"phases":1070,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":1075,"interventions":1077},"NCT04142242","Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49",[90],"2020-04-01","2022-05-25","2019-10-04",471,[1076],"Meningococcal Infection (Healthy Volunteers)",[1078],"Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine",{"nctId":1080,"briefTitle":1081,"status":123,"phases":1082,"primaryCompletion":1083,"completion":1083,"start":1084,"enrollment":1085,"conditions":1086,"interventions":1087},"NCT02842866","Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older",[90],"2017-02-13","2016-07-15",907,[27,1046,468],[582,1088],"Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined",{"nctId":1090,"briefTitle":1091,"status":123,"phases":1092,"primaryCompletion":1093,"completion":1093,"start":1094,"enrollment":1095,"conditions":1096,"interventions":1097},"NCT02955797","Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers",[90],"2017-10-26","2017-02-24",918,[27,1046,468],[582,1098,582,1098],"Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine",{"nctId":660,"briefTitle":661,"status":123,"phases":1100,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":1101,"interventions":1102},[90],[170,33],[582,668,669,670,671,672,673,486,446,674,675,676,676,671,486],{"nctId":1104,"briefTitle":1105,"status":123,"phases":1106,"primaryCompletion":1107,"completion":1107,"start":1108,"enrollment":1109,"conditions":1110,"interventions":1111},"NCT02752906","Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine",[90],"2016-12-19","2016-04-15",810,[27,1046,468],[582,668],{"nctId":1113,"briefTitle":1114,"status":123,"phases":1115,"primaryCompletion":1116,"completion":1116,"start":1084,"enrollment":1117,"conditions":1118,"interventions":1119},"NCT02842853","Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine",[90],"2017-02-28",3344,[27,1046,468],[582,1120],"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine",{"trials":1122,"activeCount":100},[],{"trials":1124,"activeCount":139,"soonestReadout":79},[1125],{"nctId":77,"briefTitle":78,"status":406,"phases":1126,"primaryCompletion":79,"completion":79,"start":1127,"enrollment":25,"conditions":1128,"interventions":1129},[],"2021-03-05",[162],[80],{"intervention":1131,"totalTrials":139,"cells":1132},"Dengue Tetravalent Vaccine, Live",{"EARLY_PHASE1":1133,"PHASE1":1135,"PHASE2":1137,"PHASE3":1139,"PHASE4":1141,"NA":1143},{"trials":1134,"activeCount":100},[],{"trials":1136,"activeCount":100},[],{"trials":1138,"activeCount":100},[],{"trials":1140,"activeCount":100},[],{"trials":1142,"activeCount":100},[],{"trials":1144,"activeCount":139,"soonestReadout":1149},[1145],{"nctId":1146,"briefTitle":1147,"status":406,"phases":1148,"primaryCompletion":1149,"completion":1149,"start":1150,"enrollment":1151,"conditions":1152,"interventions":1154},"NCT04486638","Dengvaxia US Pregnancy Registry",[],"2029-06-30","2023-01-01",500,[1153],"Dengue Virus Infection",[1131],{"intervention":1156,"totalTrials":1157,"cells":1158},"Influenza virus vaccine",9,{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1175,"PHASE4":1204,"NA":1250},{"trials":1160,"activeCount":100},[],{"trials":1162,"activeCount":100},[],{"trials":1164,"activeCount":100},[1165],{"nctId":1166,"briefTitle":1167,"status":123,"phases":1168,"primaryCompletion":1169,"completion":1170,"start":1171,"enrollment":1172,"conditions":1173,"interventions":1174},"NCT00858468","Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age",[88,89],"2006-06","2006-12","2005-04",394,[15],[1156,1156],{"trials":1176,"activeCount":100},[1177,1186,1197],{"nctId":1178,"briefTitle":1179,"status":123,"phases":1180,"primaryCompletion":1181,"completion":1181,"start":1182,"enrollment":1183,"conditions":1184,"interventions":1185},"NCT01138397","Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)",[90],"2010-07","2010-06",129,[15],[1156,1156],{"nctId":1187,"briefTitle":1188,"status":123,"phases":1189,"primaryCompletion":1190,"completion":1191,"start":1192,"enrollment":1193,"conditions":1194,"interventions":1195},"NCT00885105","Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age",[90],"2006-01","2007-09","2005-10",242,[15],[1196,1196],"Influenza Virus Vaccine",{"nctId":1198,"briefTitle":1199,"status":123,"phases":1200,"primaryCompletion":1182,"completion":1182,"start":1201,"enrollment":1183,"conditions":1202,"interventions":1203},"NCT01121822","Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)",[90],"2010-05",[15],[1156,1156],{"trials":1205,"activeCount":100},[1206,1215,1224,1232,1241],{"nctId":1207,"briefTitle":1208,"status":123,"phases":1209,"primaryCompletion":1210,"completion":1211,"start":1192,"enrollment":1212,"conditions":1213,"interventions":1214},"NCT00258817","Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine",[91],"2006-03","2007-08",30,[15],[1196,1196],{"nctId":1216,"briefTitle":1217,"status":123,"phases":1218,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":1221,"conditions":1222,"interventions":1223},"NCT00835926","A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination",[91],"2003-09","2003-07",121,[15],[1156,1156],{"nctId":1225,"briefTitle":1226,"status":123,"phases":1227,"primaryCompletion":1191,"completion":1228,"start":1229,"enrollment":11,"conditions":1230,"interventions":1231},"NCT00389857","Trial to Collect Safety Data and Sera for Immunogenicity Testing",[91],"2008-07","2006-10",[15],[1196,1196],{"nctId":1233,"briefTitle":1234,"status":123,"phases":1235,"primaryCompletion":1236,"completion":1237,"start":1229,"enrollment":1238,"conditions":1239,"interventions":1240},"NCT00389532","Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine",[91],"2008-04","2008-09",116,[15],[1196,1196],{"nctId":1242,"briefTitle":1243,"status":123,"phases":1244,"primaryCompletion":1245,"completion":1246,"start":1219,"enrollment":1247,"conditions":1248,"interventions":1249},"NCT00836953","Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®",[91],"2004-01","2004-07",33,[15],[1156],{"trials":1251,"activeCount":100},[],{"intervention":1253,"totalTrials":428,"cells":1254},"Meningococcal Polysaccharide Diphtheria Toxoid Conjugate",{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1310,"PHASE4":1335,"NA":1350},{"trials":1256,"activeCount":100},[],{"trials":1258,"activeCount":100},[],{"trials":1260,"activeCount":100},[1261,1271,1283,1294,1303],{"nctId":1262,"briefTitle":1263,"status":123,"phases":1264,"primaryCompletion":1265,"completion":1266,"start":1267,"enrollment":1268,"conditions":1269,"interventions":1270},"NCT00269477","Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®",[89],"2007-02","2007-12","2005-12",145,[27,162],[1253,1253,1253,1253],{"nctId":1272,"briefTitle":1273,"status":123,"phases":1274,"primaryCompletion":1275,"completion":1276,"start":1277,"enrollment":1278,"conditions":1279,"interventions":1281},"NCT00771849","Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children",[89],"2004-03","2004-05","2003-08",103,[27,1280],"Meningococcemia",[1253,1282],"Haemophilus Influenzae Type b (Hib) vaccine",{"nctId":1284,"briefTitle":1285,"status":123,"phases":1286,"primaryCompletion":1287,"completion":1288,"start":1289,"enrollment":1290,"conditions":1291,"interventions":1292},"NCT00700713","Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26",[89],"2009-02","2009-03","2008-06",181,[27,1280],[1293,1293,1293],"Meningococcal polysaccharide diphtheria toxoid conjugate",{"nctId":1295,"briefTitle":1296,"status":123,"phases":1297,"primaryCompletion":1298,"completion":1171,"start":1299,"enrollment":1300,"conditions":1301,"interventions":1302},"NCT00777790","Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents",[89],"2004-04","2004-02",241,[27,1280],[1253,1253,1253],{"nctId":1304,"briefTitle":1305,"status":646,"phases":1306,"primaryCompletion":1298,"completion":1298,"start":1245,"enrollment":1307,"conditions":1308,"interventions":1309},"NCT00772629","Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults",[89],18,[27,1280],[1253,1253],{"trials":1311,"activeCount":100},[1312,1322],{"nctId":1313,"briefTitle":1314,"status":123,"phases":1315,"primaryCompletion":1316,"completion":1317,"start":1318,"enrollment":1319,"conditions":1320,"interventions":1321},"NCT01519713","Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects",[90],"2012-09","2012-12","2012-01",200,[27,1046,468],[1293],{"nctId":1323,"briefTitle":1324,"status":123,"phases":1325,"primaryCompletion":1326,"completion":1287,"start":1327,"enrollment":1328,"conditions":1329,"interventions":1333},"NCT00384397","A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers",[90],"2008-08","2006-09",1128,[1046,1330,1331,1332,512],"Measles","Mumps","Rubella",[1334,1253,1253],"Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine",{"trials":1336,"activeCount":100},[1337],{"nctId":1338,"briefTitle":1339,"status":123,"phases":1340,"primaryCompletion":1341,"completion":1342,"start":1343,"enrollment":1344,"conditions":1345,"interventions":1347},"NCT01659996","Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age",[91],"2014-11","2015-09","2012-07",1394,[27,162,18,24,21,1346],"Haemophilus Influenzae Serotype b (Hib)",[1293,1348,1349],"Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed","Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate",{"trials":1351,"activeCount":100},[],{"intervention":1349,"totalTrials":1353,"cells":1354},3,{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1390,"PHASE4":1392,"NA":1398},{"trials":1356,"activeCount":100},[],{"trials":1358,"activeCount":100},[],{"trials":1360,"activeCount":100},[1361,1365],{"nctId":548,"briefTitle":549,"status":123,"phases":1362,"primaryCompletion":551,"completion":551,"start":552,"enrollment":553,"conditions":1363,"interventions":1364},[89],[27,162],[556,557,558,559,560,538,561,562],{"nctId":1366,"briefTitle":1367,"status":123,"phases":1368,"primaryCompletion":1369,"completion":1369,"start":1370,"enrollment":1371,"conditions":1372,"interventions":1384},"NCT04398706","Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants",[89],"2023-08-10","2020-05-22",852,[1373,1374,1375,1376,1377,1378,1379,1380,1381,1382,1383],"Pneumococcal Immunisation","Diphtheria Immunisation","Tetanus Immunisation","Pertussis Immunisation","Hepatitis B Immunisation","Haemophilus Influenzae Type b Immunisation","Polio Immunisation","Measles Immunisation","Rubella Immunisation","Varicella Immunisation","Mumps Immunisation",[1385,1386,1387,559,584,1388,1349,616,1389],"Pneumococcal Conjugate Vaccine formulation 1","Pneumococcal Conjugate Vaccine formulation 2","Pneumococcal Conjugate Vaccine formulation 3","Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]","Hepatitis B Vaccine* [Recombinant] *as applicable",{"trials":1391,"activeCount":100},[],{"trials":1393,"activeCount":100},[1394],{"nctId":1338,"briefTitle":1339,"status":123,"phases":1395,"primaryCompletion":1341,"completion":1342,"start":1343,"enrollment":1344,"conditions":1396,"interventions":1397},[91],[27,162,18,24,21,1346],[1293,1348,1349],{"trials":1399,"activeCount":100},[],{"intervention":1401,"totalTrials":96,"cells":1402},"Trivalent Inactivated Influenza Vaccine",{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1407,"PHASE3":1420,"PHASE4":1422,"NA":1435},{"trials":1404,"activeCount":100},[],{"trials":1406,"activeCount":100},[],{"trials":1408,"activeCount":100},[1409],{"nctId":1410,"briefTitle":1411,"status":123,"phases":1412,"primaryCompletion":1413,"completion":1414,"start":1415,"enrollment":1416,"conditions":1417,"interventions":1418},"NCT01258595","A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age",[89],"2011-03","2011-04","2010-11",300,[15],[1419,1401],"High-Dose Trivalent Inactivated Influenza Vaccine",{"trials":1421,"activeCount":100},[],{"trials":1423,"activeCount":100},[1424],{"nctId":1425,"briefTitle":1426,"status":123,"phases":1427,"primaryCompletion":1428,"completion":1429,"start":1430,"enrollment":1431,"conditions":1432,"interventions":1433},"NCT01427309","A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults",[91],"2013-05","2013-11","2011-09",31989,[15],[1434,1401],"High Dose Trivalent Inactivated Influenza Vaccine",{"trials":1436,"activeCount":100},[],{"intervention":1438,"totalTrials":96,"cells":1439},"Diphtheria, tetanus, polio and pertussis vaccination",{"EARLY_PHASE1":1440,"PHASE1":1442,"PHASE2":1444,"PHASE3":1446,"PHASE4":1457,"NA":1467},{"trials":1441,"activeCount":100},[],{"trials":1443,"activeCount":100},[],{"trials":1445,"activeCount":100},[],{"trials":1447,"activeCount":100},[1448],{"nctId":1449,"briefTitle":1450,"status":123,"phases":1451,"primaryCompletion":1452,"completion":1452,"start":1453,"enrollment":1454,"conditions":1455,"interventions":1456},"NCT01287949","Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older",[90],"2012-05","2011-01",342,[18,24,30,21],[1438],{"trials":1458,"activeCount":100},[1459],{"nctId":1460,"briefTitle":1461,"status":123,"phases":1462,"primaryCompletion":1317,"completion":1317,"start":1463,"enrollment":1464,"conditions":1465,"interventions":1466},"NCT01546909","Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE",[91],"2012-02",278,[18,24,30],[1438],{"trials":1468,"activeCount":100},[],{"intervention":1470,"totalTrials":96,"cells":1471},"Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell",{"EARLY_PHASE1":1472,"PHASE1":1474,"PHASE2":1476,"PHASE3":1478,"PHASE4":1490,"NA":1500},{"trials":1473,"activeCount":100},[],{"trials":1475,"activeCount":100},[],{"trials":1477,"activeCount":100},[],{"trials":1479,"activeCount":100},[1480],{"nctId":1481,"briefTitle":1482,"status":123,"phases":1483,"primaryCompletion":1342,"completion":1484,"start":1485,"enrollment":1486,"conditions":1487,"interventions":1489},"NCT02434822","A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic",[90],"2016-07","2015-04",336,[1488],"Cholera",[1470,1470,1470],{"trials":1491,"activeCount":100},[1492],{"nctId":1493,"briefTitle":1494,"status":123,"phases":1495,"primaryCompletion":126,"completion":1496,"start":1497,"enrollment":1486,"conditions":1498,"interventions":1499},"NCT01949675","A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines",[91],"2015-08","2014-03",[1488],[1470,1470,1470],{"trials":1501,"activeCount":100},[],{"intervention":1503,"totalTrials":96,"cells":1504},"Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine",{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1509,"PHASE3":1511,"PHASE4":1524,"NA":1536},{"trials":1506,"activeCount":100},[],{"trials":1508,"activeCount":100},[],{"trials":1510,"activeCount":100},[],{"trials":1512,"activeCount":100},[1513],{"nctId":1514,"briefTitle":1515,"status":123,"phases":1516,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":1520,"interventions":1521},"NCT04490018","Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents",[90],"2022-05-11","2021-03-16",463,[170,33],[1522,497,1523,1503],"Meningococcal Polysaccharide","Human Papillomavirus 9-valent Vaccine",{"trials":1525,"activeCount":100},[1526],{"nctId":1527,"briefTitle":1528,"status":123,"phases":1529,"primaryCompletion":1530,"completion":1530,"start":1531,"enrollment":1532,"conditions":1533,"interventions":1535},"NCT04300192","Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa",[91],"2023-01-11","2021-01-27",273,[1376,1374,1375,1534],"Poliomyelitis Vaccine",[1503],{"trials":1537,"activeCount":100},[],{"intervention":1539,"totalTrials":96,"cells":1540},"Fluzone® Quadrivalent Influenza Vaccine, No Preservative",{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1547,"PHASE4":1549,"NA":1568},{"trials":1542,"activeCount":100},[],{"trials":1544,"activeCount":100},[],{"trials":1546,"activeCount":100},[],{"trials":1548,"activeCount":100},[],{"trials":1550,"activeCount":100},[1551,1559],{"nctId":1552,"briefTitle":1553,"status":123,"phases":1554,"primaryCompletion":1555,"completion":1484,"start":1496,"enrollment":1556,"conditions":1557,"interventions":1558},"NCT02539108","Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children",[91],"2015-12",60,[15],[1539,1539],{"nctId":1560,"briefTitle":1561,"status":123,"phases":1562,"primaryCompletion":1563,"completion":1564,"start":1565,"enrollment":1556,"conditions":1566,"interventions":1567},"NCT02222870","Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine",[91],"2014-12","2015-06","2014-08",[15],[1539,1539],{"trials":1569,"activeCount":100},[],{"intervention":1571,"totalTrials":96,"cells":1572},"Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed",{"EARLY_PHASE1":1573,"PHASE1":1575,"PHASE2":1577,"PHASE3":1579,"PHASE4":1590,"NA":1603},{"trials":1574,"activeCount":100},[],{"trials":1576,"activeCount":100},[],{"trials":1578,"activeCount":100},[],{"trials":1580,"activeCount":100},[1581],{"nctId":1582,"briefTitle":1583,"status":123,"phases":1584,"primaryCompletion":1585,"completion":1586,"start":1343,"enrollment":1416,"conditions":1587,"interventions":1589},"NCT01642589","Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea",[90],"2013-01","2013-06",[27,1588],"Meningococcal Disease",[598,1571],{"trials":1591,"activeCount":100},[1592],{"nctId":1593,"briefTitle":1594,"status":123,"phases":1595,"primaryCompletion":1596,"completion":1586,"start":1597,"enrollment":1598,"conditions":1599,"interventions":1601},"NCT01629589","Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents",[91],"2013-03","2012-06",423,[24,18,21,1600],"Whooping Cough",[1571,1602],"Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed",{"trials":1604,"activeCount":100},[],{"intervention":1434,"totalTrials":139,"cells":1606},{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1613,"PHASE4":1615,"NA":1621},{"trials":1608,"activeCount":100},[],{"trials":1610,"activeCount":100},[],{"trials":1612,"activeCount":100},[],{"trials":1614,"activeCount":100},[],{"trials":1616,"activeCount":100},[1617],{"nctId":1425,"briefTitle":1426,"status":123,"phases":1618,"primaryCompletion":1428,"completion":1429,"start":1430,"enrollment":1431,"conditions":1619,"interventions":1620},[91],[15],[1434,1401],{"trials":1622,"activeCount":100},[],{"intervention":1624,"totalTrials":139,"cells":1625},"Fluzone Quadrivalent Influenza Vaccine",{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1630,"PHASE3":1632,"PHASE4":1634,"NA":1644},{"trials":1627,"activeCount":100},[],{"trials":1629,"activeCount":100},[],{"trials":1631,"activeCount":100},[],{"trials":1633,"activeCount":100},[],{"trials":1635,"activeCount":100},[1636],{"nctId":1637,"briefTitle":1638,"status":123,"phases":1639,"primaryCompletion":1640,"completion":1640,"start":1641,"enrollment":410,"conditions":1642,"interventions":1643},"NCT03546192","Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)",[91],"2015-07-17","2015-06-17",[15],[1624],{"trials":1645,"activeCount":100},[],{"intervention":1647,"totalTrials":139,"cells":1648},"Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio",{"EARLY_PHASE1":1649,"PHASE1":1651,"PHASE2":1653,"PHASE3":1655,"PHASE4":1657,"NA":1669},{"trials":1650,"activeCount":100},[],{"trials":1652,"activeCount":100},[],{"trials":1654,"activeCount":100},[],{"trials":1656,"activeCount":100},[],{"trials":1658,"activeCount":100},[1659],{"nctId":1660,"briefTitle":1661,"status":123,"phases":1662,"primaryCompletion":1428,"completion":1429,"start":1663,"enrollment":1664,"conditions":1665,"interventions":1667},"NCT01475539","Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine",[91],"2011-11",456,[1666,30],"Polio",[1647,1647,1668],"Live oral poliovirus type 1, 2 and 3",{"trials":1670,"activeCount":100},[],{"intervention":1668,"totalTrials":139,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1681,"NA":1687},{"trials":1674,"activeCount":100},[],{"trials":1676,"activeCount":100},[],{"trials":1678,"activeCount":100},[],{"trials":1680,"activeCount":100},[],{"trials":1682,"activeCount":100},[1683],{"nctId":1660,"briefTitle":1661,"status":123,"phases":1684,"primaryCompletion":1428,"completion":1429,"start":1663,"enrollment":1664,"conditions":1685,"interventions":1686},[91],[1666,30],[1647,1647,1668],{"trials":1688,"activeCount":100},[],{"intervention":1690,"totalTrials":139,"cells":1691},"T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.",{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1696,"PHASE3":1698,"PHASE4":1700,"NA":1712},{"trials":1693,"activeCount":100},[],{"trials":1695,"activeCount":100},[],{"trials":1697,"activeCount":100},[],{"trials":1699,"activeCount":100},[],{"trials":1701,"activeCount":100},[1702],{"nctId":1703,"briefTitle":1704,"status":123,"phases":1705,"primaryCompletion":1706,"completion":1191,"start":1171,"enrollment":1707,"conditions":1708,"interventions":1709},"NCT00777257","Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine",[91],"2007-03",1345,[27,1280,21,24,18],[1690,1710,1711],"Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.","Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap",{"trials":1713,"activeCount":100},[],{"intervention":1710,"totalTrials":139,"cells":1715},{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1720,"PHASE3":1722,"PHASE4":1724,"NA":1730},{"trials":1717,"activeCount":100},[],{"trials":1719,"activeCount":100},[],{"trials":1721,"activeCount":100},[],{"trials":1723,"activeCount":100},[],{"trials":1725,"activeCount":100},[1726],{"nctId":1703,"briefTitle":1704,"status":123,"phases":1727,"primaryCompletion":1706,"completion":1191,"start":1171,"enrollment":1707,"conditions":1728,"interventions":1729},[91],[27,1280,21,24,18],[1690,1710,1711],{"trials":1731,"activeCount":100},[],{"intervention":1711,"totalTrials":139,"cells":1733},{"EARLY_PHASE1":1734,"PHASE1":1736,"PHASE2":1738,"PHASE3":1740,"PHASE4":1742,"NA":1748},{"trials":1735,"activeCount":100},[],{"trials":1737,"activeCount":100},[],{"trials":1739,"activeCount":100},[],{"trials":1741,"activeCount":100},[],{"trials":1743,"activeCount":100},[1744],{"nctId":1703,"briefTitle":1704,"status":123,"phases":1745,"primaryCompletion":1706,"completion":1191,"start":1171,"enrollment":1707,"conditions":1746,"interventions":1747},[91],[27,1280,21,24,18],[1690,1710,1711],{"trials":1749,"activeCount":100},[],{"intervention":1751,"totalTrials":139,"cells":1752},"Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),",{"EARLY_PHASE1":1753,"PHASE1":1755,"PHASE2":1757,"PHASE3":1759,"PHASE4":1761,"NA":1773},{"trials":1754,"activeCount":100},[],{"trials":1756,"activeCount":100},[],{"trials":1758,"activeCount":100},[],{"trials":1760,"activeCount":100},[],{"trials":1762,"activeCount":100},[1763],{"nctId":1764,"briefTitle":1765,"status":123,"phases":1766,"primaryCompletion":1767,"completion":125,"start":367,"enrollment":1768,"conditions":1769,"interventions":1770},"NCT01946438","Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults",[91],"2013-12",208,[15],[1751,1771,1751,1772],"Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),","Fluzone® High-Dose, Influenza Virus Vaccine",{"trials":1774,"activeCount":100},[],{"intervention":1771,"totalTrials":139,"cells":1776},{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1781,"PHASE3":1783,"PHASE4":1785,"NA":1791},{"trials":1778,"activeCount":100},[],{"trials":1780,"activeCount":100},[],{"trials":1782,"activeCount":100},[],{"trials":1784,"activeCount":100},[],{"trials":1786,"activeCount":100},[1787],{"nctId":1764,"briefTitle":1765,"status":123,"phases":1788,"primaryCompletion":1767,"completion":125,"start":367,"enrollment":1768,"conditions":1789,"interventions":1790},[91],[15],[1751,1771,1751,1772],{"trials":1792,"activeCount":100},[],{"intervention":1772,"totalTrials":139,"cells":1794},{"EARLY_PHASE1":1795,"PHASE1":1797,"PHASE2":1799,"PHASE3":1801,"PHASE4":1803,"NA":1809},{"trials":1796,"activeCount":100},[],{"trials":1798,"activeCount":100},[],{"trials":1800,"activeCount":100},[],{"trials":1802,"activeCount":100},[],{"trials":1804,"activeCount":100},[1805],{"nctId":1764,"briefTitle":1765,"status":123,"phases":1806,"primaryCompletion":1767,"completion":125,"start":367,"enrollment":1768,"conditions":1807,"interventions":1808},[91],[15],[1751,1771,1751,1772],{"trials":1810,"activeCount":100},[],{"intervention":1812,"totalTrials":139,"cells":1813},"Meningococcal Polysaccharide Groups A\\C\\Y\\W-135 Combined",{"EARLY_PHASE1":1814,"PHASE1":1816,"PHASE2":1818,"PHASE3":1820,"PHASE4":1822,"NA":1834},{"trials":1815,"activeCount":100},[],{"trials":1817,"activeCount":100},[],{"trials":1819,"activeCount":100},[],{"trials":1821,"activeCount":100},[],{"trials":1823,"activeCount":100},[1824],{"nctId":1825,"briefTitle":1826,"status":123,"phases":1827,"primaryCompletion":1828,"completion":1829,"start":1830,"enrollment":1831,"conditions":1832,"interventions":1833},"NCT00850603","Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®",[91],"2003-05","2004-11","2002-10",170,[468,27],[1812,1812,1812,1812,1812],{"trials":1835,"activeCount":100},[],{"intervention":1837,"totalTrials":139,"cells":1838},"Purified Verocell Rabies Vaccine",{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1843,"PHASE3":1845,"PHASE4":1847,"NA":1859},{"trials":1840,"activeCount":100},[],{"trials":1842,"activeCount":100},[],{"trials":1844,"activeCount":100},[],{"trials":1846,"activeCount":100},[],{"trials":1848,"activeCount":100},[1849],{"nctId":1850,"briefTitle":1851,"status":123,"phases":1852,"primaryCompletion":1326,"completion":1853,"start":1854,"enrollment":1855,"conditions":1856,"interventions":1858},"NCT00260351","Immunogenicity and Safety of Verorab™ in Indian Population",[91],"2008-10","2004-12",405,[1857],"Rabies",[1837,1837,1837],{"trials":1860,"activeCount":100},[],{"intervention":1862,"totalTrials":139,"cells":1863},"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate",{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1868,"PHASE3":1870,"PHASE4":1872,"NA":1882},{"trials":1865,"activeCount":100},[],{"trials":1867,"activeCount":100},[],{"trials":1869,"activeCount":100},[],{"trials":1871,"activeCount":100},[],{"trials":1873,"activeCount":100},[1874],{"nctId":1875,"briefTitle":1876,"status":123,"phases":1877,"primaryCompletion":1878,"completion":1878,"start":1879,"enrollment":1556,"conditions":1880,"interventions":1881},"NCT02591290","Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects",[91],"2016-03-16","2015-10-20",[27,1046,468],[1862],{"trials":1883,"activeCount":100},[],{"intervention":1885,"totalTrials":139,"cells":1886},"Fluzone®: Influenza Virus Vaccine",{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1893,"PHASE4":1895,"NA":1905},{"trials":1888,"activeCount":100},[],{"trials":1890,"activeCount":100},[],{"trials":1892,"activeCount":100},[],{"trials":1894,"activeCount":100},[],{"trials":1896,"activeCount":100},[1897],{"nctId":1898,"briefTitle":1899,"status":123,"phases":1900,"primaryCompletion":1901,"completion":1706,"start":1902,"enrollment":410,"conditions":1903,"interventions":1904},"NCT00258830","Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine",[91],"2006-02","2005-09",[15],[1885,1885],{"trials":1906,"activeCount":100},[],{"intervention":1908,"totalTrials":139,"cells":1909},"Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine",{"EARLY_PHASE1":1910,"PHASE1":1912,"PHASE2":1914,"PHASE3":1916,"PHASE4":1918,"NA":1929},{"trials":1911,"activeCount":100},[],{"trials":1913,"activeCount":100},[],{"trials":1915,"activeCount":100},[],{"trials":1917,"activeCount":100},[],{"trials":1919,"activeCount":100},[1920],{"nctId":1921,"briefTitle":1922,"status":123,"phases":1923,"primaryCompletion":1924,"completion":1925,"start":1555,"enrollment":1926,"conditions":1927,"interventions":1928},"NCT02633787","Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier",[91],"2016-02","2016-03",110,[27,1046,468],[1908],{"trials":1930,"activeCount":100},[],{"intervention":1932,"totalTrials":139,"cells":1933},"IMOVAX POLIO®: Inactive Poliovirus Vaccine",{"EARLY_PHASE1":1934,"PHASE1":1936,"PHASE2":1938,"PHASE3":1940,"PHASE4":1942,"NA":1952},{"trials":1935,"activeCount":100},[],{"trials":1937,"activeCount":100},[],{"trials":1939,"activeCount":100},[],{"trials":1941,"activeCount":100},[],{"trials":1943,"activeCount":100},[1944],{"nctId":1945,"briefTitle":1946,"status":123,"phases":1947,"primaryCompletion":1948,"completion":1949,"start":1767,"enrollment":1556,"conditions":1950,"interventions":1951},"NCT02005536","Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan",[91],"2014-09","2014-10",[30,1666],[1932],{"trials":1953,"activeCount":100},[],{"intervention":1955,"totalTrials":139,"cells":1956},"Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella",{"EARLY_PHASE1":1957,"PHASE1":1959,"PHASE2":1961,"PHASE3":1963,"PHASE4":1965,"NA":1978},{"trials":1958,"activeCount":100},[],{"trials":1960,"activeCount":100},[],{"trials":1962,"activeCount":100},[],{"trials":1964,"activeCount":100},[],{"trials":1966,"activeCount":100},[1967],{"nctId":1968,"briefTitle":1969,"status":123,"phases":1970,"primaryCompletion":1971,"completion":1972,"start":1327,"enrollment":1973,"conditions":1974,"interventions":1976},"NCT00313950","Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine",[91],"2009-12","2010-04",470,[1330,1331,1332,1975],"Hepatitis A",[1955,1977,1955],"Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine",{"trials":1979,"activeCount":100},[],{"intervention":1977,"totalTrials":139,"cells":1981},{"EARLY_PHASE1":1982,"PHASE1":1984,"PHASE2":1986,"PHASE3":1988,"PHASE4":1990,"NA":1996},{"trials":1983,"activeCount":100},[],{"trials":1985,"activeCount":100},[],{"trials":1987,"activeCount":100},[],{"trials":1989,"activeCount":100},[],{"trials":1991,"activeCount":100},[1992],{"nctId":1968,"briefTitle":1969,"status":123,"phases":1993,"primaryCompletion":1971,"completion":1972,"start":1327,"enrollment":1973,"conditions":1994,"interventions":1995},[91],[1330,1331,1332,1975],[1955,1977,1955],{"trials":1997,"activeCount":100},[],{"intervention":1999,"totalTrials":139,"cells":2000},"IMOVAX Polio™: Inactivated Poliomyelitis Vaccine",{"EARLY_PHASE1":2001,"PHASE1":2003,"PHASE2":2005,"PHASE3":2007,"PHASE4":2009,"NA":2020},{"trials":2002,"activeCount":100},[],{"trials":2004,"activeCount":100},[],{"trials":2006,"activeCount":100},[],{"trials":2008,"activeCount":100},[],{"trials":2010,"activeCount":100},[2011],{"nctId":2012,"briefTitle":2013,"status":123,"phases":2014,"primaryCompletion":2015,"completion":1597,"start":2016,"enrollment":2017,"conditions":2018,"interventions":2019},"NCT01278433","A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China",[91],"2011-12","2010-12",5007,[1666,30],[1999],{"trials":2021,"activeCount":100},[],{"intervention":2023,"totalTrials":139,"cells":2024},"Fluzone Quadrivalent vaccine, 2018-2019 formulation",{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2029,"PHASE3":2031,"PHASE4":2033,"NA":2045},{"trials":2026,"activeCount":100},[],{"trials":2028,"activeCount":100},[],{"trials":2030,"activeCount":100},[],{"trials":2032,"activeCount":100},[],{"trials":2034,"activeCount":100},[2035],{"nctId":2036,"briefTitle":2037,"status":123,"phases":2038,"primaryCompletion":2039,"completion":2039,"start":464,"enrollment":2040,"conditions":2041,"interventions":2042},"NCT03617523","Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations",[91],"2018-11-12",240,[15],[2023,2043,2044],"Flublok Quadrivalent vaccine, 2018-2019 formulation","Fluzone High-Dose vaccine, 2018-2019 formulation",{"trials":2046,"activeCount":100},[],{"intervention":2043,"totalTrials":139,"cells":2048},{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2053,"PHASE3":2055,"PHASE4":2057,"NA":2063},{"trials":2050,"activeCount":100},[],{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[],{"trials":2056,"activeCount":100},[],{"trials":2058,"activeCount":100},[2059],{"nctId":2036,"briefTitle":2037,"status":123,"phases":2060,"primaryCompletion":2039,"completion":2039,"start":464,"enrollment":2040,"conditions":2061,"interventions":2062},[91],[15],[2023,2043,2044],{"trials":2064,"activeCount":100},[],{"intervention":2044,"totalTrials":139,"cells":2066},{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2071,"PHASE3":2073,"PHASE4":2075,"NA":2081},{"trials":2068,"activeCount":100},[],{"trials":2070,"activeCount":100},[],{"trials":2072,"activeCount":100},[],{"trials":2074,"activeCount":100},[],{"trials":2076,"activeCount":100},[2077],{"nctId":2036,"briefTitle":2037,"status":123,"phases":2078,"primaryCompletion":2039,"completion":2039,"start":464,"enrollment":2040,"conditions":2079,"interventions":2080},[91],[15],[2023,2043,2044],{"trials":2082,"activeCount":100},[],{"intervention":2084,"totalTrials":139,"cells":2085},"COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine",{"EARLY_PHASE1":2086,"PHASE1":2088,"PHASE2":2090,"PHASE3":2092,"PHASE4":2094,"NA":2104},{"trials":2087,"activeCount":100},[],{"trials":2089,"activeCount":100},[],{"trials":2091,"activeCount":100},[],{"trials":2093,"activeCount":100},[],{"trials":2095,"activeCount":100},[2096],{"nctId":2097,"briefTitle":2098,"status":123,"phases":2099,"primaryCompletion":1229,"completion":2100,"start":1210,"enrollment":2101,"conditions":2102,"interventions":2103},"NCT00304265","Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine",[91],"2007-10",215,[21,18,24,30],[2084],{"trials":2105,"activeCount":100},[],{"intervention":2107,"totalTrials":139,"cells":2108},"Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation",{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2115,"PHASE4":2117,"NA":2129},{"trials":2110,"activeCount":100},[],{"trials":2112,"activeCount":100},[],{"trials":2114,"activeCount":100},[],{"trials":2116,"activeCount":100},[],{"trials":2118,"activeCount":100},[2119],{"nctId":2120,"briefTitle":2121,"status":123,"phases":2122,"primaryCompletion":2123,"completion":2124,"start":1316,"enrollment":1319,"conditions":2125,"interventions":2126},"NCT01691339","Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.",[91],"2012-11","2013-02",[15],[2107,2127,2107,2128],"Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation","Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation",{"trials":2130,"activeCount":100},[],{"intervention":2127,"totalTrials":139,"cells":2132},{"EARLY_PHASE1":2133,"PHASE1":2135,"PHASE2":2137,"PHASE3":2139,"PHASE4":2141,"NA":2147},{"trials":2134,"activeCount":100},[],{"trials":2136,"activeCount":100},[],{"trials":2138,"activeCount":100},[],{"trials":2140,"activeCount":100},[],{"trials":2142,"activeCount":100},[2143],{"nctId":2120,"briefTitle":2121,"status":123,"phases":2144,"primaryCompletion":2123,"completion":2124,"start":1316,"enrollment":1319,"conditions":2145,"interventions":2146},[91],[15],[2107,2127,2107,2128],{"trials":2148,"activeCount":100},[],{"intervention":2128,"totalTrials":139,"cells":2150},{"EARLY_PHASE1":2151,"PHASE1":2153,"PHASE2":2155,"PHASE3":2157,"PHASE4":2159,"NA":2165},{"trials":2152,"activeCount":100},[],{"trials":2154,"activeCount":100},[],{"trials":2156,"activeCount":100},[],{"trials":2158,"activeCount":100},[],{"trials":2160,"activeCount":100},[2161],{"nctId":2120,"briefTitle":2121,"status":123,"phases":2162,"primaryCompletion":2123,"completion":2124,"start":1316,"enrollment":1319,"conditions":2163,"interventions":2164},[91],[15],[2107,2127,2107,2128],{"trials":2166,"activeCount":100},[],{"intervention":1348,"totalTrials":139,"cells":2168},{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2173,"PHASE3":2175,"PHASE4":2177,"NA":2183},{"trials":2170,"activeCount":100},[],{"trials":2172,"activeCount":100},[],{"trials":2174,"activeCount":100},[],{"trials":2176,"activeCount":100},[],{"trials":2178,"activeCount":100},[2179],{"nctId":1338,"briefTitle":1339,"status":123,"phases":2180,"primaryCompletion":1341,"completion":1342,"start":1343,"enrollment":1344,"conditions":2181,"interventions":2182},[91],[27,162,18,24,21,1346],[1293,1348,1349],{"trials":2184,"activeCount":100},[],{"intervention":2186,"totalTrials":139,"cells":2187},"Fluzone®: Influenza virus vaccine 2004-2005 formulation",{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2194,"PHASE4":2196,"NA":2205},{"trials":2189,"activeCount":100},[],{"trials":2191,"activeCount":100},[],{"trials":2193,"activeCount":100},[],{"trials":2195,"activeCount":100},[],{"trials":2197,"activeCount":100},[2198],{"nctId":2199,"briefTitle":2200,"status":123,"phases":2201,"primaryCompletion":1901,"completion":1901,"start":2202,"enrollment":410,"conditions":2203,"interventions":2204},"NCT00831987","Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine",[91],"2004-08",[15],[2186,2186],{"trials":2206,"activeCount":100},[],{"intervention":2208,"totalTrials":139,"cells":2209},"IDflu™: Split virion inactivated influenza vaccine",{"EARLY_PHASE1":2210,"PHASE1":2212,"PHASE2":2214,"PHASE3":2216,"PHASE4":2218,"NA":2229},{"trials":2211,"activeCount":100},[],{"trials":2213,"activeCount":100},[],{"trials":2215,"activeCount":100},[],{"trials":2217,"activeCount":100},[],{"trials":2219,"activeCount":100},[2220],{"nctId":2221,"briefTitle":2222,"status":123,"phases":2223,"primaryCompletion":2224,"completion":1414,"start":2225,"enrollment":2040,"conditions":2226,"interventions":2227},"NCT01215669","Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea",[91],"2011-02","2010-10",[15],[2208,2228,2208,2228],"Vaxigrip®: Split virion inactivated influenza vaccine",{"trials":2230,"activeCount":100},[],{"intervention":2228,"totalTrials":139,"cells":2232},{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2237,"PHASE3":2239,"PHASE4":2241,"NA":2247},{"trials":2234,"activeCount":100},[],{"trials":2236,"activeCount":100},[],{"trials":2238,"activeCount":100},[],{"trials":2240,"activeCount":100},[],{"trials":2242,"activeCount":100},[2243],{"nctId":2221,"briefTitle":2222,"status":123,"phases":2244,"primaryCompletion":2224,"completion":1414,"start":2225,"enrollment":2040,"conditions":2245,"interventions":2246},[91],[15],[2208,2228,2208,2228],{"trials":2248,"activeCount":100},[],{"intervention":2250,"totalTrials":139,"cells":2251},"Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation",{"EARLY_PHASE1":2252,"PHASE1":2254,"PHASE2":2256,"PHASE3":2258,"PHASE4":2260,"NA":2272},{"trials":2253,"activeCount":100},[],{"trials":2255,"activeCount":100},[],{"trials":2257,"activeCount":100},[],{"trials":2259,"activeCount":100},[],{"trials":2261,"activeCount":100},[2262],{"nctId":2263,"briefTitle":2264,"status":123,"phases":2265,"primaryCompletion":2266,"completion":2266,"start":2267,"enrollment":2268,"conditions":2269,"interventions":2270},"NCT04551677","Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively",[91],"2020-12-18","2020-09-16",90,[759,33],[2250,2271],"Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation",{"trials":2273,"activeCount":100},[],{"intervention":2271,"totalTrials":139,"cells":2275},{"EARLY_PHASE1":2276,"PHASE1":2278,"PHASE2":2280,"PHASE3":2282,"PHASE4":2284,"NA":2290},{"trials":2277,"activeCount":100},[],{"trials":2279,"activeCount":100},[],{"trials":2281,"activeCount":100},[],{"trials":2283,"activeCount":100},[],{"trials":2285,"activeCount":100},[2286],{"nctId":2263,"briefTitle":2264,"status":123,"phases":2287,"primaryCompletion":2266,"completion":2266,"start":2267,"enrollment":2268,"conditions":2288,"interventions":2289},[91],[759,33],[2250,2271],{"trials":2291,"activeCount":100},[],{"intervention":2293,"totalTrials":139,"cells":2294},"Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation",{"EARLY_PHASE1":2295,"PHASE1":2297,"PHASE2":2299,"PHASE3":2301,"PHASE4":2303,"NA":2314},{"trials":2296,"activeCount":100},[],{"trials":2298,"activeCount":100},[],{"trials":2300,"activeCount":100},[],{"trials":2302,"activeCount":100},[],{"trials":2304,"activeCount":100},[2305],{"nctId":2306,"briefTitle":2307,"status":123,"phases":2308,"primaryCompletion":2309,"completion":2309,"start":2310,"enrollment":2268,"conditions":2311,"interventions":2312},"NCT05050318","Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively",[91],"2021-11-10","2021-09-08",[759,33],[2293,2313],"Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation",{"trials":2315,"activeCount":100},[],{"intervention":2313,"totalTrials":139,"cells":2317},{"EARLY_PHASE1":2318,"PHASE1":2320,"PHASE2":2322,"PHASE3":2324,"PHASE4":2326,"NA":2332},{"trials":2319,"activeCount":100},[],{"trials":2321,"activeCount":100},[],{"trials":2323,"activeCount":100},[],{"trials":2325,"activeCount":100},[],{"trials":2327,"activeCount":100},[2328],{"nctId":2306,"briefTitle":2307,"status":123,"phases":2329,"primaryCompletion":2309,"completion":2309,"start":2310,"enrollment":2268,"conditions":2330,"interventions":2331},[91],[759,33],[2293,2313],{"trials":2333,"activeCount":100},[],{"intervention":2335,"totalTrials":139,"cells":2336},"Influenza Virus Vaccine No Preservative: Pediatric Dose",{"EARLY_PHASE1":2337,"PHASE1":2339,"PHASE2":2341,"PHASE3":2343,"PHASE4":2345,"NA":2356},{"trials":2338,"activeCount":100},[],{"trials":2340,"activeCount":100},[],{"trials":2342,"activeCount":100},[],{"trials":2344,"activeCount":100},[],{"trials":2346,"activeCount":100},[2347],{"nctId":2348,"briefTitle":2349,"status":123,"phases":2350,"primaryCompletion":2351,"completion":2351,"start":1237,"enrollment":2352,"conditions":2353,"interventions":2355},"NCT00755274","Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®",[91],"2009-01",32,[15,2354],"Orthomyxoviridae Infections",[2335,2335],{"trials":2357,"activeCount":100},[],{"intervention":2359,"totalTrials":139,"cells":2360},"Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative",{"EARLY_PHASE1":2361,"PHASE1":2363,"PHASE2":2365,"PHASE3":2367,"PHASE4":2369,"NA":2381},{"trials":2362,"activeCount":100},[],{"trials":2364,"activeCount":100},[],{"trials":2366,"activeCount":100},[],{"trials":2368,"activeCount":100},[],{"trials":2370,"activeCount":100},[2371],{"nctId":2372,"briefTitle":2373,"status":123,"phases":2374,"primaryCompletion":2375,"completion":2375,"start":2376,"enrollment":2377,"conditions":2378,"interventions":2379},"NCT02908269","Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations",[91],"2016-12-09","2016-09-15",180,[15],[2359,2359,2380],"Fluzone High-Dose, vaccine, 2016-2017 formulation",{"trials":2382,"activeCount":100},[],{"intervention":2380,"totalTrials":139,"cells":2384},{"EARLY_PHASE1":2385,"PHASE1":2387,"PHASE2":2389,"PHASE3":2391,"PHASE4":2393,"NA":2399},{"trials":2386,"activeCount":100},[],{"trials":2388,"activeCount":100},[],{"trials":2390,"activeCount":100},[],{"trials":2392,"activeCount":100},[],{"trials":2394,"activeCount":100},[2395],{"nctId":2372,"briefTitle":2373,"status":123,"phases":2396,"primaryCompletion":2375,"completion":2375,"start":2376,"enrollment":2377,"conditions":2397,"interventions":2398},[91],[15],[2359,2359,2380],{"trials":2400,"activeCount":100},[],{"intervention":2402,"totalTrials":139,"cells":2403},"Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation",{"EARLY_PHASE1":2404,"PHASE1":2406,"PHASE2":2408,"PHASE3":2410,"PHASE4":2412,"NA":2421},{"trials":2405,"activeCount":100},[],{"trials":2407,"activeCount":100},[],{"trials":2409,"activeCount":100},[],{"trials":2411,"activeCount":100},[],{"trials":2413,"activeCount":100},[2414],{"nctId":2415,"briefTitle":2416,"status":123,"phases":2417,"primaryCompletion":1463,"completion":1463,"start":1430,"enrollment":1416,"conditions":2418,"interventions":2419},"NCT01430819","Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults",[91],[15],[2402,2420],"Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation",{"trials":2422,"activeCount":100},[],{"intervention":2420,"totalTrials":139,"cells":2424},{"EARLY_PHASE1":2425,"PHASE1":2427,"PHASE2":2429,"PHASE3":2431,"PHASE4":2433,"NA":2439},{"trials":2426,"activeCount":100},[],{"trials":2428,"activeCount":100},[],{"trials":2430,"activeCount":100},[],{"trials":2432,"activeCount":100},[],{"trials":2434,"activeCount":100},[2435],{"nctId":2415,"briefTitle":2416,"status":123,"phases":2436,"primaryCompletion":1463,"completion":1463,"start":1430,"enrollment":1416,"conditions":2437,"interventions":2438},[91],[15],[2402,2420],{"trials":2440,"activeCount":100},[],{"intervention":2442,"totalTrials":139,"cells":2443},"Avaxim 80U Pediatric: Inactivated Hepatitis A Virus",{"EARLY_PHASE1":2444,"PHASE1":2446,"PHASE2":2448,"PHASE3":2450,"PHASE4":2452,"NA":2462},{"trials":2445,"activeCount":100},[],{"trials":2447,"activeCount":100},[],{"trials":2449,"activeCount":100},[],{"trials":2451,"activeCount":100},[],{"trials":2453,"activeCount":100},[2454],{"nctId":2455,"briefTitle":2456,"status":123,"phases":2457,"primaryCompletion":1948,"completion":1496,"start":1767,"enrollment":2458,"conditions":2459,"interventions":2461},"NCT02011763","Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) in Toddlers, Children and Adolescents",[91],355,[1975,2460],"Hepatitis A Virus",[2442],{"trials":2463,"activeCount":100},[],{"intervention":2465,"totalTrials":139,"cells":2466},"Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine",{"EARLY_PHASE1":2467,"PHASE1":2469,"PHASE2":2471,"PHASE3":2473,"PHASE4":2475,"NA":2486},{"trials":2468,"activeCount":100},[],{"trials":2470,"activeCount":100},[],{"trials":2472,"activeCount":100},[],{"trials":2474,"activeCount":100},[],{"trials":2476,"activeCount":100},[2477],{"nctId":2478,"briefTitle":2479,"status":123,"phases":2480,"primaryCompletion":1555,"completion":2481,"start":1663,"enrollment":2482,"conditions":2483,"interventions":2484},"NCT01439165","Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose",[91],"2017-02",1330,[24,18,21,1600],[2465,2485],"Tetanus and Diphtheria Toxoids Adsorbed For Adult Use",{"trials":2487,"activeCount":100},[],{"intervention":2485,"totalTrials":139,"cells":2489},{"EARLY_PHASE1":2490,"PHASE1":2492,"PHASE2":2494,"PHASE3":2496,"PHASE4":2498,"NA":2504},{"trials":2491,"activeCount":100},[],{"trials":2493,"activeCount":100},[],{"trials":2495,"activeCount":100},[],{"trials":2497,"activeCount":100},[],{"trials":2499,"activeCount":100},[2500],{"nctId":2478,"briefTitle":2479,"status":123,"phases":2501,"primaryCompletion":1555,"completion":2481,"start":1663,"enrollment":2482,"conditions":2502,"interventions":2503},[91],[24,18,21,1600],[2465,2485],{"trials":2505,"activeCount":100},[],{"intervention":2507,"totalTrials":139,"cells":2508},"DTacP IPV\u002F\u002FPRP~T combined vaccine: PENTAXIM®",{"EARLY_PHASE1":2509,"PHASE1":2511,"PHASE2":2513,"PHASE3":2515,"PHASE4":2517,"NA":2526},{"trials":2510,"activeCount":100},[],{"trials":2512,"activeCount":100},[],{"trials":2514,"activeCount":100},[],{"trials":2516,"activeCount":100},[],{"trials":2518,"activeCount":100},[2519],{"nctId":2520,"briefTitle":2521,"status":123,"phases":2522,"primaryCompletion":1343,"completion":1317,"start":2015,"enrollment":2523,"conditions":2524,"interventions":2525},"NCT01491087","Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China",[91],900,[18,24,21,1666],[2507],{"trials":2527,"activeCount":100},[],{"intervention":2529,"totalTrials":139,"cells":2530},"Live Attenuated Varicella Virus Vaccine",{"EARLY_PHASE1":2531,"PHASE1":2533,"PHASE2":2535,"PHASE3":2537,"PHASE4":2539,"NA":2549},{"trials":2532,"activeCount":100},[],{"trials":2534,"activeCount":100},[],{"trials":2536,"activeCount":100},[],{"trials":2538,"activeCount":100},[],{"trials":2540,"activeCount":100},[2541],{"nctId":2542,"briefTitle":2543,"status":123,"phases":2544,"primaryCompletion":2545,"completion":1971,"start":2351,"enrollment":2546,"conditions":2547,"interventions":2548},"NCT00830648","Safety of a Second Dose of Biken's Varicella Vaccine",[91],"2009-10",122,[512],[2529],{"trials":2550,"activeCount":100},[],{"intervention":2552,"totalTrials":139,"cells":2553},"Tetanus-diphtheria-acellular pertussis (Tdap) vaccine",{"EARLY_PHASE1":2554,"PHASE1":2556,"PHASE2":2558,"PHASE3":2560,"PHASE4":2562,"NA":2573},{"trials":2555,"activeCount":100},[],{"trials":2557,"activeCount":100},[],{"trials":2559,"activeCount":100},[],{"trials":2561,"activeCount":100},[],{"trials":2563,"activeCount":100},[2564],{"nctId":2565,"briefTitle":2566,"status":123,"phases":2567,"primaryCompletion":2568,"completion":1853,"start":2569,"enrollment":2570,"conditions":2571,"interventions":2572},"NCT00347958","Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine",[91],"2008-02","2006-08",545,[24,18,21],[2552],{"trials":2574,"activeCount":100},[],{"intervention":1602,"totalTrials":139,"cells":2576},{"EARLY_PHASE1":2577,"PHASE1":2579,"PHASE2":2581,"PHASE3":2583,"PHASE4":2585,"NA":2591},{"trials":2578,"activeCount":100},[],{"trials":2580,"activeCount":100},[],{"trials":2582,"activeCount":100},[],{"trials":2584,"activeCount":100},[],{"trials":2586,"activeCount":100},[2587],{"nctId":1593,"briefTitle":1594,"status":123,"phases":2588,"primaryCompletion":1596,"completion":1586,"start":1597,"enrollment":1598,"conditions":2589,"interventions":2590},[91],[24,18,21,1600],[1571,1602],{"trials":2592,"activeCount":100},[],{"intervention":2594,"totalTrials":139,"cells":2595},"ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined",{"EARLY_PHASE1":2596,"PHASE1":2598,"PHASE2":2600,"PHASE3":2602,"PHASE4":2604,"NA":2614},{"trials":2597,"activeCount":100},[],{"trials":2599,"activeCount":100},[],{"trials":2601,"activeCount":100},[],{"trials":2603,"activeCount":100},[],{"trials":2605,"activeCount":100},[2606],{"nctId":2607,"briefTitle":2608,"status":123,"phases":2609,"primaryCompletion":1925,"completion":2610,"start":1182,"enrollment":2611,"conditions":2612,"interventions":2613},"NCT01137435","Post Marketing Surveillance for ADACEL™ in South Korea",[91],"2016-09",659,[18,24,21],[2594],{"trials":2615,"activeCount":100},[],{"intervention":2617,"totalTrials":139,"cells":2618},"Split, Inactivated, Trivalent Influenza vaccine",{"EARLY_PHASE1":2619,"PHASE1":2621,"PHASE2":2623,"PHASE3":2625,"PHASE4":2627,"NA":2635},{"trials":2620,"activeCount":100},[],{"trials":2622,"activeCount":100},[],{"trials":2624,"activeCount":100},[],{"trials":2626,"activeCount":100},[],{"trials":2628,"activeCount":100},[2629],{"nctId":2630,"briefTitle":1217,"status":123,"phases":2631,"primaryCompletion":2632,"completion":2632,"start":1326,"enrollment":410,"conditions":2633,"interventions":2634},"NCT00743275",[91],"2008-11",[15],[2617],{"trials":2636,"activeCount":100},[],{"intervention":2638,"totalTrials":139,"cells":2639},"Influenza Virus Vaccine, Fluzone®",{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2646,"PHASE4":2648,"NA":2658},{"trials":2641,"activeCount":100},[],{"trials":2643,"activeCount":100},[],{"trials":2645,"activeCount":100},[],{"trials":2647,"activeCount":100},[],{"trials":2649,"activeCount":100},[2650],{"nctId":2651,"briefTitle":2652,"status":123,"phases":2653,"primaryCompletion":2654,"completion":1237,"start":1229,"enrollment":2655,"conditions":2656,"interventions":2657},"NCT00390884","Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.",[91],"2007-06",173,[15],[2638,2638],{"trials":2659,"activeCount":100},[],{"intervention":2661,"totalTrials":139,"cells":2662},"Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative",{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2667,"PHASE3":2669,"PHASE4":2671,"NA":2681},{"trials":2664,"activeCount":100},[],{"trials":2666,"activeCount":100},[],{"trials":2668,"activeCount":100},[],{"trials":2670,"activeCount":100},[],{"trials":2672,"activeCount":100},[2673],{"nctId":2674,"briefTitle":2675,"status":123,"phases":2676,"primaryCompletion":1555,"completion":1484,"start":1342,"enrollment":1768,"conditions":2677,"interventions":2678},"NCT02563093","Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults",[91],[15],[2661,2679,2661,2680],"Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation","Fluzone High-Dose vaccine, 2015-2016 formulation",{"trials":2682,"activeCount":100},[],{"intervention":2679,"totalTrials":139,"cells":2684},{"EARLY_PHASE1":2685,"PHASE1":2687,"PHASE2":2689,"PHASE3":2691,"PHASE4":2693,"NA":2699},{"trials":2686,"activeCount":100},[],{"trials":2688,"activeCount":100},[],{"trials":2690,"activeCount":100},[],{"trials":2692,"activeCount":100},[],{"trials":2694,"activeCount":100},[2695],{"nctId":2674,"briefTitle":2675,"status":123,"phases":2696,"primaryCompletion":1555,"completion":1484,"start":1342,"enrollment":1768,"conditions":2697,"interventions":2698},[91],[15],[2661,2679,2661,2680],{"trials":2700,"activeCount":100},[],{"intervention":2680,"totalTrials":139,"cells":2702},{"EARLY_PHASE1":2703,"PHASE1":2705,"PHASE2":2707,"PHASE3":2709,"PHASE4":2711,"NA":2717},{"trials":2704,"activeCount":100},[],{"trials":2706,"activeCount":100},[],{"trials":2708,"activeCount":100},[],{"trials":2710,"activeCount":100},[],{"trials":2712,"activeCount":100},[2713],{"nctId":2674,"briefTitle":2675,"status":123,"phases":2714,"primaryCompletion":1555,"completion":1484,"start":1342,"enrollment":1768,"conditions":2715,"interventions":2716},[91],[15],[2661,2679,2661,2680],{"trials":2718,"activeCount":100},[],{"intervention":2720,"totalTrials":139,"cells":2721},"Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose",{"EARLY_PHASE1":2722,"PHASE1":2724,"PHASE2":2726,"PHASE3":2728,"PHASE4":2730,"NA":2739},{"trials":2723,"activeCount":100},[],{"trials":2725,"activeCount":100},[],{"trials":2727,"activeCount":100},[],{"trials":2729,"activeCount":100},[],{"trials":2731,"activeCount":100},[2732],{"nctId":2733,"briefTitle":2734,"status":123,"phases":2735,"primaryCompletion":1317,"completion":2124,"start":1316,"enrollment":1556,"conditions":2736,"interventions":2737},"NCT01691326","Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)",[91],[15],[2720,2738],"Fluzone®; Influenza Virus Vaccine, No Preservative",{"trials":2740,"activeCount":100},[],{"intervention":2738,"totalTrials":139,"cells":2742},{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2747,"PHASE3":2749,"PHASE4":2751,"NA":2757},{"trials":2744,"activeCount":100},[],{"trials":2746,"activeCount":100},[],{"trials":2748,"activeCount":100},[],{"trials":2750,"activeCount":100},[],{"trials":2752,"activeCount":100},[2753],{"nctId":2733,"briefTitle":2734,"status":123,"phases":2754,"primaryCompletion":1317,"completion":2124,"start":1316,"enrollment":1556,"conditions":2755,"interventions":2756},[91],[15],[2720,2738],{"trials":2758,"activeCount":100},[],{"intervention":2760,"totalTrials":139,"cells":2761},"2007-2008 Influenza Virus Vaccine",{"EARLY_PHASE1":2762,"PHASE1":2764,"PHASE2":2766,"PHASE3":2768,"PHASE4":2770,"NA":2780},{"trials":2763,"activeCount":100},[],{"trials":2765,"activeCount":100},[],{"trials":2767,"activeCount":100},[],{"trials":2769,"activeCount":100},[],{"trials":2771,"activeCount":100},[2772],{"nctId":2773,"briefTitle":2774,"status":123,"phases":2775,"primaryCompletion":2776,"completion":1289,"start":2100,"enrollment":2777,"conditions":2778,"interventions":2779},"NCT00561002","Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine",[91],"2008-05",34,[15],[2760,2760],{"trials":2781,"activeCount":100},[],{"intervention":2783,"totalTrials":139,"cells":2784},"TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio",{"EARLY_PHASE1":2785,"PHASE1":2787,"PHASE2":2789,"PHASE3":2791,"PHASE4":2793,"NA":2804},{"trials":2786,"activeCount":100},[],{"trials":2788,"activeCount":100},[],{"trials":2790,"activeCount":100},[],{"trials":2792,"activeCount":100},[],{"trials":2794,"activeCount":100},[2795],{"nctId":2796,"briefTitle":2797,"status":123,"phases":2798,"primaryCompletion":2799,"completion":2799,"start":2800,"enrollment":2801,"conditions":2802,"interventions":2803},"NCT01437423","Regulatory Post-Marketing Surveillance Study for TETRAXIM™",[91],"2015-11","2011-06",600,[18,24,21,30],[2783],{"trials":2805,"activeCount":100},[],{"intervention":2807,"totalTrials":139,"cells":2808},"Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation",{"EARLY_PHASE1":2809,"PHASE1":2811,"PHASE2":2813,"PHASE3":2815,"PHASE4":2817,"NA":2828},{"trials":2810,"activeCount":100},[],{"trials":2812,"activeCount":100},[],{"trials":2814,"activeCount":100},[],{"trials":2816,"activeCount":100},[],{"trials":2818,"activeCount":100},[2819],{"nctId":2820,"briefTitle":2821,"status":123,"phases":2822,"primaryCompletion":2823,"completion":2823,"start":2824,"enrollment":2268,"conditions":2825,"interventions":2826},"NCT04109222","Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively",[91],"2019-12-10","2019-09-30",[15],[2807,2827],"Fluzone High-Dose vaccine, 2019-2020 formulation",{"trials":2829,"activeCount":100},[],{"intervention":2827,"totalTrials":139,"cells":2831},{"EARLY_PHASE1":2832,"PHASE1":2834,"PHASE2":2836,"PHASE3":2838,"PHASE4":2840,"NA":2846},{"trials":2833,"activeCount":100},[],{"trials":2835,"activeCount":100},[],{"trials":2837,"activeCount":100},[],{"trials":2839,"activeCount":100},[],{"trials":2841,"activeCount":100},[2842],{"nctId":2820,"briefTitle":2821,"status":123,"phases":2843,"primaryCompletion":2823,"completion":2823,"start":2824,"enrollment":2268,"conditions":2844,"interventions":2845},[91],[15],[2807,2827],{"trials":2847,"activeCount":100},[],{"intervention":2849,"totalTrials":139,"cells":2850},"Fluzone Quadrivalent vaccine, No Preservative",{"EARLY_PHASE1":2851,"PHASE1":2853,"PHASE2":2855,"PHASE3":2857,"PHASE4":2859,"NA":2870},{"trials":2852,"activeCount":100},[],{"trials":2854,"activeCount":100},[],{"trials":2856,"activeCount":100},[],{"trials":2858,"activeCount":100},[],{"trials":2860,"activeCount":100},[2861],{"nctId":2862,"briefTitle":2863,"status":123,"phases":2864,"primaryCompletion":2865,"completion":2865,"start":2866,"enrollment":2867,"conditions":2868,"interventions":2869},"NCT02915302","Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children",[91],"2017-03-06","2016-09-23",1950,[15],[2849,2849],{"trials":2871,"activeCount":100},[],{"intervention":2873,"totalTrials":139,"cells":2874},"Fluzone Quadrivalent vaccine",{"EARLY_PHASE1":2875,"PHASE1":2877,"PHASE2":2879,"PHASE3":2881,"PHASE4":2883,"NA":2895},{"trials":2876,"activeCount":100},[],{"trials":2878,"activeCount":100},[],{"trials":2880,"activeCount":100},[],{"trials":2882,"activeCount":100},[],{"trials":2884,"activeCount":100},[2885],{"nctId":2886,"briefTitle":2887,"status":123,"phases":2888,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2040,"conditions":2891,"interventions":2893},"NCT03308825","Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines",[91],"2017-11-22","2017-09-11",[15,2892],"Flu",[2873,2873,2894],"Fluzone High-Dose vaccine",{"trials":2896,"activeCount":100},[],{"intervention":2894,"totalTrials":139,"cells":2898},{"EARLY_PHASE1":2899,"PHASE1":2901,"PHASE2":2903,"PHASE3":2905,"PHASE4":2907,"NA":2913},{"trials":2900,"activeCount":100},[],{"trials":2902,"activeCount":100},[],{"trials":2904,"activeCount":100},[],{"trials":2906,"activeCount":100},[],{"trials":2908,"activeCount":100},[2909],{"nctId":2886,"briefTitle":2887,"status":123,"phases":2910,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2040,"conditions":2911,"interventions":2912},[91],[15,2892],[2873,2873,2894],{"trials":2914,"activeCount":100},[],{"intervention":2916,"totalTrials":139,"cells":2917},"Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation",{"EARLY_PHASE1":2918,"PHASE1":2920,"PHASE2":2922,"PHASE3":2924,"PHASE4":2926,"NA":2936},{"trials":2919,"activeCount":100},[],{"trials":2921,"activeCount":100},[],{"trials":2923,"activeCount":100},[],{"trials":2925,"activeCount":100},[],{"trials":2927,"activeCount":100},[2928],{"nctId":2929,"briefTitle":2930,"status":123,"phases":2931,"primaryCompletion":1563,"completion":2932,"start":1948,"enrollment":2933,"conditions":2934,"interventions":2935},"NCT02228980","Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China",[91],"2015-10",602,[15],[2916,2916,2916,2916],{"trials":2937,"activeCount":100},[],{"intervention":2939,"totalTrials":139,"cells":2940},"Diphtheria and Tetanus Toxoids and Acellular Pertussis",{"EARLY_PHASE1":2941,"PHASE1":2943,"PHASE2":2945,"PHASE3":2947,"PHASE4":2949,"NA":2960},{"trials":2942,"activeCount":100},[],{"trials":2944,"activeCount":100},[],{"trials":2946,"activeCount":100},[],{"trials":2948,"activeCount":100},[],{"trials":2950,"activeCount":100},[2951],{"nctId":2952,"briefTitle":2953,"status":123,"phases":2954,"primaryCompletion":2955,"completion":1902,"start":1299,"enrollment":2956,"conditions":2957,"interventions":2959},"NCT00802867","Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™",[91],"2005-06",989,[18,24,21,1666,2958],"Haemophilus Infection",[2939],{"trials":2961,"activeCount":100},[],{"intervention":2963,"totalTrials":139,"cells":2964},"Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine",{"EARLY_PHASE1":2965,"PHASE1":2967,"PHASE2":2969,"PHASE3":2971,"PHASE4":2973,"NA":2983},{"trials":2966,"activeCount":100},[],{"trials":2968,"activeCount":100},[],{"trials":2970,"activeCount":100},[],{"trials":2972,"activeCount":100},[],{"trials":2974,"activeCount":100},[2975],{"nctId":2976,"briefTitle":2977,"status":123,"phases":2978,"primaryCompletion":2979,"completion":2979,"start":1276,"enrollment":2980,"conditions":2981,"interventions":2982},"NCT00601835","Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td",[91],"2005-07",3651,[18,24],[2963,2963],{"trials":2984,"activeCount":100},[],{"intervention":2986,"totalTrials":139,"cells":2987},"Fluzone® Quadrivalent vaccine, 2014-2015 formulation",{"EARLY_PHASE1":2988,"PHASE1":2990,"PHASE2":2992,"PHASE3":2994,"PHASE4":2996,"NA":3006},{"trials":2989,"activeCount":100},[],{"trials":2991,"activeCount":100},[],{"trials":2993,"activeCount":100},[],{"trials":2995,"activeCount":100},[],{"trials":2997,"activeCount":100},[2998],{"nctId":2999,"briefTitle":3000,"status":123,"phases":3001,"primaryCompletion":1341,"completion":1563,"start":1949,"enrollment":1768,"conditions":3002,"interventions":3003},"NCT02258334","Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults",[91],[15],[2986,3004,2986,3005],"Fluzone I®ntradermal vaccine, 2014-2015 formulation","Fluzone High Dose vaccine, 2014-2015 formulation",{"trials":3007,"activeCount":100},[],{"intervention":3004,"totalTrials":139,"cells":3009},{"EARLY_PHASE1":3010,"PHASE1":3012,"PHASE2":3014,"PHASE3":3016,"PHASE4":3018,"NA":3024},{"trials":3011,"activeCount":100},[],{"trials":3013,"activeCount":100},[],{"trials":3015,"activeCount":100},[],{"trials":3017,"activeCount":100},[],{"trials":3019,"activeCount":100},[3020],{"nctId":2999,"briefTitle":3000,"status":123,"phases":3021,"primaryCompletion":1341,"completion":1563,"start":1949,"enrollment":1768,"conditions":3022,"interventions":3023},[91],[15],[2986,3004,2986,3005],{"trials":3025,"activeCount":100},[],{"intervention":3005,"totalTrials":139,"cells":3027},{"EARLY_PHASE1":3028,"PHASE1":3030,"PHASE2":3032,"PHASE3":3034,"PHASE4":3036,"NA":3042},{"trials":3029,"activeCount":100},[],{"trials":3031,"activeCount":100},[],{"trials":3033,"activeCount":100},[],{"trials":3035,"activeCount":100},[],{"trials":3037,"activeCount":100},[3038],{"nctId":2999,"briefTitle":3000,"status":123,"phases":3039,"primaryCompletion":1341,"completion":1563,"start":1949,"enrollment":1768,"conditions":3040,"interventions":3041},[91],[15],[2986,3004,2986,3005],{"trials":3043,"activeCount":100},[],{"intervention":3045,"totalTrials":139,"cells":3046},"IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine",{"EARLY_PHASE1":3047,"PHASE1":3049,"PHASE2":3051,"PHASE3":3053,"PHASE4":3055,"NA":3065},{"trials":3048,"activeCount":100},[],{"trials":3050,"activeCount":100},[],{"trials":3052,"activeCount":100},[],{"trials":3054,"activeCount":100},[],{"trials":3056,"activeCount":100},[3057],{"nctId":3058,"briefTitle":3059,"status":123,"phases":3060,"primaryCompletion":1485,"completion":2932,"start":1429,"enrollment":3061,"conditions":3062,"interventions":3064},"NCT01981967","Post-licensure Safety Study of IMOJEV® in Thailand",[91],10000,[3063],"Japanese Encephalitis",[3045,3045],{"trials":3066,"activeCount":100},[],{"intervention":3068,"totalTrials":139,"cells":3069},"Meningococcal (Groups A and C) Polysaccharide Vaccine",{"EARLY_PHASE1":3070,"PHASE1":3072,"PHASE2":3074,"PHASE3":3076,"PHASE4":3078,"NA":3089},{"trials":3071,"activeCount":100},[],{"trials":3073,"activeCount":100},[],{"trials":3075,"activeCount":100},[],{"trials":3077,"activeCount":100},[],{"trials":3079,"activeCount":100},[3080],{"nctId":3081,"briefTitle":3082,"status":123,"phases":3083,"primaryCompletion":3084,"completion":2123,"start":3085,"enrollment":3086,"conditions":3087,"interventions":3088},"NCT01430611","Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children",[91],"2012-08","2011-08",666,[1588,27],[3068,3068],{"trials":3090,"activeCount":100},[],{"intervention":3092,"totalTrials":139,"cells":3093},"Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis",{"EARLY_PHASE1":3094,"PHASE1":3096,"PHASE2":3098,"PHASE3":3100,"PHASE4":3102,"NA":3112},{"trials":3095,"activeCount":100},[],{"trials":3097,"activeCount":100},[],{"trials":3099,"activeCount":100},[],{"trials":3101,"activeCount":100},[],{"trials":3103,"activeCount":100},[3104],{"nctId":3105,"briefTitle":3106,"status":123,"phases":3107,"primaryCompletion":3108,"completion":1971,"start":1289,"enrollment":3109,"conditions":3110,"interventions":3111},"NCT00712959","Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose",[91],"2009-09",769,[21,24,18],[3092,3092],{"trials":3113,"activeCount":100},[],{"intervention":3115,"totalTrials":139,"cells":3116},"Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative",{"EARLY_PHASE1":3117,"PHASE1":3119,"PHASE2":3121,"PHASE3":3123,"PHASE4":3125,"NA":3133},{"trials":3118,"activeCount":100},[],{"trials":3120,"activeCount":100},[],{"trials":3122,"activeCount":100},[],{"trials":3124,"activeCount":100},[],{"trials":3126,"activeCount":100},[3127],{"nctId":3128,"briefTitle":3129,"status":123,"phases":3130,"primaryCompletion":1767,"completion":125,"start":367,"enrollment":1556,"conditions":3131,"interventions":3132},"NCT01946425","Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine",[91],[15],[3115,3115],{"trials":3134,"activeCount":100},[],{"intervention":3136,"totalTrials":139,"cells":3137},"Influenza Vaccine 2004-2005 Paediatric Formulation",{"EARLY_PHASE1":3138,"PHASE1":3140,"PHASE2":3142,"PHASE3":3144,"PHASE4":3146,"NA":3156},{"trials":3139,"activeCount":100},[],{"trials":3141,"activeCount":100},[],{"trials":3143,"activeCount":100},[],{"trials":3145,"activeCount":100},[],{"trials":3147,"activeCount":100},[3148],{"nctId":3149,"briefTitle":3150,"status":123,"phases":3151,"primaryCompletion":3152,"completion":3152,"start":3153,"enrollment":1212,"conditions":3154,"interventions":3155},"NCT00831675","Study of Safety and Immunogenicity of Fluzone® in Healthy Children",[91],"2006-04","2004-09",[15],[3136,3136],{"trials":3157,"activeCount":100},[],{"intervention":3159,"totalTrials":3160,"cells":3161},"CYD Dengue Vaccine",11,{"EARLY_PHASE1":3162,"PHASE1":3164,"PHASE2":3166,"PHASE3":3247,"PHASE4":3279,"NA":3281},{"trials":3163,"activeCount":100},[],{"trials":3165,"activeCount":100},[],{"trials":3167,"activeCount":100},[3168,3182,3190,3199,3209,3219,3229,3238],{"nctId":3169,"briefTitle":3170,"status":123,"phases":3171,"primaryCompletion":1949,"completion":3172,"start":3173,"enrollment":3174,"conditions":3175,"interventions":3179},"NCT00880893","Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore",[89],"2014-10-14","2009-04-07",1198,[3176,373,3177,3178],"Dengue Fever","Dengue Virus","Dengue Diseases",[3180,3181],"CYD Dengue vaccine","NaCl + influenza virus or hepatitis A vaccine",{"nctId":3183,"briefTitle":3184,"status":123,"phases":3185,"primaryCompletion":1430,"completion":3186,"start":2545,"enrollment":2801,"conditions":3187,"interventions":3188},"NCT00993447","Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America",[89],"2012-03",[372,373,3177,3176],[3159,3189],"Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis",{"nctId":3191,"briefTitle":3192,"status":123,"phases":3193,"primaryCompletion":3194,"completion":3194,"start":3195,"enrollment":2268,"conditions":3196,"interventions":3197},"NCT01943825","Immunologic Mechanisms of Immune Interference and\u002For Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine",[89],"2015-11-25","2013-11-05",[372,3176,373],[3159,3159,3198,3198],"Japanese Encephalitis Vaccine",{"nctId":3200,"briefTitle":3201,"status":123,"phases":3202,"primaryCompletion":3203,"completion":3203,"start":3204,"enrollment":3205,"conditions":3206,"interventions":3208},"NCT02741128","Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults",[89],"2023-01-19","2019-11-06",133,[3176,373,3207],"Human Immunodeficiency Virus",[3159],{"nctId":3210,"briefTitle":3211,"status":123,"phases":3212,"primaryCompletion":3213,"completion":3214,"start":3215,"enrollment":3216,"conditions":3217,"interventions":3218},"NCT02623725","Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule",[89],"2016-11-23","2018-10-28","2016-04-14",251,[3176,373],[3159],{"nctId":3220,"briefTitle":3221,"status":123,"phases":3222,"primaryCompletion":3223,"completion":3224,"start":3225,"enrollment":3226,"conditions":3227,"interventions":3228},"NCT02824198","Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule",[89],"2017-03-18","2019-01-18","2016-07-01",118,[3176,373],[3159],{"nctId":3230,"briefTitle":3231,"status":123,"phases":3232,"primaryCompletion":3233,"completion":3233,"start":3234,"enrollment":3235,"conditions":3236,"interventions":3237},"NCT02628444","Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age",[89],"2020-04-29","2016-05-02",1050,[3176,373],[3159],{"nctId":3239,"briefTitle":3240,"status":123,"phases":3241,"primaryCompletion":367,"completion":3242,"start":1287,"enrollment":3243,"conditions":3244,"interventions":3245},"NCT00842530","Efficacy and Safety of Dengue Vaccine in Healthy Children",[89],"2014-02",4002,[3177,3176,373,3178],[3159,3246],"Inactivated rabies virus vaccine",{"trials":3248,"activeCount":100},[3249,3260,3269],{"nctId":3250,"briefTitle":3251,"status":123,"phases":3252,"primaryCompletion":3253,"completion":3253,"start":3254,"enrollment":3255,"conditions":3256,"interventions":3258},"NCT02993757","Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®",[90],"2019-05-27","2016-12-01",528,[3176,373,3257],"Human Papillomavirus Disease",[3159,3159,3259],"Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.",{"nctId":3261,"briefTitle":3262,"status":646,"phases":3263,"primaryCompletion":2823,"completion":2823,"start":1107,"enrollment":3264,"conditions":3265,"interventions":3266},"NCT02992418","Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects",[90],688,[3176,373],[3159,3267,3268],"Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed","Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed",{"nctId":3270,"briefTitle":3271,"status":123,"phases":3272,"primaryCompletion":3273,"completion":3273,"start":3274,"enrollment":3275,"conditions":3276,"interventions":3277},"NCT02979535","Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®",[90],"2019-03-25","2016-11-16",480,[3176,373,3257],[3159,3159,3278,3278],"Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant",{"trials":3280,"activeCount":100},[],{"trials":3282,"activeCount":100},[],{"intervention":483,"totalTrials":428,"cells":3284},{"EARLY_PHASE1":3285,"PHASE1":3287,"PHASE2":3289,"PHASE3":3305,"PHASE4":3338,"NA":3340},{"trials":3286,"activeCount":100},[],{"trials":3288,"activeCount":100},[],{"trials":3290,"activeCount":100},[3291,3301],{"nctId":3292,"briefTitle":3293,"status":123,"phases":3294,"primaryCompletion":3295,"completion":3295,"start":3296,"enrollment":3297,"conditions":3298,"interventions":3299},"NCT02040636","Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis",[89],"2000-05","1999-01",277,[21,24,18,30,36],[3300,483],"Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV",{"nctId":548,"briefTitle":549,"status":123,"phases":3302,"primaryCompletion":551,"completion":551,"start":552,"enrollment":553,"conditions":3303,"interventions":3304},[89],[27,162],[556,557,558,559,560,538,561,562],{"trials":3306,"activeCount":100},[3307,3311,3315,3319,3323,3334],{"nctId":471,"briefTitle":472,"status":123,"phases":3308,"primaryCompletion":474,"completion":474,"start":475,"enrollment":476,"conditions":3309,"interventions":3310},[90],[478],[427,480,481,447,482,483,484,485,486],{"nctId":574,"briefTitle":575,"status":123,"phases":3312,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":3313,"interventions":3314},[90],[478],[582,583,584,538,585,562,586,587],{"nctId":589,"briefTitle":590,"status":123,"phases":3316,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":3317,"interventions":3318},[90],[478],[597,598,599,538,561,562,600,601],{"nctId":644,"briefTitle":645,"status":646,"phases":3320,"primaryCompletion":648,"completion":648,"start":649,"enrollment":650,"conditions":3321,"interventions":3322},[90],[652],[654,655,656,483,657,446,381,658],{"nctId":3324,"briefTitle":3325,"status":123,"phases":3326,"primaryCompletion":3327,"completion":2568,"start":3328,"enrollment":3329,"conditions":3330,"interventions":3331},"NCT00315055","Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule",[90],"2007-07","2006-07",310,[36,1666,18,21],[3332,3333,483],"DTaP-IPV-HB-PRP~T vaccine","DTaP-IPV\u002F\u002FPRP~T combined",{"nctId":603,"briefTitle":604,"status":123,"phases":3335,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":3336,"interventions":3337},[90],[478],[611,583,612,613,614,615,538,616,562,584,559],{"trials":3339,"activeCount":100},[],{"trials":3341,"activeCount":100},[],{"intervention":3343,"totalTrials":539,"cells":3344},"Inactivated, split-virion influenza vaccine",{"EARLY_PHASE1":3345,"PHASE1":3347,"PHASE2":3349,"PHASE3":3386,"PHASE4":3405,"NA":3407},{"trials":3346,"activeCount":100},[],{"trials":3348,"activeCount":100},[],{"trials":3350,"activeCount":100},[3351,3359,3370,3378],{"nctId":3352,"briefTitle":3353,"status":123,"phases":3354,"primaryCompletion":1289,"completion":1237,"start":1902,"enrollment":3355,"conditions":3356,"interventions":3357},"NCT00258934","Immunogenicity Study of the Influenza Vaccine in Adults",[89],978,[2354,15],[3343,3358],"Inactivated, split-virion, influenza virus",{"nctId":3360,"briefTitle":3361,"status":123,"phases":3362,"primaryCompletion":1287,"completion":3363,"start":1191,"enrollment":3364,"conditions":3365,"interventions":3368},"NCT00776438","Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines",[89],"2009-04",160,[15,3366,3367],"Orthomyxovirus Infections","Myxovirus Infection",[3369,3369,3343,3343],"Inactivated, split-virion, influenza vaccine",{"nctId":3371,"briefTitle":3372,"status":123,"phases":3373,"primaryCompletion":1265,"completion":1265,"start":1190,"enrollment":3374,"conditions":3375,"interventions":3377},"NCT00296829","Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly",[89],1080,[3376,15,3367],"Orthomyxoviridae Infection",[3343],{"nctId":3379,"briefTitle":3380,"status":123,"phases":3381,"primaryCompletion":3382,"completion":3328,"start":1219,"enrollment":3383,"conditions":3384,"interventions":3385},"NCT00703651","Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults",[89],"2006-05",1150,[15,3376,3367],[3343,3343,3343],{"trials":3387,"activeCount":100},[3388,3397],{"nctId":3389,"briefTitle":3390,"status":123,"phases":3391,"primaryCompletion":3327,"completion":2568,"start":1229,"enrollment":3392,"conditions":3393,"interventions":3394},"NCT00391053","Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly",[90],3851,[3376,15,3367],[3395,3395,3395,3396],"High-Dose Inactivated, Split-Virion Influenza Vaccine","Inactivated, Split-Virion Influenza Vaccine",{"nctId":3398,"briefTitle":3399,"status":123,"phases":3400,"primaryCompletion":3401,"completion":3108,"start":1327,"enrollment":3402,"conditions":3403,"interventions":3404},"NCT00383526","Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly",[90],"2009-06",3707,[3376,15,3367],[3343,3343],{"trials":3406,"activeCount":100},[],{"trials":3408,"activeCount":100},[],{"intervention":762,"totalTrials":539,"cells":3410},{"EARLY_PHASE1":3411,"PHASE1":3413,"PHASE2":3436,"PHASE3":3450,"PHASE4":3463,"NA":3465},{"trials":3412,"activeCount":100},[],{"trials":3414,"activeCount":100},[3415,3426],{"nctId":3416,"briefTitle":3417,"status":123,"phases":3418,"primaryCompletion":3419,"completion":3419,"start":3420,"enrollment":3421,"conditions":3422,"interventions":3423},"NCT05829356","Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above",[88],"2024-03-14","2023-04-12",159,[759],[3424,3425],"H3 mRNA \u002F LNP Vaccine","Quadrivalent recombinant influenza Vaccine",{"nctId":3427,"briefTitle":3428,"status":123,"phases":3429,"primaryCompletion":3430,"completion":3430,"start":3431,"enrollment":3432,"conditions":3433,"interventions":3434},"NCT06118151","Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older",[88],"2023-02-17","2022-04-11",388,[15,759],[3435,762],"Influenza Hemagglutinin mRNA vaccine",{"trials":3437,"activeCount":100},[3438,3442,3446],{"nctId":752,"briefTitle":753,"status":123,"phases":3439,"primaryCompletion":755,"completion":755,"start":756,"enrollment":757,"conditions":3440,"interventions":3441},[88,89],[759],[761,762,742,763],{"nctId":774,"briefTitle":775,"status":123,"phases":3443,"primaryCompletion":777,"completion":777,"start":778,"enrollment":779,"conditions":3444,"interventions":3445},[88,89],[759],[782,762,742,763],{"nctId":784,"briefTitle":785,"status":123,"phases":3447,"primaryCompletion":787,"completion":787,"start":788,"enrollment":789,"conditions":3448,"interventions":3449},[88,89],[759],[792,793,794,742,763,762],{"trials":3451,"activeCount":100},[3452],{"nctId":3453,"briefTitle":3454,"status":123,"phases":3455,"primaryCompletion":3456,"completion":3456,"start":3457,"enrollment":3458,"conditions":3459,"interventions":3461},"NCT05144945","Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea",[90],"2022-09-01","2021-12-07",301,[3460],"Influenza (Healthy Volunteers)",[762,3462],"Quadrivalent inactivated influenza vaccine",{"trials":3464,"activeCount":100},[],{"trials":3466,"activeCount":100},[],{"intervention":486,"totalTrials":325,"cells":3468},{"EARLY_PHASE1":3469,"PHASE1":3471,"PHASE2":3473,"PHASE3":3483,"PHASE4":3510,"NA":3512},{"trials":3470,"activeCount":100},[],{"trials":3472,"activeCount":100},[],{"trials":3474,"activeCount":100},[3475],{"nctId":3476,"briefTitle":3477,"status":123,"phases":3478,"primaryCompletion":1971,"completion":1428,"start":3479,"enrollment":1416,"conditions":3480,"interventions":3481},"NCT00621764","Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children",[89],"2008-03",[3063,1975],[3482,486,3482,486],"Japanese encephalitis vaccine",{"trials":3484,"activeCount":100},[3485,3494,3498,3502],{"nctId":3486,"briefTitle":3487,"status":123,"phases":3488,"primaryCompletion":3489,"completion":3490,"start":1326,"enrollment":3491,"conditions":3492,"interventions":3493},"NCT00735644","Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines",[90],"2009-05","2009-08",1200,[3063,1975],[3482,3482,3482,3482,486],{"nctId":471,"briefTitle":472,"status":123,"phases":3495,"primaryCompletion":474,"completion":474,"start":475,"enrollment":476,"conditions":3496,"interventions":3497},[90],[478],[427,480,481,447,482,483,484,485,486],{"nctId":660,"briefTitle":661,"status":123,"phases":3499,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":3500,"interventions":3501},[90],[170,33],[582,668,669,670,671,672,673,486,446,674,675,676,676,671,486],{"nctId":3503,"briefTitle":3504,"status":123,"phases":3505,"primaryCompletion":2776,"completion":1326,"start":2654,"enrollment":3506,"conditions":3507,"interventions":3508},"NCT00483470","Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose",[90],720,[1975],[3509,486],"Hepatitis A vaccine AVAXIM 80U",{"trials":3511,"activeCount":100},[],{"trials":3513,"activeCount":100},[],{"intervention":3515,"totalTrials":743,"cells":3516},"Purified inactivated rabies vaccine",{"EARLY_PHASE1":3517,"PHASE1":3519,"PHASE2":3521,"PHASE3":3532,"PHASE4":3571,"NA":3573},{"trials":3518,"activeCount":100},[],{"trials":3520,"activeCount":100},[],{"trials":3522,"activeCount":100},[3523],{"nctId":3524,"briefTitle":3525,"status":123,"phases":3526,"primaryCompletion":2224,"completion":3085,"start":3527,"enrollment":3528,"conditions":3529,"interventions":3530},"NCT00948272","Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults",[89],"2009-07",384,[1857],[3531,3515],"Purified Vero Rabies Vaccine - Serum Free",{"trials":3533,"activeCount":100},[3534,3546,3559],{"nctId":3535,"briefTitle":3536,"status":123,"phases":3537,"primaryCompletion":3538,"completion":3538,"start":3539,"enrollment":3540,"conditions":3541,"interventions":3543},"NCT04594551","Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland",[90],"2021-06-23","2020-10-11",201,[3542],"Rabies (Healthy Volunteers)",[3544,3515,3545],"Purified vero rabies vaccine - serum free","Human rabies immunoglobulins",{"nctId":3547,"briefTitle":3548,"status":123,"phases":3549,"primaryCompletion":3550,"completion":349,"start":3551,"enrollment":3552,"conditions":3553,"interventions":3554},"NCT03965962","Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults",[90],"2020-12-22","2019-07-01",640,[3542],[3555,3556,3557,3558],"VRVg-2","Purified Inactivated Rabies Vaccine","Human Diploid Cell Vaccine","Rabies immune globulin",{"nctId":3560,"briefTitle":3561,"status":123,"phases":3562,"primaryCompletion":3563,"completion":3564,"start":3565,"enrollment":3566,"conditions":3567,"interventions":3568},"NCT04478084","Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland",[90],"2022-03-19","2022-07-21","2020-08-04",403,[3542],[3569,3515,3570,3545],"Purified vero rabies vaccine - serum free VRVg-2","Equine rabies immunoglobulins",{"trials":3572,"activeCount":100},[],{"trials":3574,"activeCount":100},[],{"intervention":3482,"totalTrials":1353,"cells":3576},{"EARLY_PHASE1":3577,"PHASE1":3579,"PHASE2":3581,"PHASE3":3591,"PHASE4":3597,"NA":3599},{"trials":3578,"activeCount":100},[],{"trials":3580,"activeCount":100},[],{"trials":3582,"activeCount":100},[3583,3587],{"nctId":3476,"briefTitle":3477,"status":123,"phases":3584,"primaryCompletion":1971,"completion":1428,"start":3479,"enrollment":1416,"conditions":3585,"interventions":3586},[89],[3063,1975],[3482,486,3482,486],{"nctId":3191,"briefTitle":3192,"status":123,"phases":3588,"primaryCompletion":3194,"completion":3194,"start":3195,"enrollment":2268,"conditions":3589,"interventions":3590},[89],[372,3176,373],[3159,3159,3198,3198],{"trials":3592,"activeCount":100},[3593],{"nctId":3486,"briefTitle":3487,"status":123,"phases":3594,"primaryCompletion":3489,"completion":3490,"start":1326,"enrollment":3491,"conditions":3595,"interventions":3596},[90],[3063,1975],[3482,3482,3482,3482,486],{"trials":3598,"activeCount":100},[],{"trials":3600,"activeCount":100},[],{"intervention":3602,"totalTrials":1353,"cells":3603},"Inactivated Poliomyelitis vaccine",{"EARLY_PHASE1":3604,"PHASE1":3606,"PHASE2":3608,"PHASE3":3619,"PHASE4":3647,"NA":3649},{"trials":3605,"activeCount":100},[],{"trials":3607,"activeCount":100},[],{"trials":3609,"activeCount":100},[3610],{"nctId":3611,"briefTitle":3612,"status":123,"phases":3613,"primaryCompletion":1237,"completion":3614,"start":3615,"enrollment":3616,"conditions":3617,"interventions":3618},"NCT00604058","Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly",[89],"2008-12","2008-01",236,[30],[3602,3602],{"trials":3620,"activeCount":100},[3621,3639],{"nctId":3622,"briefTitle":3623,"status":123,"phases":3624,"primaryCompletion":3625,"completion":3626,"start":3627,"enrollment":3628,"conditions":3629,"interventions":3632},"NCT04429295","Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand",[90],"2021-02-26","2021-11-20","2020-06-28",460,[1376,1374,1379,1377,3630,1375,3631,1373],"Haemophilus Influenzae Type B Immunisation","Rotavirus Immunisation",[3633,3634,3635,3636,3637,3638],"DTwP-HepB-Hib-IPV hexavalent vaccine","DTwP-HepB-Hib pentavalent vaccine","Inactivated Poliomyelitis Vaccine","Poliomyelitis Vaccine bivalent types 1 and 3","Human Rotavirus, live attenuated","Pneumococcal polysaccharide conjugate vaccine",{"nctId":3640,"briefTitle":3641,"status":123,"phases":3642,"primaryCompletion":1901,"completion":3152,"start":3643,"enrollment":3644,"conditions":3645,"interventions":3646},"NCT00258843","Safety of Imovax Polio in Chinese Infants and Children",[90],"2005-11",40,[30],[3602,3602],{"trials":3648,"activeCount":100},[],{"trials":3650,"activeCount":100},[],{"intervention":3652,"totalTrials":1353,"cells":3653},"RSVt Vaccine",{"EARLY_PHASE1":3654,"PHASE1":3656,"PHASE2":3658,"PHASE3":3670,"PHASE4":3686,"NA":3688},{"trials":3655,"activeCount":100},[],{"trials":3657,"activeCount":100},[],{"trials":3659,"activeCount":100},[3660],{"nctId":3661,"briefTitle":3662,"status":123,"phases":3663,"primaryCompletion":3664,"completion":3664,"start":3665,"enrollment":3666,"conditions":3667,"interventions":3669},"NCT05687279","Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to \u003C 24 Months of Age in Puerto Rico (USA)",[88,89],"2024-12-27","2023-02-06",80,[3668],"Respiratory Syncytial Virus Infection",[3652],{"trials":3671,"activeCount":100},[3672,3682],{"nctId":3673,"briefTitle":3674,"status":646,"phases":3675,"primaryCompletion":3676,"completion":3676,"start":3677,"enrollment":3678,"conditions":3679,"interventions":3681},"NCT06252285","Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers",[90],"2025-12-04","2024-02-06",6300,[3680],"RSV Immunisation",[3652],{"nctId":644,"briefTitle":645,"status":646,"phases":3683,"primaryCompletion":648,"completion":648,"start":649,"enrollment":650,"conditions":3684,"interventions":3685},[90],[652],[654,655,656,483,657,446,381,658],{"trials":3687,"activeCount":100},[],{"trials":3689,"activeCount":100},[],{"intervention":583,"totalTrials":1353,"cells":3691},{"EARLY_PHASE1":3692,"PHASE1":3694,"PHASE2":3696,"PHASE3":3698,"PHASE4":3718,"NA":3720},{"trials":3693,"activeCount":100},[],{"trials":3695,"activeCount":100},[],{"trials":3697,"activeCount":100},[],{"trials":3699,"activeCount":100},[3700,3704,3714],{"nctId":574,"briefTitle":575,"status":123,"phases":3701,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":3702,"interventions":3703},[90],[478],[582,583,584,538,585,562,586,587],{"nctId":3705,"briefTitle":3706,"status":123,"phases":3707,"primaryCompletion":3708,"completion":3708,"start":3709,"enrollment":3710,"conditions":3711,"interventions":3712},"NCT03077438","Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years",[90],"2017-10-10","2017-02-17",1000,[27,1046,468],[3713,583],"Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate",{"nctId":603,"briefTitle":604,"status":123,"phases":3715,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":3716,"interventions":3717},[90],[478],[611,583,612,613,614,615,538,616,562,584,559],{"trials":3719,"activeCount":100},[],{"trials":3721,"activeCount":100},[],{"intervention":584,"totalTrials":1353,"cells":3723},{"EARLY_PHASE1":3724,"PHASE1":3726,"PHASE2":3728,"PHASE3":3734,"PHASE4":3744,"NA":3746},{"trials":3725,"activeCount":100},[],{"trials":3727,"activeCount":100},[],{"trials":3729,"activeCount":100},[3730],{"nctId":1366,"briefTitle":1367,"status":123,"phases":3731,"primaryCompletion":1369,"completion":1369,"start":1370,"enrollment":1371,"conditions":3732,"interventions":3733},[89],[1373,1374,1375,1376,1377,1378,1379,1380,1381,1382,1383],[1385,1386,1387,559,584,1388,1349,616,1389],{"trials":3735,"activeCount":100},[3736,3740],{"nctId":574,"briefTitle":575,"status":123,"phases":3737,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":3738,"interventions":3739},[90],[478],[582,583,584,538,585,562,586,587],{"nctId":603,"briefTitle":604,"status":123,"phases":3741,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":3742,"interventions":3743},[90],[478],[611,583,612,613,614,615,538,616,562,584,559],{"trials":3745,"activeCount":100},[],{"trials":3747,"activeCount":100},[],{"intervention":3545,"totalTrials":1353,"cells":3749},{"EARLY_PHASE1":3750,"PHASE1":3752,"PHASE2":3754,"PHASE3":3770,"PHASE4":3780,"NA":3782},{"trials":3751,"activeCount":100},[],{"trials":3753,"activeCount":100},[],{"trials":3755,"activeCount":100},[3756],{"nctId":3757,"briefTitle":3758,"status":123,"phases":3759,"primaryCompletion":3760,"completion":3760,"start":3761,"enrollment":3762,"conditions":3763,"interventions":3765},"NCT03145766","Immunogenicity and Safety of a Purified Vero Rabies Vaccine",[89],"2018-01-08","2017-04-17",320,[3764],"Rabies Virus",[3766,3767,3768,3766,3766,3769],"VRVg 2","VRVg 1","Imovax Rabies","Human Rabies Immunoglobulins",{"trials":3771,"activeCount":100},[3772,3776],{"nctId":3535,"briefTitle":3536,"status":123,"phases":3773,"primaryCompletion":3538,"completion":3538,"start":3539,"enrollment":3540,"conditions":3774,"interventions":3775},[90],[3542],[3544,3515,3545],{"nctId":3560,"briefTitle":3561,"status":123,"phases":3777,"primaryCompletion":3563,"completion":3564,"start":3565,"enrollment":3566,"conditions":3778,"interventions":3779},[90],[3542],[3569,3515,3570,3545],{"trials":3781,"activeCount":100},[],{"trials":3783,"activeCount":100},[],{"intervention":3785,"totalTrials":1353,"cells":3786},"Oral Polio Vaccine",{"EARLY_PHASE1":3787,"PHASE1":3789,"PHASE2":3791,"PHASE3":3793,"PHASE4":3824,"NA":3826},{"trials":3788,"activeCount":100},[],{"trials":3790,"activeCount":100},[],{"trials":3792,"activeCount":100},[],{"trials":3794,"activeCount":100},[3795,3804,3815],{"nctId":3796,"briefTitle":3797,"status":123,"phases":3798,"primaryCompletion":3614,"completion":3363,"start":1191,"enrollment":3799,"conditions":3800,"interventions":3801},"NCT00514709","Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants",[90],1843,[18,24,21,36,15],[3802,3803,3785],"DTaP-HB PRP~T Combined Vaccine","DTaP-HB-PRP~T vaccine",{"nctId":3805,"briefTitle":3806,"status":123,"phases":3807,"primaryCompletion":3808,"completion":1236,"start":2569,"enrollment":3809,"conditions":3810,"interventions":3812},"NCT00343889","Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB\u002FHib™, Both Given Concomitantly With Oral Polio Vaccine",[90],"2007-11",379,[18,24,21,36,3811],"Haemophilus Infections",[3813,3814,3785],"DTaP-HB-PRP~T vaccine + OPV","Tritanrix-HepB\u002FHib™ + OPV vaccine",{"nctId":3816,"briefTitle":3817,"status":123,"phases":3818,"primaryCompletion":1237,"completion":1288,"start":1191,"enrollment":3819,"conditions":3820,"interventions":3822},"NCT00534833","Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB\u002FHib™",[90],362,[18,24,21,36,3821],"Haemophilus Influenzae Type b",[3803,3823,3785],"Tritanrix-HepB\u002FHib™",{"trials":3825,"activeCount":100},[],{"trials":3827,"activeCount":100},[],{"intervention":381,"totalTrials":1353,"cells":3829},{"EARLY_PHASE1":3830,"PHASE1":3832,"PHASE2":3834,"PHASE3":3836,"PHASE4":3857,"NA":3859},{"trials":3831,"activeCount":100},[],{"trials":3833,"activeCount":100},[],{"trials":3835,"activeCount":100},[],{"trials":3837,"activeCount":100},[3838,3842,3846],{"nctId":644,"briefTitle":645,"status":646,"phases":3839,"primaryCompletion":648,"completion":648,"start":649,"enrollment":650,"conditions":3840,"interventions":3841},[90],[652],[654,655,656,483,657,446,381,658],{"nctId":364,"briefTitle":365,"status":123,"phases":3843,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":3844,"interventions":3845},[90],[372,373,352],[375,42,376,377,378,379,375,380,381,377,379,378],{"nctId":3847,"briefTitle":3848,"status":123,"phases":3849,"primaryCompletion":3850,"completion":3851,"start":3852,"enrollment":3506,"conditions":3853,"interventions":3854},"NCT01411241","Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers",[90],"2014-02-04","2014-04","2011-07-18",[372,373],[3855,3856,381,499,3855,3856,381,499],"Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus","DTaP IPV\u002F\u002FHib vaccine",{"trials":3858,"activeCount":100},[],{"trials":3860,"activeCount":100},[],{"intervention":559,"totalTrials":1353,"cells":3862},{"EARLY_PHASE1":3863,"PHASE1":3865,"PHASE2":3867,"PHASE3":3877,"PHASE4":3883,"NA":3885},{"trials":3864,"activeCount":100},[],{"trials":3866,"activeCount":100},[],{"trials":3868,"activeCount":100},[3869,3873],{"nctId":548,"briefTitle":549,"status":123,"phases":3870,"primaryCompletion":551,"completion":551,"start":552,"enrollment":553,"conditions":3871,"interventions":3872},[89],[27,162],[556,557,558,559,560,538,561,562],{"nctId":1366,"briefTitle":1367,"status":123,"phases":3874,"primaryCompletion":1369,"completion":1369,"start":1370,"enrollment":1371,"conditions":3875,"interventions":3876},[89],[1373,1374,1375,1376,1377,1378,1379,1380,1381,1382,1383],[1385,1386,1387,559,584,1388,1349,616,1389],{"trials":3878,"activeCount":100},[3879],{"nctId":603,"briefTitle":604,"status":123,"phases":3880,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":3881,"interventions":3882},[90],[478],[611,583,612,613,614,615,538,616,562,584,559],{"trials":3884,"activeCount":100},[],{"trials":3886,"activeCount":100},[],{"intervention":3888,"totalTrials":1353,"cells":3889},"Influenza Virus Vaccine USP Trivalent Types A and B",{"EARLY_PHASE1":3890,"PHASE1":3892,"PHASE2":3894,"PHASE3":3911,"PHASE4":3920,"NA":3922},{"trials":3891,"activeCount":100},[],{"trials":3893,"activeCount":100},[],{"trials":3895,"activeCount":100},[3896,3904],{"nctId":3897,"briefTitle":3898,"status":123,"phases":3899,"primaryCompletion":3401,"completion":3527,"start":1853,"enrollment":3900,"conditions":3901,"interventions":3903},"NCT00775450","Influenza Vaccine Revaccination in Ambulatory Elderly Subjects",[89],807,[15,3902,3367],"Orthomyxovirus Infection",[3888,3888,3888,3888,3888],{"nctId":3905,"briefTitle":3906,"status":123,"phases":3907,"primaryCompletion":1201,"completion":2225,"start":3108,"enrollment":3908,"conditions":3909,"interventions":3910},"NCT01011049","Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM",[89],1250,[15],[3888,3888,3888,3888],{"trials":3912,"activeCount":100},[3913],{"nctId":3914,"briefTitle":3915,"status":123,"phases":3916,"primaryCompletion":3489,"completion":3527,"start":1853,"enrollment":3917,"conditions":3918,"interventions":3919},"NCT00772109","Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults",[90],4292,[3376,15,3367],[3888,3888,3888,3888],{"trials":3921,"activeCount":100},[],{"trials":3923,"activeCount":100},[],{"intervention":3332,"totalTrials":1353,"cells":3925},{"EARLY_PHASE1":3926,"PHASE1":3928,"PHASE2":3930,"PHASE3":3932,"PHASE4":3953,"NA":3955},{"trials":3927,"activeCount":100},[],{"trials":3929,"activeCount":100},[],{"trials":3931,"activeCount":100},[],{"trials":3933,"activeCount":100},[3934,3938,3947],{"nctId":3324,"briefTitle":3325,"status":123,"phases":3935,"primaryCompletion":3327,"completion":2568,"start":3328,"enrollment":3329,"conditions":3936,"interventions":3937},[90],[36,1666,18,21],[3332,3333,483],{"nctId":3939,"briefTitle":3940,"status":123,"phases":3941,"primaryCompletion":1236,"completion":1228,"start":3942,"enrollment":3943,"conditions":3944,"interventions":3945},"NCT00404651","Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants",[90],"2006-11",1189,[18,24,21,36,30],[3332,3332,3332,3946],"DTaP-HBV-IPV vaccine",{"nctId":3948,"briefTitle":3949,"status":123,"phases":3950,"primaryCompletion":1228,"completion":1228,"start":1266,"enrollment":388,"conditions":3951,"interventions":3952},"NCT00619502","Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants",[90],[18,1666,21,36],[3332],{"trials":3954,"activeCount":100},[],{"trials":3956,"activeCount":100},[],{"intervention":3958,"totalTrials":1353,"cells":3959},"DTaP-IPV-HB-PRP~T",{"EARLY_PHASE1":3960,"PHASE1":3962,"PHASE2":3964,"PHASE3":3975,"PHASE4":3994,"NA":3996},{"trials":3961,"activeCount":100},[],{"trials":3963,"activeCount":100},[],{"trials":3965,"activeCount":100},[3966],{"nctId":3967,"briefTitle":3968,"status":123,"phases":3969,"primaryCompletion":3643,"completion":1706,"start":3970,"enrollment":3971,"conditions":3972,"interventions":3973},"NCT00831311","Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants",[89],"2004-10",624,[18,24,21,3821,30],[3958,3974],"DTaP-IPV\u002F\u002FPRP~T combined vaccine & Recombinant hep B vaccine",{"trials":3976,"activeCount":100},[3977,3986],{"nctId":3978,"briefTitle":3979,"status":123,"phases":3980,"primaryCompletion":2776,"completion":3490,"start":2569,"enrollment":3981,"conditions":3982,"interventions":3983},"NCT00362336","Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV",[90],622,[36,1666,18,21,3821],[3958,3984,3985],"CombAct-HIB®","Engerix B® Pediatric",{"nctId":3987,"briefTitle":3988,"status":123,"phases":3989,"primaryCompletion":3615,"completion":2568,"start":3328,"enrollment":3990,"conditions":3991,"interventions":3992},"NCT00313911","Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB\u002FHib™ and OPV Given at Age 2, 4, and 6 Months.",[90],2133,[18,24,21,3821,36],[3958,3993],"Tritanrix-HepB\u002FHib",{"trials":3995,"activeCount":100},[],{"trials":3997,"activeCount":100},[],{"intervention":3999,"totalTrials":96,"cells":4000},"Purified Vero Rabies Vaccine",{"EARLY_PHASE1":4001,"PHASE1":4003,"PHASE2":4005,"PHASE3":4015,"PHASE4":4025,"NA":4027},{"trials":4002,"activeCount":100},[],{"trials":4004,"activeCount":100},[],{"trials":4006,"activeCount":100},[4007],{"nctId":4008,"briefTitle":4009,"status":123,"phases":4010,"primaryCompletion":4011,"completion":1948,"start":1586,"enrollment":1454,"conditions":4012,"interventions":4013},"NCT01877395","Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen",[89],"2014-05",[1857],[3999,4014],"Imovax® Rabies: inactivated rabies vaccine",{"trials":4016,"activeCount":100},[4017],{"nctId":4018,"briefTitle":4019,"status":123,"phases":4020,"primaryCompletion":3186,"completion":1316,"start":1414,"enrollment":4021,"conditions":4022,"interventions":4023},"NCT01339312","Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine",[90],816,[1857,3764],[4024,4024,3999,3999],"Purified inactivated rabies vaccine, serum free",{"trials":4026,"activeCount":100},[],{"trials":4028,"activeCount":100},[],{"intervention":485,"totalTrials":96,"cells":4030},{"EARLY_PHASE1":4031,"PHASE1":4033,"PHASE2":4035,"PHASE3":4037,"PHASE4":4055,"NA":4057},{"trials":4032,"activeCount":100},[],{"trials":4034,"activeCount":100},[],{"trials":4036,"activeCount":100},[],{"trials":4038,"activeCount":100},[4039,4043],{"nctId":471,"briefTitle":472,"status":123,"phases":4040,"primaryCompletion":474,"completion":474,"start":475,"enrollment":476,"conditions":4041,"interventions":4042},[90],[478],[427,480,481,447,482,483,484,485,486],{"nctId":4044,"briefTitle":4045,"status":123,"phases":4046,"primaryCompletion":4047,"completion":4048,"start":4049,"enrollment":4050,"conditions":4051,"interventions":4052},"NCT01190228","Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV",[90],"2010-10-29","2015-10-12","2010-08-25",454,[3063,512],[4053,4054],"JE-CV Vaccine","Varicella Vaccine",{"trials":4056,"activeCount":100},[],{"trials":4058,"activeCount":100},[],{"intervention":4060,"totalTrials":96,"cells":4061},"Live, attenuated, dengue serotype 1, 2, 3, 4 virus",{"EARLY_PHASE1":4062,"PHASE1":4064,"PHASE2":4066,"PHASE3":4068,"PHASE4":4089,"NA":4091},{"trials":4063,"activeCount":100},[],{"trials":4065,"activeCount":100},[],{"trials":4067,"activeCount":100},[],{"trials":4069,"activeCount":100},[4070,4080],{"nctId":4071,"briefTitle":4072,"status":123,"phases":4073,"primaryCompletion":4074,"completion":4075,"start":4076,"enrollment":4077,"conditions":4078,"interventions":4079},"NCT01373281","Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia",[90],"2014-08-01","2017-11-21","2011-06-03",10275,[372,3176,373],[4060],{"nctId":4081,"briefTitle":4082,"status":123,"phases":4083,"primaryCompletion":1341,"completion":4084,"start":4085,"enrollment":4086,"conditions":4087,"interventions":4088},"NCT01374516","Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America",[90],"2018-03-05","2011-06-08",20869,[3176,373,372],[4060],{"trials":4090,"activeCount":100},[],{"trials":4092,"activeCount":100},[],{"intervention":597,"totalTrials":96,"cells":4094},{"EARLY_PHASE1":4095,"PHASE1":4097,"PHASE2":4099,"PHASE3":4101,"PHASE4":4111,"NA":4113},{"trials":4096,"activeCount":100},[],{"trials":4098,"activeCount":100},[],{"trials":4100,"activeCount":100},[],{"trials":4102,"activeCount":100},[4103,4107],{"nctId":589,"briefTitle":590,"status":123,"phases":4104,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":4105,"interventions":4106},[90],[478],[597,598,599,538,561,562,600,601],{"nctId":1514,"briefTitle":1515,"status":123,"phases":4108,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":4109,"interventions":4110},[90],[170,33],[1522,497,1523,1503],{"trials":4112,"activeCount":100},[],{"trials":4114,"activeCount":100},[],{"intervention":598,"totalTrials":96,"cells":4116},{"EARLY_PHASE1":4117,"PHASE1":4119,"PHASE2":4121,"PHASE3":4123,"PHASE4":4133,"NA":4135},{"trials":4118,"activeCount":100},[],{"trials":4120,"activeCount":100},[],{"trials":4122,"activeCount":100},[],{"trials":4124,"activeCount":100},[4125,4129],{"nctId":589,"briefTitle":590,"status":123,"phases":4126,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":4127,"interventions":4128},[90],[478],[597,598,599,538,561,562,600,601],{"nctId":1582,"briefTitle":1583,"status":123,"phases":4130,"primaryCompletion":1585,"completion":1586,"start":1343,"enrollment":1416,"conditions":4131,"interventions":4132},[90],[27,1588],[598,1571],{"trials":4134,"activeCount":100},[],{"trials":4136,"activeCount":100},[],{"intervention":601,"totalTrials":96,"cells":4138},{"EARLY_PHASE1":4139,"PHASE1":4141,"PHASE2":4143,"PHASE3":4145,"PHASE4":4155,"NA":4157},{"trials":4140,"activeCount":100},[],{"trials":4142,"activeCount":100},[],{"trials":4144,"activeCount":100},[],{"trials":4146,"activeCount":100},[4147,4151],{"nctId":589,"briefTitle":590,"status":123,"phases":4148,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":4149,"interventions":4150},[90],[478],[597,598,599,538,561,562,600,601],{"nctId":644,"briefTitle":645,"status":646,"phases":4152,"primaryCompletion":648,"completion":648,"start":649,"enrollment":650,"conditions":4153,"interventions":4154},[90],[652],[654,655,656,483,657,446,381,658],{"trials":4156,"activeCount":100},[],{"trials":4158,"activeCount":100},[],{"intervention":3544,"totalTrials":96,"cells":4160},{"EARLY_PHASE1":4161,"PHASE1":4163,"PHASE2":4165,"PHASE3":4171,"PHASE4":4177,"NA":4179},{"trials":4162,"activeCount":100},[],{"trials":4164,"activeCount":100},[],{"trials":4166,"activeCount":100},[4167],{"nctId":3524,"briefTitle":3525,"status":123,"phases":4168,"primaryCompletion":2224,"completion":3085,"start":3527,"enrollment":3528,"conditions":4169,"interventions":4170},[89],[1857],[3531,3515],{"trials":4172,"activeCount":100},[4173],{"nctId":3535,"briefTitle":3536,"status":123,"phases":4174,"primaryCompletion":3538,"completion":3538,"start":3539,"enrollment":3540,"conditions":4175,"interventions":4176},[90],[3542],[3544,3515,3545],{"trials":4178,"activeCount":100},[],{"trials":4180,"activeCount":100},[],{"intervention":3803,"totalTrials":96,"cells":4182},{"EARLY_PHASE1":4183,"PHASE1":4185,"PHASE2":4187,"PHASE3":4189,"PHASE4":4199,"NA":4201},{"trials":4184,"activeCount":100},[],{"trials":4186,"activeCount":100},[],{"trials":4188,"activeCount":100},[],{"trials":4190,"activeCount":100},[4191,4195],{"nctId":3796,"briefTitle":3797,"status":123,"phases":4192,"primaryCompletion":3614,"completion":3363,"start":1191,"enrollment":3799,"conditions":4193,"interventions":4194},[90],[18,24,21,36,15],[3802,3803,3785],{"nctId":3816,"briefTitle":3817,"status":123,"phases":4196,"primaryCompletion":1237,"completion":1288,"start":1191,"enrollment":3819,"conditions":4197,"interventions":4198},[90],[18,24,21,36,3821],[3803,3823,3785],{"trials":4200,"activeCount":100},[],{"trials":4202,"activeCount":100},[],{"intervention":4204,"totalTrials":96,"cells":4205},"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®",{"EARLY_PHASE1":4206,"PHASE1":4208,"PHASE2":4210,"PHASE3":4219,"PHASE4":4230,"NA":4232},{"trials":4207,"activeCount":100},[],{"trials":4209,"activeCount":100},[],{"trials":4211,"activeCount":100},[4212],{"nctId":4213,"briefTitle":4214,"status":123,"phases":4215,"primaryCompletion":1597,"completion":1317,"start":1430,"enrollment":4216,"conditions":4217,"interventions":4218},"NCT01442675","Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine",[89],834,[27,162],[4204],{"trials":4220,"activeCount":100},[4221],{"nctId":4222,"briefTitle":4223,"status":123,"phases":4224,"primaryCompletion":1343,"completion":2123,"start":4225,"enrollment":4226,"conditions":4227,"interventions":4228},"NCT01359449","Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations",[90],"2011-05",123,[27,162],[4204,4229],"Meningococcal Group C Conjugate vaccine: MenC",{"trials":4231,"activeCount":100},[],{"trials":4233,"activeCount":100},[],{"intervention":3267,"totalTrials":96,"cells":4235},{"EARLY_PHASE1":4236,"PHASE1":4238,"PHASE2":4240,"PHASE3":4242,"PHASE4":4257,"NA":4259},{"trials":4237,"activeCount":100},[],{"trials":4239,"activeCount":100},[],{"trials":4241,"activeCount":100},[],{"trials":4243,"activeCount":100},[4244,4248],{"nctId":3261,"briefTitle":3262,"status":646,"phases":4245,"primaryCompletion":2823,"completion":2823,"start":1107,"enrollment":3264,"conditions":4246,"interventions":4247},[90],[3176,373],[3159,3267,3268],{"nctId":4249,"briefTitle":4250,"status":123,"phases":4251,"primaryCompletion":1948,"completion":4252,"start":1497,"enrollment":4253,"conditions":4254,"interventions":4255},"NCT02089347","Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old",[90],"2015-03",534,[24,18,21],[3268,4256],"Diphtheria and Tetanus toxoids adsorbed",{"trials":4258,"activeCount":100},[],{"trials":4260,"activeCount":100},[],{"intervention":497,"totalTrials":96,"cells":4262},{"EARLY_PHASE1":4263,"PHASE1":4265,"PHASE2":4267,"PHASE3":4269,"PHASE4":4279,"NA":4281},{"trials":4264,"activeCount":100},[],{"trials":4266,"activeCount":100},[],{"trials":4268,"activeCount":100},[],{"trials":4270,"activeCount":100},[4271,4275],{"nctId":488,"briefTitle":489,"status":123,"phases":4272,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":4273,"interventions":4274},[90],[468],[427,497,498,499,499,500],{"nctId":1514,"briefTitle":1515,"status":123,"phases":4276,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":4277,"interventions":4278},[90],[170,33],[1522,497,1523,1503],{"trials":4280,"activeCount":100},[],{"trials":4282,"activeCount":100},[],{"intervention":499,"totalTrials":96,"cells":4284},{"EARLY_PHASE1":4285,"PHASE1":4287,"PHASE2":4289,"PHASE3":4291,"PHASE4":4301,"NA":4303},{"trials":4286,"activeCount":100},[],{"trials":4288,"activeCount":100},[],{"trials":4290,"activeCount":100},[],{"trials":4292,"activeCount":100},[4293,4297],{"nctId":488,"briefTitle":489,"status":123,"phases":4294,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":4295,"interventions":4296},[90],[468],[427,497,498,499,499,500],{"nctId":3847,"briefTitle":3848,"status":123,"phases":4298,"primaryCompletion":3850,"completion":3851,"start":3852,"enrollment":3506,"conditions":4299,"interventions":4300},[90],[372,373],[3855,3856,381,499,3855,3856,381,499],{"trials":4302,"activeCount":100},[],{"trials":4304,"activeCount":100},[],{"intervention":721,"totalTrials":96,"cells":4306},{"EARLY_PHASE1":4307,"PHASE1":4309,"PHASE2":4311,"PHASE3":4313,"PHASE4":4331,"NA":4333},{"trials":4308,"activeCount":100},[],{"trials":4310,"activeCount":100},[],{"trials":4312,"activeCount":100},[],{"trials":4314,"activeCount":100},[4315,4319],{"nctId":713,"briefTitle":714,"status":123,"phases":4316,"primaryCompletion":716,"completion":716,"start":717,"enrollment":718,"conditions":4317,"interventions":4318},[90],[478],[721,443,722,723,724],{"nctId":4320,"briefTitle":4321,"status":123,"phases":4322,"primaryCompletion":4323,"completion":4323,"start":4324,"enrollment":4325,"conditions":4326,"interventions":4327},"NCT04143061","Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa",[90],"2023-01-28","2019-12-30",1328,[441,33],[4328,4329,4330],"Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine","Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine","Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine",{"trials":4332,"activeCount":100},[],{"trials":4334,"activeCount":100},[],{"intervention":616,"totalTrials":96,"cells":4336},{"EARLY_PHASE1":4337,"PHASE1":4339,"PHASE2":4341,"PHASE3":4347,"PHASE4":4353,"NA":4355},{"trials":4338,"activeCount":100},[],{"trials":4340,"activeCount":100},[],{"trials":4342,"activeCount":100},[4343],{"nctId":1366,"briefTitle":1367,"status":123,"phases":4344,"primaryCompletion":1369,"completion":1369,"start":1370,"enrollment":1371,"conditions":4345,"interventions":4346},[89],[1373,1374,1375,1376,1377,1378,1379,1380,1381,1382,1383],[1385,1386,1387,559,584,1388,1349,616,1389],{"trials":4348,"activeCount":100},[4349],{"nctId":603,"briefTitle":604,"status":123,"phases":4350,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":4351,"interventions":4352},[90],[478],[611,583,612,613,614,615,538,616,562,584,559],{"trials":4354,"activeCount":100},[],{"trials":4356,"activeCount":100},[],{"intervention":735,"totalTrials":96,"cells":4358},{"EARLY_PHASE1":4359,"PHASE1":4361,"PHASE2":4367,"PHASE3":4369,"PHASE4":4375,"NA":4377},{"trials":4360,"activeCount":100},[],{"trials":4362,"activeCount":100},[4363],{"nctId":688,"briefTitle":689,"status":646,"phases":4364,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":4365,"interventions":4366},[88],[170,33],[696,697,698,699],{"trials":4368,"activeCount":100},[],{"trials":4370,"activeCount":100},[4371],{"nctId":726,"briefTitle":727,"status":123,"phases":4372,"primaryCompletion":729,"completion":729,"start":730,"enrollment":731,"conditions":4373,"interventions":4374},[90],[733],[735,736,443],{"trials":4376,"activeCount":100},[],{"trials":4378,"activeCount":100},[],{"intervention":4329,"totalTrials":96,"cells":4380},{"EARLY_PHASE1":4381,"PHASE1":4383,"PHASE2":4385,"PHASE3":4387,"PHASE4":4397,"NA":4399},{"trials":4382,"activeCount":100},[],{"trials":4384,"activeCount":100},[],{"trials":4386,"activeCount":100},[],{"trials":4388,"activeCount":100},[4389,4393],{"nctId":4320,"briefTitle":4321,"status":123,"phases":4390,"primaryCompletion":4323,"completion":4323,"start":4324,"enrollment":4325,"conditions":4391,"interventions":4392},[90],[441,33],[4328,4329,4330],{"nctId":603,"briefTitle":604,"status":123,"phases":4394,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":4395,"interventions":4396},[90],[478],[611,583,612,613,614,615,538,616,562,584,559],{"trials":4398,"activeCount":100},[],{"trials":4400,"activeCount":100},[],{"intervention":4402,"totalTrials":96,"cells":4403},"Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap",{"EARLY_PHASE1":4404,"PHASE1":4406,"PHASE2":4416,"PHASE3":4418,"PHASE4":4429,"NA":4431},{"trials":4405,"activeCount":100},[],{"trials":4407,"activeCount":100},[4408],{"nctId":4409,"briefTitle":4410,"status":123,"phases":4411,"primaryCompletion":1429,"completion":4412,"start":4413,"enrollment":3644,"conditions":4414,"interventions":4415},"NCT01933776","Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China",[88],"2014-01","2013-08",[18,24,21],[4402,4402],{"trials":4417,"activeCount":100},[],{"trials":4419,"activeCount":100},[4420],{"nctId":4421,"briefTitle":4422,"status":123,"phases":4423,"primaryCompletion":3242,"completion":1485,"start":1429,"enrollment":4424,"conditions":4425,"interventions":4426},"NCT01993173","Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.",[90],1440,[18,24,21],[4402,4427,4428],"DT vaccine","Td vaccine",{"trials":4430,"activeCount":100},[],{"trials":4432,"activeCount":100},[],{"intervention":4434,"totalTrials":96,"cells":4435},"PVRV",{"EARLY_PHASE1":4436,"PHASE1":4438,"PHASE2":4440,"PHASE3":4442,"PHASE4":4464,"NA":4466},{"trials":4437,"activeCount":100},[],{"trials":4439,"activeCount":100},[],{"trials":4441,"activeCount":100},[],{"trials":4443,"activeCount":100},[4444,4453],{"nctId":4445,"briefTitle":4446,"status":123,"phases":4447,"primaryCompletion":4448,"completion":4448,"start":4449,"enrollment":2801,"conditions":4450,"interventions":4451},"NCT01622062","Immunogenicity and Safety of Verorab® in a \"One-week\" Intradermal Post-exposure Prophylaxis Regimen",[90],"2018-11-14","2012-06-29",[1857],[4434,4452,4452],"PVRV and pERIG Favirab®",{"nctId":4454,"briefTitle":4455,"status":123,"phases":4456,"primaryCompletion":4457,"completion":4458,"start":4459,"enrollment":731,"conditions":4460,"interventions":4462},"NCT03700242","Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year",[90],"2019-01-19","2020-04-08","2018-09-26",[4461],"Healthy Volunteers (Rabies Immunization)",[4463,4463,4434,4434],"HDCV",{"trials":4465,"activeCount":100},[],{"trials":4467,"activeCount":100},[],{"intervention":1098,"totalTrials":96,"cells":4469},{"EARLY_PHASE1":4470,"PHASE1":4472,"PHASE2":4474,"PHASE3":4480,"PHASE4":4486,"NA":4488},{"trials":4471,"activeCount":100},[],{"trials":4473,"activeCount":100},[],{"trials":4475,"activeCount":100},[4476],{"nctId":1039,"briefTitle":1040,"status":123,"phases":4477,"primaryCompletion":1042,"completion":1042,"start":1043,"enrollment":1044,"conditions":4478,"interventions":4479},[89],[27,1046,468],[582,1048],{"trials":4481,"activeCount":100},[4482],{"nctId":1090,"briefTitle":1091,"status":123,"phases":4483,"primaryCompletion":1093,"completion":1093,"start":1094,"enrollment":1095,"conditions":4484,"interventions":4485},[90],[27,1046,468],[582,1098,582,1098],{"trials":4487,"activeCount":100},[],{"trials":4489,"activeCount":100},[],{"intervention":1120,"totalTrials":96,"cells":4491},{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4496,"PHASE3":4507,"PHASE4":4513,"NA":4515},{"trials":4493,"activeCount":100},[],{"trials":4495,"activeCount":100},[],{"trials":4497,"activeCount":100},[4498],{"nctId":4499,"briefTitle":4500,"status":123,"phases":4501,"primaryCompletion":4502,"completion":4502,"start":4503,"enrollment":4504,"conditions":4505,"interventions":4506},"NCT02640404","Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam",[89],"2016-12-05","2016-06-06",224,[27,1046,468],[1120,1120],{"trials":4508,"activeCount":100},[4509],{"nctId":1113,"briefTitle":1114,"status":123,"phases":4510,"primaryCompletion":1116,"completion":1116,"start":1084,"enrollment":1117,"conditions":4511,"interventions":4512},[90],[27,1046,468],[582,1120],{"trials":4514,"activeCount":100},[],{"trials":4516,"activeCount":100},[],{"intervention":4518,"totalTrials":96,"cells":4519},"Live attenuated Japanese encephalitis chimeric virus vaccine",{"EARLY_PHASE1":4520,"PHASE1":4522,"PHASE2":4524,"PHASE3":4526,"PHASE4":4546,"NA":4548},{"trials":4521,"activeCount":100},[],{"trials":4523,"activeCount":100},[],{"trials":4525,"activeCount":100},[],{"trials":4527,"activeCount":100},[4528,4538],{"nctId":4529,"briefTitle":4530,"status":123,"phases":4531,"primaryCompletion":1596,"completion":1586,"start":4532,"enrollment":4533,"conditions":4534,"interventions":4536},"NCT01396512","Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers",[90],"2011-07",274,[3063,4535],"Japanese Encephalitis Virus Disease",[4518,4537],"Japanese encephalitis live attenuated vaccine",{"nctId":4539,"briefTitle":4540,"status":123,"phases":4541,"primaryCompletion":1925,"completion":4542,"start":1564,"enrollment":4543,"conditions":4544,"interventions":4545},"NCT02492165","Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects",[90],"2016-06",250,[3063],[4518,4518,4518,4518],{"trials":4547,"activeCount":100},[],{"trials":4549,"activeCount":100},[],{"intervention":4551,"totalTrials":96,"cells":4552},"DT5aP-IPV-Hib 5-component Pertussis vaccine",{"EARLY_PHASE1":4553,"PHASE1":4555,"PHASE2":4557,"PHASE3":4559,"PHASE4":4579,"NA":4581},{"trials":4554,"activeCount":100},[],{"trials":4556,"activeCount":100},[],{"trials":4558,"activeCount":100},[],{"trials":4560,"activeCount":100},[4561,4571],{"nctId":4562,"briefTitle":4563,"status":123,"phases":4564,"primaryCompletion":1191,"completion":1228,"start":1327,"enrollment":4565,"conditions":4566,"interventions":4569},"NCT00355654","Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®",[90],847,[4567,4568],"Infant","Healthy",[4551,4570],"DT3aP-HBs-IPV",{"nctId":4572,"briefTitle":4573,"status":123,"phases":4574,"primaryCompletion":4575,"completion":1237,"start":1901,"enrollment":3900,"conditions":4576,"interventions":4577},"NCT00287092","Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants",[90],"2007-05",[21,18,24,30,3821],[4551,4578],"Infanrix® -IPV+Hib",{"trials":4580,"activeCount":100},[],{"trials":4582,"activeCount":100},[],{"intervention":611,"totalTrials":96,"cells":4584},{"EARLY_PHASE1":4585,"PHASE1":4587,"PHASE2":4589,"PHASE3":4591,"PHASE4":4607,"NA":4609},{"trials":4586,"activeCount":100},[],{"trials":4588,"activeCount":100},[],{"trials":4590,"activeCount":100},[],{"trials":4592,"activeCount":100},[4593,4597],{"nctId":603,"briefTitle":604,"status":123,"phases":4594,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":4595,"interventions":4596},[90],[478],[611,583,612,613,614,615,538,616,562,584,559],{"nctId":4598,"briefTitle":4599,"status":123,"phases":4600,"primaryCompletion":4601,"completion":4601,"start":4602,"enrollment":4603,"conditions":4604,"interventions":4605},"NCT03869866","Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon",[90],"2022-03-18","2019-04-09",290,[478],[4606],"Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine",{"trials":4608,"activeCount":100},[],{"trials":4610,"activeCount":100},[],{"intervention":3259,"totalTrials":139,"cells":4612},{"EARLY_PHASE1":4613,"PHASE1":4615,"PHASE2":4617,"PHASE3":4619,"PHASE4":4625,"NA":4627},{"trials":4614,"activeCount":100},[],{"trials":4616,"activeCount":100},[],{"trials":4618,"activeCount":100},[],{"trials":4620,"activeCount":100},[4621],{"nctId":3250,"briefTitle":3251,"status":123,"phases":4622,"primaryCompletion":3253,"completion":3253,"start":3254,"enrollment":3255,"conditions":4623,"interventions":4624},[90],[3176,373,3257],[3159,3159,3259],{"trials":4626,"activeCount":100},[],{"trials":4628,"activeCount":100},[],{"intervention":4630,"totalTrials":139,"cells":4631},"Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine",{"EARLY_PHASE1":4632,"PHASE1":4634,"PHASE2":4636,"PHASE3":4638,"PHASE4":4648,"NA":4650},{"trials":4633,"activeCount":100},[],{"trials":4635,"activeCount":100},[],{"trials":4637,"activeCount":100},[],{"trials":4639,"activeCount":100},[4640],{"nctId":4641,"briefTitle":4642,"status":123,"phases":4643,"primaryCompletion":2568,"completion":1287,"start":1265,"enrollment":4644,"conditions":4645,"interventions":4646},"NCT00444951","Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia",[90],450,[130,468],[4630,4647,4630],"Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine",{"trials":4649,"activeCount":100},[],{"trials":4651,"activeCount":100},[],{"intervention":4647,"totalTrials":139,"cells":4653},{"EARLY_PHASE1":4654,"PHASE1":4656,"PHASE2":4658,"PHASE3":4660,"PHASE4":4666,"NA":4668},{"trials":4655,"activeCount":100},[],{"trials":4657,"activeCount":100},[],{"trials":4659,"activeCount":100},[],{"trials":4661,"activeCount":100},[4662],{"nctId":4641,"briefTitle":4642,"status":123,"phases":4663,"primaryCompletion":2568,"completion":1287,"start":1265,"enrollment":4644,"conditions":4664,"interventions":4665},[90],[130,468],[4630,4647,4630],{"trials":4667,"activeCount":100},[],{"trials":4669,"activeCount":100},[],{"intervention":4671,"totalTrials":139,"cells":4672},"REPEVAX® after REVAXIS®",{"EARLY_PHASE1":4673,"PHASE1":4675,"PHASE2":4677,"PHASE3":4679,"PHASE4":4689,"NA":4691},{"trials":4674,"activeCount":100},[],{"trials":4676,"activeCount":100},[],{"trials":4678,"activeCount":100},[],{"trials":4680,"activeCount":100},[4681],{"nctId":4682,"briefTitle":4683,"status":123,"phases":4684,"primaryCompletion":1265,"completion":1265,"start":1169,"enrollment":1151,"conditions":4685,"interventions":4687},"NCT00400309","Safety of REPEVAX® Given One Month After REVAXIS®",[90],[4686],"Healthy Adult",[4671,4688],"REPEVAX® after Placebo",{"trials":4690,"activeCount":100},[],{"trials":4692,"activeCount":100},[],{"intervention":4688,"totalTrials":139,"cells":4694},{"EARLY_PHASE1":4695,"PHASE1":4697,"PHASE2":4699,"PHASE3":4701,"PHASE4":4707,"NA":4709},{"trials":4696,"activeCount":100},[],{"trials":4698,"activeCount":100},[],{"trials":4700,"activeCount":100},[],{"trials":4702,"activeCount":100},[4703],{"nctId":4682,"briefTitle":4683,"status":123,"phases":4704,"primaryCompletion":1265,"completion":1265,"start":1169,"enrollment":1151,"conditions":4705,"interventions":4706},[90],[4686],[4671,4688],{"trials":4708,"activeCount":100},[],{"trials":4710,"activeCount":100},[],{"intervention":4712,"totalTrials":139,"cells":4713},"SARS-CoV-2 adjuvanted recombinant protein vaccine",{"EARLY_PHASE1":4714,"PHASE1":4716,"PHASE2":4718,"PHASE3":4720,"PHASE4":4734,"NA":4736},{"trials":4715,"activeCount":100},[],{"trials":4717,"activeCount":100},[],{"trials":4719,"activeCount":100},[],{"trials":4721,"activeCount":100},[4722],{"nctId":4723,"briefTitle":4724,"status":123,"phases":4725,"primaryCompletion":4726,"completion":4726,"start":4727,"enrollment":4728,"conditions":4729,"interventions":4731},"NCT04904549","Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older",[90],"2024-08-31","2020-08-20",23726,[4730],"COVID-19",[4712,4712,4732,4733],"SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination","SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination",{"trials":4735,"activeCount":100},[],{"trials":4737,"activeCount":100},[],{"intervention":4732,"totalTrials":139,"cells":4739},{"EARLY_PHASE1":4740,"PHASE1":4742,"PHASE2":4744,"PHASE3":4746,"PHASE4":4752,"NA":4754},{"trials":4741,"activeCount":100},[],{"trials":4743,"activeCount":100},[],{"trials":4745,"activeCount":100},[],{"trials":4747,"activeCount":100},[4748],{"nctId":4723,"briefTitle":4724,"status":123,"phases":4749,"primaryCompletion":4726,"completion":4726,"start":4727,"enrollment":4728,"conditions":4750,"interventions":4751},[90],[4730],[4712,4712,4732,4733],{"trials":4753,"activeCount":100},[],{"trials":4755,"activeCount":100},[],{"intervention":4733,"totalTrials":139,"cells":4757},{"EARLY_PHASE1":4758,"PHASE1":4760,"PHASE2":4762,"PHASE3":4764,"PHASE4":4770,"NA":4772},{"trials":4759,"activeCount":100},[],{"trials":4761,"activeCount":100},[],{"trials":4763,"activeCount":100},[],{"trials":4765,"activeCount":100},[4766],{"nctId":4723,"briefTitle":4724,"status":123,"phases":4767,"primaryCompletion":4726,"completion":4726,"start":4727,"enrollment":4728,"conditions":4768,"interventions":4769},[90],[4730],[4712,4712,4732,4733],{"trials":4771,"activeCount":100},[],{"trials":4773,"activeCount":100},[],{"intervention":1061,"totalTrials":139,"cells":4775},{"EARLY_PHASE1":4776,"PHASE1":4778,"PHASE2":4780,"PHASE3":4782,"PHASE4":4788,"NA":4790},{"trials":4777,"activeCount":100},[],{"trials":4779,"activeCount":100},[],{"trials":4781,"activeCount":100},[],{"trials":4783,"activeCount":100},[4784],{"nctId":1052,"briefTitle":1053,"status":123,"phases":4785,"primaryCompletion":1055,"completion":1055,"start":1056,"enrollment":1057,"conditions":4786,"interventions":4787},[90],[733],[1060,1061,1062],{"trials":4789,"activeCount":100},[],{"trials":4791,"activeCount":100},[],{"intervention":1062,"totalTrials":139,"cells":4793},{"EARLY_PHASE1":4794,"PHASE1":4796,"PHASE2":4798,"PHASE3":4800,"PHASE4":4806,"NA":4808},{"trials":4795,"activeCount":100},[],{"trials":4797,"activeCount":100},[],{"trials":4799,"activeCount":100},[],{"trials":4801,"activeCount":100},[4802],{"nctId":1052,"briefTitle":1053,"status":123,"phases":4803,"primaryCompletion":1055,"completion":1055,"start":1056,"enrollment":1057,"conditions":4804,"interventions":4805},[90],[733],[1060,1061,1062],{"trials":4807,"activeCount":100},[],{"trials":4809,"activeCount":100},[],{"intervention":4811,"totalTrials":139,"cells":4812},"Low Dose (LD) RSVt vaccine",{"EARLY_PHASE1":4813,"PHASE1":4815,"PHASE2":4817,"PHASE3":4819,"PHASE4":4832,"NA":4834},{"trials":4814,"activeCount":100},[],{"trials":4816,"activeCount":100},[],{"trials":4818,"activeCount":100},[],{"trials":4820,"activeCount":100},[4821],{"nctId":4822,"briefTitle":4823,"status":646,"phases":4824,"primaryCompletion":4825,"completion":4825,"start":4826,"enrollment":4827,"conditions":4828,"interventions":4829},"NCT06705140","A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers",[90],"2025-06-11","2024-11-25",947,[3680],[4811,4830,4831],"Standard Dose (SD) RSVt vaccine","High Dose (HD) RSVt vaccine",{"trials":4833,"activeCount":100},[],{"trials":4835,"activeCount":100},[],{"intervention":4830,"totalTrials":139,"cells":4837},{"EARLY_PHASE1":4838,"PHASE1":4840,"PHASE2":4842,"PHASE3":4844,"PHASE4":4850,"NA":4852},{"trials":4839,"activeCount":100},[],{"trials":4841,"activeCount":100},[],{"trials":4843,"activeCount":100},[],{"trials":4845,"activeCount":100},[4846],{"nctId":4822,"briefTitle":4823,"status":646,"phases":4847,"primaryCompletion":4825,"completion":4825,"start":4826,"enrollment":4827,"conditions":4848,"interventions":4849},[90],[3680],[4811,4830,4831],{"trials":4851,"activeCount":100},[],{"trials":4853,"activeCount":100},[],{"intervention":4831,"totalTrials":139,"cells":4855},{"EARLY_PHASE1":4856,"PHASE1":4858,"PHASE2":4860,"PHASE3":4862,"PHASE4":4868,"NA":4870},{"trials":4857,"activeCount":100},[],{"trials":4859,"activeCount":100},[],{"trials":4861,"activeCount":100},[],{"trials":4863,"activeCount":100},[4864],{"nctId":4822,"briefTitle":4823,"status":646,"phases":4865,"primaryCompletion":4825,"completion":4825,"start":4826,"enrollment":4827,"conditions":4866,"interventions":4867},[90],[3680],[4811,4830,4831],{"trials":4869,"activeCount":100},[],{"trials":4871,"activeCount":100},[],{"intervention":4873,"totalTrials":139,"cells":4874},"REPEVAX",{"EARLY_PHASE1":4875,"PHASE1":4877,"PHASE2":4879,"PHASE3":4881,"PHASE4":4891,"NA":4893},{"trials":4876,"activeCount":100},[],{"trials":4878,"activeCount":100},[],{"trials":4880,"activeCount":100},[],{"trials":4882,"activeCount":100},[4883],{"nctId":4884,"briefTitle":4885,"status":123,"phases":4886,"primaryCompletion":1971,"completion":1971,"start":3527,"enrollment":4887,"conditions":4888,"interventions":4889},"NCT00928785","Study Comparing a Tdap-IPV Combined Vaccine With a Tetanus Monovalent Vaccine in Healthy Adults",[90],52,[4568],[4873,4890],"Monovalent Tetanus vaccine",{"trials":4892,"activeCount":100},[],{"trials":4894,"activeCount":100},[],{"intervention":4890,"totalTrials":139,"cells":4896},{"EARLY_PHASE1":4897,"PHASE1":4899,"PHASE2":4901,"PHASE3":4903,"PHASE4":4909,"NA":4911},{"trials":4898,"activeCount":100},[],{"trials":4900,"activeCount":100},[],{"trials":4902,"activeCount":100},[],{"trials":4904,"activeCount":100},[4905],{"nctId":4884,"briefTitle":4885,"status":123,"phases":4906,"primaryCompletion":1971,"completion":1971,"start":3527,"enrollment":4887,"conditions":4907,"interventions":4908},[90],[4568],[4873,4890],{"trials":4910,"activeCount":100},[],{"trials":4912,"activeCount":100},[],{"intervention":480,"totalTrials":139,"cells":4914},{"EARLY_PHASE1":4915,"PHASE1":4917,"PHASE2":4919,"PHASE3":4921,"PHASE4":4927,"NA":4929},{"trials":4916,"activeCount":100},[],{"trials":4918,"activeCount":100},[],{"trials":4920,"activeCount":100},[],{"trials":4922,"activeCount":100},[4923],{"nctId":471,"briefTitle":472,"status":123,"phases":4924,"primaryCompletion":474,"completion":474,"start":475,"enrollment":476,"conditions":4925,"interventions":4926},[90],[478],[427,480,481,447,482,483,484,485,486],{"trials":4928,"activeCount":100},[],{"trials":4930,"activeCount":100},[],{"intervention":481,"totalTrials":139,"cells":4932},{"EARLY_PHASE1":4933,"PHASE1":4935,"PHASE2":4937,"PHASE3":4939,"PHASE4":4945,"NA":4947},{"trials":4934,"activeCount":100},[],{"trials":4936,"activeCount":100},[],{"trials":4938,"activeCount":100},[],{"trials":4940,"activeCount":100},[4941],{"nctId":471,"briefTitle":472,"status":123,"phases":4942,"primaryCompletion":474,"completion":474,"start":475,"enrollment":476,"conditions":4943,"interventions":4944},[90],[478],[427,480,481,447,482,483,484,485,486],{"trials":4946,"activeCount":100},[],{"trials":4948,"activeCount":100},[],{"intervention":482,"totalTrials":139,"cells":4950},{"EARLY_PHASE1":4951,"PHASE1":4953,"PHASE2":4955,"PHASE3":4957,"PHASE4":4963,"NA":4965},{"trials":4952,"activeCount":100},[],{"trials":4954,"activeCount":100},[],{"trials":4956,"activeCount":100},[],{"trials":4958,"activeCount":100},[4959],{"nctId":471,"briefTitle":472,"status":123,"phases":4960,"primaryCompletion":474,"completion":474,"start":475,"enrollment":476,"conditions":4961,"interventions":4962},[90],[478],[427,480,481,447,482,483,484,485,486],{"trials":4964,"activeCount":100},[],{"trials":4966,"activeCount":100},[],{"intervention":484,"totalTrials":139,"cells":4968},{"EARLY_PHASE1":4969,"PHASE1":4971,"PHASE2":4973,"PHASE3":4975,"PHASE4":4981,"NA":4983},{"trials":4970,"activeCount":100},[],{"trials":4972,"activeCount":100},[],{"trials":4974,"activeCount":100},[],{"trials":4976,"activeCount":100},[4977],{"nctId":471,"briefTitle":472,"status":123,"phases":4978,"primaryCompletion":474,"completion":474,"start":475,"enrollment":476,"conditions":4979,"interventions":4980},[90],[478],[427,480,481,447,482,483,484,485,486],{"trials":4982,"activeCount":100},[],{"trials":4984,"activeCount":100},[],{"intervention":4986,"totalTrials":139,"cells":4987},"DTaP-IPV-Hep B-PRP~T vaccine",{"EARLY_PHASE1":4988,"PHASE1":4990,"PHASE2":4992,"PHASE3":4994,"PHASE4":5005,"NA":5007},{"trials":4989,"activeCount":100},[],{"trials":4991,"activeCount":100},[],{"trials":4993,"activeCount":100},[],{"trials":4995,"activeCount":100},[4996],{"nctId":4997,"briefTitle":4998,"status":123,"phases":4999,"primaryCompletion":3489,"completion":3527,"start":3479,"enrollment":5000,"conditions":5001,"interventions":5003},"NCT00654901","Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™",[90],881,[18,24,21,36,30,5002],"Haemophilus Influenzae Type B Infection",[4986,4986,4986,5004],"Infanrix Hexa™",{"trials":5006,"activeCount":100},[],{"trials":5008,"activeCount":100},[],{"intervention":5004,"totalTrials":139,"cells":5010},{"EARLY_PHASE1":5011,"PHASE1":5013,"PHASE2":5015,"PHASE3":5017,"PHASE4":5023,"NA":5025},{"trials":5012,"activeCount":100},[],{"trials":5014,"activeCount":100},[],{"trials":5016,"activeCount":100},[],{"trials":5018,"activeCount":100},[5019],{"nctId":4997,"briefTitle":4998,"status":123,"phases":5020,"primaryCompletion":3489,"completion":3527,"start":3479,"enrollment":5000,"conditions":5021,"interventions":5022},[90],[18,24,21,36,30,5002],[4986,4986,4986,5004],{"trials":5024,"activeCount":100},[],{"trials":5026,"activeCount":100},[],{"intervention":585,"totalTrials":139,"cells":5028},{"EARLY_PHASE1":5029,"PHASE1":5031,"PHASE2":5033,"PHASE3":5035,"PHASE4":5041,"NA":5043},{"trials":5030,"activeCount":100},[],{"trials":5032,"activeCount":100},[],{"trials":5034,"activeCount":100},[],{"trials":5036,"activeCount":100},[5037],{"nctId":574,"briefTitle":575,"status":123,"phases":5038,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":5039,"interventions":5040},[90],[478],[582,583,584,538,585,562,586,587],{"trials":5042,"activeCount":100},[],{"trials":5044,"activeCount":100},[],{"intervention":586,"totalTrials":139,"cells":5046},{"EARLY_PHASE1":5047,"PHASE1":5049,"PHASE2":5051,"PHASE3":5053,"PHASE4":5059,"NA":5061},{"trials":5048,"activeCount":100},[],{"trials":5050,"activeCount":100},[],{"trials":5052,"activeCount":100},[],{"trials":5054,"activeCount":100},[5055],{"nctId":574,"briefTitle":575,"status":123,"phases":5056,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":5057,"interventions":5058},[90],[478],[582,583,584,538,585,562,586,587],{"trials":5060,"activeCount":100},[],{"trials":5062,"activeCount":100},[],{"intervention":587,"totalTrials":139,"cells":5064},{"EARLY_PHASE1":5065,"PHASE1":5067,"PHASE2":5069,"PHASE3":5071,"PHASE4":5077,"NA":5079},{"trials":5066,"activeCount":100},[],{"trials":5068,"activeCount":100},[],{"trials":5070,"activeCount":100},[],{"trials":5072,"activeCount":100},[5073],{"nctId":574,"briefTitle":575,"status":123,"phases":5074,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":5075,"interventions":5076},[90],[478],[582,583,584,538,585,562,586,587],{"trials":5078,"activeCount":100},[],{"trials":5080,"activeCount":100},[],{"intervention":5082,"totalTrials":139,"cells":5083},"HBVAXPRO 5µg",{"EARLY_PHASE1":5084,"PHASE1":5086,"PHASE2":5088,"PHASE3":5090,"PHASE4":5099,"NA":5101},{"trials":5085,"activeCount":100},[],{"trials":5087,"activeCount":100},[],{"trials":5089,"activeCount":100},[],{"trials":5091,"activeCount":100},[5092],{"nctId":5093,"briefTitle":5094,"status":123,"phases":5095,"primaryCompletion":126,"completion":126,"start":4412,"enrollment":5096,"conditions":5097,"interventions":5098},"NCT02012998","Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA",[90],751,[132,36],[5082],{"trials":5100,"activeCount":100},[],{"trials":5102,"activeCount":100},[],{"intervention":4053,"totalTrials":139,"cells":5104},{"EARLY_PHASE1":5105,"PHASE1":5107,"PHASE2":5109,"PHASE3":5111,"PHASE4":5117,"NA":5119},{"trials":5106,"activeCount":100},[],{"trials":5108,"activeCount":100},[],{"trials":5110,"activeCount":100},[],{"trials":5112,"activeCount":100},[5113],{"nctId":4044,"briefTitle":4045,"status":123,"phases":5114,"primaryCompletion":4047,"completion":4048,"start":4049,"enrollment":4050,"conditions":5115,"interventions":5116},[90],[3063,512],[4053,4054],{"trials":5118,"activeCount":100},[],{"trials":5120,"activeCount":100},[],{"intervention":599,"totalTrials":139,"cells":5122},{"EARLY_PHASE1":5123,"PHASE1":5125,"PHASE2":5127,"PHASE3":5129,"PHASE4":5135,"NA":5137},{"trials":5124,"activeCount":100},[],{"trials":5126,"activeCount":100},[],{"trials":5128,"activeCount":100},[],{"trials":5130,"activeCount":100},[5131],{"nctId":589,"briefTitle":590,"status":123,"phases":5132,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":5133,"interventions":5134},[90],[478],[597,598,599,538,561,562,600,601],{"trials":5136,"activeCount":100},[],{"trials":5138,"activeCount":100},[],{"intervention":600,"totalTrials":139,"cells":5140},{"EARLY_PHASE1":5141,"PHASE1":5143,"PHASE2":5145,"PHASE3":5147,"PHASE4":5153,"NA":5155},{"trials":5142,"activeCount":100},[],{"trials":5144,"activeCount":100},[],{"trials":5146,"activeCount":100},[],{"trials":5148,"activeCount":100},[5149],{"nctId":589,"briefTitle":590,"status":123,"phases":5150,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":5151,"interventions":5152},[90],[478],[597,598,599,538,561,562,600,601],{"trials":5154,"activeCount":100},[],{"trials":5156,"activeCount":100},[],{"intervention":5158,"totalTrials":139,"cells":5159},"Inactivated Split-virion influenza vaccine",{"EARLY_PHASE1":5160,"PHASE1":5162,"PHASE2":5164,"PHASE3":5166,"PHASE4":5175,"NA":5177},{"trials":5161,"activeCount":100},[],{"trials":5163,"activeCount":100},[],{"trials":5165,"activeCount":100},[],{"trials":5167,"activeCount":100},[5168],{"nctId":5169,"briefTitle":5170,"status":123,"phases":5171,"primaryCompletion":3327,"completion":1266,"start":1327,"enrollment":5172,"conditions":5173,"interventions":5174},"NCT00383539","Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults",[90],2256,[3376,15,3367],[5158,5158,5158,5158],{"trials":5176,"activeCount":100},[],{"trials":5178,"activeCount":100},[],{"intervention":5180,"totalTrials":139,"cells":5181},"Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative",{"EARLY_PHASE1":5182,"PHASE1":5184,"PHASE2":5186,"PHASE3":5188,"PHASE4":5199,"NA":5201},{"trials":5183,"activeCount":100},[],{"trials":5185,"activeCount":100},[],{"trials":5187,"activeCount":100},[],{"trials":5189,"activeCount":100},[5190],{"nctId":5191,"briefTitle":5192,"status":123,"phases":5193,"primaryCompletion":1413,"completion":1414,"start":2225,"enrollment":5194,"conditions":5195,"interventions":5196},"NCT01218646","Study of Quadrivalent Influenza Vaccine Among Adults",[90],739,[15],[5180,5197,5198,5198],"Investigational Trivalent Inactivated Influenza Vaccine, No Preservative","Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative",{"trials":5200,"activeCount":100},[],{"trials":5202,"activeCount":100},[],{"intervention":5197,"totalTrials":139,"cells":5204},{"EARLY_PHASE1":5205,"PHASE1":5207,"PHASE2":5209,"PHASE3":5211,"PHASE4":5217,"NA":5219},{"trials":5206,"activeCount":100},[],{"trials":5208,"activeCount":100},[],{"trials":5210,"activeCount":100},[],{"trials":5212,"activeCount":100},[5213],{"nctId":5191,"briefTitle":5192,"status":123,"phases":5214,"primaryCompletion":1413,"completion":1414,"start":2225,"enrollment":5194,"conditions":5215,"interventions":5216},[90],[15],[5180,5197,5198,5198],{"trials":5218,"activeCount":100},[],{"trials":5220,"activeCount":100},[],{"intervention":5198,"totalTrials":139,"cells":5222},{"EARLY_PHASE1":5223,"PHASE1":5225,"PHASE2":5227,"PHASE3":5229,"PHASE4":5235,"NA":5237},{"trials":5224,"activeCount":100},[],{"trials":5226,"activeCount":100},[],{"trials":5228,"activeCount":100},[],{"trials":5230,"activeCount":100},[5231],{"nctId":5191,"briefTitle":5192,"status":123,"phases":5232,"primaryCompletion":1413,"completion":1414,"start":2225,"enrollment":5194,"conditions":5233,"interventions":5234},[90],[15],[5180,5197,5198,5198],{"trials":5236,"activeCount":100},[],{"trials":5238,"activeCount":100},[],{"intervention":5240,"totalTrials":139,"cells":5241},"A\u002FH1N1 pandemic influenza vaccine",{"EARLY_PHASE1":5242,"PHASE1":5244,"PHASE2":5246,"PHASE3":5248,"PHASE4":5262,"NA":5264},{"trials":5243,"activeCount":100},[],{"trials":5245,"activeCount":100},[],{"trials":5247,"activeCount":100},[],{"trials":5249,"activeCount":100},[5250],{"nctId":5251,"briefTitle":5252,"status":123,"phases":5253,"primaryCompletion":5254,"completion":5255,"start":5256,"enrollment":5257,"conditions":5258,"interventions":5261},"NCT01053143","Study of Swine-Origin A\u002FH1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India",[90],"2010-08","2010-09","2010-01",100,[15,5259,5260],"Pandemic Influenza","Influenza A Virus, H1N1 Subtype",[5240],{"trials":5263,"activeCount":100},[],{"trials":5265,"activeCount":100},[],{"intervention":5267,"totalTrials":139,"cells":5268},"Standard-Dose influenza virus surface antigens",{"EARLY_PHASE1":5269,"PHASE1":5271,"PHASE2":5273,"PHASE3":5275,"PHASE4":5288,"NA":5290},{"trials":5270,"activeCount":100},[],{"trials":5272,"activeCount":100},[],{"trials":5274,"activeCount":100},[],{"trials":5276,"activeCount":100},[5277],{"nctId":5278,"briefTitle":5279,"status":123,"phases":5280,"primaryCompletion":5281,"completion":5282,"start":5283,"enrollment":5284,"conditions":5285,"interventions":5286},"NCT04024228","Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older",[90],"2020-01-09","2020-06-05","2019-10-28",1539,[759,33],[5267,5287],"High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation",{"trials":5289,"activeCount":100},[],{"trials":5291,"activeCount":100},[],{"intervention":5287,"totalTrials":139,"cells":5293},{"EARLY_PHASE1":5294,"PHASE1":5296,"PHASE2":5298,"PHASE3":5300,"PHASE4":5306,"NA":5308},{"trials":5295,"activeCount":100},[],{"trials":5297,"activeCount":100},[],{"trials":5299,"activeCount":100},[],{"trials":5301,"activeCount":100},[5302],{"nctId":5278,"briefTitle":5279,"status":123,"phases":5303,"primaryCompletion":5281,"completion":5282,"start":5283,"enrollment":5284,"conditions":5304,"interventions":5305},[90],[759,33],[5267,5287],{"trials":5307,"activeCount":100},[],{"trials":5309,"activeCount":100},[],{"intervention":3802,"totalTrials":139,"cells":5311},{"EARLY_PHASE1":5312,"PHASE1":5314,"PHASE2":5316,"PHASE3":5318,"PHASE4":5324,"NA":5326},{"trials":5313,"activeCount":100},[],{"trials":5315,"activeCount":100},[],{"trials":5317,"activeCount":100},[],{"trials":5319,"activeCount":100},[5320],{"nctId":3796,"briefTitle":3797,"status":123,"phases":5321,"primaryCompletion":3614,"completion":3363,"start":1191,"enrollment":3799,"conditions":5322,"interventions":5323},[90],[18,24,21,36,15],[3802,3803,3785],{"trials":5325,"activeCount":100},[],{"trials":5327,"activeCount":100},[],{"intervention":5329,"totalTrials":139,"cells":5330},"DAPTACEL®: DTaP",{"EARLY_PHASE1":5331,"PHASE1":5333,"PHASE2":5335,"PHASE3":5337,"PHASE4":5348,"NA":5350},{"trials":5332,"activeCount":100},[],{"trials":5334,"activeCount":100},[],{"trials":5336,"activeCount":100},[],{"trials":5338,"activeCount":100},[5339],{"nctId":5340,"briefTitle":5341,"status":123,"phases":5342,"primaryCompletion":1170,"completion":5343,"start":5344,"enrollment":5345,"conditions":5346,"interventions":5347},"NCT00258895","Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®",[90],"2007-04","2005-03",649,[18,24,21],[5329,5329],{"trials":5349,"activeCount":100},[],{"trials":5351,"activeCount":100},[],{"intervention":5353,"totalTrials":139,"cells":5354},"HBVaxPRO® 5 µg \u002F 0.5 mL",{"EARLY_PHASE1":5355,"PHASE1":5357,"PHASE2":5359,"PHASE3":5361,"PHASE4":5372,"NA":5374},{"trials":5356,"activeCount":100},[],{"trials":5358,"activeCount":100},[],{"trials":5360,"activeCount":100},[],{"trials":5362,"activeCount":100},[5363],{"nctId":5364,"briefTitle":5365,"status":123,"phases":5366,"primaryCompletion":1971,"completion":5367,"start":1853,"enrollment":5368,"conditions":5369,"interventions":5370},"NCT00693186","A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA",[90],"2010-03",410,[36],[5353,5371],"Engerix B® 10 µg \u002F 0.5 mL",{"trials":5373,"activeCount":100},[],{"trials":5375,"activeCount":100},[],{"intervention":5371,"totalTrials":139,"cells":5377},{"EARLY_PHASE1":5378,"PHASE1":5380,"PHASE2":5382,"PHASE3":5384,"PHASE4":5390,"NA":5392},{"trials":5379,"activeCount":100},[],{"trials":5381,"activeCount":100},[],{"trials":5383,"activeCount":100},[],{"trials":5385,"activeCount":100},[5386],{"nctId":5364,"briefTitle":5365,"status":123,"phases":5387,"primaryCompletion":1971,"completion":5367,"start":1853,"enrollment":5368,"conditions":5388,"interventions":5389},[90],[36],[5353,5371],{"trials":5391,"activeCount":100},[],{"trials":5393,"activeCount":100},[],{"intervention":5395,"totalTrials":139,"cells":5396},"Measles-mumps-rubella-varicella vaccine",{"EARLY_PHASE1":5397,"PHASE1":5399,"PHASE2":5401,"PHASE3":5403,"PHASE4":5415,"NA":5417},{"trials":5398,"activeCount":100},[],{"trials":5400,"activeCount":100},[],{"trials":5402,"activeCount":100},[],{"trials":5404,"activeCount":100},[5405],{"nctId":5406,"briefTitle":5407,"status":123,"phases":5408,"primaryCompletion":2351,"completion":3363,"start":4575,"enrollment":5409,"conditions":5410,"interventions":5411},"NCT00483574","Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers",[90],1378,[1046,1330,1331,1332,512],[5412,5395,5413,5414],"Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate","Routine paediatric vaccine - Pneumococcal conjugate","Routine paediatric vaccine - Hepatitis A",{"trials":5416,"activeCount":100},[],{"trials":5418,"activeCount":100},[],{"intervention":5413,"totalTrials":139,"cells":5420},{"EARLY_PHASE1":5421,"PHASE1":5423,"PHASE2":5425,"PHASE3":5427,"PHASE4":5433,"NA":5435},{"trials":5422,"activeCount":100},[],{"trials":5424,"activeCount":100},[],{"trials":5426,"activeCount":100},[],{"trials":5428,"activeCount":100},[5429],{"nctId":5406,"briefTitle":5407,"status":123,"phases":5430,"primaryCompletion":2351,"completion":3363,"start":4575,"enrollment":5409,"conditions":5431,"interventions":5432},[90],[1046,1330,1331,1332,512],[5412,5395,5413,5414],{"trials":5434,"activeCount":100},[],{"trials":5436,"activeCount":100},[],{"intervention":5414,"totalTrials":139,"cells":5438},{"EARLY_PHASE1":5439,"PHASE1":5441,"PHASE2":5443,"PHASE3":5445,"PHASE4":5451,"NA":5453},{"trials":5440,"activeCount":100},[],{"trials":5442,"activeCount":100},[],{"trials":5444,"activeCount":100},[],{"trials":5446,"activeCount":100},[5447],{"nctId":5406,"briefTitle":5407,"status":123,"phases":5448,"primaryCompletion":2351,"completion":3363,"start":4575,"enrollment":5409,"conditions":5449,"interventions":5450},[90],[1046,1330,1331,1332,512],[5412,5395,5413,5414],{"trials":5452,"activeCount":100},[],{"trials":5454,"activeCount":100},[],{"intervention":4229,"totalTrials":139,"cells":5456},{"EARLY_PHASE1":5457,"PHASE1":5459,"PHASE2":5461,"PHASE3":5463,"PHASE4":5469,"NA":5471},{"trials":5458,"activeCount":100},[],{"trials":5460,"activeCount":100},[],{"trials":5462,"activeCount":100},[],{"trials":5464,"activeCount":100},[5465],{"nctId":4222,"briefTitle":4223,"status":123,"phases":5466,"primaryCompletion":1343,"completion":2123,"start":4225,"enrollment":4226,"conditions":5467,"interventions":5468},[90],[27,162],[4204,4229],{"trials":5470,"activeCount":100},[],{"trials":5472,"activeCount":100},[],{"intervention":1088,"totalTrials":139,"cells":5474},{"EARLY_PHASE1":5475,"PHASE1":5477,"PHASE2":5479,"PHASE3":5481,"PHASE4":5487,"NA":5489},{"trials":5476,"activeCount":100},[],{"trials":5478,"activeCount":100},[],{"trials":5480,"activeCount":100},[],{"trials":5482,"activeCount":100},[5483],{"nctId":1080,"briefTitle":1081,"status":123,"phases":5484,"primaryCompletion":1083,"completion":1083,"start":1084,"enrollment":1085,"conditions":5485,"interventions":5486},[90],[27,1046,468],[582,1088],{"trials":5488,"activeCount":100},[],{"trials":5490,"activeCount":100},[],{"intervention":3462,"totalTrials":139,"cells":5492},{"EARLY_PHASE1":5493,"PHASE1":5495,"PHASE2":5497,"PHASE3":5499,"PHASE4":5505,"NA":5507},{"trials":5494,"activeCount":100},[],{"trials":5496,"activeCount":100},[],{"trials":5498,"activeCount":100},[],{"trials":5500,"activeCount":100},[5501],{"nctId":3453,"briefTitle":3454,"status":123,"phases":5502,"primaryCompletion":3456,"completion":3456,"start":3457,"enrollment":3458,"conditions":5503,"interventions":5504},[90],[3460],[762,3462],{"trials":5506,"activeCount":100},[],{"trials":5508,"activeCount":100},[],{"intervention":5510,"totalTrials":139,"cells":5511},"DTaP IPV HB PRP~T vaccine",{"EARLY_PHASE1":5512,"PHASE1":5514,"PHASE2":5516,"PHASE3":5518,"PHASE4":5529,"NA":5531},{"trials":5513,"activeCount":100},[],{"trials":5515,"activeCount":100},[],{"trials":5517,"activeCount":100},[],{"trials":5519,"activeCount":100},[5520],{"nctId":5521,"briefTitle":5522,"status":123,"phases":5523,"primaryCompletion":3489,"completion":5524,"start":2776,"enrollment":5525,"conditions":5526,"interventions":5527},"NCT00831753","Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants",[90],"2009-11",263,[18,24,21,3821,36],[5510,5528],"DTaP-HB-IPV and Haemophilus influenzae type b",{"trials":5530,"activeCount":100},[],{"trials":5532,"activeCount":100},[],{"intervention":5528,"totalTrials":139,"cells":5534},{"EARLY_PHASE1":5535,"PHASE1":5537,"PHASE2":5539,"PHASE3":5541,"PHASE4":5547,"NA":5549},{"trials":5536,"activeCount":100},[],{"trials":5538,"activeCount":100},[],{"trials":5540,"activeCount":100},[],{"trials":5542,"activeCount":100},[5543],{"nctId":5521,"briefTitle":5522,"status":123,"phases":5544,"primaryCompletion":3489,"completion":5524,"start":2776,"enrollment":5525,"conditions":5545,"interventions":5546},[90],[18,24,21,3821,36],[5510,5528],{"trials":5548,"activeCount":100},[],{"trials":5550,"activeCount":100},[],{"intervention":134,"totalTrials":139,"cells":5552},{"EARLY_PHASE1":5553,"PHASE1":5555,"PHASE2":5557,"PHASE3":5559,"PHASE4":5565,"NA":5567},{"trials":5554,"activeCount":100},[],{"trials":5556,"activeCount":100},[],{"trials":5558,"activeCount":100},[],{"trials":5560,"activeCount":100},[5561],{"nctId":121,"briefTitle":122,"status":123,"phases":5562,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":5563,"interventions":5564},[90],[130,131,132],[134,135,136,95,137,138],{"trials":5566,"activeCount":100},[],{"trials":5568,"activeCount":100},[],{"intervention":135,"totalTrials":139,"cells":5570},{"EARLY_PHASE1":5571,"PHASE1":5573,"PHASE2":5575,"PHASE3":5577,"PHASE4":5583,"NA":5585},{"trials":5572,"activeCount":100},[],{"trials":5574,"activeCount":100},[],{"trials":5576,"activeCount":100},[],{"trials":5578,"activeCount":100},[5579],{"nctId":121,"briefTitle":122,"status":123,"phases":5580,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":5581,"interventions":5582},[90],[130,131,132],[134,135,136,95,137,138],{"trials":5584,"activeCount":100},[],{"trials":5586,"activeCount":100},[],{"intervention":136,"totalTrials":139,"cells":5588},{"EARLY_PHASE1":5589,"PHASE1":5591,"PHASE2":5593,"PHASE3":5595,"PHASE4":5601,"NA":5603},{"trials":5590,"activeCount":100},[],{"trials":5592,"activeCount":100},[],{"trials":5594,"activeCount":100},[],{"trials":5596,"activeCount":100},[5597],{"nctId":121,"briefTitle":122,"status":123,"phases":5598,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":5599,"interventions":5600},[90],[130,131,132],[134,135,136,95,137,138],{"trials":5602,"activeCount":100},[],{"trials":5604,"activeCount":100},[],{"intervention":137,"totalTrials":139,"cells":5606},{"EARLY_PHASE1":5607,"PHASE1":5609,"PHASE2":5611,"PHASE3":5613,"PHASE4":5619,"NA":5621},{"trials":5608,"activeCount":100},[],{"trials":5610,"activeCount":100},[],{"trials":5612,"activeCount":100},[],{"trials":5614,"activeCount":100},[5615],{"nctId":121,"briefTitle":122,"status":123,"phases":5616,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":5617,"interventions":5618},[90],[130,131,132],[134,135,136,95,137,138],{"trials":5620,"activeCount":100},[],{"trials":5622,"activeCount":100},[],{"intervention":138,"totalTrials":139,"cells":5624},{"EARLY_PHASE1":5625,"PHASE1":5627,"PHASE2":5629,"PHASE3":5631,"PHASE4":5637,"NA":5639},{"trials":5626,"activeCount":100},[],{"trials":5628,"activeCount":100},[],{"trials":5630,"activeCount":100},[],{"trials":5632,"activeCount":100},[5633],{"nctId":121,"briefTitle":122,"status":123,"phases":5634,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":5635,"interventions":5636},[90],[130,131,132],[134,135,136,95,137,138],{"trials":5638,"activeCount":100},[],{"trials":5640,"activeCount":100},[],{"intervention":498,"totalTrials":139,"cells":5642},{"EARLY_PHASE1":5643,"PHASE1":5645,"PHASE2":5647,"PHASE3":5649,"PHASE4":5655,"NA":5657},{"trials":5644,"activeCount":100},[],{"trials":5646,"activeCount":100},[],{"trials":5648,"activeCount":100},[],{"trials":5650,"activeCount":100},[5651],{"nctId":488,"briefTitle":489,"status":123,"phases":5652,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":5653,"interventions":5654},[90],[468],[427,497,498,499,499,500],{"trials":5656,"activeCount":100},[],{"trials":5658,"activeCount":100},[],{"intervention":500,"totalTrials":139,"cells":5660},{"EARLY_PHASE1":5661,"PHASE1":5663,"PHASE2":5665,"PHASE3":5667,"PHASE4":5673,"NA":5675},{"trials":5662,"activeCount":100},[],{"trials":5664,"activeCount":100},[],{"trials":5666,"activeCount":100},[],{"trials":5668,"activeCount":100},[5669],{"nctId":488,"briefTitle":489,"status":123,"phases":5670,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":5671,"interventions":5672},[90],[468],[427,497,498,499,499,500],{"trials":5674,"activeCount":100},[],{"trials":5676,"activeCount":100},[],{"intervention":722,"totalTrials":139,"cells":5678},{"EARLY_PHASE1":5679,"PHASE1":5681,"PHASE2":5683,"PHASE3":5685,"PHASE4":5691,"NA":5693},{"trials":5680,"activeCount":100},[],{"trials":5682,"activeCount":100},[],{"trials":5684,"activeCount":100},[],{"trials":5686,"activeCount":100},[5687],{"nctId":713,"briefTitle":714,"status":123,"phases":5688,"primaryCompletion":716,"completion":716,"start":717,"enrollment":718,"conditions":5689,"interventions":5690},[90],[478],[721,443,722,723,724],{"trials":5692,"activeCount":100},[],{"trials":5694,"activeCount":100},[],{"intervention":723,"totalTrials":139,"cells":5696},{"EARLY_PHASE1":5697,"PHASE1":5699,"PHASE2":5701,"PHASE3":5703,"PHASE4":5709,"NA":5711},{"trials":5698,"activeCount":100},[],{"trials":5700,"activeCount":100},[],{"trials":5702,"activeCount":100},[],{"trials":5704,"activeCount":100},[5705],{"nctId":713,"briefTitle":714,"status":123,"phases":5706,"primaryCompletion":716,"completion":716,"start":717,"enrollment":718,"conditions":5707,"interventions":5708},[90],[478],[721,443,722,723,724],{"trials":5710,"activeCount":100},[],{"trials":5712,"activeCount":100},[],{"intervention":724,"totalTrials":139,"cells":5714},{"EARLY_PHASE1":5715,"PHASE1":5717,"PHASE2":5719,"PHASE3":5721,"PHASE4":5727,"NA":5729},{"trials":5716,"activeCount":100},[],{"trials":5718,"activeCount":100},[],{"trials":5720,"activeCount":100},[],{"trials":5722,"activeCount":100},[5723],{"nctId":713,"briefTitle":714,"status":123,"phases":5724,"primaryCompletion":716,"completion":716,"start":717,"enrollment":718,"conditions":5725,"interventions":5726},[90],[478],[721,443,722,723,724],{"trials":5728,"activeCount":100},[],{"trials":5730,"activeCount":100},[],{"intervention":3633,"totalTrials":139,"cells":5732},{"EARLY_PHASE1":5733,"PHASE1":5735,"PHASE2":5737,"PHASE3":5739,"PHASE4":5745,"NA":5747},{"trials":5734,"activeCount":100},[],{"trials":5736,"activeCount":100},[],{"trials":5738,"activeCount":100},[],{"trials":5740,"activeCount":100},[5741],{"nctId":3622,"briefTitle":3623,"status":123,"phases":5742,"primaryCompletion":3625,"completion":3626,"start":3627,"enrollment":3628,"conditions":5743,"interventions":5744},[90],[1376,1374,1379,1377,3630,1375,3631,1373],[3633,3634,3635,3636,3637,3638],{"trials":5746,"activeCount":100},[],{"trials":5748,"activeCount":100},[],{"intervention":3634,"totalTrials":139,"cells":5750},{"EARLY_PHASE1":5751,"PHASE1":5753,"PHASE2":5755,"PHASE3":5757,"PHASE4":5763,"NA":5765},{"trials":5752,"activeCount":100},[],{"trials":5754,"activeCount":100},[],{"trials":5756,"activeCount":100},[],{"trials":5758,"activeCount":100},[5759],{"nctId":3622,"briefTitle":3623,"status":123,"phases":5760,"primaryCompletion":3625,"completion":3626,"start":3627,"enrollment":3628,"conditions":5761,"interventions":5762},[90],[1376,1374,1379,1377,3630,1375,3631,1373],[3633,3634,3635,3636,3637,3638],{"trials":5764,"activeCount":100},[],{"trials":5766,"activeCount":100},[],{"intervention":3636,"totalTrials":139,"cells":5768},{"EARLY_PHASE1":5769,"PHASE1":5771,"PHASE2":5773,"PHASE3":5775,"PHASE4":5781,"NA":5783},{"trials":5770,"activeCount":100},[],{"trials":5772,"activeCount":100},[],{"trials":5774,"activeCount":100},[],{"trials":5776,"activeCount":100},[5777],{"nctId":3622,"briefTitle":3623,"status":123,"phases":5778,"primaryCompletion":3625,"completion":3626,"start":3627,"enrollment":3628,"conditions":5779,"interventions":5780},[90],[1376,1374,1379,1377,3630,1375,3631,1373],[3633,3634,3635,3636,3637,3638],{"trials":5782,"activeCount":100},[],{"trials":5784,"activeCount":100},[],{"intervention":3637,"totalTrials":139,"cells":5786},{"EARLY_PHASE1":5787,"PHASE1":5789,"PHASE2":5791,"PHASE3":5793,"PHASE4":5799,"NA":5801},{"trials":5788,"activeCount":100},[],{"trials":5790,"activeCount":100},[],{"trials":5792,"activeCount":100},[],{"trials":5794,"activeCount":100},[5795],{"nctId":3622,"briefTitle":3623,"status":123,"phases":5796,"primaryCompletion":3625,"completion":3626,"start":3627,"enrollment":3628,"conditions":5797,"interventions":5798},[90],[1376,1374,1379,1377,3630,1375,3631,1373],[3633,3634,3635,3636,3637,3638],{"trials":5800,"activeCount":100},[],{"trials":5802,"activeCount":100},[],{"intervention":3638,"totalTrials":139,"cells":5804},{"EARLY_PHASE1":5805,"PHASE1":5807,"PHASE2":5809,"PHASE3":5811,"PHASE4":5817,"NA":5819},{"trials":5806,"activeCount":100},[],{"trials":5808,"activeCount":100},[],{"trials":5810,"activeCount":100},[],{"trials":5812,"activeCount":100},[5813],{"nctId":3622,"briefTitle":3623,"status":123,"phases":5814,"primaryCompletion":3625,"completion":3626,"start":3627,"enrollment":3628,"conditions":5815,"interventions":5816},[90],[1376,1374,1379,1377,3630,1375,3631,1373],[3633,3634,3635,3636,3637,3638],{"trials":5818,"activeCount":100},[],{"trials":5820,"activeCount":100},[],{"intervention":655,"totalTrials":139,"cells":5822},{"EARLY_PHASE1":5823,"PHASE1":5825,"PHASE2":5827,"PHASE3":5829,"PHASE4":5835,"NA":5837},{"trials":5824,"activeCount":100},[],{"trials":5826,"activeCount":100},[],{"trials":5828,"activeCount":100},[],{"trials":5830,"activeCount":100},[5831],{"nctId":644,"briefTitle":645,"status":646,"phases":5832,"primaryCompletion":648,"completion":648,"start":649,"enrollment":650,"conditions":5833,"interventions":5834},[90],[652],[654,655,656,483,657,446,381,658],{"trials":5836,"activeCount":100},[],{"trials":5838,"activeCount":100},[],{"intervention":656,"totalTrials":139,"cells":5840},{"EARLY_PHASE1":5841,"PHASE1":5843,"PHASE2":5845,"PHASE3":5847,"PHASE4":5853,"NA":5855},{"trials":5842,"activeCount":100},[],{"trials":5844,"activeCount":100},[],{"trials":5846,"activeCount":100},[],{"trials":5848,"activeCount":100},[5849],{"nctId":644,"briefTitle":645,"status":646,"phases":5850,"primaryCompletion":648,"completion":648,"start":649,"enrollment":650,"conditions":5851,"interventions":5852},[90],[652],[654,655,656,483,657,446,381,658],{"trials":5854,"activeCount":100},[],{"trials":5856,"activeCount":100},[],{"intervention":657,"totalTrials":139,"cells":5858},{"EARLY_PHASE1":5859,"PHASE1":5861,"PHASE2":5863,"PHASE3":5865,"PHASE4":5871,"NA":5873},{"trials":5860,"activeCount":100},[],{"trials":5862,"activeCount":100},[],{"trials":5864,"activeCount":100},[],{"trials":5866,"activeCount":100},[5867],{"nctId":644,"briefTitle":645,"status":646,"phases":5868,"primaryCompletion":648,"completion":648,"start":649,"enrollment":650,"conditions":5869,"interventions":5870},[90],[652],[654,655,656,483,657,446,381,658],{"trials":5872,"activeCount":100},[],{"trials":5874,"activeCount":100},[],{"intervention":5876,"totalTrials":139,"cells":5877},"Nirsevimab",{"EARLY_PHASE1":5878,"PHASE1":5880,"PHASE2":5882,"PHASE3":5884,"PHASE4":5897,"NA":5899},{"trials":5879,"activeCount":100},[],{"trials":5881,"activeCount":100},[],{"trials":5883,"activeCount":100},[],{"trials":5885,"activeCount":100},[5886],{"nctId":5887,"briefTitle":5888,"status":123,"phases":5889,"primaryCompletion":5890,"completion":5891,"start":5892,"enrollment":5893,"conditions":5894,"interventions":5896},"NCT05437510","Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life",[90],"2024-03-27","2025-04-09","2022-08-08",8057,[652,5895],"Healthy Volunteer",[5876],{"trials":5898,"activeCount":100},[],{"trials":5900,"activeCount":100},[],{"intervention":5902,"totalTrials":139,"cells":5903},"DTaP-IPV\u002FHib Combined vaccine",{"EARLY_PHASE1":5904,"PHASE1":5906,"PHASE2":5908,"PHASE3":5910,"PHASE4":5922,"NA":5924},{"trials":5905,"activeCount":100},[],{"trials":5907,"activeCount":100},[],{"trials":5909,"activeCount":100},[],{"trials":5911,"activeCount":100},[5912],{"nctId":5913,"briefTitle":5914,"status":123,"phases":5915,"primaryCompletion":5916,"completion":5916,"start":1949,"enrollment":5917,"conditions":5918,"interventions":5920},"NCT02274285","DTaP-IPV\u002FHib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants",[90],"2016-05-28",424,[24,18,21,30,5919],"Bacterial Meningitis",[5902,5921,5902],"DTaP-IPV vaccine and Hib vaccine",{"trials":5923,"activeCount":100},[],{"trials":5925,"activeCount":100},[],{"intervention":5921,"totalTrials":139,"cells":5927},{"EARLY_PHASE1":5928,"PHASE1":5930,"PHASE2":5932,"PHASE3":5934,"PHASE4":5940,"NA":5942},{"trials":5929,"activeCount":100},[],{"trials":5931,"activeCount":100},[],{"trials":5933,"activeCount":100},[],{"trials":5935,"activeCount":100},[5936],{"nctId":5913,"briefTitle":5914,"status":123,"phases":5937,"primaryCompletion":5916,"completion":5916,"start":1949,"enrollment":5917,"conditions":5938,"interventions":5939},[90],[24,18,21,30,5919],[5902,5921,5902],{"trials":5941,"activeCount":100},[],{"trials":5943,"activeCount":100},[],{"intervention":511,"totalTrials":139,"cells":5945},{"EARLY_PHASE1":5946,"PHASE1":5948,"PHASE2":5950,"PHASE3":5952,"PHASE4":5958,"NA":5960},{"trials":5947,"activeCount":100},[],{"trials":5949,"activeCount":100},[],{"trials":5951,"activeCount":100},[],{"trials":5953,"activeCount":100},[5954],{"nctId":502,"briefTitle":503,"status":123,"phases":5955,"primaryCompletion":505,"completion":505,"start":506,"enrollment":507,"conditions":5956,"interventions":5957},[90],[509],[427,511,512,513,514],{"trials":5959,"activeCount":100},[],{"trials":5961,"activeCount":100},[],{"intervention":512,"totalTrials":139,"cells":5963},{"EARLY_PHASE1":5964,"PHASE1":5966,"PHASE2":5968,"PHASE3":5970,"PHASE4":5976,"NA":5978},{"trials":5965,"activeCount":100},[],{"trials":5967,"activeCount":100},[],{"trials":5969,"activeCount":100},[],{"trials":5971,"activeCount":100},[5972],{"nctId":502,"briefTitle":503,"status":123,"phases":5973,"primaryCompletion":505,"completion":505,"start":506,"enrollment":507,"conditions":5974,"interventions":5975},[90],[509],[427,511,512,513,514],{"trials":5977,"activeCount":100},[],{"trials":5979,"activeCount":100},[],{"intervention":513,"totalTrials":139,"cells":5981},{"EARLY_PHASE1":5982,"PHASE1":5984,"PHASE2":5986,"PHASE3":5988,"PHASE4":5994,"NA":5996},{"trials":5983,"activeCount":100},[],{"trials":5985,"activeCount":100},[],{"trials":5987,"activeCount":100},[],{"trials":5989,"activeCount":100},[5990],{"nctId":502,"briefTitle":503,"status":123,"phases":5991,"primaryCompletion":505,"completion":505,"start":506,"enrollment":507,"conditions":5992,"interventions":5993},[90],[509],[427,511,512,513,514],{"trials":5995,"activeCount":100},[],{"trials":5997,"activeCount":100},[],{"intervention":514,"totalTrials":139,"cells":5999},{"EARLY_PHASE1":6000,"PHASE1":6002,"PHASE2":6004,"PHASE3":6006,"PHASE4":6012,"NA":6014},{"trials":6001,"activeCount":100},[],{"trials":6003,"activeCount":100},[],{"trials":6005,"activeCount":100},[],{"trials":6007,"activeCount":100},[6008],{"nctId":502,"briefTitle":503,"status":123,"phases":6009,"primaryCompletion":505,"completion":505,"start":506,"enrollment":507,"conditions":6010,"interventions":6011},[90],[509],[427,511,512,513,514],{"trials":6013,"activeCount":100},[],{"trials":6015,"activeCount":100},[],{"intervention":6017,"totalTrials":139,"cells":6018},"IMOJEV",{"EARLY_PHASE1":6019,"PHASE1":6021,"PHASE2":6023,"PHASE3":6025,"PHASE4":6036,"NA":6038},{"trials":6020,"activeCount":100},[],{"trials":6022,"activeCount":100},[],{"trials":6024,"activeCount":100},[],{"trials":6026,"activeCount":100},[6027],{"nctId":6028,"briefTitle":6029,"status":123,"phases":6030,"primaryCompletion":6031,"completion":6031,"start":6032,"enrollment":6033,"conditions":6034,"interventions":6035},"NCT01900444","Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea",[90],"2014-03-11","2013-07-11",119,[3063],[6017],{"trials":6037,"activeCount":100},[],{"trials":6039,"activeCount":100},[],{"intervention":6041,"totalTrials":139,"cells":6042},"2011 to 2012 Trivalent Influenza Vaccine",{"EARLY_PHASE1":6043,"PHASE1":6045,"PHASE2":6047,"PHASE3":6049,"PHASE4":6060,"NA":6062},{"trials":6044,"activeCount":100},[],{"trials":6046,"activeCount":100},[],{"trials":6048,"activeCount":100},[],{"trials":6050,"activeCount":100},[6051],{"nctId":6052,"briefTitle":6053,"status":123,"phases":6054,"primaryCompletion":6055,"completion":1317,"start":3186,"enrollment":6056,"conditions":6057,"interventions":6058},"NCT01481454","Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children\u002FAdolescents and Adults",[90],"2012-10",1701,[15],[6059,6059,6059,6041],"Quadrivalent Influenza Vaccine",{"trials":6061,"activeCount":100},[],{"trials":6063,"activeCount":100},[],{"intervention":6065,"totalTrials":139,"cells":6066},"Quadrivalent Recombinant influenza vaccine (RIV4) season\u002F2022-2023\u002FNH",{"EARLY_PHASE1":6067,"PHASE1":6069,"PHASE2":6071,"PHASE3":6073,"PHASE4":6084,"NA":6086},{"trials":6068,"activeCount":100},[],{"trials":6070,"activeCount":100},[],{"trials":6072,"activeCount":100},[],{"trials":6074,"activeCount":100},[6075],{"nctId":6076,"briefTitle":6077,"status":123,"phases":6078,"primaryCompletion":6079,"completion":6079,"start":6080,"enrollment":6081,"conditions":6082,"interventions":6083},"NCT05513053","Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.",[90],"2023-10-27","2022-10-27",1308,[759],[6065],{"trials":6085,"activeCount":100},[],{"trials":6087,"activeCount":100},[],{"intervention":4330,"totalTrials":139,"cells":6089},{"EARLY_PHASE1":6090,"PHASE1":6092,"PHASE2":6094,"PHASE3":6096,"PHASE4":6102,"NA":6104},{"trials":6091,"activeCount":100},[],{"trials":6093,"activeCount":100},[],{"trials":6095,"activeCount":100},[],{"trials":6097,"activeCount":100},[6098],{"nctId":4320,"briefTitle":4321,"status":123,"phases":6099,"primaryCompletion":4323,"completion":4323,"start":4324,"enrollment":4325,"conditions":6100,"interventions":6101},[90],[441,33],[4328,4329,4330],{"trials":6103,"activeCount":100},[],{"trials":6105,"activeCount":100},[],{"intervention":4452,"totalTrials":139,"cells":6107},{"EARLY_PHASE1":6108,"PHASE1":6110,"PHASE2":6112,"PHASE3":6114,"PHASE4":6120,"NA":6122},{"trials":6109,"activeCount":100},[],{"trials":6111,"activeCount":100},[],{"trials":6113,"activeCount":100},[],{"trials":6115,"activeCount":100},[6116],{"nctId":4445,"briefTitle":4446,"status":123,"phases":6117,"primaryCompletion":4448,"completion":4448,"start":4449,"enrollment":2801,"conditions":6118,"interventions":6119},[90],[1857],[4434,4452,4452],{"trials":6121,"activeCount":100},[],{"trials":6123,"activeCount":100},[],{"intervention":1523,"totalTrials":139,"cells":6125},{"EARLY_PHASE1":6126,"PHASE1":6128,"PHASE2":6130,"PHASE3":6132,"PHASE4":6138,"NA":6140},{"trials":6127,"activeCount":100},[],{"trials":6129,"activeCount":100},[],{"trials":6131,"activeCount":100},[],{"trials":6133,"activeCount":100},[6134],{"nctId":1514,"briefTitle":1515,"status":123,"phases":6135,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":6136,"interventions":6137},[90],[170,33],[1522,497,1523,1503],{"trials":6139,"activeCount":100},[],{"trials":6141,"activeCount":100},[],{"intervention":3333,"totalTrials":139,"cells":6143},{"EARLY_PHASE1":6144,"PHASE1":6146,"PHASE2":6148,"PHASE3":6150,"PHASE4":6156,"NA":6158},{"trials":6145,"activeCount":100},[],{"trials":6147,"activeCount":100},[],{"trials":6149,"activeCount":100},[],{"trials":6151,"activeCount":100},[6152],{"nctId":3324,"briefTitle":3325,"status":123,"phases":6153,"primaryCompletion":3327,"completion":2568,"start":3328,"enrollment":3329,"conditions":6154,"interventions":6155},[90],[36,1666,18,21],[3332,3333,483],{"trials":6157,"activeCount":100},[],{"trials":6159,"activeCount":100},[],{"intervention":6161,"totalTrials":139,"cells":6162},"Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus",{"EARLY_PHASE1":6163,"PHASE1":6165,"PHASE2":6167,"PHASE3":6169,"PHASE4":6179,"NA":6181},{"trials":6164,"activeCount":100},[],{"trials":6166,"activeCount":100},[],{"trials":6168,"activeCount":100},[],{"trials":6170,"activeCount":100},[6171],{"nctId":6172,"briefTitle":6173,"status":123,"phases":6174,"primaryCompletion":1428,"completion":367,"start":1414,"enrollment":6175,"conditions":6176,"interventions":6177},"NCT01346293","Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age",[90],3372,[24,18,21,1330,1666],[6161,6178,6161,6178],"Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus",{"trials":6180,"activeCount":100},[],{"trials":6182,"activeCount":100},[],{"intervention":6178,"totalTrials":139,"cells":6184},{"EARLY_PHASE1":6185,"PHASE1":6187,"PHASE2":6189,"PHASE3":6191,"PHASE4":6197,"NA":6199},{"trials":6186,"activeCount":100},[],{"trials":6188,"activeCount":100},[],{"trials":6190,"activeCount":100},[],{"trials":6192,"activeCount":100},[6193],{"nctId":6172,"briefTitle":6173,"status":123,"phases":6194,"primaryCompletion":1428,"completion":367,"start":1414,"enrollment":6175,"conditions":6195,"interventions":6196},[90],[24,18,21,1330,1666],[6161,6178,6161,6178],{"trials":6198,"activeCount":100},[],{"trials":6200,"activeCount":100},[],{"intervention":6202,"totalTrials":139,"cells":6203},"Hexaxim®",{"EARLY_PHASE1":6204,"PHASE1":6206,"PHASE2":6208,"PHASE3":6210,"PHASE4":6221,"NA":6223},{"trials":6205,"activeCount":100},[],{"trials":6207,"activeCount":100},[],{"trials":6209,"activeCount":100},[],{"trials":6211,"activeCount":100},[6212],{"nctId":6213,"briefTitle":6214,"status":123,"phases":6215,"primaryCompletion":6216,"completion":6216,"start":6217,"enrollment":6218,"conditions":6219,"interventions":6220},"NCT02428491","Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth",[90],"2017-01-11","2015-04-20",354,[18,24,21,30,36,3821],[6202],{"trials":6222,"activeCount":100},[],{"trials":6224,"activeCount":100},[],{"intervention":6226,"totalTrials":139,"cells":6227},"Concomitant administration",{"EARLY_PHASE1":6228,"PHASE1":6230,"PHASE2":6232,"PHASE3":6234,"PHASE4":6244,"NA":6246},{"trials":6229,"activeCount":100},[],{"trials":6231,"activeCount":100},[],{"trials":6233,"activeCount":100},[],{"trials":6235,"activeCount":100},[6236],{"nctId":6237,"briefTitle":6238,"status":123,"phases":6239,"primaryCompletion":1430,"completion":1430,"start":2225,"enrollment":6240,"conditions":6241,"interventions":6242},"NCT01249183","Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old",[90],954,[18,24,21,30],[6226,6243],"Separate administration",{"trials":6245,"activeCount":100},[],{"trials":6247,"activeCount":100},[],{"intervention":6243,"totalTrials":139,"cells":6249},{"EARLY_PHASE1":6250,"PHASE1":6252,"PHASE2":6254,"PHASE3":6256,"PHASE4":6262,"NA":6264},{"trials":6251,"activeCount":100},[],{"trials":6253,"activeCount":100},[],{"trials":6255,"activeCount":100},[],{"trials":6257,"activeCount":100},[6258],{"nctId":6237,"briefTitle":6238,"status":123,"phases":6259,"primaryCompletion":1430,"completion":1430,"start":2225,"enrollment":6240,"conditions":6260,"interventions":6261},[90],[18,24,21,30],[6226,6243],{"trials":6263,"activeCount":100},[],{"trials":6265,"activeCount":100},[],{"intervention":6267,"totalTrials":139,"cells":6268},"Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains",{"EARLY_PHASE1":6269,"PHASE1":6271,"PHASE2":6273,"PHASE3":6275,"PHASE4":6286,"NA":6288},{"trials":6270,"activeCount":100},[],{"trials":6272,"activeCount":100},[],{"trials":6274,"activeCount":100},[],{"trials":6276,"activeCount":100},[6277],{"nctId":6278,"briefTitle":6279,"status":646,"phases":6280,"primaryCompletion":6281,"completion":6281,"start":6282,"enrollment":6283,"conditions":6284,"interventions":6285},"NCT04137887","Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older",[90],"2020-05-31","2019-11-04",33096,[3460],[6059,6267],{"trials":6287,"activeCount":100},[],{"trials":6289,"activeCount":100},[],{"intervention":6291,"totalTrials":139,"cells":6292},"Quadrivalent influenza vaccine, high-dose",{"EARLY_PHASE1":6293,"PHASE1":6295,"PHASE2":6297,"PHASE3":6299,"PHASE4":6310,"NA":6312},{"trials":6294,"activeCount":100},[],{"trials":6296,"activeCount":100},[],{"trials":6298,"activeCount":100},[],{"trials":6300,"activeCount":100},[6301],{"nctId":6302,"briefTitle":6303,"status":646,"phases":6304,"primaryCompletion":6305,"completion":6305,"start":6306,"enrollment":5257,"conditions":6307,"interventions":6308},"NCT04544267","Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age",[90],"2021-06-02","2020-09-15",[15],[6291,6309],"Quadrivalent influenza vaccine, standard dose",{"trials":6311,"activeCount":100},[],{"trials":6313,"activeCount":100},[],{"intervention":6309,"totalTrials":139,"cells":6315},{"EARLY_PHASE1":6316,"PHASE1":6318,"PHASE2":6320,"PHASE3":6322,"PHASE4":6328,"NA":6330},{"trials":6317,"activeCount":100},[],{"trials":6319,"activeCount":100},[],{"trials":6321,"activeCount":100},[],{"trials":6323,"activeCount":100},[6324],{"nctId":6302,"briefTitle":6303,"status":646,"phases":6325,"primaryCompletion":6305,"completion":6305,"start":6306,"enrollment":5257,"conditions":6326,"interventions":6327},[90],[15],[6291,6309],{"trials":6329,"activeCount":100},[],{"trials":6331,"activeCount":100},[],{"intervention":3946,"totalTrials":139,"cells":6333},{"EARLY_PHASE1":6334,"PHASE1":6336,"PHASE2":6338,"PHASE3":6340,"PHASE4":6346,"NA":6348},{"trials":6335,"activeCount":100},[],{"trials":6337,"activeCount":100},[],{"trials":6339,"activeCount":100},[],{"trials":6341,"activeCount":100},[6342],{"nctId":3939,"briefTitle":3940,"status":123,"phases":6343,"primaryCompletion":1236,"completion":1228,"start":3942,"enrollment":3943,"conditions":6344,"interventions":6345},[90],[18,24,21,36,30],[3332,3332,3332,3946],{"trials":6347,"activeCount":100},[],{"trials":6349,"activeCount":100},[],{"intervention":6351,"totalTrials":139,"cells":6352},"DAPTACEL®. (DTaP), IPOL®., and ActHIB®.",{"EARLY_PHASE1":6353,"PHASE1":6355,"PHASE2":6357,"PHASE3":6359,"PHASE4":6370,"NA":6372},{"trials":6354,"activeCount":100},[],{"trials":6356,"activeCount":100},[],{"trials":6358,"activeCount":100},[],{"trials":6360,"activeCount":100},[6361],{"nctId":6362,"briefTitle":6363,"status":123,"phases":6364,"primaryCompletion":1228,"completion":1287,"start":3643,"enrollment":6365,"conditions":6366,"interventions":6367},"NCT00255047","Safety and Immune Response of Different Pediatric Combination Vaccines.",[90],2167,[18,1666,21],[6351,6368,6369,6368],"Pentacel®: DTaP-IPV\u002FHib combined","DTaP-IPV and ActHIB®",{"trials":6371,"activeCount":100},[],{"trials":6373,"activeCount":100},[],{"intervention":6368,"totalTrials":139,"cells":6375},{"EARLY_PHASE1":6376,"PHASE1":6378,"PHASE2":6380,"PHASE3":6382,"PHASE4":6388,"NA":6390},{"trials":6377,"activeCount":100},[],{"trials":6379,"activeCount":100},[],{"trials":6381,"activeCount":100},[],{"trials":6383,"activeCount":100},[6384],{"nctId":6362,"briefTitle":6363,"status":123,"phases":6385,"primaryCompletion":1228,"completion":1287,"start":3643,"enrollment":6365,"conditions":6386,"interventions":6387},[90],[18,1666,21],[6351,6368,6369,6368],{"trials":6389,"activeCount":100},[],{"trials":6391,"activeCount":100},[],{"intervention":6369,"totalTrials":139,"cells":6393},{"EARLY_PHASE1":6394,"PHASE1":6396,"PHASE2":6398,"PHASE3":6400,"PHASE4":6406,"NA":6408},{"trials":6395,"activeCount":100},[],{"trials":6397,"activeCount":100},[],{"trials":6399,"activeCount":100},[],{"trials":6401,"activeCount":100},[6402],{"nctId":6362,"briefTitle":6363,"status":123,"phases":6403,"primaryCompletion":1228,"completion":1287,"start":3643,"enrollment":6365,"conditions":6404,"interventions":6405},[90],[18,1666,21],[6351,6368,6369,6368],{"trials":6407,"activeCount":100},[],{"trials":6409,"activeCount":100},[],{"intervention":3555,"totalTrials":139,"cells":6411},{"EARLY_PHASE1":6412,"PHASE1":6414,"PHASE2":6416,"PHASE3":6418,"PHASE4":6424,"NA":6426},{"trials":6413,"activeCount":100},[],{"trials":6415,"activeCount":100},[],{"trials":6417,"activeCount":100},[],{"trials":6419,"activeCount":100},[6420],{"nctId":3547,"briefTitle":3548,"status":123,"phases":6421,"primaryCompletion":3550,"completion":349,"start":3551,"enrollment":3552,"conditions":6422,"interventions":6423},[90],[3542],[3555,3556,3557,3558],{"trials":6425,"activeCount":100},[],{"trials":6427,"activeCount":100},[],{"intervention":3557,"totalTrials":139,"cells":6429},{"EARLY_PHASE1":6430,"PHASE1":6432,"PHASE2":6434,"PHASE3":6436,"PHASE4":6442,"NA":6444},{"trials":6431,"activeCount":100},[],{"trials":6433,"activeCount":100},[],{"trials":6435,"activeCount":100},[],{"trials":6437,"activeCount":100},[6438],{"nctId":3547,"briefTitle":3548,"status":123,"phases":6439,"primaryCompletion":3550,"completion":349,"start":3551,"enrollment":3552,"conditions":6440,"interventions":6441},[90],[3542],[3555,3556,3557,3558],{"trials":6443,"activeCount":100},[],{"trials":6445,"activeCount":100},[],{"intervention":3558,"totalTrials":139,"cells":6447},{"EARLY_PHASE1":6448,"PHASE1":6450,"PHASE2":6452,"PHASE3":6454,"PHASE4":6460,"NA":6462},{"trials":6449,"activeCount":100},[],{"trials":6451,"activeCount":100},[],{"trials":6453,"activeCount":100},[],{"trials":6455,"activeCount":100},[6456],{"nctId":3547,"briefTitle":3548,"status":123,"phases":6457,"primaryCompletion":3550,"completion":349,"start":3551,"enrollment":3552,"conditions":6458,"interventions":6459},[90],[3542],[3555,3556,3557,3558],{"trials":6461,"activeCount":100},[],{"trials":6463,"activeCount":100},[],{"intervention":375,"totalTrials":139,"cells":6465},{"EARLY_PHASE1":6466,"PHASE1":6468,"PHASE2":6470,"PHASE3":6472,"PHASE4":6478,"NA":6480},{"trials":6467,"activeCount":100},[],{"trials":6469,"activeCount":100},[],{"trials":6471,"activeCount":100},[],{"trials":6473,"activeCount":100},[6474],{"nctId":364,"briefTitle":365,"status":123,"phases":6475,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":6476,"interventions":6477},[90],[372,373,352],[375,42,376,377,378,379,375,380,381,377,379,378],{"trials":6479,"activeCount":100},[],{"trials":6481,"activeCount":100},[],{"intervention":376,"totalTrials":139,"cells":6483},{"EARLY_PHASE1":6484,"PHASE1":6486,"PHASE2":6488,"PHASE3":6490,"PHASE4":6496,"NA":6498},{"trials":6485,"activeCount":100},[],{"trials":6487,"activeCount":100},[],{"trials":6489,"activeCount":100},[],{"trials":6491,"activeCount":100},[6492],{"nctId":364,"briefTitle":365,"status":123,"phases":6493,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":6494,"interventions":6495},[90],[372,373,352],[375,42,376,377,378,379,375,380,381,377,379,378],{"trials":6497,"activeCount":100},[],{"trials":6499,"activeCount":100},[],{"intervention":377,"totalTrials":139,"cells":6501},{"EARLY_PHASE1":6502,"PHASE1":6504,"PHASE2":6506,"PHASE3":6508,"PHASE4":6514,"NA":6516},{"trials":6503,"activeCount":100},[],{"trials":6505,"activeCount":100},[],{"trials":6507,"activeCount":100},[],{"trials":6509,"activeCount":100},[6510],{"nctId":364,"briefTitle":365,"status":123,"phases":6511,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":6512,"interventions":6513},[90],[372,373,352],[375,42,376,377,378,379,375,380,381,377,379,378],{"trials":6515,"activeCount":100},[],{"trials":6517,"activeCount":100},[],{"intervention":378,"totalTrials":139,"cells":6519},{"EARLY_PHASE1":6520,"PHASE1":6522,"PHASE2":6524,"PHASE3":6526,"PHASE4":6532,"NA":6534},{"trials":6521,"activeCount":100},[],{"trials":6523,"activeCount":100},[],{"trials":6525,"activeCount":100},[],{"trials":6527,"activeCount":100},[6528],{"nctId":364,"briefTitle":365,"status":123,"phases":6529,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":6530,"interventions":6531},[90],[372,373,352],[375,42,376,377,378,379,375,380,381,377,379,378],{"trials":6533,"activeCount":100},[],{"trials":6535,"activeCount":100},[],{"intervention":379,"totalTrials":139,"cells":6537},{"EARLY_PHASE1":6538,"PHASE1":6540,"PHASE2":6542,"PHASE3":6544,"PHASE4":6550,"NA":6552},{"trials":6539,"activeCount":100},[],{"trials":6541,"activeCount":100},[],{"trials":6543,"activeCount":100},[],{"trials":6545,"activeCount":100},[6546],{"nctId":364,"briefTitle":365,"status":123,"phases":6547,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":6548,"interventions":6549},[90],[372,373,352],[375,42,376,377,378,379,375,380,381,377,379,378],{"trials":6551,"activeCount":100},[],{"trials":6553,"activeCount":100},[],{"intervention":3395,"totalTrials":139,"cells":6555},{"EARLY_PHASE1":6556,"PHASE1":6558,"PHASE2":6560,"PHASE3":6562,"PHASE4":6568,"NA":6570},{"trials":6557,"activeCount":100},[],{"trials":6559,"activeCount":100},[],{"trials":6561,"activeCount":100},[],{"trials":6563,"activeCount":100},[6564],{"nctId":3389,"briefTitle":3390,"status":123,"phases":6565,"primaryCompletion":3327,"completion":2568,"start":1229,"enrollment":3392,"conditions":6566,"interventions":6567},[90],[3376,15,3367],[3395,3395,3395,3396],{"trials":6569,"activeCount":100},[],{"trials":6571,"activeCount":100},[],{"intervention":6573,"totalTrials":139,"cells":6574},"DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine",{"EARLY_PHASE1":6575,"PHASE1":6577,"PHASE2":6579,"PHASE3":6581,"PHASE4":6593,"NA":6595},{"trials":6576,"activeCount":100},[],{"trials":6578,"activeCount":100},[],{"trials":6580,"activeCount":100},[],{"trials":6582,"activeCount":100},[6583],{"nctId":6584,"briefTitle":6585,"status":123,"phases":6586,"primaryCompletion":1564,"completion":1555,"start":6587,"enrollment":6588,"conditions":6589,"interventions":6590},"NCT01983540","Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination",[90],"2013-10",558,[18,24,1600,36,30,3821],[6573,6591,6592],"DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine","Infanrix hexa + Prevenar + Rotarix vaccine",{"trials":6594,"activeCount":100},[],{"trials":6596,"activeCount":100},[],{"intervention":6591,"totalTrials":139,"cells":6598},{"EARLY_PHASE1":6599,"PHASE1":6601,"PHASE2":6603,"PHASE3":6605,"PHASE4":6611,"NA":6613},{"trials":6600,"activeCount":100},[],{"trials":6602,"activeCount":100},[],{"trials":6604,"activeCount":100},[],{"trials":6606,"activeCount":100},[6607],{"nctId":6584,"briefTitle":6585,"status":123,"phases":6608,"primaryCompletion":1564,"completion":1555,"start":6587,"enrollment":6588,"conditions":6609,"interventions":6610},[90],[18,24,1600,36,30,3821],[6573,6591,6592],{"trials":6612,"activeCount":100},[],{"trials":6614,"activeCount":100},[],{"intervention":6592,"totalTrials":139,"cells":6616},{"EARLY_PHASE1":6617,"PHASE1":6619,"PHASE2":6621,"PHASE3":6623,"PHASE4":6629,"NA":6631},{"trials":6618,"activeCount":100},[],{"trials":6620,"activeCount":100},[],{"trials":6622,"activeCount":100},[],{"trials":6624,"activeCount":100},[6625],{"nctId":6584,"briefTitle":6585,"status":123,"phases":6626,"primaryCompletion":1564,"completion":1555,"start":6587,"enrollment":6588,"conditions":6627,"interventions":6628},[90],[18,24,1600,36,30,3821],[6573,6591,6592],{"trials":6630,"activeCount":100},[],{"trials":6632,"activeCount":100},[],{"intervention":6634,"totalTrials":139,"cells":6635},"Euvax B®: Hepatitis B vaccine",{"EARLY_PHASE1":6636,"PHASE1":6638,"PHASE2":6640,"PHASE3":6642,"PHASE4":6652,"NA":6654},{"trials":6637,"activeCount":100},[],{"trials":6639,"activeCount":100},[],{"trials":6641,"activeCount":100},[],{"trials":6643,"activeCount":100},[6644],{"nctId":6645,"briefTitle":6646,"status":123,"phases":6647,"primaryCompletion":4542,"completion":6648,"start":1924,"enrollment":6649,"conditions":6650,"interventions":6651},"NCT02697474","Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.",[90],"2017-01",150,[36],[6634,6634],{"trials":6653,"activeCount":100},[],{"trials":6655,"activeCount":100},[],{"intervention":669,"totalTrials":139,"cells":6657},{"EARLY_PHASE1":6658,"PHASE1":6660,"PHASE2":6662,"PHASE3":6664,"PHASE4":6670,"NA":6672},{"trials":6659,"activeCount":100},[],{"trials":6661,"activeCount":100},[],{"trials":6663,"activeCount":100},[],{"trials":6665,"activeCount":100},[6666],{"nctId":660,"briefTitle":661,"status":123,"phases":6667,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":6668,"interventions":6669},[90],[170,33],[582,668,669,670,671,672,673,486,446,674,675,676,676,671,486],{"trials":6671,"activeCount":100},[],{"trials":6673,"activeCount":100},[],{"intervention":670,"totalTrials":139,"cells":6675},{"EARLY_PHASE1":6676,"PHASE1":6678,"PHASE2":6680,"PHASE3":6682,"PHASE4":6688,"NA":6690},{"trials":6677,"activeCount":100},[],{"trials":6679,"activeCount":100},[],{"trials":6681,"activeCount":100},[],{"trials":6683,"activeCount":100},[6684],{"nctId":660,"briefTitle":661,"status":123,"phases":6685,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":6686,"interventions":6687},[90],[170,33],[582,668,669,670,671,672,673,486,446,674,675,676,676,671,486],{"trials":6689,"activeCount":100},[],{"trials":6691,"activeCount":100},[],{"intervention":671,"totalTrials":139,"cells":6693},{"EARLY_PHASE1":6694,"PHASE1":6696,"PHASE2":6698,"PHASE3":6700,"PHASE4":6706,"NA":6708},{"trials":6695,"activeCount":100},[],{"trials":6697,"activeCount":100},[],{"trials":6699,"activeCount":100},[],{"trials":6701,"activeCount":100},[6702],{"nctId":660,"briefTitle":661,"status":123,"phases":6703,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":6704,"interventions":6705},[90],[170,33],[582,668,669,670,671,672,673,486,446,674,675,676,676,671,486],{"trials":6707,"activeCount":100},[],{"trials":6709,"activeCount":100},[],{"intervention":672,"totalTrials":139,"cells":6711},{"EARLY_PHASE1":6712,"PHASE1":6714,"PHASE2":6716,"PHASE3":6718,"PHASE4":6724,"NA":6726},{"trials":6713,"activeCount":100},[],{"trials":6715,"activeCount":100},[],{"trials":6717,"activeCount":100},[],{"trials":6719,"activeCount":100},[6720],{"nctId":660,"briefTitle":661,"status":123,"phases":6721,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":6722,"interventions":6723},[90],[170,33],[582,668,669,670,671,672,673,486,446,674,675,676,676,671,486],{"trials":6725,"activeCount":100},[],{"trials":6727,"activeCount":100},[],{"intervention":673,"totalTrials":139,"cells":6729},{"EARLY_PHASE1":6730,"PHASE1":6732,"PHASE2":6734,"PHASE3":6736,"PHASE4":6742,"NA":6744},{"trials":6731,"activeCount":100},[],{"trials":6733,"activeCount":100},[],{"trials":6735,"activeCount":100},[],{"trials":6737,"activeCount":100},[6738],{"nctId":660,"briefTitle":661,"status":123,"phases":6739,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":6740,"interventions":6741},[90],[170,33],[582,668,669,670,671,672,673,486,446,674,675,676,676,671,486],{"trials":6743,"activeCount":100},[],{"trials":6745,"activeCount":100},[],{"intervention":674,"totalTrials":139,"cells":6747},{"EARLY_PHASE1":6748,"PHASE1":6750,"PHASE2":6752,"PHASE3":6754,"PHASE4":6760,"NA":6762},{"trials":6749,"activeCount":100},[],{"trials":6751,"activeCount":100},[],{"trials":6753,"activeCount":100},[],{"trials":6755,"activeCount":100},[6756],{"nctId":660,"briefTitle":661,"status":123,"phases":6757,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":6758,"interventions":6759},[90],[170,33],[582,668,669,670,671,672,673,486,446,674,675,676,676,671,486],{"trials":6761,"activeCount":100},[],{"trials":6763,"activeCount":100},[],{"intervention":675,"totalTrials":139,"cells":6765},{"EARLY_PHASE1":6766,"PHASE1":6768,"PHASE2":6770,"PHASE3":6772,"PHASE4":6778,"NA":6780},{"trials":6767,"activeCount":100},[],{"trials":6769,"activeCount":100},[],{"trials":6771,"activeCount":100},[],{"trials":6773,"activeCount":100},[6774],{"nctId":660,"briefTitle":661,"status":123,"phases":6775,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":6776,"interventions":6777},[90],[170,33],[582,668,669,670,671,672,673,486,446,674,675,676,676,671,486],{"trials":6779,"activeCount":100},[],{"trials":6781,"activeCount":100},[],{"intervention":676,"totalTrials":139,"cells":6783},{"EARLY_PHASE1":6784,"PHASE1":6786,"PHASE2":6788,"PHASE3":6790,"PHASE4":6796,"NA":6798},{"trials":6785,"activeCount":100},[],{"trials":6787,"activeCount":100},[],{"trials":6789,"activeCount":100},[],{"trials":6791,"activeCount":100},[6792],{"nctId":660,"briefTitle":661,"status":123,"phases":6793,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":6794,"interventions":6795},[90],[170,33],[582,668,669,670,671,672,673,486,446,674,675,676,676,671,486],{"trials":6797,"activeCount":100},[],{"trials":6799,"activeCount":100},[],{"intervention":3278,"totalTrials":139,"cells":6801},{"EARLY_PHASE1":6802,"PHASE1":6804,"PHASE2":6806,"PHASE3":6808,"PHASE4":6814,"NA":6816},{"trials":6803,"activeCount":100},[],{"trials":6805,"activeCount":100},[],{"trials":6807,"activeCount":100},[],{"trials":6809,"activeCount":100},[6810],{"nctId":3270,"briefTitle":3271,"status":123,"phases":6811,"primaryCompletion":3273,"completion":3273,"start":3274,"enrollment":3275,"conditions":6812,"interventions":6813},[90],[3176,373,3257],[3159,3159,3278,3278],{"trials":6815,"activeCount":100},[],{"trials":6817,"activeCount":100},[],{"intervention":6819,"totalTrials":139,"cells":6820},"Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016",{"EARLY_PHASE1":6821,"PHASE1":6823,"PHASE2":6825,"PHASE3":6827,"PHASE4":6837,"NA":6839},{"trials":6822,"activeCount":100},[],{"trials":6824,"activeCount":100},[],{"trials":6826,"activeCount":100},[],{"trials":6828,"activeCount":100},[6829],{"nctId":6830,"briefTitle":6831,"status":123,"phases":6832,"primaryCompletion":6833,"completion":1484,"start":1342,"enrollment":1416,"conditions":6834,"interventions":6835},"NCT02550197","Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years",[90],"2016-04",[15],[6819,6836],"Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation",{"trials":6838,"activeCount":100},[],{"trials":6840,"activeCount":100},[],{"intervention":6836,"totalTrials":139,"cells":6842},{"EARLY_PHASE1":6843,"PHASE1":6845,"PHASE2":6847,"PHASE3":6849,"PHASE4":6855,"NA":6857},{"trials":6844,"activeCount":100},[],{"trials":6846,"activeCount":100},[],{"trials":6848,"activeCount":100},[],{"trials":6850,"activeCount":100},[6851],{"nctId":6830,"briefTitle":6831,"status":123,"phases":6852,"primaryCompletion":6833,"completion":1484,"start":1342,"enrollment":1416,"conditions":6853,"interventions":6854},[90],[15],[6819,6836],{"trials":6856,"activeCount":100},[],{"trials":6858,"activeCount":100},[],{"intervention":6860,"totalTrials":139,"cells":6861},"DTaP-HB-PRP~T combined vaccine",{"EARLY_PHASE1":6862,"PHASE1":6864,"PHASE2":6866,"PHASE3":6868,"PHASE4":6878,"NA":6880},{"trials":6863,"activeCount":100},[],{"trials":6865,"activeCount":100},[],{"trials":6867,"activeCount":100},[],{"trials":6869,"activeCount":100},[6870],{"nctId":6871,"briefTitle":6872,"status":123,"phases":6873,"primaryCompletion":2100,"completion":1289,"start":1169,"enrollment":3990,"conditions":6874,"interventions":6875},"NCT00348881","Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB\u002FHib™, Concomitantly With OPV in Healthy Infants",[90],[18,24,21,36,15],[6860,6876,6877],"Tritanrix-HepB\u002FHib™ vaccine","Oral poliomyelitis vaccine",{"trials":6879,"activeCount":100},[],{"trials":6881,"activeCount":100},[],{"intervention":6876,"totalTrials":139,"cells":6883},{"EARLY_PHASE1":6884,"PHASE1":6886,"PHASE2":6888,"PHASE3":6890,"PHASE4":6896,"NA":6898},{"trials":6885,"activeCount":100},[],{"trials":6887,"activeCount":100},[],{"trials":6889,"activeCount":100},[],{"trials":6891,"activeCount":100},[6892],{"nctId":6871,"briefTitle":6872,"status":123,"phases":6893,"primaryCompletion":2100,"completion":1289,"start":1169,"enrollment":3990,"conditions":6894,"interventions":6895},[90],[18,24,21,36,15],[6860,6876,6877],{"trials":6897,"activeCount":100},[],{"trials":6899,"activeCount":100},[],{"intervention":6877,"totalTrials":139,"cells":6901},{"EARLY_PHASE1":6902,"PHASE1":6904,"PHASE2":6906,"PHASE3":6908,"PHASE4":6914,"NA":6916},{"trials":6903,"activeCount":100},[],{"trials":6905,"activeCount":100},[],{"trials":6907,"activeCount":100},[],{"trials":6909,"activeCount":100},[6910],{"nctId":6871,"briefTitle":6872,"status":123,"phases":6911,"primaryCompletion":2100,"completion":1289,"start":1169,"enrollment":3990,"conditions":6912,"interventions":6913},[90],[18,24,21,36,15],[6860,6876,6877],{"trials":6915,"activeCount":100},[],{"trials":6917,"activeCount":100},[],{"intervention":3855,"totalTrials":139,"cells":6919},{"EARLY_PHASE1":6920,"PHASE1":6922,"PHASE2":6924,"PHASE3":6926,"PHASE4":6932,"NA":6934},{"trials":6921,"activeCount":100},[],{"trials":6923,"activeCount":100},[],{"trials":6925,"activeCount":100},[],{"trials":6927,"activeCount":100},[6928],{"nctId":3847,"briefTitle":3848,"status":123,"phases":6929,"primaryCompletion":3850,"completion":3851,"start":3852,"enrollment":3506,"conditions":6930,"interventions":6931},[90],[372,373],[3855,3856,381,499,3855,3856,381,499],{"trials":6933,"activeCount":100},[],{"trials":6935,"activeCount":100},[],{"intervention":3856,"totalTrials":139,"cells":6937},{"EARLY_PHASE1":6938,"PHASE1":6940,"PHASE2":6942,"PHASE3":6944,"PHASE4":6950,"NA":6952},{"trials":6939,"activeCount":100},[],{"trials":6941,"activeCount":100},[],{"trials":6943,"activeCount":100},[],{"trials":6945,"activeCount":100},[6946],{"nctId":3847,"briefTitle":3848,"status":123,"phases":6947,"primaryCompletion":3850,"completion":3851,"start":3852,"enrollment":3506,"conditions":6948,"interventions":6949},[90],[372,373],[3855,3856,381,499,3855,3856,381,499],{"trials":6951,"activeCount":100},[],{"trials":6953,"activeCount":100},[],{"intervention":6955,"totalTrials":139,"cells":6956},"Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative",{"EARLY_PHASE1":6957,"PHASE1":6959,"PHASE2":6961,"PHASE3":6963,"PHASE4":6977,"NA":6979},{"trials":6958,"activeCount":100},[],{"trials":6960,"activeCount":100},[],{"trials":6962,"activeCount":100},[],{"trials":6964,"activeCount":100},[6965],{"nctId":6966,"briefTitle":6967,"status":123,"phases":6968,"primaryCompletion":6969,"completion":6969,"start":6970,"enrollment":6971,"conditions":6972,"interventions":6973},"NCT02451358","Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India",[90],"2017-01-28","2015-07-27",400,[15],[6955,6974,6975,6976],"Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative","Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative","Quadrivalent Inactivated Influenza Vaccine (2015 SH formulation), No Preservative",{"trials":6978,"activeCount":100},[],{"trials":6980,"activeCount":100},[],{"intervention":6974,"totalTrials":139,"cells":6982},{"EARLY_PHASE1":6983,"PHASE1":6985,"PHASE2":6987,"PHASE3":6989,"PHASE4":6995,"NA":6997},{"trials":6984,"activeCount":100},[],{"trials":6986,"activeCount":100},[],{"trials":6988,"activeCount":100},[],{"trials":6990,"activeCount":100},[6991],{"nctId":6966,"briefTitle":6967,"status":123,"phases":6992,"primaryCompletion":6969,"completion":6969,"start":6970,"enrollment":6971,"conditions":6993,"interventions":6994},[90],[15],[6955,6974,6975,6976],{"trials":6996,"activeCount":100},[],{"trials":6998,"activeCount":100},[],{"intervention":6975,"totalTrials":139,"cells":7000},{"EARLY_PHASE1":7001,"PHASE1":7003,"PHASE2":7005,"PHASE3":7007,"PHASE4":7013,"NA":7015},{"trials":7002,"activeCount":100},[],{"trials":7004,"activeCount":100},[],{"trials":7006,"activeCount":100},[],{"trials":7008,"activeCount":100},[7009],{"nctId":6966,"briefTitle":6967,"status":123,"phases":7010,"primaryCompletion":6969,"completion":6969,"start":6970,"enrollment":6971,"conditions":7011,"interventions":7012},[90],[15],[6955,6974,6975,6976],{"trials":7014,"activeCount":100},[],{"trials":7016,"activeCount":100},[],{"intervention":6976,"totalTrials":139,"cells":7018},{"EARLY_PHASE1":7019,"PHASE1":7021,"PHASE2":7023,"PHASE3":7025,"PHASE4":7031,"NA":7033},{"trials":7020,"activeCount":100},[],{"trials":7022,"activeCount":100},[],{"trials":7024,"activeCount":100},[],{"trials":7026,"activeCount":100},[7027],{"nctId":6966,"briefTitle":6967,"status":123,"phases":7028,"primaryCompletion":6969,"completion":6969,"start":6970,"enrollment":6971,"conditions":7029,"interventions":7030},[90],[15],[6955,6974,6975,6976],{"trials":7032,"activeCount":100},[],{"trials":7034,"activeCount":100},[],{"intervention":7036,"totalTrials":139,"cells":7037},"REVAXIS®",{"EARLY_PHASE1":7038,"PHASE1":7040,"PHASE2":7042,"PHASE3":7044,"PHASE4":7054,"NA":7056},{"trials":7039,"activeCount":100},[],{"trials":7041,"activeCount":100},[],{"trials":7043,"activeCount":100},[],{"trials":7045,"activeCount":100},[7046],{"nctId":7047,"briefTitle":7048,"status":123,"phases":7049,"primaryCompletion":3615,"completion":3615,"start":1265,"enrollment":7050,"conditions":7051,"interventions":7052},"NCT00447525","REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children",[90],760,[18,24,30],[7036,7053],"DT-Polio®",{"trials":7055,"activeCount":100},[],{"trials":7057,"activeCount":100},[],{"intervention":7053,"totalTrials":139,"cells":7059},{"EARLY_PHASE1":7060,"PHASE1":7062,"PHASE2":7064,"PHASE3":7066,"PHASE4":7072,"NA":7074},{"trials":7061,"activeCount":100},[],{"trials":7063,"activeCount":100},[],{"trials":7065,"activeCount":100},[],{"trials":7067,"activeCount":100},[7068],{"nctId":7047,"briefTitle":7048,"status":123,"phases":7069,"primaryCompletion":3615,"completion":3615,"start":1265,"enrollment":7050,"conditions":7070,"interventions":7071},[90],[18,24,30],[7036,7053],{"trials":7073,"activeCount":100},[],{"trials":7075,"activeCount":100},[],{"intervention":7077,"totalTrials":139,"cells":7078},"PEDIACEL® and Prevenar®",{"EARLY_PHASE1":7079,"PHASE1":7081,"PHASE2":7083,"PHASE3":7085,"PHASE4":7095,"NA":7097},{"trials":7080,"activeCount":100},[],{"trials":7082,"activeCount":100},[],{"trials":7084,"activeCount":100},[],{"trials":7086,"activeCount":100},[7087],{"nctId":7088,"briefTitle":7089,"status":123,"phases":7090,"primaryCompletion":1289,"completion":3401,"start":3328,"enrollment":7091,"conditions":7092,"interventions":7093},"NCT00343421","Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers",[90],588,[18,24,21,30,3821],[7077,7094],"Infanrix®-IPV+Hib and Prevenar®",{"trials":7096,"activeCount":100},[],{"trials":7098,"activeCount":100},[],{"intervention":7094,"totalTrials":139,"cells":7100},{"EARLY_PHASE1":7101,"PHASE1":7103,"PHASE2":7105,"PHASE3":7107,"PHASE4":7113,"NA":7115},{"trials":7102,"activeCount":100},[],{"trials":7104,"activeCount":100},[],{"trials":7106,"activeCount":100},[],{"trials":7108,"activeCount":100},[7109],{"nctId":7088,"briefTitle":7089,"status":123,"phases":7110,"primaryCompletion":1289,"completion":3401,"start":3328,"enrollment":7091,"conditions":7111,"interventions":7112},[90],[18,24,21,30,3821],[7077,7094],{"trials":7114,"activeCount":100},[],{"trials":7116,"activeCount":100},[],{"intervention":7118,"totalTrials":139,"cells":7119},"DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide",{"EARLY_PHASE1":7120,"PHASE1":7122,"PHASE2":7124,"PHASE3":7126,"PHASE4":7137,"NA":7139},{"trials":7121,"activeCount":100},[],{"trials":7123,"activeCount":100},[],{"trials":7125,"activeCount":100},[],{"trials":7127,"activeCount":100},[7128],{"nctId":7129,"briefTitle":7130,"status":123,"phases":7131,"primaryCompletion":127,"completion":6587,"start":1430,"enrollment":7132,"conditions":7133,"interventions":7134},"NCT01444781","Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants",[90],1106,[18,24,1600,36,30],[7118,7135,7136],"DTaP-Hep B-IPV \u002F\u002F Hib Vaccine + Pneumococcal polysaccharide","DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine",{"trials":7138,"activeCount":100},[],{"trials":7140,"activeCount":100},[],{"intervention":7135,"totalTrials":139,"cells":7142},{"EARLY_PHASE1":7143,"PHASE1":7145,"PHASE2":7147,"PHASE3":7149,"PHASE4":7155,"NA":7157},{"trials":7144,"activeCount":100},[],{"trials":7146,"activeCount":100},[],{"trials":7148,"activeCount":100},[],{"trials":7150,"activeCount":100},[7151],{"nctId":7129,"briefTitle":7130,"status":123,"phases":7152,"primaryCompletion":127,"completion":6587,"start":1430,"enrollment":7132,"conditions":7153,"interventions":7154},[90],[18,24,1600,36,30],[7118,7135,7136],{"trials":7156,"activeCount":100},[],{"trials":7158,"activeCount":100},[],{"intervention":7136,"totalTrials":139,"cells":7160},{"EARLY_PHASE1":7161,"PHASE1":7163,"PHASE2":7165,"PHASE3":7167,"PHASE4":7173,"NA":7175},{"trials":7162,"activeCount":100},[],{"trials":7164,"activeCount":100},[],{"trials":7166,"activeCount":100},[],{"trials":7168,"activeCount":100},[7169],{"nctId":7129,"briefTitle":7130,"status":123,"phases":7170,"primaryCompletion":127,"completion":6587,"start":1430,"enrollment":7132,"conditions":7171,"interventions":7172},[90],[18,24,1600,36,30],[7118,7135,7136],{"trials":7174,"activeCount":100},[],{"trials":7176,"activeCount":100},[],{"intervention":7178,"totalTrials":139,"cells":7179},"Trivalent Influenza Vaccine 1 SP Shz TIV1",{"EARLY_PHASE1":7180,"PHASE1":7182,"PHASE2":7184,"PHASE3":7186,"PHASE4":7197,"NA":7199},{"trials":7181,"activeCount":100},[],{"trials":7183,"activeCount":100},[],{"trials":7185,"activeCount":100},[],{"trials":7187,"activeCount":100},[7188],{"nctId":7189,"briefTitle":7190,"status":123,"phases":7191,"primaryCompletion":7192,"completion":7192,"start":5281,"enrollment":7193,"conditions":7194,"interventions":7195},"NCT04210349","Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age",[90],"2020-12-01",7106,[15],[6059,7178,7196],"Trivalent Influenza Vaccine 2 SP Shz TIV2",{"trials":7198,"activeCount":100},[],{"trials":7200,"activeCount":100},[],{"intervention":7196,"totalTrials":139,"cells":7202},{"EARLY_PHASE1":7203,"PHASE1":7205,"PHASE2":7207,"PHASE3":7209,"PHASE4":7215,"NA":7217},{"trials":7204,"activeCount":100},[],{"trials":7206,"activeCount":100},[],{"trials":7208,"activeCount":100},[],{"trials":7210,"activeCount":100},[7211],{"nctId":7189,"briefTitle":7190,"status":123,"phases":7212,"primaryCompletion":7192,"completion":7192,"start":5281,"enrollment":7193,"conditions":7213,"interventions":7214},[90],[15],[6059,7178,7196],{"trials":7216,"activeCount":100},[],{"trials":7218,"activeCount":100},[],{"intervention":7220,"totalTrials":139,"cells":7221},"DTaP-IPV-Hep B-PRP~T combined vaccine",{"EARLY_PHASE1":7222,"PHASE1":7224,"PHASE2":7226,"PHASE3":7228,"PHASE4":7239,"NA":7241},{"trials":7223,"activeCount":100},[],{"trials":7225,"activeCount":100},[],{"trials":7227,"activeCount":100},[],{"trials":7229,"activeCount":100},[7230],{"nctId":7231,"briefTitle":7232,"status":123,"phases":7233,"primaryCompletion":6833,"completion":7234,"start":1497,"enrollment":3329,"conditions":7235,"interventions":7237},"NCT02094833","DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV\u002F\u002FPRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants",[90],"2016-11",[18,24,21,7236,30,36],"Haemophilus Influenzae Type b Infection",[7220,7238],"DTaP-IPV\u002F\u002FPRP~T and Hepatitis B vaccine",{"trials":7240,"activeCount":100},[],{"trials":7242,"activeCount":100},[],{"intervention":7238,"totalTrials":139,"cells":7244},{"EARLY_PHASE1":7245,"PHASE1":7247,"PHASE2":7249,"PHASE3":7251,"PHASE4":7257,"NA":7259},{"trials":7246,"activeCount":100},[],{"trials":7248,"activeCount":100},[],{"trials":7250,"activeCount":100},[],{"trials":7252,"activeCount":100},[7253],{"nctId":7231,"briefTitle":7232,"status":123,"phases":7254,"primaryCompletion":6833,"completion":7234,"start":1497,"enrollment":3329,"conditions":7255,"interventions":7256},[90],[18,24,21,7236,30,36],[7220,7238],{"trials":7258,"activeCount":100},[],{"trials":7260,"activeCount":100},[],{"intervention":7262,"totalTrials":139,"cells":7263},"Poliomyelitis Vaccine inactivated",{"EARLY_PHASE1":7264,"PHASE1":7266,"PHASE2":7268,"PHASE3":7270,"PHASE4":7279,"NA":7281},{"trials":7265,"activeCount":100},[],{"trials":7267,"activeCount":100},[],{"trials":7269,"activeCount":100},[],{"trials":7271,"activeCount":100},[7272],{"nctId":7273,"briefTitle":7274,"status":123,"phases":7275,"primaryCompletion":1237,"completion":3614,"start":1169,"enrollment":2801,"conditions":7276,"interventions":7277},"NCT00348387","Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV",[90],[30,1666],[7262,7278],"Poliomyelitis Vaccine in Dragee Candy",{"trials":7280,"activeCount":100},[],{"trials":7282,"activeCount":100},[],{"intervention":7278,"totalTrials":139,"cells":7284},{"EARLY_PHASE1":7285,"PHASE1":7287,"PHASE2":7289,"PHASE3":7291,"PHASE4":7297,"NA":7299},{"trials":7286,"activeCount":100},[],{"trials":7288,"activeCount":100},[],{"trials":7290,"activeCount":100},[],{"trials":7292,"activeCount":100},[7293],{"nctId":7273,"briefTitle":7274,"status":123,"phases":7294,"primaryCompletion":1237,"completion":3614,"start":1169,"enrollment":2801,"conditions":7295,"interventions":7296},[90],[30,1666],[7262,7278],{"trials":7298,"activeCount":100},[],{"trials":7300,"activeCount":100},[],{"intervention":7302,"totalTrials":139,"cells":7303},"Typhoid Vi polysaccharide",{"EARLY_PHASE1":7304,"PHASE1":7306,"PHASE2":7308,"PHASE3":7310,"PHASE4":7320,"NA":7322},{"trials":7305,"activeCount":100},[],{"trials":7307,"activeCount":100},[],{"trials":7309,"activeCount":100},[],{"trials":7311,"activeCount":100},[7312],{"nctId":7313,"briefTitle":7314,"status":123,"phases":7315,"primaryCompletion":1316,"completion":1317,"start":1452,"enrollment":1319,"conditions":7316,"interventions":7319},"NCT01608815","Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects",[90],[7317,7318,131],"Salmonella Infections","Typhoid Fever",[7302],{"trials":7321,"activeCount":100},[],{"trials":7323,"activeCount":100},[],{"intervention":3713,"totalTrials":139,"cells":7325},{"EARLY_PHASE1":7326,"PHASE1":7328,"PHASE2":7330,"PHASE3":7332,"PHASE4":7338,"NA":7340},{"trials":7327,"activeCount":100},[],{"trials":7329,"activeCount":100},[],{"trials":7331,"activeCount":100},[],{"trials":7333,"activeCount":100},[7334],{"nctId":3705,"briefTitle":3706,"status":123,"phases":7335,"primaryCompletion":3708,"completion":3708,"start":3709,"enrollment":3710,"conditions":7336,"interventions":7337},[90],[27,1046,468],[3713,583],{"trials":7339,"activeCount":100},[],{"trials":7341,"activeCount":100},[],{"intervention":4256,"totalTrials":139,"cells":7343},{"EARLY_PHASE1":7344,"PHASE1":7346,"PHASE2":7348,"PHASE3":7350,"PHASE4":7356,"NA":7358},{"trials":7345,"activeCount":100},[],{"trials":7347,"activeCount":100},[],{"trials":7349,"activeCount":100},[],{"trials":7351,"activeCount":100},[7352],{"nctId":4249,"briefTitle":4250,"status":123,"phases":7353,"primaryCompletion":1948,"completion":4252,"start":1497,"enrollment":4253,"conditions":7354,"interventions":7355},[90],[24,18,21],[3268,4256],{"trials":7357,"activeCount":100},[],{"trials":7359,"activeCount":100},[],{"intervention":7361,"totalTrials":139,"cells":7362},"Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus",{"EARLY_PHASE1":7363,"PHASE1":7365,"PHASE2":7367,"PHASE3":7369,"PHASE4":7378,"NA":7380},{"trials":7364,"activeCount":100},[],{"trials":7366,"activeCount":100},[],{"trials":7368,"activeCount":100},[],{"trials":7370,"activeCount":100},[7371],{"nctId":7372,"briefTitle":7373,"status":123,"phases":7374,"primaryCompletion":1343,"completion":1317,"start":5254,"enrollment":7375,"conditions":7376,"interventions":7377},"NCT01188343","Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers",[90],542,[3063,1330,1331,1332],[7361,7361,7361],{"trials":7379,"activeCount":100},[],{"trials":7381,"activeCount":100},[],{"intervention":7383,"totalTrials":139,"cells":7384},"Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine",{"EARLY_PHASE1":7385,"PHASE1":7387,"PHASE2":7389,"PHASE3":7391,"PHASE4":7403,"NA":7405},{"trials":7386,"activeCount":100},[],{"trials":7388,"activeCount":100},[],{"trials":7390,"activeCount":100},[],{"trials":7392,"activeCount":100},[7393],{"nctId":7394,"briefTitle":7395,"status":123,"phases":7396,"primaryCompletion":7397,"completion":7397,"start":7398,"enrollment":7399,"conditions":7400,"interventions":7402},"NCT02817451","DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants",[90],"2019-02-22","2016-07-14",53,[18,24,21,36,1666,7401],"Human Immunodeficiency Virus Infection",[7383,7383],{"trials":7404,"activeCount":100},[],{"trials":7406,"activeCount":100},[],{"intervention":7408,"totalTrials":139,"cells":7409},"Purified vero rabies vaccine - serum free - VRVg-2",{"EARLY_PHASE1":7410,"PHASE1":7412,"PHASE2":7414,"PHASE3":7416,"PHASE4":7430,"NA":7432},{"trials":7411,"activeCount":100},[],{"trials":7413,"activeCount":100},[],{"trials":7415,"activeCount":100},[],{"trials":7417,"activeCount":100},[7418],{"nctId":7419,"briefTitle":7420,"status":123,"phases":7421,"primaryCompletion":7422,"completion":7423,"start":7424,"enrollment":7425,"conditions":7426,"interventions":7427},"NCT04127786","Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults",[90],"2020-03-25","2025-04-24","2019-10-21",1708,[1857,33],[7408,7428,7429],"Purified inactivated rabies vaccine - Verorab®","Purified inactivated rabies vaccine - Imovax® Rabies",{"trials":7431,"activeCount":100},[],{"trials":7433,"activeCount":100},[],{"intervention":7428,"totalTrials":139,"cells":7435},{"EARLY_PHASE1":7436,"PHASE1":7438,"PHASE2":7440,"PHASE3":7442,"PHASE4":7448,"NA":7450},{"trials":7437,"activeCount":100},[],{"trials":7439,"activeCount":100},[],{"trials":7441,"activeCount":100},[],{"trials":7443,"activeCount":100},[7444],{"nctId":7419,"briefTitle":7420,"status":123,"phases":7445,"primaryCompletion":7422,"completion":7423,"start":7424,"enrollment":7425,"conditions":7446,"interventions":7447},[90],[1857,33],[7408,7428,7429],{"trials":7449,"activeCount":100},[],{"trials":7451,"activeCount":100},[],{"intervention":7429,"totalTrials":139,"cells":7453},{"EARLY_PHASE1":7454,"PHASE1":7456,"PHASE2":7458,"PHASE3":7460,"PHASE4":7466,"NA":7468},{"trials":7455,"activeCount":100},[],{"trials":7457,"activeCount":100},[],{"trials":7459,"activeCount":100},[],{"trials":7461,"activeCount":100},[7462],{"nctId":7419,"briefTitle":7420,"status":123,"phases":7463,"primaryCompletion":7422,"completion":7423,"start":7424,"enrollment":7425,"conditions":7464,"interventions":7465},[90],[1857,33],[7408,7428,7429],{"trials":7467,"activeCount":100},[],{"trials":7469,"activeCount":100},[],{"intervention":7471,"totalTrials":139,"cells":7472},"Japanese encephalitis chimeric virus vaccine",{"EARLY_PHASE1":7473,"PHASE1":7475,"PHASE2":7477,"PHASE3":7479,"PHASE4":7490,"NA":7492},{"trials":7474,"activeCount":100},[],{"trials":7476,"activeCount":100},[],{"trials":7478,"activeCount":100},[],{"trials":7480,"activeCount":100},[7481],{"nctId":7482,"briefTitle":7483,"status":123,"phases":7484,"primaryCompletion":1430,"completion":7485,"start":5367,"enrollment":1416,"conditions":7486,"interventions":7488},"NCT01092507","A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers",[90],"2011-10",[7487,3063],"Encephalitis",[7471,7489],"Japanese encephalitis live vaccine",{"trials":7491,"activeCount":100},[],{"trials":7493,"activeCount":100},[],{"intervention":7489,"totalTrials":139,"cells":7495},{"EARLY_PHASE1":7496,"PHASE1":7498,"PHASE2":7500,"PHASE3":7502,"PHASE4":7508,"NA":7510},{"trials":7497,"activeCount":100},[],{"trials":7499,"activeCount":100},[],{"trials":7501,"activeCount":100},[],{"trials":7503,"activeCount":100},[7504],{"nctId":7482,"briefTitle":7483,"status":123,"phases":7505,"primaryCompletion":1430,"completion":7485,"start":5367,"enrollment":1416,"conditions":7506,"interventions":7507},[90],[7487,3063],[7471,7489],{"trials":7509,"activeCount":100},[],{"trials":7511,"activeCount":100},[],{"intervention":7513,"totalTrials":139,"cells":7514},"High-Dose trivalent influenza vaccine",{"EARLY_PHASE1":7515,"PHASE1":7517,"PHASE2":7519,"PHASE3":7521,"PHASE4":7534,"NA":7536},{"trials":7516,"activeCount":100},[],{"trials":7518,"activeCount":100},[],{"trials":7520,"activeCount":100},[],{"trials":7522,"activeCount":100},[7523],{"nctId":7524,"briefTitle":7525,"status":123,"phases":7526,"primaryCompletion":7527,"completion":7528,"start":7529,"enrollment":7530,"conditions":7531,"interventions":7532},"NCT06641180","Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age",[90],"2025-01-28","2025-06-24","2024-11-04",1180,[15],[7513,7533],"Standard-dose trivalent influenza vaccine",{"trials":7535,"activeCount":100},[],{"trials":7537,"activeCount":100},[],{"intervention":7533,"totalTrials":139,"cells":7539},{"EARLY_PHASE1":7540,"PHASE1":7542,"PHASE2":7544,"PHASE3":7546,"PHASE4":7552,"NA":7554},{"trials":7541,"activeCount":100},[],{"trials":7543,"activeCount":100},[],{"trials":7545,"activeCount":100},[],{"trials":7547,"activeCount":100},[7548],{"nctId":7524,"briefTitle":7525,"status":123,"phases":7549,"primaryCompletion":7527,"completion":7528,"start":7529,"enrollment":7530,"conditions":7550,"interventions":7551},[90],[15],[7513,7533],{"trials":7553,"activeCount":100},[],{"trials":7555,"activeCount":100},[],{"intervention":7557,"totalTrials":139,"cells":7558},"Standard-Dose Quadrivalent Influenza Vaccine",{"EARLY_PHASE1":7559,"PHASE1":7561,"PHASE2":7563,"PHASE3":7565,"PHASE4":7577,"NA":7579},{"trials":7560,"activeCount":100},[],{"trials":7562,"activeCount":100},[],{"trials":7564,"activeCount":100},[],{"trials":7566,"activeCount":100},[7567],{"nctId":7568,"briefTitle":7569,"status":123,"phases":7570,"primaryCompletion":7571,"completion":7571,"start":7572,"enrollment":7573,"conditions":7574,"interventions":7575},"NCT04537234","Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older",[90],"2021-02-09","2020-11-10",165,[3460],[7576,7557],"High-Dose Quadrivalent Influenza Vaccine",{"trials":7578,"activeCount":100},[],{"trials":7580,"activeCount":100},[],{"intervention":7582,"totalTrials":139,"cells":7583},"Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine",{"EARLY_PHASE1":7584,"PHASE1":7586,"PHASE2":7588,"PHASE3":7590,"PHASE4":7600,"NA":7602},{"trials":7585,"activeCount":100},[],{"trials":7587,"activeCount":100},[],{"trials":7589,"activeCount":100},[],{"trials":7591,"activeCount":100},[7592],{"nctId":7593,"briefTitle":7594,"status":123,"phases":7595,"primaryCompletion":1563,"completion":1564,"start":3242,"enrollment":7596,"conditions":7597,"interventions":7599},"NCT01948193","Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth",[90],177,[18,24,1600,36,30,7598],"Invasive Hib Infections",[7582],{"trials":7601,"activeCount":100},[],{"trials":7603,"activeCount":100},[],{"intervention":7605,"totalTrials":139,"cells":7606},"SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1",{"EARLY_PHASE1":7607,"PHASE1":7609,"PHASE2":7611,"PHASE3":7613,"PHASE4":7634,"NA":7636},{"trials":7608,"activeCount":100},[],{"trials":7610,"activeCount":100},[],{"trials":7612,"activeCount":100},[],{"trials":7614,"activeCount":100},[7615],{"nctId":7616,"briefTitle":7617,"status":123,"phases":7618,"primaryCompletion":7619,"completion":7619,"start":7620,"enrollment":7621,"conditions":7622,"interventions":7623},"NCT04762680","Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older",[89,90],"2023-06-29","2021-02-24",3159,[4730],[7605,7624,7625,7626,7627,7628,7629,7630,7631,7632,7633],"SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2","SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3","SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A","SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03","SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B","SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1","SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2","SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3","SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4","SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03",{"trials":7635,"activeCount":100},[],{"trials":7637,"activeCount":100},[],{"intervention":7624,"totalTrials":139,"cells":7639},{"EARLY_PHASE1":7640,"PHASE1":7642,"PHASE2":7644,"PHASE3":7646,"PHASE4":7652,"NA":7654},{"trials":7641,"activeCount":100},[],{"trials":7643,"activeCount":100},[],{"trials":7645,"activeCount":100},[],{"trials":7647,"activeCount":100},[7648],{"nctId":7616,"briefTitle":7617,"status":123,"phases":7649,"primaryCompletion":7619,"completion":7619,"start":7620,"enrollment":7621,"conditions":7650,"interventions":7651},[89,90],[4730],[7605,7624,7625,7626,7627,7628,7629,7630,7631,7632,7633],{"trials":7653,"activeCount":100},[],{"trials":7655,"activeCount":100},[],{"intervention":7625,"totalTrials":139,"cells":7657},{"EARLY_PHASE1":7658,"PHASE1":7660,"PHASE2":7662,"PHASE3":7664,"PHASE4":7670,"NA":7672},{"trials":7659,"activeCount":100},[],{"trials":7661,"activeCount":100},[],{"trials":7663,"activeCount":100},[],{"trials":7665,"activeCount":100},[7666],{"nctId":7616,"briefTitle":7617,"status":123,"phases":7667,"primaryCompletion":7619,"completion":7619,"start":7620,"enrollment":7621,"conditions":7668,"interventions":7669},[89,90],[4730],[7605,7624,7625,7626,7627,7628,7629,7630,7631,7632,7633],{"trials":7671,"activeCount":100},[],{"trials":7673,"activeCount":100},[],{"intervention":7626,"totalTrials":139,"cells":7675},{"EARLY_PHASE1":7676,"PHASE1":7678,"PHASE2":7680,"PHASE3":7682,"PHASE4":7688,"NA":7690},{"trials":7677,"activeCount":100},[],{"trials":7679,"activeCount":100},[],{"trials":7681,"activeCount":100},[],{"trials":7683,"activeCount":100},[7684],{"nctId":7616,"briefTitle":7617,"status":123,"phases":7685,"primaryCompletion":7619,"completion":7619,"start":7620,"enrollment":7621,"conditions":7686,"interventions":7687},[89,90],[4730],[7605,7624,7625,7626,7627,7628,7629,7630,7631,7632,7633],{"trials":7689,"activeCount":100},[],{"trials":7691,"activeCount":100},[],{"intervention":7627,"totalTrials":139,"cells":7693},{"EARLY_PHASE1":7694,"PHASE1":7696,"PHASE2":7698,"PHASE3":7700,"PHASE4":7706,"NA":7708},{"trials":7695,"activeCount":100},[],{"trials":7697,"activeCount":100},[],{"trials":7699,"activeCount":100},[],{"trials":7701,"activeCount":100},[7702],{"nctId":7616,"briefTitle":7617,"status":123,"phases":7703,"primaryCompletion":7619,"completion":7619,"start":7620,"enrollment":7621,"conditions":7704,"interventions":7705},[89,90],[4730],[7605,7624,7625,7626,7627,7628,7629,7630,7631,7632,7633],{"trials":7707,"activeCount":100},[],{"trials":7709,"activeCount":100},[],{"intervention":7628,"totalTrials":139,"cells":7711},{"EARLY_PHASE1":7712,"PHASE1":7714,"PHASE2":7716,"PHASE3":7718,"PHASE4":7724,"NA":7726},{"trials":7713,"activeCount":100},[],{"trials":7715,"activeCount":100},[],{"trials":7717,"activeCount":100},[],{"trials":7719,"activeCount":100},[7720],{"nctId":7616,"briefTitle":7617,"status":123,"phases":7721,"primaryCompletion":7619,"completion":7619,"start":7620,"enrollment":7621,"conditions":7722,"interventions":7723},[89,90],[4730],[7605,7624,7625,7626,7627,7628,7629,7630,7631,7632,7633],{"trials":7725,"activeCount":100},[],{"trials":7727,"activeCount":100},[],{"intervention":7629,"totalTrials":139,"cells":7729},{"EARLY_PHASE1":7730,"PHASE1":7732,"PHASE2":7734,"PHASE3":7736,"PHASE4":7742,"NA":7744},{"trials":7731,"activeCount":100},[],{"trials":7733,"activeCount":100},[],{"trials":7735,"activeCount":100},[],{"trials":7737,"activeCount":100},[7738],{"nctId":7616,"briefTitle":7617,"status":123,"phases":7739,"primaryCompletion":7619,"completion":7619,"start":7620,"enrollment":7621,"conditions":7740,"interventions":7741},[89,90],[4730],[7605,7624,7625,7626,7627,7628,7629,7630,7631,7632,7633],{"trials":7743,"activeCount":100},[],{"trials":7745,"activeCount":100},[],{"intervention":7630,"totalTrials":139,"cells":7747},{"EARLY_PHASE1":7748,"PHASE1":7750,"PHASE2":7752,"PHASE3":7754,"PHASE4":7760,"NA":7762},{"trials":7749,"activeCount":100},[],{"trials":7751,"activeCount":100},[],{"trials":7753,"activeCount":100},[],{"trials":7755,"activeCount":100},[7756],{"nctId":7616,"briefTitle":7617,"status":123,"phases":7757,"primaryCompletion":7619,"completion":7619,"start":7620,"enrollment":7621,"conditions":7758,"interventions":7759},[89,90],[4730],[7605,7624,7625,7626,7627,7628,7629,7630,7631,7632,7633],{"trials":7761,"activeCount":100},[],{"trials":7763,"activeCount":100},[],{"intervention":7631,"totalTrials":139,"cells":7765},{"EARLY_PHASE1":7766,"PHASE1":7768,"PHASE2":7770,"PHASE3":7772,"PHASE4":7778,"NA":7780},{"trials":7767,"activeCount":100},[],{"trials":7769,"activeCount":100},[],{"trials":7771,"activeCount":100},[],{"trials":7773,"activeCount":100},[7774],{"nctId":7616,"briefTitle":7617,"status":123,"phases":7775,"primaryCompletion":7619,"completion":7619,"start":7620,"enrollment":7621,"conditions":7776,"interventions":7777},[89,90],[4730],[7605,7624,7625,7626,7627,7628,7629,7630,7631,7632,7633],{"trials":7779,"activeCount":100},[],{"trials":7781,"activeCount":100},[],{"intervention":7632,"totalTrials":139,"cells":7783},{"EARLY_PHASE1":7784,"PHASE1":7786,"PHASE2":7788,"PHASE3":7790,"PHASE4":7796,"NA":7798},{"trials":7785,"activeCount":100},[],{"trials":7787,"activeCount":100},[],{"trials":7789,"activeCount":100},[],{"trials":7791,"activeCount":100},[7792],{"nctId":7616,"briefTitle":7617,"status":123,"phases":7793,"primaryCompletion":7619,"completion":7619,"start":7620,"enrollment":7621,"conditions":7794,"interventions":7795},[89,90],[4730],[7605,7624,7625,7626,7627,7628,7629,7630,7631,7632,7633],{"trials":7797,"activeCount":100},[],{"trials":7799,"activeCount":100},[],{"intervention":7633,"totalTrials":139,"cells":7801},{"EARLY_PHASE1":7802,"PHASE1":7804,"PHASE2":7806,"PHASE3":7808,"PHASE4":7814,"NA":7816},{"trials":7803,"activeCount":100},[],{"trials":7805,"activeCount":100},[],{"trials":7807,"activeCount":100},[],{"trials":7809,"activeCount":100},[7810],{"nctId":7616,"briefTitle":7617,"status":123,"phases":7811,"primaryCompletion":7619,"completion":7619,"start":7620,"enrollment":7621,"conditions":7812,"interventions":7813},[89,90],[4730],[7605,7624,7625,7626,7627,7628,7629,7630,7631,7632,7633],{"trials":7815,"activeCount":100},[],{"trials":7817,"activeCount":100},[],{"intervention":7819,"totalTrials":139,"cells":7820},"Recombinant influenza vaccine",{"EARLY_PHASE1":7821,"PHASE1":7823,"PHASE2":7825,"PHASE3":7827,"PHASE4":7839,"NA":7841},{"trials":7822,"activeCount":100},[],{"trials":7824,"activeCount":100},[],{"trials":7826,"activeCount":100},[],{"trials":7828,"activeCount":100},[7829],{"nctId":7830,"briefTitle":7831,"status":646,"phases":7832,"primaryCompletion":7833,"completion":7833,"start":7834,"enrollment":7835,"conditions":7836,"interventions":7837},"NCT05513391","Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years",[90],"2023-10-03","2022-11-10",366,[759],[7819,7838],"Quadrivalent influenza vaccine",{"trials":7840,"activeCount":100},[],{"trials":7842,"activeCount":100},[],{"intervention":3813,"totalTrials":139,"cells":7844},{"EARLY_PHASE1":7845,"PHASE1":7847,"PHASE2":7849,"PHASE3":7851,"PHASE4":7857,"NA":7859},{"trials":7846,"activeCount":100},[],{"trials":7848,"activeCount":100},[],{"trials":7850,"activeCount":100},[],{"trials":7852,"activeCount":100},[7853],{"nctId":3805,"briefTitle":3806,"status":123,"phases":7854,"primaryCompletion":3808,"completion":1236,"start":2569,"enrollment":3809,"conditions":7855,"interventions":7856},[90],[18,24,21,36,3811],[3813,3814,3785],{"trials":7858,"activeCount":100},[],{"trials":7860,"activeCount":100},[],{"intervention":3814,"totalTrials":139,"cells":7862},{"EARLY_PHASE1":7863,"PHASE1":7865,"PHASE2":7867,"PHASE3":7869,"PHASE4":7875,"NA":7877},{"trials":7864,"activeCount":100},[],{"trials":7866,"activeCount":100},[],{"trials":7868,"activeCount":100},[],{"trials":7870,"activeCount":100},[7871],{"nctId":3805,"briefTitle":3806,"status":123,"phases":7872,"primaryCompletion":3808,"completion":1236,"start":2569,"enrollment":3809,"conditions":7873,"interventions":7874},[90],[18,24,21,36,3811],[3813,3814,3785],{"trials":7876,"activeCount":100},[],{"trials":7878,"activeCount":100},[],{"intervention":3984,"totalTrials":139,"cells":7880},{"EARLY_PHASE1":7881,"PHASE1":7883,"PHASE2":7885,"PHASE3":7887,"PHASE4":7893,"NA":7895},{"trials":7882,"activeCount":100},[],{"trials":7884,"activeCount":100},[],{"trials":7886,"activeCount":100},[],{"trials":7888,"activeCount":100},[7889],{"nctId":3978,"briefTitle":3979,"status":123,"phases":7890,"primaryCompletion":2776,"completion":3490,"start":2569,"enrollment":3981,"conditions":7891,"interventions":7892},[90],[36,1666,18,21,3821],[3958,3984,3985],{"trials":7894,"activeCount":100},[],{"trials":7896,"activeCount":100},[],{"intervention":3985,"totalTrials":139,"cells":7898},{"EARLY_PHASE1":7899,"PHASE1":7901,"PHASE2":7903,"PHASE3":7905,"PHASE4":7911,"NA":7913},{"trials":7900,"activeCount":100},[],{"trials":7902,"activeCount":100},[],{"trials":7904,"activeCount":100},[],{"trials":7906,"activeCount":100},[7907],{"nctId":3978,"briefTitle":3979,"status":123,"phases":7908,"primaryCompletion":2776,"completion":3490,"start":2569,"enrollment":3981,"conditions":7909,"interventions":7910},[90],[36,1666,18,21,3821],[3958,3984,3985],{"trials":7912,"activeCount":100},[],{"trials":7914,"activeCount":100},[],{"intervention":3993,"totalTrials":139,"cells":7916},{"EARLY_PHASE1":7917,"PHASE1":7919,"PHASE2":7921,"PHASE3":7923,"PHASE4":7929,"NA":7931},{"trials":7918,"activeCount":100},[],{"trials":7920,"activeCount":100},[],{"trials":7922,"activeCount":100},[],{"trials":7924,"activeCount":100},[7925],{"nctId":3987,"briefTitle":3988,"status":123,"phases":7926,"primaryCompletion":3615,"completion":2568,"start":3328,"enrollment":3990,"conditions":7927,"interventions":7928},[90],[18,24,21,3821,36],[3958,3993],{"trials":7930,"activeCount":100},[],{"trials":7932,"activeCount":100},[],{"intervention":7934,"totalTrials":139,"cells":7935},"Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation",{"EARLY_PHASE1":7936,"PHASE1":7938,"PHASE2":7940,"PHASE3":7942,"PHASE4":7953,"NA":7955},{"trials":7937,"activeCount":100},[],{"trials":7939,"activeCount":100},[],{"trials":7941,"activeCount":100},[],{"trials":7943,"activeCount":100},[7944],{"nctId":7945,"briefTitle":7946,"status":123,"phases":7947,"primaryCompletion":1586,"completion":6587,"start":6055,"enrollment":7948,"conditions":7949,"interventions":7950},"NCT01712984","Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years",[90],3360,[15],[7934,7951,7952],"Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal","Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal",{"trials":7954,"activeCount":100},[],{"trials":7956,"activeCount":100},[],{"intervention":7951,"totalTrials":139,"cells":7958},{"EARLY_PHASE1":7959,"PHASE1":7961,"PHASE2":7963,"PHASE3":7965,"PHASE4":7971,"NA":7973},{"trials":7960,"activeCount":100},[],{"trials":7962,"activeCount":100},[],{"trials":7964,"activeCount":100},[],{"trials":7966,"activeCount":100},[7967],{"nctId":7945,"briefTitle":7946,"status":123,"phases":7968,"primaryCompletion":1586,"completion":6587,"start":6055,"enrollment":7948,"conditions":7969,"interventions":7970},[90],[15],[7934,7951,7952],{"trials":7972,"activeCount":100},[],{"trials":7974,"activeCount":100},[],{"intervention":7952,"totalTrials":139,"cells":7976},{"EARLY_PHASE1":7977,"PHASE1":7979,"PHASE2":7981,"PHASE3":7983,"PHASE4":7989,"NA":7991},{"trials":7978,"activeCount":100},[],{"trials":7980,"activeCount":100},[],{"trials":7982,"activeCount":100},[],{"trials":7984,"activeCount":100},[7985],{"nctId":7945,"briefTitle":7946,"status":123,"phases":7986,"primaryCompletion":1586,"completion":6587,"start":6055,"enrollment":7948,"conditions":7987,"interventions":7988},[90],[15],[7934,7951,7952],{"trials":7990,"activeCount":100},[],{"trials":7992,"activeCount":100},[],{"intervention":7994,"totalTrials":139,"cells":7995},"Flu-ID 15μg",{"EARLY_PHASE1":7996,"PHASE1":7998,"PHASE2":8000,"PHASE3":8002,"PHASE4":8012,"NA":8014},{"trials":7997,"activeCount":100},[],{"trials":7999,"activeCount":100},[],{"trials":8001,"activeCount":100},[],{"trials":8003,"activeCount":100},[8004],{"nctId":8005,"briefTitle":8006,"status":123,"phases":8007,"primaryCompletion":1266,"completion":1266,"start":2100,"enrollment":8008,"conditions":8009,"interventions":8010},"NCT00554333","Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine",[90],795,[15],[7994,8011],"Inactivated adjuvanted Influenza Vaccine",{"trials":8013,"activeCount":100},[],{"trials":8015,"activeCount":100},[],{"intervention":8011,"totalTrials":139,"cells":8017},{"EARLY_PHASE1":8018,"PHASE1":8020,"PHASE2":8022,"PHASE3":8024,"PHASE4":8030,"NA":8032},{"trials":8019,"activeCount":100},[],{"trials":8021,"activeCount":100},[],{"trials":8023,"activeCount":100},[],{"trials":8025,"activeCount":100},[8026],{"nctId":8005,"briefTitle":8006,"status":123,"phases":8027,"primaryCompletion":1266,"completion":1266,"start":2100,"enrollment":8008,"conditions":8028,"interventions":8029},[90],[15],[7994,8011],{"trials":8031,"activeCount":100},[],{"trials":8033,"activeCount":100},[],{"intervention":4537,"totalTrials":139,"cells":8035},{"EARLY_PHASE1":8036,"PHASE1":8038,"PHASE2":8040,"PHASE3":8042,"PHASE4":8048,"NA":8050},{"trials":8037,"activeCount":100},[],{"trials":8039,"activeCount":100},[],{"trials":8041,"activeCount":100},[],{"trials":8043,"activeCount":100},[8044],{"nctId":4529,"briefTitle":4530,"status":123,"phases":8045,"primaryCompletion":1596,"completion":1586,"start":4532,"enrollment":4533,"conditions":8046,"interventions":8047},[90],[3063,4535],[4518,4537],{"trials":8049,"activeCount":100},[],{"trials":8051,"activeCount":100},[],{"intervention":3569,"totalTrials":139,"cells":8053},{"EARLY_PHASE1":8054,"PHASE1":8056,"PHASE2":8058,"PHASE3":8060,"PHASE4":8066,"NA":8068},{"trials":8055,"activeCount":100},[],{"trials":8057,"activeCount":100},[],{"trials":8059,"activeCount":100},[],{"trials":8061,"activeCount":100},[8062],{"nctId":3560,"briefTitle":3561,"status":123,"phases":8063,"primaryCompletion":3563,"completion":3564,"start":3565,"enrollment":3566,"conditions":8064,"interventions":8065},[90],[3542],[3569,3515,3570,3545],{"trials":8067,"activeCount":100},[],{"trials":8069,"activeCount":100},[],{"intervention":3570,"totalTrials":139,"cells":8071},{"EARLY_PHASE1":8072,"PHASE1":8074,"PHASE2":8076,"PHASE3":8078,"PHASE4":8084,"NA":8086},{"trials":8073,"activeCount":100},[],{"trials":8075,"activeCount":100},[],{"trials":8077,"activeCount":100},[],{"trials":8079,"activeCount":100},[8080],{"nctId":3560,"briefTitle":3561,"status":123,"phases":8081,"primaryCompletion":3563,"completion":3564,"start":3565,"enrollment":3566,"conditions":8082,"interventions":8083},[90],[3542],[3569,3515,3570,3545],{"trials":8085,"activeCount":100},[],{"trials":8087,"activeCount":100},[],{"intervention":8089,"totalTrials":139,"cells":8090},"Adacel®",{"EARLY_PHASE1":8091,"PHASE1":8093,"PHASE2":8095,"PHASE3":8097,"PHASE4":8106,"NA":8108},{"trials":8092,"activeCount":100},[],{"trials":8094,"activeCount":100},[],{"trials":8096,"activeCount":100},[],{"trials":8098,"activeCount":100},[8099],{"nctId":8100,"briefTitle":8101,"status":123,"phases":8102,"primaryCompletion":8103,"completion":1972,"start":1971,"enrollment":1212,"conditions":8104,"interventions":8105},"NCT01040052","A Study to Assess the Safety of Adacel® Vaccine",[90],"2010-02",[18,24,21],[8089],{"trials":8107,"activeCount":100},[],{"trials":8109,"activeCount":100},[],{"intervention":4463,"totalTrials":139,"cells":8111},{"EARLY_PHASE1":8112,"PHASE1":8114,"PHASE2":8116,"PHASE3":8118,"PHASE4":8124,"NA":8126},{"trials":8113,"activeCount":100},[],{"trials":8115,"activeCount":100},[],{"trials":8117,"activeCount":100},[],{"trials":8119,"activeCount":100},[8120],{"nctId":4454,"briefTitle":4455,"status":123,"phases":8121,"primaryCompletion":4457,"completion":4458,"start":4459,"enrollment":731,"conditions":8122,"interventions":8123},[90],[4461],[4463,4463,4434,4434],{"trials":8125,"activeCount":100},[],{"trials":8127,"activeCount":100},[],{"intervention":4024,"totalTrials":139,"cells":8129},{"EARLY_PHASE1":8130,"PHASE1":8132,"PHASE2":8134,"PHASE3":8136,"PHASE4":8142,"NA":8144},{"trials":8131,"activeCount":100},[],{"trials":8133,"activeCount":100},[],{"trials":8135,"activeCount":100},[],{"trials":8137,"activeCount":100},[8138],{"nctId":4018,"briefTitle":4019,"status":123,"phases":8139,"primaryCompletion":3186,"completion":1316,"start":1414,"enrollment":4021,"conditions":8140,"interventions":8141},[90],[1857,3764],[4024,4024,3999,3999],{"trials":8143,"activeCount":100},[],{"trials":8145,"activeCount":100},[],{"intervention":8147,"totalTrials":139,"cells":8148},"Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative",{"EARLY_PHASE1":8149,"PHASE1":8151,"PHASE2":8153,"PHASE3":8155,"PHASE4":8166,"NA":8168},{"trials":8150,"activeCount":100},[],{"trials":8152,"activeCount":100},[],{"trials":8154,"activeCount":100},[],{"trials":8156,"activeCount":100},[8157],{"nctId":8158,"briefTitle":8159,"status":123,"phases":8160,"primaryCompletion":2015,"completion":1463,"start":1415,"enrollment":8161,"conditions":8162,"interventions":8163},"NCT01240746","Study of Quadrivalent Influenza Vaccine Among Children",[90],4363,[15],[8147,8164,8165],"Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative","Quadrivalent Influenza Vaccine, No Preservative",{"trials":8167,"activeCount":100},[],{"trials":8169,"activeCount":100},[],{"intervention":8164,"totalTrials":139,"cells":8171},{"EARLY_PHASE1":8172,"PHASE1":8174,"PHASE2":8176,"PHASE3":8178,"PHASE4":8184,"NA":8186},{"trials":8173,"activeCount":100},[],{"trials":8175,"activeCount":100},[],{"trials":8177,"activeCount":100},[],{"trials":8179,"activeCount":100},[8180],{"nctId":8158,"briefTitle":8159,"status":123,"phases":8181,"primaryCompletion":2015,"completion":1463,"start":1415,"enrollment":8161,"conditions":8182,"interventions":8183},[90],[15],[8147,8164,8165],{"trials":8185,"activeCount":100},[],{"trials":8187,"activeCount":100},[],{"intervention":8165,"totalTrials":139,"cells":8189},{"EARLY_PHASE1":8190,"PHASE1":8192,"PHASE2":8194,"PHASE3":8196,"PHASE4":8202,"NA":8204},{"trials":8191,"activeCount":100},[],{"trials":8193,"activeCount":100},[],{"trials":8195,"activeCount":100},[],{"trials":8197,"activeCount":100},[8198],{"nctId":8158,"briefTitle":8159,"status":123,"phases":8199,"primaryCompletion":2015,"completion":1463,"start":1415,"enrollment":8161,"conditions":8200,"interventions":8201},[90],[15],[8147,8164,8165],{"trials":8203,"activeCount":100},[],{"trials":8205,"activeCount":100},[],{"intervention":4570,"totalTrials":139,"cells":8207},{"EARLY_PHASE1":8208,"PHASE1":8210,"PHASE2":8212,"PHASE3":8214,"PHASE4":8220,"NA":8222},{"trials":8209,"activeCount":100},[],{"trials":8211,"activeCount":100},[],{"trials":8213,"activeCount":100},[],{"trials":8215,"activeCount":100},[8216],{"nctId":4562,"briefTitle":4563,"status":123,"phases":8217,"primaryCompletion":1191,"completion":1228,"start":1327,"enrollment":4565,"conditions":8218,"interventions":8219},[90],[4567,4568],[4551,4570],{"trials":8221,"activeCount":100},[],{"trials":8223,"activeCount":100},[],{"intervention":613,"totalTrials":139,"cells":8225},{"EARLY_PHASE1":8226,"PHASE1":8228,"PHASE2":8230,"PHASE3":8232,"PHASE4":8238,"NA":8240},{"trials":8227,"activeCount":100},[],{"trials":8229,"activeCount":100},[],{"trials":8231,"activeCount":100},[],{"trials":8233,"activeCount":100},[8234],{"nctId":603,"briefTitle":604,"status":123,"phases":8235,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":8236,"interventions":8237},[90],[478],[611,583,612,613,614,615,538,616,562,584,559],{"trials":8239,"activeCount":100},[],{"trials":8241,"activeCount":100},[],{"intervention":614,"totalTrials":139,"cells":8243},{"EARLY_PHASE1":8244,"PHASE1":8246,"PHASE2":8248,"PHASE3":8250,"PHASE4":8256,"NA":8258},{"trials":8245,"activeCount":100},[],{"trials":8247,"activeCount":100},[],{"trials":8249,"activeCount":100},[],{"trials":8251,"activeCount":100},[8252],{"nctId":603,"briefTitle":604,"status":123,"phases":8253,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":8254,"interventions":8255},[90],[478],[611,583,612,613,614,615,538,616,562,584,559],{"trials":8257,"activeCount":100},[],{"trials":8259,"activeCount":100},[],{"intervention":615,"totalTrials":139,"cells":8261},{"EARLY_PHASE1":8262,"PHASE1":8264,"PHASE2":8266,"PHASE3":8268,"PHASE4":8274,"NA":8276},{"trials":8263,"activeCount":100},[],{"trials":8265,"activeCount":100},[],{"trials":8267,"activeCount":100},[],{"trials":8269,"activeCount":100},[8270],{"nctId":603,"briefTitle":604,"status":123,"phases":8271,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":8272,"interventions":8273},[90],[478],[611,583,612,613,614,615,538,616,562,584,559],{"trials":8275,"activeCount":100},[],{"trials":8277,"activeCount":100},[],{"intervention":8279,"totalTrials":139,"cells":8280},"QIV-HD",{"EARLY_PHASE1":8281,"PHASE1":8283,"PHASE2":8285,"PHASE3":8287,"PHASE4":8301,"NA":8303},{"trials":8282,"activeCount":100},[],{"trials":8284,"activeCount":100},[],{"trials":8286,"activeCount":100},[],{"trials":8288,"activeCount":100},[8289],{"nctId":8290,"briefTitle":8291,"status":123,"phases":8292,"primaryCompletion":8293,"completion":8294,"start":8295,"enrollment":8296,"conditions":8297,"interventions":8298},"NCT03282240","Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US",[90],"2017-11-02","2018-04-19","2017-09-08",2670,[15],[8279,8299,8300],"Licensed TIV-HD1","Investigational TIV-HD2",{"trials":8302,"activeCount":100},[],{"trials":8304,"activeCount":100},[],{"intervention":8299,"totalTrials":139,"cells":8306},{"EARLY_PHASE1":8307,"PHASE1":8309,"PHASE2":8311,"PHASE3":8313,"PHASE4":8319,"NA":8321},{"trials":8308,"activeCount":100},[],{"trials":8310,"activeCount":100},[],{"trials":8312,"activeCount":100},[],{"trials":8314,"activeCount":100},[8315],{"nctId":8290,"briefTitle":8291,"status":123,"phases":8316,"primaryCompletion":8293,"completion":8294,"start":8295,"enrollment":8296,"conditions":8317,"interventions":8318},[90],[15],[8279,8299,8300],{"trials":8320,"activeCount":100},[],{"trials":8322,"activeCount":100},[],{"intervention":8300,"totalTrials":139,"cells":8324},{"EARLY_PHASE1":8325,"PHASE1":8327,"PHASE2":8329,"PHASE3":8331,"PHASE4":8337,"NA":8339},{"trials":8326,"activeCount":100},[],{"trials":8328,"activeCount":100},[],{"trials":8330,"activeCount":100},[],{"trials":8332,"activeCount":100},[8333],{"nctId":8290,"briefTitle":8291,"status":123,"phases":8334,"primaryCompletion":8293,"completion":8294,"start":8295,"enrollment":8296,"conditions":8335,"interventions":8336},[90],[15],[8279,8299,8300],{"trials":8338,"activeCount":100},[],{"trials":8340,"activeCount":100},[],{"intervention":8342,"totalTrials":139,"cells":8343},"DTaP-IPV-Hep B-PRP-T Vaccine",{"EARLY_PHASE1":8344,"PHASE1":8346,"PHASE2":8348,"PHASE3":8350,"PHASE4":8360,"NA":8362},{"trials":8345,"activeCount":100},[],{"trials":8347,"activeCount":100},[],{"trials":8349,"activeCount":100},[],{"trials":8351,"activeCount":100},[8352],{"nctId":8353,"briefTitle":8354,"status":123,"phases":8355,"primaryCompletion":7485,"completion":2015,"start":5254,"enrollment":8356,"conditions":8357,"interventions":8358},"NCT01177722","A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants",[90],1375,[18,24,1600,36,30],[8342,8342,8342,8359],"DTaP-Hep B-IPV vaccine",{"trials":8361,"activeCount":100},[],{"trials":8363,"activeCount":100},[],{"intervention":8359,"totalTrials":139,"cells":8365},{"EARLY_PHASE1":8366,"PHASE1":8368,"PHASE2":8370,"PHASE3":8372,"PHASE4":8378,"NA":8380},{"trials":8367,"activeCount":100},[],{"trials":8369,"activeCount":100},[],{"trials":8371,"activeCount":100},[],{"trials":8373,"activeCount":100},[8374],{"nctId":8353,"briefTitle":8354,"status":123,"phases":8375,"primaryCompletion":7485,"completion":2015,"start":5254,"enrollment":8356,"conditions":8376,"interventions":8377},[90],[18,24,1600,36,30],[8342,8342,8342,8359],{"trials":8379,"activeCount":100},[],{"trials":8381,"activeCount":100},[],{"intervention":8383,"totalTrials":139,"cells":8384},"C. difficile Toxoid Vaccine",{"EARLY_PHASE1":8385,"PHASE1":8387,"PHASE2":8389,"PHASE3":8391,"PHASE4":8403,"NA":8405},{"trials":8386,"activeCount":100},[],{"trials":8388,"activeCount":100},[],{"trials":8390,"activeCount":100},[],{"trials":8392,"activeCount":100},[8393],{"nctId":8394,"briefTitle":8395,"status":646,"phases":8396,"primaryCompletion":8397,"completion":8397,"start":8398,"enrollment":8399,"conditions":8400,"interventions":8402},"NCT01887912","Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection",[90],"2018-06-12","2013-07-30",9302,[8401],"Clostridium Difficile Infection",[8383],{"trials":8404,"activeCount":100},[],{"trials":8406,"activeCount":100},[],{"intervention":8408,"totalTrials":139,"cells":8409},"Pneumo 23",{"EARLY_PHASE1":8410,"PHASE1":8412,"PHASE2":8414,"PHASE3":8416,"PHASE4":8427,"NA":8429},{"trials":8411,"activeCount":100},[],{"trials":8413,"activeCount":100},[],{"trials":8415,"activeCount":100},[],{"trials":8417,"activeCount":100},[8418],{"nctId":8419,"briefTitle":8420,"status":123,"phases":8421,"primaryCompletion":3479,"completion":3363,"start":3808,"enrollment":8422,"conditions":8423,"interventions":8425},"NCT00594347","Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar",[90],339,[8424],"Streptococcus Pneumoniae",[8408,8426],"Prevnar",{"trials":8428,"activeCount":100},[],{"trials":8430,"activeCount":100},[],{"intervention":8426,"totalTrials":139,"cells":8432},{"EARLY_PHASE1":8433,"PHASE1":8435,"PHASE2":8437,"PHASE3":8439,"PHASE4":8445,"NA":8447},{"trials":8434,"activeCount":100},[],{"trials":8436,"activeCount":100},[],{"trials":8438,"activeCount":100},[],{"trials":8440,"activeCount":100},[8441],{"nctId":8419,"briefTitle":8420,"status":123,"phases":8442,"primaryCompletion":3479,"completion":3363,"start":3808,"enrollment":8422,"conditions":8443,"interventions":8444},[90],[8424],[8408,8426],{"trials":8446,"activeCount":100},[],{"trials":8448,"activeCount":100},[],{"intervention":8450,"totalTrials":139,"cells":8451},"Diphteria, tetanus, and Acellular Pertussis vaccine",{"EARLY_PHASE1":8452,"PHASE1":8454,"PHASE2":8456,"PHASE3":8458,"PHASE4":8467,"NA":8469},{"trials":8453,"activeCount":100},[],{"trials":8455,"activeCount":100},[],{"trials":8457,"activeCount":100},[],{"trials":8459,"activeCount":100},[8460],{"nctId":8461,"briefTitle":8462,"status":123,"phases":8463,"primaryCompletion":2569,"completion":2569,"start":3643,"enrollment":8464,"conditions":8465,"interventions":8466},"NCT00258908","Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan",[90],115,[18,24,21],[8450],{"trials":8468,"activeCount":100},[],{"trials":8470,"activeCount":100},[],{"intervention":8472,"totalTrials":139,"cells":8473},"Tdap",{"EARLY_PHASE1":8474,"PHASE1":8476,"PHASE2":8478,"PHASE3":8480,"PHASE4":8490,"NA":8492},{"trials":8475,"activeCount":100},[],{"trials":8477,"activeCount":100},[],{"trials":8479,"activeCount":100},[],{"trials":8481,"activeCount":100},[8482],{"nctId":8483,"briefTitle":8484,"status":123,"phases":8485,"primaryCompletion":5524,"completion":1971,"start":5343,"enrollment":8486,"conditions":8487,"interventions":8488},"NCT00467519","Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age",[90],1045,[24,18,21],[8472,8489],"DTaP",{"trials":8491,"activeCount":100},[],{"trials":8493,"activeCount":100},[],{"intervention":8489,"totalTrials":139,"cells":8495},{"EARLY_PHASE1":8496,"PHASE1":8498,"PHASE2":8500,"PHASE3":8502,"PHASE4":8508,"NA":8510},{"trials":8497,"activeCount":100},[],{"trials":8499,"activeCount":100},[],{"trials":8501,"activeCount":100},[],{"trials":8503,"activeCount":100},[8504],{"nctId":8483,"briefTitle":8484,"status":123,"phases":8505,"primaryCompletion":5524,"completion":1971,"start":5343,"enrollment":8486,"conditions":8506,"interventions":8507},[90],[24,18,21],[8472,8489],{"trials":8509,"activeCount":100},[],{"trials":8511,"activeCount":100},[],{"intervention":8513,"totalTrials":139,"cells":8514},"JE-CV administered in Study JEC02",{"EARLY_PHASE1":8515,"PHASE1":8517,"PHASE2":8519,"PHASE3":8521,"PHASE4":8532,"NA":8534},{"trials":8516,"activeCount":100},[],{"trials":8518,"activeCount":100},[],{"trials":8520,"activeCount":100},[],{"trials":8522,"activeCount":100},[8523],{"nctId":8524,"briefTitle":8525,"status":123,"phases":8526,"primaryCompletion":8527,"completion":8527,"start":8528,"enrollment":8529,"conditions":8530,"interventions":8531},"NCT01001988","Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers",[90],"2013-10-16","2009-08-07",596,[7487,3063],[8513],{"trials":8533,"activeCount":100},[],{"trials":8535,"activeCount":100},[],{"intervention":3509,"totalTrials":139,"cells":8537},{"EARLY_PHASE1":8538,"PHASE1":8540,"PHASE2":8542,"PHASE3":8544,"PHASE4":8550,"NA":8552},{"trials":8539,"activeCount":100},[],{"trials":8541,"activeCount":100},[],{"trials":8543,"activeCount":100},[],{"trials":8545,"activeCount":100},[8546],{"nctId":3503,"briefTitle":3504,"status":123,"phases":8547,"primaryCompletion":2776,"completion":1326,"start":2654,"enrollment":3506,"conditions":8548,"interventions":8549},[90],[1975],[3509,486],{"trials":8551,"activeCount":100},[],{"trials":8553,"activeCount":100},[],{"intervention":8555,"totalTrials":139,"cells":8556},"Meningococcal Diphtheria Toxoid Vaccine",{"EARLY_PHASE1":8557,"PHASE1":8559,"PHASE2":8561,"PHASE3":8563,"PHASE4":8573,"NA":8575},{"trials":8558,"activeCount":100},[],{"trials":8560,"activeCount":100},[],{"trials":8562,"activeCount":100},[],{"trials":8564,"activeCount":100},[8565],{"nctId":8566,"briefTitle":8567,"status":123,"phases":8568,"primaryCompletion":8569,"completion":8569,"start":8570,"enrollment":1416,"conditions":8571,"interventions":8572},"NCT01890759","Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation",[90],"2016-04-12","2013-06-25",[27,162],[8555],{"trials":8574,"activeCount":100},[],{"trials":8576,"activeCount":100},[],{"intervention":4427,"totalTrials":139,"cells":8578},{"EARLY_PHASE1":8579,"PHASE1":8581,"PHASE2":8583,"PHASE3":8585,"PHASE4":8591,"NA":8593},{"trials":8580,"activeCount":100},[],{"trials":8582,"activeCount":100},[],{"trials":8584,"activeCount":100},[],{"trials":8586,"activeCount":100},[8587],{"nctId":4421,"briefTitle":4422,"status":123,"phases":8588,"primaryCompletion":3242,"completion":1485,"start":1429,"enrollment":4424,"conditions":8589,"interventions":8590},[90],[18,24,21],[4402,4427,4428],{"trials":8592,"activeCount":100},[],{"trials":8594,"activeCount":100},[],{"intervention":4428,"totalTrials":139,"cells":8596},{"EARLY_PHASE1":8597,"PHASE1":8599,"PHASE2":8601,"PHASE3":8603,"PHASE4":8609,"NA":8611},{"trials":8598,"activeCount":100},[],{"trials":8600,"activeCount":100},[],{"trials":8602,"activeCount":100},[],{"trials":8604,"activeCount":100},[8605],{"nctId":4421,"briefTitle":4422,"status":123,"phases":8606,"primaryCompletion":3242,"completion":1485,"start":1429,"enrollment":4424,"conditions":8607,"interventions":8608},[90],[18,24,21],[4402,4427,4428],{"trials":8610,"activeCount":100},[],{"trials":8612,"activeCount":100},[],{"intervention":8614,"totalTrials":139,"cells":8615},"Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus",{"EARLY_PHASE1":8616,"PHASE1":8618,"PHASE2":8620,"PHASE3":8622,"PHASE4":8632,"NA":8634},{"trials":8617,"activeCount":100},[],{"trials":8619,"activeCount":100},[],{"trials":8621,"activeCount":100},[],{"trials":8623,"activeCount":100},[8624],{"nctId":8625,"briefTitle":8626,"status":123,"phases":8627,"primaryCompletion":2123,"completion":2124,"start":8628,"enrollment":8629,"conditions":8630,"interventions":8631},"NCT01134263","Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia",[90],"2010-10-05",715,[3176,373],[8614,8614,8614,8614],{"trials":8633,"activeCount":100},[],{"trials":8635,"activeCount":100},[],{"intervention":1334,"totalTrials":139,"cells":8637},{"EARLY_PHASE1":8638,"PHASE1":8640,"PHASE2":8642,"PHASE3":8644,"PHASE4":8650,"NA":8652},{"trials":8639,"activeCount":100},[],{"trials":8641,"activeCount":100},[],{"trials":8643,"activeCount":100},[],{"trials":8645,"activeCount":100},[8646],{"nctId":1323,"briefTitle":1324,"status":123,"phases":8647,"primaryCompletion":1326,"completion":1287,"start":1327,"enrollment":1328,"conditions":8648,"interventions":8649},[90],[1046,1330,1331,1332,512],[1334,1253,1253],{"trials":8651,"activeCount":100},[],{"trials":8653,"activeCount":100},[],{"intervention":4578,"totalTrials":139,"cells":8655},{"EARLY_PHASE1":8656,"PHASE1":8658,"PHASE2":8660,"PHASE3":8662,"PHASE4":8668,"NA":8670},{"trials":8657,"activeCount":100},[],{"trials":8659,"activeCount":100},[],{"trials":8661,"activeCount":100},[],{"trials":8663,"activeCount":100},[8664],{"nctId":4572,"briefTitle":4573,"status":123,"phases":8665,"primaryCompletion":4575,"completion":1237,"start":1901,"enrollment":3900,"conditions":8666,"interventions":8667},[90],[21,18,24,30,3821],[4551,4578],{"trials":8669,"activeCount":100},[],{"trials":8671,"activeCount":100},[],{"intervention":8673,"totalTrials":139,"cells":8674},"Inactive Poliovirus Vaccine",{"EARLY_PHASE1":8675,"PHASE1":8677,"PHASE2":8679,"PHASE3":8681,"PHASE4":8690,"NA":8692},{"trials":8676,"activeCount":100},[],{"trials":8678,"activeCount":100},[],{"trials":8680,"activeCount":100},[],{"trials":8682,"activeCount":100},[8683],{"nctId":8684,"briefTitle":8685,"status":123,"phases":8686,"primaryCompletion":1318,"completion":1318,"start":4532,"enrollment":8687,"conditions":8688,"interventions":8689},"NCT01389687","Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan",[90],74,[30,1666],[8673],{"trials":8691,"activeCount":100},[],{"trials":8693,"activeCount":100},[],{"intervention":8695,"totalTrials":139,"cells":8696},"Multi-dose Quadrivalent Influenza Vaccine",{"EARLY_PHASE1":8697,"PHASE1":8699,"PHASE2":8701,"PHASE3":8703,"PHASE4":8715,"NA":8717},{"trials":8698,"activeCount":100},[],{"trials":8700,"activeCount":100},[],{"trials":8702,"activeCount":100},[],{"trials":8704,"activeCount":100},[8705],{"nctId":8706,"briefTitle":8707,"status":123,"phases":8708,"primaryCompletion":8709,"completion":8710,"start":8711,"enrollment":3458,"conditions":8712,"interventions":8713},"NCT03391193","Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine",[90],"2018-03-28","2018-08-25","2017-12-19",[15],[8695,8714],"Single-dose Quadrivalent Influenza Vaccine",{"trials":8716,"activeCount":100},[],{"trials":8718,"activeCount":100},[],{"intervention":8714,"totalTrials":139,"cells":8720},{"EARLY_PHASE1":8721,"PHASE1":8723,"PHASE2":8725,"PHASE3":8727,"PHASE4":8733,"NA":8735},{"trials":8722,"activeCount":100},[],{"trials":8724,"activeCount":100},[],{"trials":8726,"activeCount":100},[],{"trials":8728,"activeCount":100},[8729],{"nctId":8706,"briefTitle":8707,"status":123,"phases":8730,"primaryCompletion":8709,"completion":8710,"start":8711,"enrollment":3458,"conditions":8731,"interventions":8732},[90],[15],[8695,8714],{"trials":8734,"activeCount":100},[],{"trials":8736,"activeCount":100},[],{"intervention":8738,"totalTrials":139,"cells":8739},"High-Dose Quadrivalent Influenza Vaccine,",{"EARLY_PHASE1":8740,"PHASE1":8742,"PHASE2":8744,"PHASE3":8746,"PHASE4":8758,"NA":8760},{"trials":8741,"activeCount":100},[],{"trials":8743,"activeCount":100},[],{"trials":8745,"activeCount":100},[],{"trials":8747,"activeCount":100},[8748],{"nctId":8749,"briefTitle":8750,"status":123,"phases":8751,"primaryCompletion":8752,"completion":8752,"start":8753,"enrollment":8754,"conditions":8755,"interventions":8756},"NCT04498832","Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older",[90],"2021-01-14","2020-10-21",2100,[759,33],[8738,8757],"Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains",{"trials":8759,"activeCount":100},[],{"trials":8761,"activeCount":100},[],{"intervention":8757,"totalTrials":139,"cells":8763},{"EARLY_PHASE1":8764,"PHASE1":8766,"PHASE2":8768,"PHASE3":8770,"PHASE4":8776,"NA":8778},{"trials":8765,"activeCount":100},[],{"trials":8767,"activeCount":100},[],{"trials":8769,"activeCount":100},[],{"trials":8771,"activeCount":100},[8772],{"nctId":8749,"briefTitle":8750,"status":123,"phases":8773,"primaryCompletion":8752,"completion":8752,"start":8753,"enrollment":8754,"conditions":8774,"interventions":8775},[90],[759,33],[8738,8757],{"trials":8777,"activeCount":100},[],{"trials":8779,"activeCount":100},[],{"intervention":8781,"totalTrials":139,"cells":8782},"Meningococcal Polysaccharide Diphtheria Conjugate Vaccine",{"EARLY_PHASE1":8783,"PHASE1":8785,"PHASE2":8787,"PHASE3":8789,"PHASE4":8799,"NA":8801},{"trials":8784,"activeCount":100},[],{"trials":8786,"activeCount":100},[],{"trials":8788,"activeCount":100},[],{"trials":8790,"activeCount":100},[8791],{"nctId":8792,"briefTitle":8793,"status":123,"phases":8794,"primaryCompletion":2351,"completion":3363,"start":1170,"enrollment":8795,"conditions":8796,"interventions":8797},"NCT00422292","Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers",[90],1664,[1046,1330,1331,1332,512],[8781,8781,8781,8798],"Measles, Mumps, Rubella and Varicella",{"trials":8800,"activeCount":100},[],{"trials":8802,"activeCount":100},[],{"intervention":8798,"totalTrials":139,"cells":8804},{"EARLY_PHASE1":8805,"PHASE1":8807,"PHASE2":8809,"PHASE3":8811,"PHASE4":8817,"NA":8819},{"trials":8806,"activeCount":100},[],{"trials":8808,"activeCount":100},[],{"trials":8810,"activeCount":100},[],{"trials":8812,"activeCount":100},[8813],{"nctId":8792,"briefTitle":8793,"status":123,"phases":8814,"primaryCompletion":2351,"completion":3363,"start":1170,"enrollment":8795,"conditions":8815,"interventions":8816},[90],[1046,1330,1331,1332,512],[8781,8781,8781,8798],{"trials":8818,"activeCount":100},[],{"trials":8820,"activeCount":100},[],{"intervention":3823,"totalTrials":139,"cells":8822},{"EARLY_PHASE1":8823,"PHASE1":8825,"PHASE2":8827,"PHASE3":8829,"PHASE4":8835,"NA":8837},{"trials":8824,"activeCount":100},[],{"trials":8826,"activeCount":100},[],{"trials":8828,"activeCount":100},[],{"trials":8830,"activeCount":100},[8831],{"nctId":3816,"briefTitle":3817,"status":123,"phases":8832,"primaryCompletion":1237,"completion":1288,"start":1191,"enrollment":3819,"conditions":8833,"interventions":8834},[90],[18,24,21,36,3821],[3803,3823,3785],{"trials":8836,"activeCount":100},[],{"trials":8838,"activeCount":100},[],{"intervention":8840,"totalTrials":743,"cells":8841},"Swine A\u002FH1N1 influenza vaccine",{"EARLY_PHASE1":8842,"PHASE1":8844,"PHASE2":8846,"PHASE3":8876,"PHASE4":8878,"NA":8880},{"trials":8843,"activeCount":100},[],{"trials":8845,"activeCount":100},[],{"trials":8847,"activeCount":100},[8848,8856,8863,8870],{"nctId":8849,"briefTitle":8850,"status":123,"phases":8851,"primaryCompletion":5255,"completion":1415,"start":3490,"enrollment":8852,"conditions":8853,"interventions":8855},"NCT00956202","A Study of Inactivated Swine-Origin A\u002FH1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years",[89],303,[15,8854],"Swine-origin A\u002FH1N1 Influenza",[8840,8840,8840],{"nctId":8857,"briefTitle":8858,"status":123,"phases":8859,"primaryCompletion":1453,"completion":2800,"start":3108,"enrollment":8860,"conditions":8861,"interventions":8862},"NCT00956046","A Study of Swine-origin A\u002FH1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months",[89],401,[15,8854],[8840,8840,8840],{"nctId":8864,"briefTitle":8865,"status":123,"phases":8866,"primaryCompletion":5255,"completion":2016,"start":5367,"enrollment":8867,"conditions":8868,"interventions":8869},"NCT01089660","A Study of the Immunogenicity of Swine-origin A\u002FH1N1 Influenza Vaccine in Healthy Adults",[89],202,[15,8854],[8840,8840],{"nctId":8871,"briefTitle":8872,"status":123,"phases":8873,"primaryCompletion":2016,"completion":1413,"start":3490,"enrollment":4644,"conditions":8874,"interventions":8875},"NCT00954798","A Study of Swine-origin A\u002FH1N1 Influenza Vaccines in Healthy European Adults and the Elderly",[89],[15,8854],[8840,8840,8840],{"trials":8877,"activeCount":100},[],{"trials":8879,"activeCount":100},[],{"trials":8881,"activeCount":100},[],{"intervention":763,"totalTrials":1353,"cells":8883},{"EARLY_PHASE1":8884,"PHASE1":8886,"PHASE2":8888,"PHASE3":8902,"PHASE4":8904,"NA":8906},{"trials":8885,"activeCount":100},[],{"trials":8887,"activeCount":100},[],{"trials":8889,"activeCount":100},[8890,8894,8898],{"nctId":752,"briefTitle":753,"status":123,"phases":8891,"primaryCompletion":755,"completion":755,"start":756,"enrollment":757,"conditions":8892,"interventions":8893},[88,89],[759],[761,762,742,763],{"nctId":774,"briefTitle":775,"status":123,"phases":8895,"primaryCompletion":777,"completion":777,"start":778,"enrollment":779,"conditions":8896,"interventions":8897},[88,89],[759],[782,762,742,763],{"nctId":784,"briefTitle":785,"status":123,"phases":8899,"primaryCompletion":787,"completion":787,"start":788,"enrollment":789,"conditions":8900,"interventions":8901},[88,89],[759],[792,793,794,742,763,762],{"trials":8903,"activeCount":100},[],{"trials":8905,"activeCount":100},[],{"trials":8907,"activeCount":100},[],{"intervention":4014,"totalTrials":96,"cells":8909},{"EARLY_PHASE1":8910,"PHASE1":8912,"PHASE2":8914,"PHASE3":8928,"PHASE4":8930,"NA":8932},{"trials":8911,"activeCount":100},[],{"trials":8913,"activeCount":100},[],{"trials":8915,"activeCount":100},[8916,8920],{"nctId":4008,"briefTitle":4009,"status":123,"phases":8917,"primaryCompletion":4011,"completion":1948,"start":1586,"enrollment":1454,"conditions":8918,"interventions":8919},[89],[1857],[3999,4014],{"nctId":8921,"briefTitle":8922,"status":123,"phases":8923,"primaryCompletion":3851,"completion":1555,"start":2124,"enrollment":8924,"conditions":8925,"interventions":8926},"NCT01784874","Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use",[89],408,[1857],[8927,4014],"Purified Vero Rabies Vaccine (VRVg) - Serum Free",{"trials":8929,"activeCount":100},[],{"trials":8931,"activeCount":100},[],{"trials":8933,"activeCount":100},[],{"intervention":8935,"totalTrials":96,"cells":8936},"A\u002FC\u002FY\u002FW-135, Meningococcal Polysaccharide Vaccine",{"EARLY_PHASE1":8937,"PHASE1":8939,"PHASE2":8941,"PHASE3":8958,"PHASE4":8960,"NA":8962},{"trials":8938,"activeCount":100},[],{"trials":8940,"activeCount":100},[],{"trials":8942,"activeCount":100},[8943,8950],{"nctId":8944,"briefTitle":8945,"status":123,"phases":8946,"primaryCompletion":1277,"completion":1276,"start":8947,"enrollment":2655,"conditions":8948,"interventions":8949},"NCT00772070","Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine",[89],"2003-03",[27,1280,130],[8935,8935],{"nctId":8951,"briefTitle":8952,"status":123,"phases":8953,"primaryCompletion":1210,"completion":2100,"start":1854,"enrollment":8954,"conditions":8955,"interventions":8956},"NCT00643916","Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age",[89],378,[27,162],[8957,8957,8957,8957,8957,8935],"Meningococcal Polysaccharide Diphtheria Protein Conjugate",{"trials":8959,"activeCount":100},[],{"trials":8961,"activeCount":100},[],{"trials":8963,"activeCount":100},[],{"intervention":8965,"totalTrials":96,"cells":8966},"A\u002FH5N1 Inactivated, Split Virion Pandemic Influenza Vaccine",{"EARLY_PHASE1":8967,"PHASE1":8969,"PHASE2":8971,"PHASE3":8988,"PHASE4":8990,"NA":8992},{"trials":8968,"activeCount":100},[],{"trials":8970,"activeCount":100},[],{"trials":8972,"activeCount":100},[8973,8979],{"nctId":8974,"briefTitle":8975,"status":123,"phases":8976,"primaryCompletion":5367,"completion":1182,"start":3363,"enrollment":128,"conditions":8977,"interventions":8978},"NCT00884182","Safety and Immunogenicity of an Intramuscular A\u002FH5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children",[89],[15,2354,3366],[8965],{"nctId":8980,"briefTitle":8981,"status":123,"phases":8982,"primaryCompletion":1971,"completion":1182,"start":2654,"enrollment":2040,"conditions":8983,"interventions":8985},"NCT00491985","Safety and Immunogenicity of 2 Formulations of an Intramuscular A\u002FH5N1 Pandemic Influenza Vaccine in Children",[89],[15,2354,8984],"Influenza A Virus Infection",[8986,8987,8987],"A\u002FH5N1 Inactivated, split-virion pandemic influenza vaccine","A\u002FH5N1 Inactivated, split virion pandemic influenza vaccine",{"trials":8989,"activeCount":100},[],{"trials":8991,"activeCount":100},[],{"trials":8993,"activeCount":100},[],{"intervention":8995,"totalTrials":96,"cells":8996},"Inactivated, split-virion influenza virus",{"EARLY_PHASE1":8997,"PHASE1":8999,"PHASE2":9001,"PHASE3":9018,"PHASE4":9020,"NA":9022},{"trials":8998,"activeCount":100},[],{"trials":9000,"activeCount":100},[],{"trials":9002,"activeCount":100},[9003,9010],{"nctId":9004,"briefTitle":9005,"status":123,"phases":9006,"primaryCompletion":2568,"completion":1289,"start":3808,"enrollment":9007,"conditions":9008,"interventions":9009},"NCT00606359","Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects",[89],62,[15,2354],[8995,8995],{"nctId":9011,"briefTitle":9012,"status":123,"phases":9013,"primaryCompletion":1191,"completion":1266,"start":1211,"enrollment":9014,"conditions":9015,"interventions":9016},"NCT00524940","Trial to Describe the Safety and Immunogenicity of Fluzone®",[89],124,[15],[9017],"Inactivated, Split-Virion Influenza Virus",{"trials":9019,"activeCount":100},[],{"trials":9021,"activeCount":100},[],{"trials":9023,"activeCount":100},[],{"intervention":9025,"totalTrials":96,"cells":9026},"Monovalent Subvirion A\u002FH1N1 Influenza vaccine",{"EARLY_PHASE1":9027,"PHASE1":9029,"PHASE2":9031,"PHASE3":9048,"PHASE4":9050,"NA":9052},{"trials":9028,"activeCount":100},[],{"trials":9030,"activeCount":100},[],{"trials":9032,"activeCount":100},[9033,9041],{"nctId":9034,"briefTitle":9035,"status":123,"phases":9036,"primaryCompletion":5367,"completion":2016,"start":3490,"enrollment":9037,"conditions":9038,"interventions":9039},"NCT00953524","A Study of Different Formulations of an A\u002FH1N1 Pandemic Vaccine in Healthy Adults and the Elderly",[89],849,[15,8854],[9025,9025,9025,9040],"Normal saline solution",{"nctId":9042,"briefTitle":9043,"status":123,"phases":9044,"primaryCompletion":5367,"completion":1182,"start":3490,"enrollment":9045,"conditions":9046,"interventions":9047},"NCT00952419","A Study of Different Formulations of an A\u002FH1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years",[89],474,[15,8854],[9025,9025,9040],{"trials":9049,"activeCount":100},[],{"trials":9051,"activeCount":100},[],{"trials":9053,"activeCount":100},[],{"intervention":9040,"totalTrials":96,"cells":9055},{"EARLY_PHASE1":9056,"PHASE1":9058,"PHASE2":9060,"PHASE3":9070,"PHASE4":9072,"NA":9074},{"trials":9057,"activeCount":100},[],{"trials":9059,"activeCount":100},[],{"trials":9061,"activeCount":100},[9062,9066],{"nctId":9034,"briefTitle":9035,"status":123,"phases":9063,"primaryCompletion":5367,"completion":2016,"start":3490,"enrollment":9037,"conditions":9064,"interventions":9065},[89],[15,8854],[9025,9025,9025,9040],{"nctId":9042,"briefTitle":9043,"status":123,"phases":9067,"primaryCompletion":5367,"completion":1182,"start":3490,"enrollment":9045,"conditions":9068,"interventions":9069},[89],[15,8854],[9025,9025,9040],{"trials":9071,"activeCount":100},[],{"trials":9073,"activeCount":100},[],{"trials":9075,"activeCount":100},[],{"intervention":9077,"totalTrials":96,"cells":9078},"MVA Smallpox vaccine",{"EARLY_PHASE1":9079,"PHASE1":9081,"PHASE2":9092,"PHASE3":9101,"PHASE4":9103,"NA":9105},{"trials":9080,"activeCount":100},[],{"trials":9082,"activeCount":100},[9083],{"nctId":9084,"briefTitle":9085,"status":646,"phases":9086,"primaryCompletion":3327,"completion":3327,"start":1229,"enrollment":96,"conditions":9087,"interventions":9090},"NCT00282581","Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive",[88],[9088,9089],"HIV Infections","Smallpox",[9091],"MVA Smallpox Vaccine",{"trials":9093,"activeCount":100},[9094],{"nctId":9095,"briefTitle":9096,"status":123,"phases":9097,"primaryCompletion":1169,"completion":1169,"start":2979,"enrollment":9098,"conditions":9099,"interventions":9100},"NCT00466245","Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine",[89],590,[9089],[9077],{"trials":9102,"activeCount":100},[],{"trials":9104,"activeCount":100},[],{"trials":9106,"activeCount":100},[],{"intervention":1419,"totalTrials":96,"cells":9108},{"EARLY_PHASE1":9109,"PHASE1":9111,"PHASE2":9113,"PHASE3":9129,"PHASE4":9131,"NA":9133},{"trials":9110,"activeCount":100},[],{"trials":9112,"activeCount":100},[],{"trials":9114,"activeCount":100},[9115,9119],{"nctId":1410,"briefTitle":1411,"status":123,"phases":9116,"primaryCompletion":1413,"completion":1414,"start":1415,"enrollment":1416,"conditions":9117,"interventions":9118},[89],[15],[1419,1401],{"nctId":9120,"briefTitle":9121,"status":123,"phases":9122,"primaryCompletion":9123,"completion":9123,"start":1342,"enrollment":370,"conditions":9124,"interventions":9125},"NCT02553343","A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older",[89],"2016-04-04",[15],[9126,9127,9128,9128],"High-dose quadrivalent influenza virus vaccine","High-dose influenza virus vaccine","High-dose trivalent inactivated influenza vaccine",{"trials":9130,"activeCount":100},[],{"trials":9132,"activeCount":100},[],{"trials":9134,"activeCount":100},[],{"intervention":9136,"totalTrials":96,"cells":9137},"0.9% Normal Saline",{"EARLY_PHASE1":9138,"PHASE1":9140,"PHASE2":9142,"PHASE3":9164,"PHASE4":9166,"NA":9168},{"trials":9139,"activeCount":100},[],{"trials":9141,"activeCount":100},[],{"trials":9143,"activeCount":100},[9144,9153],{"nctId":9145,"briefTitle":9146,"status":123,"phases":9147,"primaryCompletion":4532,"completion":1597,"start":1287,"enrollment":1238,"conditions":9148,"interventions":9150},"NCT00772343","Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection",[89],[9149,8401],"Diarrhea",[9136,9151,9152,9151],"Clostridium difficile toxoid vaccine","Clostridium difficile toxoid vaccine with adjuvant",{"nctId":9154,"briefTitle":9155,"status":123,"phases":9156,"primaryCompletion":6587,"completion":9157,"start":9158,"enrollment":9159,"conditions":9160,"interventions":9161},"NCT01896830","Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan",[88,89],"2014-06","2013-07",102,[8401],[9162,9163],"Clostridium difficile Toxoid Vaccine","0.9% normal saline",{"trials":9165,"activeCount":100},[],{"trials":9167,"activeCount":100},[],{"trials":9169,"activeCount":100},[],{"intervention":9151,"totalTrials":96,"cells":9171},{"EARLY_PHASE1":9172,"PHASE1":9174,"PHASE2":9176,"PHASE3":9186,"PHASE4":9188,"NA":9190},{"trials":9173,"activeCount":100},[],{"trials":9175,"activeCount":100},[],{"trials":9177,"activeCount":100},[9178,9182],{"nctId":9145,"briefTitle":9146,"status":123,"phases":9179,"primaryCompletion":4532,"completion":1597,"start":1287,"enrollment":1238,"conditions":9180,"interventions":9181},[89],[9149,8401],[9136,9151,9152,9151],{"nctId":9154,"briefTitle":9155,"status":123,"phases":9183,"primaryCompletion":6587,"completion":9157,"start":9158,"enrollment":9159,"conditions":9184,"interventions":9185},[88,89],[8401],[9162,9163],{"trials":9187,"activeCount":100},[],{"trials":9189,"activeCount":100},[],{"trials":9191,"activeCount":100},[],{"intervention":9193,"totalTrials":96,"cells":9194},"A\u002FH5N1 inactivated, split-virion influenza virus",{"EARLY_PHASE1":9195,"PHASE1":9197,"PHASE2":9199,"PHASE3":9213,"PHASE4":9215,"NA":9217},{"trials":9196,"activeCount":100},[],{"trials":9198,"activeCount":100},[],{"trials":9200,"activeCount":100},[9201,9207],{"nctId":9202,"briefTitle":9203,"status":123,"phases":9204,"primaryCompletion":3614,"completion":1288,"start":1169,"enrollment":2801,"conditions":9205,"interventions":9206},"NCT00415129","Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly",[89],[15,2354],[9193,9193],{"nctId":9208,"briefTitle":9209,"status":123,"phases":9210,"primaryCompletion":1289,"completion":1237,"start":2100,"enrollment":5257,"conditions":9211,"interventions":9212},"NCT00545701","Immunogenicity and Safety of an Intramuscular A\u002FH5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults",[89],[15,2354],[9193],{"trials":9214,"activeCount":100},[],{"trials":9216,"activeCount":100},[],{"trials":9218,"activeCount":100},[],{"intervention":9220,"totalTrials":139,"cells":9221},"RSV\u002FhMPV vaccine candidate Dose L",{"EARLY_PHASE1":9222,"PHASE1":9224,"PHASE2":9226,"PHASE3":9240,"PHASE4":9242,"NA":9244},{"trials":9223,"activeCount":100},[],{"trials":9225,"activeCount":100},[],{"trials":9227,"activeCount":100},[9228],{"nctId":9229,"briefTitle":9230,"status":123,"phases":9231,"primaryCompletion":9232,"completion":9232,"start":9233,"enrollment":9234,"conditions":9235,"interventions":9237},"NCT06134648","Study of a Respiratory Syncytial Virus\u002FHuman Metapneumovirus Vaccine Candidate",[88,89],"2026-02-27","2023-11-01",646,[3668,33,9236],"Human Metapneumovirus",[9220,9238,9239],"RSV\u002FhMPV vaccine candidate Dose A","RSV\u002FhMPV vaccine candidate Dose B",{"trials":9241,"activeCount":100},[],{"trials":9243,"activeCount":100},[],{"trials":9245,"activeCount":100},[],{"intervention":9238,"totalTrials":139,"cells":9247},{"EARLY_PHASE1":9248,"PHASE1":9250,"PHASE2":9252,"PHASE3":9258,"PHASE4":9260,"NA":9262},{"trials":9249,"activeCount":100},[],{"trials":9251,"activeCount":100},[],{"trials":9253,"activeCount":100},[9254],{"nctId":9229,"briefTitle":9230,"status":123,"phases":9255,"primaryCompletion":9232,"completion":9232,"start":9233,"enrollment":9234,"conditions":9256,"interventions":9257},[88,89],[3668,33,9236],[9220,9238,9239],{"trials":9259,"activeCount":100},[],{"trials":9261,"activeCount":100},[],{"trials":9263,"activeCount":100},[],{"intervention":9239,"totalTrials":139,"cells":9265},{"EARLY_PHASE1":9266,"PHASE1":9268,"PHASE2":9270,"PHASE3":9276,"PHASE4":9278,"NA":9280},{"trials":9267,"activeCount":100},[],{"trials":9269,"activeCount":100},[],{"trials":9271,"activeCount":100},[9272],{"nctId":9229,"briefTitle":9230,"status":123,"phases":9273,"primaryCompletion":9232,"completion":9232,"start":9233,"enrollment":9234,"conditions":9274,"interventions":9275},[88,89],[3668,33,9236],[9220,9238,9239],{"trials":9277,"activeCount":100},[],{"trials":9279,"activeCount":100},[],{"trials":9281,"activeCount":100},[],{"intervention":3300,"totalTrials":139,"cells":9283},{"EARLY_PHASE1":9284,"PHASE1":9286,"PHASE2":9288,"PHASE3":9294,"PHASE4":9296,"NA":9298},{"trials":9285,"activeCount":100},[],{"trials":9287,"activeCount":100},[],{"trials":9289,"activeCount":100},[9290],{"nctId":3292,"briefTitle":3293,"status":123,"phases":9291,"primaryCompletion":3295,"completion":3295,"start":3296,"enrollment":3297,"conditions":9292,"interventions":9293},[89],[21,24,18,30,36],[3300,483],{"trials":9295,"activeCount":100},[],{"trials":9297,"activeCount":100},[],{"trials":9299,"activeCount":100},[],{"intervention":3181,"totalTrials":139,"cells":9301},{"EARLY_PHASE1":9302,"PHASE1":9304,"PHASE2":9306,"PHASE3":9312,"PHASE4":9314,"NA":9316},{"trials":9303,"activeCount":100},[],{"trials":9305,"activeCount":100},[],{"trials":9307,"activeCount":100},[9308],{"nctId":3169,"briefTitle":3170,"status":123,"phases":9309,"primaryCompletion":1949,"completion":3172,"start":3173,"enrollment":3174,"conditions":9310,"interventions":9311},[89],[3176,373,3177,3178],[3180,3181],{"trials":9313,"activeCount":100},[],{"trials":9315,"activeCount":100},[],{"trials":9317,"activeCount":100},[],{"intervention":9319,"totalTrials":139,"cells":9320},"Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC",{"EARLY_PHASE1":9321,"PHASE1":9323,"PHASE2":9325,"PHASE3":9333,"PHASE4":9335,"NA":9337},{"trials":9322,"activeCount":100},[],{"trials":9324,"activeCount":100},[],{"trials":9326,"activeCount":100},[9327],{"nctId":9328,"briefTitle":9329,"status":123,"phases":9330,"primaryCompletion":1287,"completion":1288,"start":2569,"enrollment":3628,"conditions":9331,"interventions":9332},"NCT00362427","Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®",[89],[18,21,1666,36,24],[9319,9319,9319],{"trials":9334,"activeCount":100},[],{"trials":9336,"activeCount":100},[],{"trials":9338,"activeCount":100},[],{"intervention":9340,"totalTrials":139,"cells":9341},"Split virion, inactivated Influenza vaccine",{"EARLY_PHASE1":9342,"PHASE1":9344,"PHASE2":9346,"PHASE3":9355,"PHASE4":9357,"NA":9359},{"trials":9343,"activeCount":100},[],{"trials":9345,"activeCount":100},[],{"trials":9347,"activeCount":100},[9348],{"nctId":9349,"briefTitle":9350,"status":123,"phases":9351,"primaryCompletion":1326,"completion":1237,"start":1289,"enrollment":9352,"conditions":9353,"interventions":9354},"NCT00718146","Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation",[89],130,[15,2354],[9340,9340],{"trials":9356,"activeCount":100},[],{"trials":9358,"activeCount":100},[],{"trials":9360,"activeCount":100},[],{"intervention":3358,"totalTrials":139,"cells":9362},{"EARLY_PHASE1":9363,"PHASE1":9365,"PHASE2":9367,"PHASE3":9373,"PHASE4":9375,"NA":9377},{"trials":9364,"activeCount":100},[],{"trials":9366,"activeCount":100},[],{"trials":9368,"activeCount":100},[9369],{"nctId":3352,"briefTitle":3353,"status":123,"phases":9370,"primaryCompletion":1289,"completion":1237,"start":1902,"enrollment":3355,"conditions":9371,"interventions":9372},[89],[2354,15],[3343,3358],{"trials":9374,"activeCount":100},[],{"trials":9376,"activeCount":100},[],{"trials":9378,"activeCount":100},[],{"intervention":9380,"totalTrials":139,"cells":9381},"ALVAC(2) Melanoma multi-antigen therapeutic vaccine",{"EARLY_PHASE1":9382,"PHASE1":9384,"PHASE2":9386,"PHASE3":9398,"PHASE4":9400,"NA":9402},{"trials":9383,"activeCount":100},[],{"trials":9385,"activeCount":100},[],{"trials":9387,"activeCount":100},[9388],{"nctId":9389,"briefTitle":9390,"status":646,"phases":9391,"primaryCompletion":1972,"completion":1182,"start":1289,"enrollment":9392,"conditions":9393,"interventions":9396},"NCT00613509","Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma",[89],23,[9394,9395],"Melanoma","Cancer",[9380,9397],"Intron A, Interferon alpha -2b",{"trials":9399,"activeCount":100},[],{"trials":9401,"activeCount":100},[],{"trials":9403,"activeCount":100},[],{"intervention":9397,"totalTrials":139,"cells":9405},{"EARLY_PHASE1":9406,"PHASE1":9408,"PHASE2":9410,"PHASE3":9416,"PHASE4":9418,"NA":9420},{"trials":9407,"activeCount":100},[],{"trials":9409,"activeCount":100},[],{"trials":9411,"activeCount":100},[9412],{"nctId":9389,"briefTitle":9390,"status":646,"phases":9413,"primaryCompletion":1972,"completion":1182,"start":1289,"enrollment":9392,"conditions":9414,"interventions":9415},[89],[9394,9395],[9380,9397],{"trials":9417,"activeCount":100},[],{"trials":9419,"activeCount":100},[],{"trials":9421,"activeCount":100},[],{"intervention":9423,"totalTrials":139,"cells":9424},"CYD Dengue Vaccine Serotypes 1, 2, 3, and 4",{"EARLY_PHASE1":9425,"PHASE1":9427,"PHASE2":9429,"PHASE3":9441,"PHASE4":9443,"NA":9445},{"trials":9426,"activeCount":100},[],{"trials":9428,"activeCount":100},[],{"trials":9430,"activeCount":100},[9431],{"nctId":9432,"briefTitle":9433,"status":123,"phases":9434,"primaryCompletion":9435,"completion":9436,"start":9437,"enrollment":1416,"conditions":9438,"interventions":9439},"NCT00788151","Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years",[89],"2010-02-16","2010-08-16","2008-09-26",[3177,3176,373,3178],[9423,9440],"Pneumococcal polysaccharide vaccine",{"trials":9442,"activeCount":100},[],{"trials":9444,"activeCount":100},[],{"trials":9446,"activeCount":100},[],{"intervention":9440,"totalTrials":139,"cells":9448},{"EARLY_PHASE1":9449,"PHASE1":9451,"PHASE2":9453,"PHASE3":9459,"PHASE4":9461,"NA":9463},{"trials":9450,"activeCount":100},[],{"trials":9452,"activeCount":100},[],{"trials":9454,"activeCount":100},[9455],{"nctId":9432,"briefTitle":9433,"status":123,"phases":9456,"primaryCompletion":9435,"completion":9436,"start":9437,"enrollment":1416,"conditions":9457,"interventions":9458},[89],[3177,3176,373,3178],[9423,9440],{"trials":9460,"activeCount":100},[],{"trials":9462,"activeCount":100},[],{"trials":9464,"activeCount":100},[],{"intervention":9466,"totalTrials":139,"cells":9467},"Inactivated influenza vaccine (split virion) NH 2007-2008 formulation",{"EARLY_PHASE1":9468,"PHASE1":9470,"PHASE2":9472,"PHASE3":9480,"PHASE4":9482,"NA":9484},{"trials":9469,"activeCount":100},[],{"trials":9471,"activeCount":100},[],{"trials":9473,"activeCount":100},[9474],{"nctId":9475,"briefTitle":9476,"status":123,"phases":9477,"primaryCompletion":3327,"completion":3327,"start":2654,"enrollment":9352,"conditions":9478,"interventions":9479},"NCT00491257","A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine",[89],[15,2354],[9466],{"trials":9481,"activeCount":100},[],{"trials":9483,"activeCount":100},[],{"trials":9485,"activeCount":100},[],{"intervention":761,"totalTrials":139,"cells":9487},{"EARLY_PHASE1":9488,"PHASE1":9490,"PHASE2":9492,"PHASE3":9498,"PHASE4":9500,"NA":9502},{"trials":9489,"activeCount":100},[],{"trials":9491,"activeCount":100},[],{"trials":9493,"activeCount":100},[9494],{"nctId":752,"briefTitle":753,"status":123,"phases":9495,"primaryCompletion":755,"completion":755,"start":756,"enrollment":757,"conditions":9496,"interventions":9497},[88,89],[759],[761,762,742,763],{"trials":9499,"activeCount":100},[],{"trials":9501,"activeCount":100},[],{"trials":9503,"activeCount":100},[],{"intervention":9505,"totalTrials":139,"cells":9506},"Influenza virus vaccine 2009-2010 formulation",{"EARLY_PHASE1":9507,"PHASE1":9509,"PHASE2":9511,"PHASE3":9520,"PHASE4":9522,"NA":9524},{"trials":9508,"activeCount":100},[],{"trials":9510,"activeCount":100},[],{"trials":9512,"activeCount":100},[9513],{"nctId":9514,"briefTitle":9515,"status":123,"phases":9516,"primaryCompletion":3401,"completion":3527,"start":3489,"enrollment":9517,"conditions":9518,"interventions":9519},"NCT00945438","Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)",[89],131,[15],[9505,9505],{"trials":9521,"activeCount":100},[],{"trials":9523,"activeCount":100},[],{"trials":9525,"activeCount":100},[],{"intervention":9527,"totalTrials":139,"cells":9528},"Bivalent CYD-1,3 Dengue",{"EARLY_PHASE1":9529,"PHASE1":9531,"PHASE2":9533,"PHASE3":9545,"PHASE4":9547,"NA":9549},{"trials":9530,"activeCount":100},[],{"trials":9532,"activeCount":100},[],{"trials":9534,"activeCount":100},[9535],{"nctId":9536,"briefTitle":9537,"status":123,"phases":9538,"primaryCompletion":2545,"completion":5256,"start":1326,"enrollment":9539,"conditions":9540,"interventions":9541},"NCT00740155","Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults",[89],154,[3177,3176,373,3178],[9527,9527,9542,9543,9544],"Tetravalent blending VDV-2\u002FCYD-1,3,4 Dengue","Tetravalent CYD-1,2,3,4 Dengue","JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue",{"trials":9546,"activeCount":100},[],{"trials":9548,"activeCount":100},[],{"trials":9550,"activeCount":100},[],{"intervention":9542,"totalTrials":139,"cells":9552},{"EARLY_PHASE1":9553,"PHASE1":9555,"PHASE2":9557,"PHASE3":9563,"PHASE4":9565,"NA":9567},{"trials":9554,"activeCount":100},[],{"trials":9556,"activeCount":100},[],{"trials":9558,"activeCount":100},[9559],{"nctId":9536,"briefTitle":9537,"status":123,"phases":9560,"primaryCompletion":2545,"completion":5256,"start":1326,"enrollment":9539,"conditions":9561,"interventions":9562},[89],[3177,3176,373,3178],[9527,9527,9542,9543,9544],{"trials":9564,"activeCount":100},[],{"trials":9566,"activeCount":100},[],{"trials":9568,"activeCount":100},[],{"intervention":9543,"totalTrials":139,"cells":9570},{"EARLY_PHASE1":9571,"PHASE1":9573,"PHASE2":9575,"PHASE3":9581,"PHASE4":9583,"NA":9585},{"trials":9572,"activeCount":100},[],{"trials":9574,"activeCount":100},[],{"trials":9576,"activeCount":100},[9577],{"nctId":9536,"briefTitle":9537,"status":123,"phases":9578,"primaryCompletion":2545,"completion":5256,"start":1326,"enrollment":9539,"conditions":9579,"interventions":9580},[89],[3177,3176,373,3178],[9527,9527,9542,9543,9544],{"trials":9582,"activeCount":100},[],{"trials":9584,"activeCount":100},[],{"trials":9586,"activeCount":100},[],{"intervention":9544,"totalTrials":139,"cells":9588},{"EARLY_PHASE1":9589,"PHASE1":9591,"PHASE2":9593,"PHASE3":9599,"PHASE4":9601,"NA":9603},{"trials":9590,"activeCount":100},[],{"trials":9592,"activeCount":100},[],{"trials":9594,"activeCount":100},[9595],{"nctId":9536,"briefTitle":9537,"status":123,"phases":9596,"primaryCompletion":2545,"completion":5256,"start":1326,"enrollment":9539,"conditions":9597,"interventions":9598},[89],[3177,3176,373,3178],[9527,9527,9542,9543,9544],{"trials":9600,"activeCount":100},[],{"trials":9602,"activeCount":100},[],{"trials":9604,"activeCount":100},[],{"intervention":9606,"totalTrials":139,"cells":9607},"Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide",{"EARLY_PHASE1":9608,"PHASE1":9610,"PHASE2":9612,"PHASE3":9622,"PHASE4":9624,"NA":9626},{"trials":9609,"activeCount":100},[],{"trials":9611,"activeCount":100},[],{"trials":9613,"activeCount":100},[9614],{"nctId":9615,"briefTitle":9616,"status":123,"phases":9617,"primaryCompletion":3615,"completion":1853,"start":2100,"enrollment":9618,"conditions":9619,"interventions":9620},"NCT00874549","Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years",[88,89],216,[468,1046],[9606,9621,9621,9621],"Menactra®: Polysaccharide Diphtheria Toxoid Conjugate",{"trials":9623,"activeCount":100},[],{"trials":9625,"activeCount":100},[],{"trials":9627,"activeCount":100},[],{"intervention":9621,"totalTrials":139,"cells":9629},{"EARLY_PHASE1":9630,"PHASE1":9632,"PHASE2":9634,"PHASE3":9640,"PHASE4":9642,"NA":9644},{"trials":9631,"activeCount":100},[],{"trials":9633,"activeCount":100},[],{"trials":9635,"activeCount":100},[9636],{"nctId":9615,"briefTitle":9616,"status":123,"phases":9637,"primaryCompletion":3615,"completion":1853,"start":2100,"enrollment":9618,"conditions":9638,"interventions":9639},[88,89],[468,1046],[9606,9621,9621,9621],{"trials":9641,"activeCount":100},[],{"trials":9643,"activeCount":100},[],{"trials":9645,"activeCount":100},[],{"intervention":9647,"totalTrials":139,"cells":9648},"Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus",{"EARLY_PHASE1":9649,"PHASE1":9651,"PHASE2":9653,"PHASE3":9664,"PHASE4":9666,"NA":9668},{"trials":9650,"activeCount":100},[],{"trials":9652,"activeCount":100},[],{"trials":9654,"activeCount":100},[9655],{"nctId":9656,"briefTitle":9657,"status":123,"phases":9658,"primaryCompletion":6055,"completion":1317,"start":5254,"enrollment":6649,"conditions":9659,"interventions":9660},"NCT01187433","Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America",[89],[372,373],[9647,9661,9662,9663],"NaCl 0.9%","Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed","Meningococcal A+C vaccine",{"trials":9665,"activeCount":100},[],{"trials":9667,"activeCount":100},[],{"trials":9669,"activeCount":100},[],{"intervention":9661,"totalTrials":139,"cells":9671},{"EARLY_PHASE1":9672,"PHASE1":9674,"PHASE2":9676,"PHASE3":9682,"PHASE4":9684,"NA":9686},{"trials":9673,"activeCount":100},[],{"trials":9675,"activeCount":100},[],{"trials":9677,"activeCount":100},[9678],{"nctId":9656,"briefTitle":9657,"status":123,"phases":9679,"primaryCompletion":6055,"completion":1317,"start":5254,"enrollment":6649,"conditions":9680,"interventions":9681},[89],[372,373],[9647,9661,9662,9663],{"trials":9683,"activeCount":100},[],{"trials":9685,"activeCount":100},[],{"trials":9687,"activeCount":100},[],{"intervention":9662,"totalTrials":139,"cells":9689},{"EARLY_PHASE1":9690,"PHASE1":9692,"PHASE2":9694,"PHASE3":9700,"PHASE4":9702,"NA":9704},{"trials":9691,"activeCount":100},[],{"trials":9693,"activeCount":100},[],{"trials":9695,"activeCount":100},[9696],{"nctId":9656,"briefTitle":9657,"status":123,"phases":9697,"primaryCompletion":6055,"completion":1317,"start":5254,"enrollment":6649,"conditions":9698,"interventions":9699},[89],[372,373],[9647,9661,9662,9663],{"trials":9701,"activeCount":100},[],{"trials":9703,"activeCount":100},[],{"trials":9705,"activeCount":100},[],{"intervention":9663,"totalTrials":139,"cells":9707},{"EARLY_PHASE1":9708,"PHASE1":9710,"PHASE2":9712,"PHASE3":9718,"PHASE4":9720,"NA":9722},{"trials":9709,"activeCount":100},[],{"trials":9711,"activeCount":100},[],{"trials":9713,"activeCount":100},[9714],{"nctId":9656,"briefTitle":9657,"status":123,"phases":9715,"primaryCompletion":6055,"completion":1317,"start":5254,"enrollment":6649,"conditions":9716,"interventions":9717},[89],[372,373],[9647,9661,9662,9663],{"trials":9719,"activeCount":100},[],{"trials":9721,"activeCount":100},[],{"trials":9723,"activeCount":100},[],{"intervention":9725,"totalTrials":139,"cells":9726},"QIV-HD by IM",{"EARLY_PHASE1":9727,"PHASE1":9729,"PHASE2":9731,"PHASE3":9744,"PHASE4":9746,"NA":9748},{"trials":9728,"activeCount":100},[],{"trials":9730,"activeCount":100},[],{"trials":9732,"activeCount":100},[9733],{"nctId":9734,"briefTitle":9735,"status":123,"phases":9736,"primaryCompletion":9737,"completion":9737,"start":9738,"enrollment":9739,"conditions":9740,"interventions":9741},"NCT03233217","Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years",[88,89],"2017-11-28","2017-09-15",175,[15],[9725,9742,9743],"QIV-SD by SC","QIV-HD by SC",{"trials":9745,"activeCount":100},[],{"trials":9747,"activeCount":100},[],{"trials":9749,"activeCount":100},[],{"intervention":9742,"totalTrials":139,"cells":9751},{"EARLY_PHASE1":9752,"PHASE1":9754,"PHASE2":9756,"PHASE3":9762,"PHASE4":9764,"NA":9766},{"trials":9753,"activeCount":100},[],{"trials":9755,"activeCount":100},[],{"trials":9757,"activeCount":100},[9758],{"nctId":9734,"briefTitle":9735,"status":123,"phases":9759,"primaryCompletion":9737,"completion":9737,"start":9738,"enrollment":9739,"conditions":9760,"interventions":9761},[88,89],[15],[9725,9742,9743],{"trials":9763,"activeCount":100},[],{"trials":9765,"activeCount":100},[],{"trials":9767,"activeCount":100},[],{"intervention":9743,"totalTrials":139,"cells":9769},{"EARLY_PHASE1":9770,"PHASE1":9772,"PHASE2":9774,"PHASE3":9780,"PHASE4":9782,"NA":9784},{"trials":9771,"activeCount":100},[],{"trials":9773,"activeCount":100},[],{"trials":9775,"activeCount":100},[9776],{"nctId":9734,"briefTitle":9735,"status":123,"phases":9777,"primaryCompletion":9737,"completion":9737,"start":9738,"enrollment":9739,"conditions":9778,"interventions":9779},[88,89],[15],[9725,9742,9743],{"trials":9781,"activeCount":100},[],{"trials":9783,"activeCount":100},[],{"trials":9785,"activeCount":100},[],{"intervention":3189,"totalTrials":139,"cells":9787},{"EARLY_PHASE1":9788,"PHASE1":9790,"PHASE2":9792,"PHASE3":9798,"PHASE4":9800,"NA":9802},{"trials":9789,"activeCount":100},[],{"trials":9791,"activeCount":100},[],{"trials":9793,"activeCount":100},[9794],{"nctId":3183,"briefTitle":3184,"status":123,"phases":9795,"primaryCompletion":1430,"completion":3186,"start":2545,"enrollment":2801,"conditions":9796,"interventions":9797},[89],[372,373,3177,3176],[3159,3189],{"trials":9799,"activeCount":100},[],{"trials":9801,"activeCount":100},[],{"trials":9803,"activeCount":100},[],{"intervention":9805,"totalTrials":139,"cells":9806},"Panblok + MF59 Dose 1",{"EARLY_PHASE1":9807,"PHASE1":9809,"PHASE2":9811,"PHASE3":9825,"PHASE4":9827,"NA":9829},{"trials":9808,"activeCount":100},[],{"trials":9810,"activeCount":100},[],{"trials":9812,"activeCount":100},[9813],{"nctId":9814,"briefTitle":9815,"status":123,"phases":9816,"primaryCompletion":9817,"completion":9818,"start":9819,"enrollment":9820,"conditions":9821,"interventions":9822},"NCT05608005","Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older",[88,89],"2023-02-18","2024-02-13","2022-11-03",581,[15,33],[9805,9823,9824],"Panblok + MF59 Dose 2","Unadjuvanted Panblok Dose 3",{"trials":9826,"activeCount":100},[],{"trials":9828,"activeCount":100},[],{"trials":9830,"activeCount":100},[],{"intervention":9823,"totalTrials":139,"cells":9832},{"EARLY_PHASE1":9833,"PHASE1":9835,"PHASE2":9837,"PHASE3":9843,"PHASE4":9845,"NA":9847},{"trials":9834,"activeCount":100},[],{"trials":9836,"activeCount":100},[],{"trials":9838,"activeCount":100},[9839],{"nctId":9814,"briefTitle":9815,"status":123,"phases":9840,"primaryCompletion":9817,"completion":9818,"start":9819,"enrollment":9820,"conditions":9841,"interventions":9842},[88,89],[15,33],[9805,9823,9824],{"trials":9844,"activeCount":100},[],{"trials":9846,"activeCount":100},[],{"trials":9848,"activeCount":100},[],{"intervention":9824,"totalTrials":139,"cells":9850},{"EARLY_PHASE1":9851,"PHASE1":9853,"PHASE2":9855,"PHASE3":9861,"PHASE4":9863,"NA":9865},{"trials":9852,"activeCount":100},[],{"trials":9854,"activeCount":100},[],{"trials":9856,"activeCount":100},[9857],{"nctId":9814,"briefTitle":9815,"status":123,"phases":9858,"primaryCompletion":9817,"completion":9818,"start":9819,"enrollment":9820,"conditions":9859,"interventions":9860},[88,89],[15,33],[9805,9823,9824],{"trials":9862,"activeCount":100},[],{"trials":9864,"activeCount":100},[],{"trials":9866,"activeCount":100},[],{"intervention":9868,"totalTrials":139,"cells":9869},"Quadrivalent Inactivated Influenza High Dose",{"EARLY_PHASE1":9870,"PHASE1":9872,"PHASE2":9874,"PHASE3":9886,"PHASE4":9888,"NA":9890},{"trials":9871,"activeCount":100},[],{"trials":9873,"activeCount":100},[],{"trials":9875,"activeCount":100},[9876],{"nctId":9877,"briefTitle":9878,"status":123,"phases":9879,"primaryCompletion":9880,"completion":9880,"start":9881,"enrollment":9882,"conditions":9883,"interventions":9884},"NCT04969276","Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine",[89],"2022-02-08","2021-07-16",306,[759,33],[9868,9885],"COVID-19 mRNA Vaccine",{"trials":9887,"activeCount":100},[],{"trials":9889,"activeCount":100},[],{"trials":9891,"activeCount":100},[],{"intervention":9885,"totalTrials":139,"cells":9893},{"EARLY_PHASE1":9894,"PHASE1":9896,"PHASE2":9898,"PHASE3":9904,"PHASE4":9906,"NA":9908},{"trials":9895,"activeCount":100},[],{"trials":9897,"activeCount":100},[],{"trials":9899,"activeCount":100},[9900],{"nctId":9877,"briefTitle":9878,"status":123,"phases":9901,"primaryCompletion":9880,"completion":9880,"start":9881,"enrollment":9882,"conditions":9902,"interventions":9903},[89],[759,33],[9868,9885],{"trials":9905,"activeCount":100},[],{"trials":9907,"activeCount":100},[],{"trials":9909,"activeCount":100},[],{"intervention":1282,"totalTrials":139,"cells":9911},{"EARLY_PHASE1":9912,"PHASE1":9914,"PHASE2":9916,"PHASE3":9922,"PHASE4":9924,"NA":9926},{"trials":9913,"activeCount":100},[],{"trials":9915,"activeCount":100},[],{"trials":9917,"activeCount":100},[9918],{"nctId":1272,"briefTitle":1273,"status":123,"phases":9919,"primaryCompletion":1275,"completion":1276,"start":1277,"enrollment":1278,"conditions":9920,"interventions":9921},[89],[27,1280],[1253,1282],{"trials":9923,"activeCount":100},[],{"trials":9925,"activeCount":100},[],{"trials":9927,"activeCount":100},[],{"intervention":9929,"totalTrials":139,"cells":9930},"Inactivated types 1, 2, and 3 poliovirus, D antigens",{"EARLY_PHASE1":9931,"PHASE1":9933,"PHASE2":9935,"PHASE3":9944,"PHASE4":9946,"NA":9948},{"trials":9932,"activeCount":100},[],{"trials":9934,"activeCount":100},[],{"trials":9936,"activeCount":100},[9937],{"nctId":9938,"briefTitle":9939,"status":123,"phases":9940,"primaryCompletion":2545,"completion":1971,"start":3363,"enrollment":9941,"conditions":9942,"interventions":9943},"NCT00885157","Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly",[89],225,[30],[9929,9929],{"trials":9945,"activeCount":100},[],{"trials":9947,"activeCount":100},[],{"trials":9949,"activeCount":100},[],{"intervention":3766,"totalTrials":139,"cells":9951},{"EARLY_PHASE1":9952,"PHASE1":9954,"PHASE2":9956,"PHASE3":9962,"PHASE4":9964,"NA":9966},{"trials":9953,"activeCount":100},[],{"trials":9955,"activeCount":100},[],{"trials":9957,"activeCount":100},[9958],{"nctId":3757,"briefTitle":3758,"status":123,"phases":9959,"primaryCompletion":3760,"completion":3760,"start":3761,"enrollment":3762,"conditions":9960,"interventions":9961},[89],[3764],[3766,3767,3768,3766,3766,3769],{"trials":9963,"activeCount":100},[],{"trials":9965,"activeCount":100},[],{"trials":9967,"activeCount":100},[],{"intervention":3767,"totalTrials":139,"cells":9969},{"EARLY_PHASE1":9970,"PHASE1":9972,"PHASE2":9974,"PHASE3":9980,"PHASE4":9982,"NA":9984},{"trials":9971,"activeCount":100},[],{"trials":9973,"activeCount":100},[],{"trials":9975,"activeCount":100},[9976],{"nctId":3757,"briefTitle":3758,"status":123,"phases":9977,"primaryCompletion":3760,"completion":3760,"start":3761,"enrollment":3762,"conditions":9978,"interventions":9979},[89],[3764],[3766,3767,3768,3766,3766,3769],{"trials":9981,"activeCount":100},[],{"trials":9983,"activeCount":100},[],{"trials":9985,"activeCount":100},[],{"intervention":3768,"totalTrials":139,"cells":9987},{"EARLY_PHASE1":9988,"PHASE1":9990,"PHASE2":9992,"PHASE3":9998,"PHASE4":10000,"NA":10002},{"trials":9989,"activeCount":100},[],{"trials":9991,"activeCount":100},[],{"trials":9993,"activeCount":100},[9994],{"nctId":3757,"briefTitle":3758,"status":123,"phases":9995,"primaryCompletion":3760,"completion":3760,"start":3761,"enrollment":3762,"conditions":9996,"interventions":9997},[89],[3764],[3766,3767,3768,3766,3766,3769],{"trials":9999,"activeCount":100},[],{"trials":10001,"activeCount":100},[],{"trials":10003,"activeCount":100},[],{"intervention":10005,"totalTrials":139,"cells":10006},"Fluarix Quadrivalent Influenza vaccine",{"EARLY_PHASE1":10007,"PHASE1":10009,"PHASE2":10011,"PHASE3":10023,"PHASE4":10025,"NA":10027},{"trials":10008,"activeCount":100},[],{"trials":10010,"activeCount":100},[],{"trials":10012,"activeCount":100},[10013],{"nctId":10014,"briefTitle":10015,"status":123,"phases":10016,"primaryCompletion":10017,"completion":10017,"start":10018,"enrollment":10019,"conditions":10020,"interventions":10021},"NCT03698279","Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age",[89],"2019-10-16","2018-10-09",665,[15],[7576,7576,7576,10005,10022],"FLUAD Pediatric",{"trials":10024,"activeCount":100},[],{"trials":10026,"activeCount":100},[],{"trials":10028,"activeCount":100},[],{"intervention":10022,"totalTrials":139,"cells":10030},{"EARLY_PHASE1":10031,"PHASE1":10033,"PHASE2":10035,"PHASE3":10041,"PHASE4":10043,"NA":10045},{"trials":10032,"activeCount":100},[],{"trials":10034,"activeCount":100},[],{"trials":10036,"activeCount":100},[10037],{"nctId":10014,"briefTitle":10015,"status":123,"phases":10038,"primaryCompletion":10017,"completion":10017,"start":10018,"enrollment":10019,"conditions":10039,"interventions":10040},[89],[15],[7576,7576,7576,10005,10022],{"trials":10042,"activeCount":100},[],{"trials":10044,"activeCount":100},[],{"trials":10046,"activeCount":100},[],{"intervention":10048,"totalTrials":139,"cells":10049},"Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus",{"EARLY_PHASE1":10050,"PHASE1":10052,"PHASE2":10054,"PHASE3":10065,"PHASE4":10067,"NA":10069},{"trials":10051,"activeCount":100},[],{"trials":10053,"activeCount":100},[],{"trials":10055,"activeCount":100},[10056],{"nctId":10057,"briefTitle":10058,"status":123,"phases":10059,"primaryCompletion":10060,"completion":10060,"start":10061,"enrollment":10062,"conditions":10063,"interventions":10064},"NCT01488890","Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine",[89],"2013-09-27","2011-12-06",390,[372,3176,373,352],[10048,10048,10048,352],{"trials":10066,"activeCount":100},[],{"trials":10068,"activeCount":100},[],{"trials":10070,"activeCount":100},[],{"intervention":352,"totalTrials":139,"cells":10072},{"EARLY_PHASE1":10073,"PHASE1":10075,"PHASE2":10077,"PHASE3":10083,"PHASE4":10085,"NA":10087},{"trials":10074,"activeCount":100},[],{"trials":10076,"activeCount":100},[],{"trials":10078,"activeCount":100},[10079],{"nctId":10057,"briefTitle":10058,"status":123,"phases":10080,"primaryCompletion":10060,"completion":10060,"start":10061,"enrollment":10062,"conditions":10081,"interventions":10082},[89],[372,3176,373,352],[10048,10048,10048,352],{"trials":10084,"activeCount":100},[],{"trials":10086,"activeCount":100},[],{"trials":10088,"activeCount":100},[],{"intervention":556,"totalTrials":139,"cells":10090},{"EARLY_PHASE1":10091,"PHASE1":10093,"PHASE2":10095,"PHASE3":10101,"PHASE4":10103,"NA":10105},{"trials":10092,"activeCount":100},[],{"trials":10094,"activeCount":100},[],{"trials":10096,"activeCount":100},[10097],{"nctId":548,"briefTitle":549,"status":123,"phases":10098,"primaryCompletion":551,"completion":551,"start":552,"enrollment":553,"conditions":10099,"interventions":10100},[89],[27,162],[556,557,558,559,560,538,561,562],{"trials":10102,"activeCount":100},[],{"trials":10104,"activeCount":100},[],{"trials":10106,"activeCount":100},[],{"intervention":558,"totalTrials":139,"cells":10108},{"EARLY_PHASE1":10109,"PHASE1":10111,"PHASE2":10113,"PHASE3":10119,"PHASE4":10121,"NA":10123},{"trials":10110,"activeCount":100},[],{"trials":10112,"activeCount":100},[],{"trials":10114,"activeCount":100},[10115],{"nctId":548,"briefTitle":549,"status":123,"phases":10116,"primaryCompletion":551,"completion":551,"start":552,"enrollment":553,"conditions":10117,"interventions":10118},[89],[27,162],[556,557,558,559,560,538,561,562],{"trials":10120,"activeCount":100},[],{"trials":10122,"activeCount":100},[],{"trials":10124,"activeCount":100},[],{"intervention":560,"totalTrials":139,"cells":10126},{"EARLY_PHASE1":10127,"PHASE1":10129,"PHASE2":10131,"PHASE3":10137,"PHASE4":10139,"NA":10141},{"trials":10128,"activeCount":100},[],{"trials":10130,"activeCount":100},[],{"trials":10132,"activeCount":100},[10133],{"nctId":548,"briefTitle":549,"status":123,"phases":10134,"primaryCompletion":551,"completion":551,"start":552,"enrollment":553,"conditions":10135,"interventions":10136},[89],[27,162],[556,557,558,559,560,538,561,562],{"trials":10138,"activeCount":100},[],{"trials":10140,"activeCount":100},[],{"trials":10142,"activeCount":100},[],{"intervention":3369,"totalTrials":139,"cells":10144},{"EARLY_PHASE1":10145,"PHASE1":10147,"PHASE2":10149,"PHASE3":10155,"PHASE4":10157,"NA":10159},{"trials":10146,"activeCount":100},[],{"trials":10148,"activeCount":100},[],{"trials":10150,"activeCount":100},[10151],{"nctId":3360,"briefTitle":3361,"status":123,"phases":10152,"primaryCompletion":1287,"completion":3363,"start":1191,"enrollment":3364,"conditions":10153,"interventions":10154},[89],[15,3366,3367],[3369,3369,3343,3343],{"trials":10156,"activeCount":100},[],{"trials":10158,"activeCount":100},[],{"trials":10160,"activeCount":100},[],{"intervention":8957,"totalTrials":139,"cells":10162},{"EARLY_PHASE1":10163,"PHASE1":10165,"PHASE2":10167,"PHASE3":10173,"PHASE4":10175,"NA":10177},{"trials":10164,"activeCount":100},[],{"trials":10166,"activeCount":100},[],{"trials":10168,"activeCount":100},[10169],{"nctId":8951,"briefTitle":8952,"status":123,"phases":10170,"primaryCompletion":1210,"completion":2100,"start":1854,"enrollment":8954,"conditions":10171,"interventions":10172},[89],[27,162],[8957,8957,8957,8957,8957,8935],{"trials":10174,"activeCount":100},[],{"trials":10176,"activeCount":100},[],{"trials":10178,"activeCount":100},[],{"intervention":1385,"totalTrials":139,"cells":10180},{"EARLY_PHASE1":10181,"PHASE1":10183,"PHASE2":10185,"PHASE3":10191,"PHASE4":10193,"NA":10195},{"trials":10182,"activeCount":100},[],{"trials":10184,"activeCount":100},[],{"trials":10186,"activeCount":100},[10187],{"nctId":1366,"briefTitle":1367,"status":123,"phases":10188,"primaryCompletion":1369,"completion":1369,"start":1370,"enrollment":1371,"conditions":10189,"interventions":10190},[89],[1373,1374,1375,1376,1377,1378,1379,1380,1381,1382,1383],[1385,1386,1387,559,584,1388,1349,616,1389],{"trials":10192,"activeCount":100},[],{"trials":10194,"activeCount":100},[],{"trials":10196,"activeCount":100},[],{"intervention":1386,"totalTrials":139,"cells":10198},{"EARLY_PHASE1":10199,"PHASE1":10201,"PHASE2":10203,"PHASE3":10209,"PHASE4":10211,"NA":10213},{"trials":10200,"activeCount":100},[],{"trials":10202,"activeCount":100},[],{"trials":10204,"activeCount":100},[10205],{"nctId":1366,"briefTitle":1367,"status":123,"phases":10206,"primaryCompletion":1369,"completion":1369,"start":1370,"enrollment":1371,"conditions":10207,"interventions":10208},[89],[1373,1374,1375,1376,1377,1378,1379,1380,1381,1382,1383],[1385,1386,1387,559,584,1388,1349,616,1389],{"trials":10210,"activeCount":100},[],{"trials":10212,"activeCount":100},[],{"trials":10214,"activeCount":100},[],{"intervention":1387,"totalTrials":139,"cells":10216},{"EARLY_PHASE1":10217,"PHASE1":10219,"PHASE2":10221,"PHASE3":10227,"PHASE4":10229,"NA":10231},{"trials":10218,"activeCount":100},[],{"trials":10220,"activeCount":100},[],{"trials":10222,"activeCount":100},[10223],{"nctId":1366,"briefTitle":1367,"status":123,"phases":10224,"primaryCompletion":1369,"completion":1369,"start":1370,"enrollment":1371,"conditions":10225,"interventions":10226},[89],[1373,1374,1375,1376,1377,1378,1379,1380,1381,1382,1383],[1385,1386,1387,559,584,1388,1349,616,1389],{"trials":10228,"activeCount":100},[],{"trials":10230,"activeCount":100},[],{"trials":10232,"activeCount":100},[],{"intervention":1388,"totalTrials":139,"cells":10234},{"EARLY_PHASE1":10235,"PHASE1":10237,"PHASE2":10239,"PHASE3":10245,"PHASE4":10247,"NA":10249},{"trials":10236,"activeCount":100},[],{"trials":10238,"activeCount":100},[],{"trials":10240,"activeCount":100},[10241],{"nctId":1366,"briefTitle":1367,"status":123,"phases":10242,"primaryCompletion":1369,"completion":1369,"start":1370,"enrollment":1371,"conditions":10243,"interventions":10244},[89],[1373,1374,1375,1376,1377,1378,1379,1380,1381,1382,1383],[1385,1386,1387,559,584,1388,1349,616,1389],{"trials":10246,"activeCount":100},[],{"trials":10248,"activeCount":100},[],{"trials":10250,"activeCount":100},[],{"intervention":1389,"totalTrials":139,"cells":10252},{"EARLY_PHASE1":10253,"PHASE1":10255,"PHASE2":10257,"PHASE3":10263,"PHASE4":10265,"NA":10267},{"trials":10254,"activeCount":100},[],{"trials":10256,"activeCount":100},[],{"trials":10258,"activeCount":100},[10259],{"nctId":1366,"briefTitle":1367,"status":123,"phases":10260,"primaryCompletion":1369,"completion":1369,"start":1370,"enrollment":1371,"conditions":10261,"interventions":10262},[89],[1373,1374,1375,1376,1377,1378,1379,1380,1381,1382,1383],[1385,1386,1387,559,584,1388,1349,616,1389],{"trials":10264,"activeCount":100},[],{"trials":10266,"activeCount":100},[],{"trials":10268,"activeCount":100},[],{"intervention":10270,"totalTrials":139,"cells":10271},"CoV2 preS dTM-AF03",{"EARLY_PHASE1":10272,"PHASE1":10274,"PHASE2":10276,"PHASE3":10290,"PHASE4":10292,"NA":10294},{"trials":10273,"activeCount":100},[],{"trials":10275,"activeCount":100},[],{"trials":10277,"activeCount":100},[10278],{"nctId":10279,"briefTitle":10280,"status":123,"phases":10281,"primaryCompletion":10282,"completion":10282,"start":10283,"enrollment":10284,"conditions":10285,"interventions":10287},"NCT04537208","Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older",[88,89],"2021-11-19","2020-09-03",441,[10286],"COVID-19 (Healthy Volunteers)",[10270,10270,10288,10288,10289],"CoV2 preS dTM-AS03","CoV2 preS dTM (high-dose) without adjuvant",{"trials":10291,"activeCount":100},[],{"trials":10293,"activeCount":100},[],{"trials":10295,"activeCount":100},[],{"intervention":10288,"totalTrials":139,"cells":10297},{"EARLY_PHASE1":10298,"PHASE1":10300,"PHASE2":10302,"PHASE3":10308,"PHASE4":10310,"NA":10312},{"trials":10299,"activeCount":100},[],{"trials":10301,"activeCount":100},[],{"trials":10303,"activeCount":100},[10304],{"nctId":10279,"briefTitle":10280,"status":123,"phases":10305,"primaryCompletion":10282,"completion":10282,"start":10283,"enrollment":10284,"conditions":10306,"interventions":10307},[88,89],[10286],[10270,10270,10288,10288,10289],{"trials":10309,"activeCount":100},[],{"trials":10311,"activeCount":100},[],{"trials":10313,"activeCount":100},[],{"intervention":10289,"totalTrials":139,"cells":10315},{"EARLY_PHASE1":10316,"PHASE1":10318,"PHASE2":10320,"PHASE3":10326,"PHASE4":10328,"NA":10330},{"trials":10317,"activeCount":100},[],{"trials":10319,"activeCount":100},[],{"trials":10321,"activeCount":100},[10322],{"nctId":10279,"briefTitle":10280,"status":123,"phases":10323,"primaryCompletion":10282,"completion":10282,"start":10283,"enrollment":10284,"conditions":10324,"interventions":10325},[88,89],[10286],[10270,10270,10288,10288,10289],{"trials":10327,"activeCount":100},[],{"trials":10329,"activeCount":100},[],{"trials":10331,"activeCount":100},[],{"intervention":10333,"totalTrials":139,"cells":10334},"RSV vaccine candiate formulation 1",{"EARLY_PHASE1":10335,"PHASE1":10337,"PHASE2":10339,"PHASE3":10351,"PHASE4":10353,"NA":10355},{"trials":10336,"activeCount":100},[],{"trials":10338,"activeCount":100},[],{"trials":10340,"activeCount":100},[10341],{"nctId":10342,"briefTitle":10343,"status":123,"phases":10344,"primaryCompletion":10345,"completion":10345,"start":10346,"enrollment":10347,"conditions":10348,"interventions":10349},"NCT05639894","Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older",[88,89],"2025-05-02","2022-11-17",865,[837],[10333,10350],"RSV vaccine candidate formulation 2",{"trials":10352,"activeCount":100},[],{"trials":10354,"activeCount":100},[],{"trials":10356,"activeCount":100},[],{"intervention":10350,"totalTrials":139,"cells":10358},{"EARLY_PHASE1":10359,"PHASE1":10361,"PHASE2":10363,"PHASE3":10369,"PHASE4":10371,"NA":10373},{"trials":10360,"activeCount":100},[],{"trials":10362,"activeCount":100},[],{"trials":10364,"activeCount":100},[10365],{"nctId":10342,"briefTitle":10343,"status":123,"phases":10366,"primaryCompletion":10345,"completion":10345,"start":10346,"enrollment":10347,"conditions":10367,"interventions":10368},[88,89],[837],[10333,10350],{"trials":10370,"activeCount":100},[],{"trials":10372,"activeCount":100},[],{"trials":10374,"activeCount":100},[],{"intervention":10376,"totalTrials":139,"cells":10377},"ACAM1000",{"EARLY_PHASE1":10378,"PHASE1":10380,"PHASE2":10382,"PHASE3":10392,"PHASE4":10394,"NA":10396},{"trials":10379,"activeCount":100},[],{"trials":10381,"activeCount":100},[],{"trials":10383,"activeCount":100},[10384],{"nctId":10385,"briefTitle":10386,"status":646,"phases":10387,"primaryCompletion":8947,"completion":1219,"start":10388,"enrollment":4533,"conditions":10389,"interventions":10390},"NCT00053508","Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination",[89],"2002-09",[9089],[10376,10391],"vaccinia virus (calf lymph) smallpox vaccine: Dryvax",{"trials":10393,"activeCount":100},[],{"trials":10395,"activeCount":100},[],{"trials":10397,"activeCount":100},[],{"intervention":10391,"totalTrials":139,"cells":10399},{"EARLY_PHASE1":10400,"PHASE1":10402,"PHASE2":10404,"PHASE3":10410,"PHASE4":10412,"NA":10414},{"trials":10401,"activeCount":100},[],{"trials":10403,"activeCount":100},[],{"trials":10405,"activeCount":100},[10406],{"nctId":10385,"briefTitle":10386,"status":646,"phases":10407,"primaryCompletion":8947,"completion":1219,"start":10388,"enrollment":4533,"conditions":10408,"interventions":10409},[89],[9089],[10376,10391],{"trials":10411,"activeCount":100},[],{"trials":10413,"activeCount":100},[],{"trials":10415,"activeCount":100},[],{"intervention":8986,"totalTrials":139,"cells":10417},{"EARLY_PHASE1":10418,"PHASE1":10420,"PHASE2":10422,"PHASE3":10428,"PHASE4":10430,"NA":10432},{"trials":10419,"activeCount":100},[],{"trials":10421,"activeCount":100},[],{"trials":10423,"activeCount":100},[10424],{"nctId":8980,"briefTitle":8981,"status":123,"phases":10425,"primaryCompletion":1971,"completion":1182,"start":2654,"enrollment":2040,"conditions":10426,"interventions":10427},[89],[15,2354,8984],[8986,8987,8987],{"trials":10429,"activeCount":100},[],{"trials":10431,"activeCount":100},[],{"trials":10433,"activeCount":100},[],{"intervention":10435,"totalTrials":139,"cells":10436},"Purified Vero Rabies Vaccine Serum Free",{"EARLY_PHASE1":10437,"PHASE1":10439,"PHASE2":10441,"PHASE3":10450,"PHASE4":10452,"NA":10454},{"trials":10438,"activeCount":100},[],{"trials":10440,"activeCount":100},[],{"trials":10442,"activeCount":100},[10443],{"nctId":10444,"briefTitle":10445,"status":123,"phases":10446,"primaryCompletion":1565,"completion":1564,"start":367,"enrollment":1454,"conditions":10447,"interventions":10448},"NCT01930357","Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen",[89],[1857],[10435,10449],"Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),",{"trials":10451,"activeCount":100},[],{"trials":10453,"activeCount":100},[],{"trials":10455,"activeCount":100},[],{"intervention":10449,"totalTrials":139,"cells":10457},{"EARLY_PHASE1":10458,"PHASE1":10460,"PHASE2":10462,"PHASE3":10468,"PHASE4":10470,"NA":10472},{"trials":10459,"activeCount":100},[],{"trials":10461,"activeCount":100},[],{"trials":10463,"activeCount":100},[10464],{"nctId":10444,"briefTitle":10445,"status":123,"phases":10465,"primaryCompletion":1565,"completion":1564,"start":367,"enrollment":1454,"conditions":10466,"interventions":10467},[89],[1857],[10435,10449],{"trials":10469,"activeCount":100},[],{"trials":10471,"activeCount":100},[],{"trials":10473,"activeCount":100},[],{"intervention":10475,"totalTrials":139,"cells":10476},"2009-2010 Trivalent Influenza Virus Vaccine",{"EARLY_PHASE1":10477,"PHASE1":10479,"PHASE2":10481,"PHASE3":10491,"PHASE4":10493,"NA":10495},{"trials":10478,"activeCount":100},[],{"trials":10480,"activeCount":100},[],{"trials":10482,"activeCount":100},[10483],{"nctId":10484,"briefTitle":10485,"status":123,"phases":10486,"primaryCompletion":1971,"completion":5367,"start":2545,"enrollment":2801,"conditions":10487,"interventions":10488},"NCT00988143","A Study of Influenza Virus Vaccines in Children and Adults",[89],[15],[10475,10489,10490],"2008-2009 Trivalent Influenza Virus Vaccine","Quadrivalent Influenza Virus Vaccine",{"trials":10492,"activeCount":100},[],{"trials":10494,"activeCount":100},[],{"trials":10496,"activeCount":100},[],{"intervention":10489,"totalTrials":139,"cells":10498},{"EARLY_PHASE1":10499,"PHASE1":10501,"PHASE2":10503,"PHASE3":10509,"PHASE4":10511,"NA":10513},{"trials":10500,"activeCount":100},[],{"trials":10502,"activeCount":100},[],{"trials":10504,"activeCount":100},[10505],{"nctId":10484,"briefTitle":10485,"status":123,"phases":10506,"primaryCompletion":1971,"completion":5367,"start":2545,"enrollment":2801,"conditions":10507,"interventions":10508},[89],[15],[10475,10489,10490],{"trials":10510,"activeCount":100},[],{"trials":10512,"activeCount":100},[],{"trials":10514,"activeCount":100},[],{"intervention":10490,"totalTrials":139,"cells":10516},{"EARLY_PHASE1":10517,"PHASE1":10519,"PHASE2":10521,"PHASE3":10527,"PHASE4":10529,"NA":10531},{"trials":10518,"activeCount":100},[],{"trials":10520,"activeCount":100},[],{"trials":10522,"activeCount":100},[10523],{"nctId":10484,"briefTitle":10485,"status":123,"phases":10524,"primaryCompletion":1971,"completion":5367,"start":2545,"enrollment":2801,"conditions":10525,"interventions":10526},[89],[15],[10475,10489,10490],{"trials":10528,"activeCount":100},[],{"trials":10530,"activeCount":100},[],{"trials":10532,"activeCount":100},[],{"intervention":10534,"totalTrials":139,"cells":10535},"ChimeriVax-WN02 Low Dose",{"EARLY_PHASE1":10536,"PHASE1":10538,"PHASE2":10540,"PHASE3":10553,"PHASE4":10555,"NA":10557},{"trials":10537,"activeCount":100},[],{"trials":10539,"activeCount":100},[],{"trials":10541,"activeCount":100},[10542],{"nctId":10543,"briefTitle":10544,"status":123,"phases":10545,"primaryCompletion":1289,"completion":3363,"start":1267,"enrollment":1768,"conditions":10546,"interventions":10548},"NCT00442169","Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults",[89],[10547],"West Nile Fever",[10534,10549,10550,10551,10550,10552],"ChimeriVax-WN02 Medium Dose","ChimeriVax-WN02 High Dose","0.9% Saline solution","0.9 % NaCl solution",{"trials":10554,"activeCount":100},[],{"trials":10556,"activeCount":100},[],{"trials":10558,"activeCount":100},[],{"intervention":10549,"totalTrials":139,"cells":10560},{"EARLY_PHASE1":10561,"PHASE1":10563,"PHASE2":10565,"PHASE3":10571,"PHASE4":10573,"NA":10575},{"trials":10562,"activeCount":100},[],{"trials":10564,"activeCount":100},[],{"trials":10566,"activeCount":100},[10567],{"nctId":10543,"briefTitle":10544,"status":123,"phases":10568,"primaryCompletion":1289,"completion":3363,"start":1267,"enrollment":1768,"conditions":10569,"interventions":10570},[89],[10547],[10534,10549,10550,10551,10550,10552],{"trials":10572,"activeCount":100},[],{"trials":10574,"activeCount":100},[],{"trials":10576,"activeCount":100},[],{"intervention":10550,"totalTrials":139,"cells":10578},{"EARLY_PHASE1":10579,"PHASE1":10581,"PHASE2":10583,"PHASE3":10589,"PHASE4":10591,"NA":10593},{"trials":10580,"activeCount":100},[],{"trials":10582,"activeCount":100},[],{"trials":10584,"activeCount":100},[10585],{"nctId":10543,"briefTitle":10544,"status":123,"phases":10586,"primaryCompletion":1289,"completion":3363,"start":1267,"enrollment":1768,"conditions":10587,"interventions":10588},[89],[10547],[10534,10549,10550,10551,10550,10552],{"trials":10590,"activeCount":100},[],{"trials":10592,"activeCount":100},[],{"trials":10594,"activeCount":100},[],{"intervention":10551,"totalTrials":139,"cells":10596},{"EARLY_PHASE1":10597,"PHASE1":10599,"PHASE2":10601,"PHASE3":10607,"PHASE4":10609,"NA":10611},{"trials":10598,"activeCount":100},[],{"trials":10600,"activeCount":100},[],{"trials":10602,"activeCount":100},[10603],{"nctId":10543,"briefTitle":10544,"status":123,"phases":10604,"primaryCompletion":1289,"completion":3363,"start":1267,"enrollment":1768,"conditions":10605,"interventions":10606},[89],[10547],[10534,10549,10550,10551,10550,10552],{"trials":10608,"activeCount":100},[],{"trials":10610,"activeCount":100},[],{"trials":10612,"activeCount":100},[],{"intervention":10552,"totalTrials":139,"cells":10614},{"EARLY_PHASE1":10615,"PHASE1":10617,"PHASE2":10619,"PHASE3":10625,"PHASE4":10627,"NA":10629},{"trials":10616,"activeCount":100},[],{"trials":10618,"activeCount":100},[],{"trials":10620,"activeCount":100},[10621],{"nctId":10543,"briefTitle":10544,"status":123,"phases":10622,"primaryCompletion":1289,"completion":3363,"start":1267,"enrollment":1768,"conditions":10623,"interventions":10624},[89],[10547],[10534,10549,10550,10551,10550,10552],{"trials":10626,"activeCount":100},[],{"trials":10628,"activeCount":100},[],{"trials":10630,"activeCount":100},[],{"intervention":10632,"totalTrials":139,"cells":10633},"Pandemic flu H5 mRNA vaccine",{"EARLY_PHASE1":10634,"PHASE1":10636,"PHASE2":10638,"PHASE3":10649,"PHASE4":10651,"NA":10653},{"trials":10635,"activeCount":100},[],{"trials":10637,"activeCount":100},[],{"trials":10639,"activeCount":100},[10640],{"nctId":10641,"briefTitle":10642,"status":123,"phases":10643,"primaryCompletion":10644,"completion":10644,"start":10645,"enrollment":10646,"conditions":10647,"interventions":10648},"NCT06727058","Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older",[88,89],"2026-03-24","2024-12-09",276,[759],[10632],{"trials":10650,"activeCount":100},[],{"trials":10652,"activeCount":100},[],{"trials":10654,"activeCount":100},[],{"intervention":10656,"totalTrials":139,"cells":10657},"Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus",{"EARLY_PHASE1":10658,"PHASE1":10660,"PHASE2":10662,"PHASE3":10671,"PHASE4":10673,"NA":10675},{"trials":10659,"activeCount":100},[],{"trials":10661,"activeCount":100},[],{"trials":10663,"activeCount":100},[10664],{"nctId":10665,"briefTitle":10666,"status":123,"phases":10667,"primaryCompletion":1767,"completion":3242,"start":3186,"enrollment":10668,"conditions":10669,"interventions":10670},"NCT01550289","Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India",[89],189,[372,3176,373],[10656],{"trials":10672,"activeCount":100},[],{"trials":10674,"activeCount":100},[],{"trials":10676,"activeCount":100},[],{"intervention":10678,"totalTrials":139,"cells":10679},"Influenza virus (split virion, inactivated) vaccine",{"EARLY_PHASE1":10680,"PHASE1":10682,"PHASE2":10684,"PHASE3":10692,"PHASE4":10694,"NA":10696},{"trials":10681,"activeCount":100},[],{"trials":10683,"activeCount":100},[],{"trials":10685,"activeCount":100},[10686],{"nctId":10687,"briefTitle":10688,"status":123,"phases":10689,"primaryCompletion":3401,"completion":3527,"start":3489,"enrollment":9352,"conditions":10690,"interventions":10691},"NCT00946179","Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation",[89],[15],[10678],{"trials":10693,"activeCount":100},[],{"trials":10695,"activeCount":100},[],{"trials":10697,"activeCount":100},[],{"intervention":782,"totalTrials":139,"cells":10699},{"EARLY_PHASE1":10700,"PHASE1":10702,"PHASE2":10704,"PHASE3":10710,"PHASE4":10712,"NA":10714},{"trials":10701,"activeCount":100},[],{"trials":10703,"activeCount":100},[],{"trials":10705,"activeCount":100},[10706],{"nctId":774,"briefTitle":775,"status":123,"phases":10707,"primaryCompletion":777,"completion":777,"start":778,"enrollment":779,"conditions":10708,"interventions":10709},[88,89],[759],[782,762,742,763],{"trials":10711,"activeCount":100},[],{"trials":10713,"activeCount":100},[],{"trials":10715,"activeCount":100},[],{"intervention":10717,"totalTrials":139,"cells":10718},"Polysaccharide Diphtheria Conjugate Vaccine",{"EARLY_PHASE1":10719,"PHASE1":10721,"PHASE2":10723,"PHASE3":10732,"PHASE4":10734,"NA":10736},{"trials":10720,"activeCount":100},[],{"trials":10722,"activeCount":100},[],{"trials":10724,"activeCount":100},[10725],{"nctId":10726,"briefTitle":10727,"status":123,"phases":10728,"primaryCompletion":1706,"completion":3808,"start":1190,"enrollment":10729,"conditions":10730,"interventions":10731},"NCT00258856","Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®",[89],234,[27,162],[10717,10717,10717,10717],{"trials":10733,"activeCount":100},[],{"trials":10735,"activeCount":100},[],{"trials":10737,"activeCount":100},[],{"intervention":10739,"totalTrials":139,"cells":10740},"Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine",{"EARLY_PHASE1":10741,"PHASE1":10743,"PHASE2":10745,"PHASE3":10759,"PHASE4":10761,"NA":10763},{"trials":10742,"activeCount":100},[],{"trials":10744,"activeCount":100},[],{"trials":10746,"activeCount":100},[10747],{"nctId":10748,"briefTitle":10749,"status":123,"phases":10750,"primaryCompletion":10751,"completion":10751,"start":10752,"enrollment":10753,"conditions":10754,"interventions":10755},"NCT02199691","Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents",[89],"2015-10-02","2014-07-22",1715,[27,1046,468],[10739,10756,10757,10758,10739,10757,10758],"Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine","Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed","GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant",{"trials":10760,"activeCount":100},[],{"trials":10762,"activeCount":100},[],{"trials":10764,"activeCount":100},[],{"intervention":10756,"totalTrials":139,"cells":10766},{"EARLY_PHASE1":10767,"PHASE1":10769,"PHASE2":10771,"PHASE3":10777,"PHASE4":10779,"NA":10781},{"trials":10768,"activeCount":100},[],{"trials":10770,"activeCount":100},[],{"trials":10772,"activeCount":100},[10773],{"nctId":10748,"briefTitle":10749,"status":123,"phases":10774,"primaryCompletion":10751,"completion":10751,"start":10752,"enrollment":10753,"conditions":10775,"interventions":10776},[89],[27,1046,468],[10739,10756,10757,10758,10739,10757,10758],{"trials":10778,"activeCount":100},[],{"trials":10780,"activeCount":100},[],{"trials":10782,"activeCount":100},[],{"intervention":10757,"totalTrials":139,"cells":10784},{"EARLY_PHASE1":10785,"PHASE1":10787,"PHASE2":10789,"PHASE3":10795,"PHASE4":10797,"NA":10799},{"trials":10786,"activeCount":100},[],{"trials":10788,"activeCount":100},[],{"trials":10790,"activeCount":100},[10791],{"nctId":10748,"briefTitle":10749,"status":123,"phases":10792,"primaryCompletion":10751,"completion":10751,"start":10752,"enrollment":10753,"conditions":10793,"interventions":10794},[89],[27,1046,468],[10739,10756,10757,10758,10739,10757,10758],{"trials":10796,"activeCount":100},[],{"trials":10798,"activeCount":100},[],{"trials":10800,"activeCount":100},[],{"intervention":10758,"totalTrials":139,"cells":10802},{"EARLY_PHASE1":10803,"PHASE1":10805,"PHASE2":10807,"PHASE3":10813,"PHASE4":10815,"NA":10817},{"trials":10804,"activeCount":100},[],{"trials":10806,"activeCount":100},[],{"trials":10808,"activeCount":100},[10809],{"nctId":10748,"briefTitle":10749,"status":123,"phases":10810,"primaryCompletion":10751,"completion":10751,"start":10752,"enrollment":10753,"conditions":10811,"interventions":10812},[89],[27,1046,468],[10739,10756,10757,10758,10739,10757,10758],{"trials":10814,"activeCount":100},[],{"trials":10816,"activeCount":100},[],{"trials":10818,"activeCount":100},[],{"intervention":10820,"totalTrials":139,"cells":10821},"SARS-CoV-2 mRNA vaccine formulation 1",{"EARLY_PHASE1":10822,"PHASE1":10824,"PHASE2":10826,"PHASE3":10839,"PHASE4":10841,"NA":10843},{"trials":10823,"activeCount":100},[],{"trials":10825,"activeCount":100},[],{"trials":10827,"activeCount":100},[10828],{"nctId":10829,"briefTitle":10830,"status":646,"phases":10831,"primaryCompletion":10832,"completion":10832,"start":10833,"enrollment":10834,"conditions":10835,"interventions":10836},"NCT04798027","Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older",[88,89],"2022-06-27","2021-03-12",182,[4730],[10820,10837,10838],"SARS-CoV-2 mRNA vaccine formulation 2","SARS-CoV-2 mRNA vaccine formulation 3",{"trials":10840,"activeCount":100},[],{"trials":10842,"activeCount":100},[],{"trials":10844,"activeCount":100},[],{"intervention":10837,"totalTrials":139,"cells":10846},{"EARLY_PHASE1":10847,"PHASE1":10849,"PHASE2":10851,"PHASE3":10857,"PHASE4":10859,"NA":10861},{"trials":10848,"activeCount":100},[],{"trials":10850,"activeCount":100},[],{"trials":10852,"activeCount":100},[10853],{"nctId":10829,"briefTitle":10830,"status":646,"phases":10854,"primaryCompletion":10832,"completion":10832,"start":10833,"enrollment":10834,"conditions":10855,"interventions":10856},[88,89],[4730],[10820,10837,10838],{"trials":10858,"activeCount":100},[],{"trials":10860,"activeCount":100},[],{"trials":10862,"activeCount":100},[],{"intervention":10838,"totalTrials":139,"cells":10864},{"EARLY_PHASE1":10865,"PHASE1":10867,"PHASE2":10869,"PHASE3":10875,"PHASE4":10877,"NA":10879},{"trials":10866,"activeCount":100},[],{"trials":10868,"activeCount":100},[],{"trials":10870,"activeCount":100},[10871],{"nctId":10829,"briefTitle":10830,"status":646,"phases":10872,"primaryCompletion":10832,"completion":10832,"start":10833,"enrollment":10834,"conditions":10873,"interventions":10874},[88,89],[4730],[10820,10837,10838],{"trials":10876,"activeCount":100},[],{"trials":10878,"activeCount":100},[],{"trials":10880,"activeCount":100},[],{"intervention":10882,"totalTrials":139,"cells":10883},"CYD dengue vaccine serotypes (1, 2, 3, 4).",{"EARLY_PHASE1":10884,"PHASE1":10886,"PHASE2":10888,"PHASE3":10898,"PHASE4":10900,"NA":10902},{"trials":10885,"activeCount":100},[],{"trials":10887,"activeCount":100},[],{"trials":10889,"activeCount":100},[10890],{"nctId":10891,"briefTitle":10892,"status":123,"phases":10893,"primaryCompletion":1565,"completion":1563,"start":1288,"enrollment":2377,"conditions":10894,"interventions":10896},"NCT00875524","Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects",[89],[3177,3176,373,10895],"Dengue Disease",[10882,10897],"Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide",{"trials":10899,"activeCount":100},[],{"trials":10901,"activeCount":100},[],{"trials":10903,"activeCount":100},[],{"intervention":10897,"totalTrials":139,"cells":10905},{"EARLY_PHASE1":10906,"PHASE1":10908,"PHASE2":10910,"PHASE3":10916,"PHASE4":10918,"NA":10920},{"trials":10907,"activeCount":100},[],{"trials":10909,"activeCount":100},[],{"trials":10911,"activeCount":100},[10912],{"nctId":10891,"briefTitle":10892,"status":123,"phases":10913,"primaryCompletion":1565,"completion":1563,"start":1288,"enrollment":2377,"conditions":10914,"interventions":10915},[89],[3177,3176,373,10895],[10882,10897],{"trials":10917,"activeCount":100},[],{"trials":10919,"activeCount":100},[],{"trials":10921,"activeCount":100},[],{"intervention":10923,"totalTrials":139,"cells":10924},"Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine",{"EARLY_PHASE1":10925,"PHASE1":10927,"PHASE2":10929,"PHASE3":10941,"PHASE4":10943,"NA":10945},{"trials":10926,"activeCount":100},[],{"trials":10928,"activeCount":100},[],{"trials":10930,"activeCount":100},[10931],{"nctId":10932,"briefTitle":10933,"status":123,"phases":10934,"primaryCompletion":10935,"completion":10935,"start":10936,"enrollment":3458,"conditions":10937,"interventions":10939},"NCT01732627","Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older",[89],"2013-01-17","2012-11-12",[27,1046,468,10938],"Invasive Meningococcal Disease",[10923,10940],"Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined",{"trials":10942,"activeCount":100},[],{"trials":10944,"activeCount":100},[],{"trials":10946,"activeCount":100},[],{"intervention":10940,"totalTrials":139,"cells":10948},{"EARLY_PHASE1":10949,"PHASE1":10951,"PHASE2":10953,"PHASE3":10959,"PHASE4":10961,"NA":10963},{"trials":10950,"activeCount":100},[],{"trials":10952,"activeCount":100},[],{"trials":10954,"activeCount":100},[10955],{"nctId":10932,"briefTitle":10933,"status":123,"phases":10956,"primaryCompletion":10935,"completion":10935,"start":10936,"enrollment":3458,"conditions":10957,"interventions":10958},[89],[27,1046,468,10938],[10923,10940],{"trials":10960,"activeCount":100},[],{"trials":10962,"activeCount":100},[],{"trials":10964,"activeCount":100},[],{"intervention":10966,"totalTrials":139,"cells":10967},"RSV vaccine candidate",{"EARLY_PHASE1":10968,"PHASE1":10970,"PHASE2":10972,"PHASE3":10982,"PHASE4":10984,"NA":10986},{"trials":10969,"activeCount":100},[],{"trials":10971,"activeCount":100},[],{"trials":10973,"activeCount":100},[10974],{"nctId":10975,"briefTitle":10976,"status":123,"phases":10977,"primaryCompletion":10978,"completion":10978,"start":755,"enrollment":10979,"conditions":10980,"interventions":10981},"NCT06251024","Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older",[89],"2025-03-11",4541,[3668,33],[10966],{"trials":10983,"activeCount":100},[],{"trials":10985,"activeCount":100},[],{"trials":10987,"activeCount":100},[],{"intervention":9152,"totalTrials":139,"cells":10989},{"EARLY_PHASE1":10990,"PHASE1":10992,"PHASE2":10994,"PHASE3":11000,"PHASE4":11002,"NA":11004},{"trials":10991,"activeCount":100},[],{"trials":10993,"activeCount":100},[],{"trials":10995,"activeCount":100},[10996],{"nctId":9145,"briefTitle":9146,"status":123,"phases":10997,"primaryCompletion":4532,"completion":1597,"start":1287,"enrollment":1238,"conditions":10998,"interventions":10999},[89],[9149,8401],[9136,9151,9152,9151],{"trials":11001,"activeCount":100},[],{"trials":11003,"activeCount":100},[],{"trials":11005,"activeCount":100},[],{"intervention":8927,"totalTrials":139,"cells":11007},{"EARLY_PHASE1":11008,"PHASE1":11010,"PHASE2":11012,"PHASE3":11018,"PHASE4":11020,"NA":11022},{"trials":11009,"activeCount":100},[],{"trials":11011,"activeCount":100},[],{"trials":11013,"activeCount":100},[11014],{"nctId":8921,"briefTitle":8922,"status":123,"phases":11015,"primaryCompletion":3851,"completion":1555,"start":2124,"enrollment":8924,"conditions":11016,"interventions":11017},[89],[1857],[8927,4014],{"trials":11019,"activeCount":100},[],{"trials":11021,"activeCount":100},[],{"trials":11023,"activeCount":100},[],{"intervention":11025,"totalTrials":139,"cells":11026},"(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis",{"EARLY_PHASE1":11027,"PHASE1":11029,"PHASE2":11031,"PHASE3":11040,"PHASE4":11042,"NA":11044},{"trials":11028,"activeCount":100},[],{"trials":11030,"activeCount":100},[],{"trials":11032,"activeCount":100},[11033],{"nctId":11034,"briefTitle":11035,"status":123,"phases":11036,"primaryCompletion":2123,"completion":1428,"start":1316,"enrollment":11037,"conditions":11038,"interventions":11039},"NCT01689324","Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents",[88,89],43,[21,24,18],[11025],{"trials":11041,"activeCount":100},[],{"trials":11043,"activeCount":100},[],{"trials":11045,"activeCount":100},[],{"intervention":11047,"totalTrials":139,"cells":11048},"RSV vaccine formulation 1",{"EARLY_PHASE1":11049,"PHASE1":11051,"PHASE2":11053,"PHASE3":11065,"PHASE4":11067,"NA":11069},{"trials":11050,"activeCount":100},[],{"trials":11052,"activeCount":100},[],{"trials":11054,"activeCount":100},[11055],{"nctId":11056,"briefTitle":11057,"status":123,"phases":11058,"primaryCompletion":11059,"completion":11059,"start":11060,"enrollment":11061,"conditions":11062,"interventions":11063},"NCT04491877","Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers",[88,89],"2023-04-13","2020-09-17",259,[3668],[11047,11064],"RSV vaccine formulation 2",{"trials":11066,"activeCount":100},[],{"trials":11068,"activeCount":100},[],{"trials":11070,"activeCount":100},[],{"intervention":11064,"totalTrials":139,"cells":11072},{"EARLY_PHASE1":11073,"PHASE1":11075,"PHASE2":11077,"PHASE3":11083,"PHASE4":11085,"NA":11087},{"trials":11074,"activeCount":100},[],{"trials":11076,"activeCount":100},[],{"trials":11078,"activeCount":100},[11079],{"nctId":11056,"briefTitle":11057,"status":123,"phases":11080,"primaryCompletion":11059,"completion":11059,"start":11060,"enrollment":11061,"conditions":11081,"interventions":11082},[88,89],[3668],[11047,11064],{"trials":11084,"activeCount":100},[],{"trials":11086,"activeCount":100},[],{"trials":11088,"activeCount":100},[],{"intervention":11090,"totalTrials":139,"cells":11091},"ChimeriVax-WN02 vaccine",{"EARLY_PHASE1":11092,"PHASE1":11094,"PHASE2":11096,"PHASE3":11105,"PHASE4":11107,"NA":11109},{"trials":11093,"activeCount":100},[],{"trials":11095,"activeCount":100},[],{"trials":11097,"activeCount":100},[11098],{"nctId":11099,"briefTitle":11100,"status":123,"phases":11101,"primaryCompletion":3401,"completion":1971,"start":1853,"enrollment":11102,"conditions":11103,"interventions":11104},"NCT00746798","Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults",[89],479,[10547],[11090,11090,11090],{"trials":11106,"activeCount":100},[],{"trials":11108,"activeCount":100},[],{"trials":11110,"activeCount":100},[],{"intervention":9126,"totalTrials":139,"cells":11112},{"EARLY_PHASE1":11113,"PHASE1":11115,"PHASE2":11117,"PHASE3":11123,"PHASE4":11125,"NA":11127},{"trials":11114,"activeCount":100},[],{"trials":11116,"activeCount":100},[],{"trials":11118,"activeCount":100},[11119],{"nctId":9120,"briefTitle":9121,"status":123,"phases":11120,"primaryCompletion":9123,"completion":9123,"start":1342,"enrollment":370,"conditions":11121,"interventions":11122},[89],[15],[9126,9127,9128,9128],{"trials":11124,"activeCount":100},[],{"trials":11126,"activeCount":100},[],{"trials":11128,"activeCount":100},[],{"intervention":9127,"totalTrials":139,"cells":11130},{"EARLY_PHASE1":11131,"PHASE1":11133,"PHASE2":11135,"PHASE3":11141,"PHASE4":11143,"NA":11145},{"trials":11132,"activeCount":100},[],{"trials":11134,"activeCount":100},[],{"trials":11136,"activeCount":100},[11137],{"nctId":9120,"briefTitle":9121,"status":123,"phases":11138,"primaryCompletion":9123,"completion":9123,"start":1342,"enrollment":370,"conditions":11139,"interventions":11140},[89],[15],[9126,9127,9128,9128],{"trials":11142,"activeCount":100},[],{"trials":11144,"activeCount":100},[],{"trials":11146,"activeCount":100},[],{"intervention":11148,"totalTrials":139,"cells":11149},"Quadrivalent Influenza mRNA Vaccine MRT5410",{"EARLY_PHASE1":11150,"PHASE1":11152,"PHASE2":11154,"PHASE3":11167,"PHASE4":11169,"NA":11171},{"trials":11151,"activeCount":100},[],{"trials":11153,"activeCount":100},[],{"trials":11155,"activeCount":100},[11156],{"nctId":11157,"briefTitle":11158,"status":123,"phases":11159,"primaryCompletion":11160,"completion":11160,"start":11161,"enrollment":757,"conditions":11162,"interventions":11163},"NCT05624606","Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older",[88,89],"2024-03-28","2022-11-28",[759],[11148,11164,11165,11166],"Quadrivalent Recombinant Influenza vaccine RIV4","Quadrivalent Inactivated Influenza Standard Dose QIV-SD","Quadrivalent Inactivated Influenza High Dose QIV-HD",{"trials":11168,"activeCount":100},[],{"trials":11170,"activeCount":100},[],{"trials":11172,"activeCount":100},[],{"intervention":11164,"totalTrials":139,"cells":11174},{"EARLY_PHASE1":11175,"PHASE1":11177,"PHASE2":11179,"PHASE3":11185,"PHASE4":11187,"NA":11189},{"trials":11176,"activeCount":100},[],{"trials":11178,"activeCount":100},[],{"trials":11180,"activeCount":100},[11181],{"nctId":11157,"briefTitle":11158,"status":123,"phases":11182,"primaryCompletion":11160,"completion":11160,"start":11161,"enrollment":757,"conditions":11183,"interventions":11184},[88,89],[759],[11148,11164,11165,11166],{"trials":11186,"activeCount":100},[],{"trials":11188,"activeCount":100},[],{"trials":11190,"activeCount":100},[],{"intervention":11165,"totalTrials":139,"cells":11192},{"EARLY_PHASE1":11193,"PHASE1":11195,"PHASE2":11197,"PHASE3":11203,"PHASE4":11205,"NA":11207},{"trials":11194,"activeCount":100},[],{"trials":11196,"activeCount":100},[],{"trials":11198,"activeCount":100},[11199],{"nctId":11157,"briefTitle":11158,"status":123,"phases":11200,"primaryCompletion":11160,"completion":11160,"start":11161,"enrollment":757,"conditions":11201,"interventions":11202},[88,89],[759],[11148,11164,11165,11166],{"trials":11204,"activeCount":100},[],{"trials":11206,"activeCount":100},[],{"trials":11208,"activeCount":100},[],{"intervention":11166,"totalTrials":139,"cells":11210},{"EARLY_PHASE1":11211,"PHASE1":11213,"PHASE2":11215,"PHASE3":11221,"PHASE4":11223,"NA":11225},{"trials":11212,"activeCount":100},[],{"trials":11214,"activeCount":100},[],{"trials":11216,"activeCount":100},[11217],{"nctId":11157,"briefTitle":11158,"status":123,"phases":11218,"primaryCompletion":11160,"completion":11160,"start":11161,"enrollment":757,"conditions":11219,"interventions":11220},[88,89],[759],[11148,11164,11165,11166],{"trials":11222,"activeCount":100},[],{"trials":11224,"activeCount":100},[],{"trials":11226,"activeCount":100},[],{"intervention":3974,"totalTrials":139,"cells":11228},{"EARLY_PHASE1":11229,"PHASE1":11231,"PHASE2":11233,"PHASE3":11239,"PHASE4":11241,"NA":11243},{"trials":11230,"activeCount":100},[],{"trials":11232,"activeCount":100},[],{"trials":11234,"activeCount":100},[11235],{"nctId":3967,"briefTitle":3968,"status":123,"phases":11236,"primaryCompletion":3643,"completion":1706,"start":3970,"enrollment":3971,"conditions":11237,"interventions":11238},[89],[18,24,21,3821,30],[3958,3974],{"trials":11240,"activeCount":100},[],{"trials":11242,"activeCount":100},[],{"trials":11244,"activeCount":100},[],{"intervention":11246,"totalTrials":139,"cells":11247},"Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate",{"EARLY_PHASE1":11248,"PHASE1":11250,"PHASE2":11252,"PHASE3":11261,"PHASE4":11263,"NA":11265},{"trials":11249,"activeCount":100},[],{"trials":11251,"activeCount":100},[],{"trials":11253,"activeCount":100},[11254],{"nctId":11255,"briefTitle":11256,"status":123,"phases":11257,"primaryCompletion":3489,"completion":2545,"start":1289,"enrollment":11258,"conditions":11259,"interventions":11260},"NCT00700635","Dose Comparison Study of Menactra® in US Children",[89],333,[27,162,130],[11246,11246,11246],{"trials":11262,"activeCount":100},[],{"trials":11264,"activeCount":100},[],{"trials":11266,"activeCount":100},[],{"intervention":792,"totalTrials":139,"cells":11268},{"EARLY_PHASE1":11269,"PHASE1":11271,"PHASE2":11273,"PHASE3":11279,"PHASE4":11281,"NA":11283},{"trials":11270,"activeCount":100},[],{"trials":11272,"activeCount":100},[],{"trials":11274,"activeCount":100},[11275],{"nctId":784,"briefTitle":785,"status":123,"phases":11276,"primaryCompletion":787,"completion":787,"start":788,"enrollment":789,"conditions":11277,"interventions":11278},[88,89],[759],[792,793,794,742,763,762],{"trials":11280,"activeCount":100},[],{"trials":11282,"activeCount":100},[],{"trials":11284,"activeCount":100},[],{"intervention":793,"totalTrials":139,"cells":11286},{"EARLY_PHASE1":11287,"PHASE1":11289,"PHASE2":11291,"PHASE3":11297,"PHASE4":11299,"NA":11301},{"trials":11288,"activeCount":100},[],{"trials":11290,"activeCount":100},[],{"trials":11292,"activeCount":100},[11293],{"nctId":784,"briefTitle":785,"status":123,"phases":11294,"primaryCompletion":787,"completion":787,"start":788,"enrollment":789,"conditions":11295,"interventions":11296},[88,89],[759],[792,793,794,742,763,762],{"trials":11298,"activeCount":100},[],{"trials":11300,"activeCount":100},[],{"trials":11302,"activeCount":100},[],{"intervention":794,"totalTrials":139,"cells":11304},{"EARLY_PHASE1":11305,"PHASE1":11307,"PHASE2":11309,"PHASE3":11315,"PHASE4":11317,"NA":11319},{"trials":11306,"activeCount":100},[],{"trials":11308,"activeCount":100},[],{"trials":11310,"activeCount":100},[11311],{"nctId":784,"briefTitle":785,"status":123,"phases":11312,"primaryCompletion":787,"completion":787,"start":788,"enrollment":789,"conditions":11313,"interventions":11314},[88,89],[759],[792,793,794,742,763,762],{"trials":11316,"activeCount":100},[],{"trials":11318,"activeCount":100},[],{"trials":11320,"activeCount":100},[],{"intervention":457,"totalTrials":139,"cells":11322},{"EARLY_PHASE1":11323,"PHASE1":11325,"PHASE2":11327,"PHASE3":11333,"PHASE4":11335,"NA":11337},{"trials":11324,"activeCount":100},[],{"trials":11326,"activeCount":100},[],{"trials":11328,"activeCount":100},[11329],{"nctId":449,"briefTitle":450,"status":123,"phases":11330,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":11331,"interventions":11332},[88,89],[170,33],[75,427,443,443,443,427,457],{"trials":11334,"activeCount":100},[],{"trials":11336,"activeCount":100},[],{"trials":11338,"activeCount":100},[],{"intervention":11340,"totalTrials":139,"cells":11341},"Fluzone: Influenza virus vaccine",{"EARLY_PHASE1":11342,"PHASE1":11344,"PHASE2":11346,"PHASE3":11354,"PHASE4":11356,"NA":11358},{"trials":11343,"activeCount":100},[],{"trials":11345,"activeCount":100},[],{"trials":11347,"activeCount":100},[11348],{"nctId":11349,"briefTitle":11350,"status":123,"phases":11351,"primaryCompletion":2776,"completion":1289,"start":3615,"enrollment":1926,"conditions":11352,"interventions":11353},"NCT00623181","Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults",[89],[15],[11340,11340],{"trials":11355,"activeCount":100},[],{"trials":11357,"activeCount":100},[],{"trials":11359,"activeCount":100},[],{"intervention":11361,"totalTrials":139,"cells":11362},"Inactivated influenza vaccine",{"EARLY_PHASE1":11363,"PHASE1":11365,"PHASE2":11367,"PHASE3":11375,"PHASE4":11377,"NA":11379},{"trials":11364,"activeCount":100},[],{"trials":11366,"activeCount":100},[],{"trials":11368,"activeCount":100},[11369],{"nctId":11370,"briefTitle":11371,"status":123,"phases":11372,"primaryCompletion":1211,"completion":1211,"start":3328,"enrollment":410,"conditions":11373,"interventions":11374},"NCT00343681","A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine",[89],[15,2354],[11361],{"trials":11376,"activeCount":100},[],{"trials":11378,"activeCount":100},[],{"trials":11380,"activeCount":100},[],{"intervention":11382,"totalTrials":139,"cells":11383},"Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1",{"EARLY_PHASE1":11384,"PHASE1":11386,"PHASE2":11388,"PHASE3":11404,"PHASE4":11406,"NA":11408},{"trials":11385,"activeCount":100},[],{"trials":11387,"activeCount":100},[],{"trials":11389,"activeCount":100},[11390],{"nctId":11391,"briefTitle":11392,"status":123,"phases":11393,"primaryCompletion":11394,"completion":11394,"start":11395,"enrollment":11396,"conditions":11397,"interventions":11398},"NCT02587520","Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects",[88,89],"2017-02-21","2015-10-22",1363,[24,18,21,1600],[11382,11399,11400,11401,11402,11403],"Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2","Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3","Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4","Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed","Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine",{"trials":11405,"activeCount":100},[],{"trials":11407,"activeCount":100},[],{"trials":11409,"activeCount":100},[],{"intervention":11399,"totalTrials":139,"cells":11411},{"EARLY_PHASE1":11412,"PHASE1":11414,"PHASE2":11416,"PHASE3":11422,"PHASE4":11424,"NA":11426},{"trials":11413,"activeCount":100},[],{"trials":11415,"activeCount":100},[],{"trials":11417,"activeCount":100},[11418],{"nctId":11391,"briefTitle":11392,"status":123,"phases":11419,"primaryCompletion":11394,"completion":11394,"start":11395,"enrollment":11396,"conditions":11420,"interventions":11421},[88,89],[24,18,21,1600],[11382,11399,11400,11401,11402,11403],{"trials":11423,"activeCount":100},[],{"trials":11425,"activeCount":100},[],{"trials":11427,"activeCount":100},[],{"intervention":11400,"totalTrials":139,"cells":11429},{"EARLY_PHASE1":11430,"PHASE1":11432,"PHASE2":11434,"PHASE3":11440,"PHASE4":11442,"NA":11444},{"trials":11431,"activeCount":100},[],{"trials":11433,"activeCount":100},[],{"trials":11435,"activeCount":100},[11436],{"nctId":11391,"briefTitle":11392,"status":123,"phases":11437,"primaryCompletion":11394,"completion":11394,"start":11395,"enrollment":11396,"conditions":11438,"interventions":11439},[88,89],[24,18,21,1600],[11382,11399,11400,11401,11402,11403],{"trials":11441,"activeCount":100},[],{"trials":11443,"activeCount":100},[],{"trials":11445,"activeCount":100},[],{"intervention":11401,"totalTrials":139,"cells":11447},{"EARLY_PHASE1":11448,"PHASE1":11450,"PHASE2":11452,"PHASE3":11458,"PHASE4":11460,"NA":11462},{"trials":11449,"activeCount":100},[],{"trials":11451,"activeCount":100},[],{"trials":11453,"activeCount":100},[11454],{"nctId":11391,"briefTitle":11392,"status":123,"phases":11455,"primaryCompletion":11394,"completion":11394,"start":11395,"enrollment":11396,"conditions":11456,"interventions":11457},[88,89],[24,18,21,1600],[11382,11399,11400,11401,11402,11403],{"trials":11459,"activeCount":100},[],{"trials":11461,"activeCount":100},[],{"trials":11463,"activeCount":100},[],{"intervention":11402,"totalTrials":139,"cells":11465},{"EARLY_PHASE1":11466,"PHASE1":11468,"PHASE2":11470,"PHASE3":11476,"PHASE4":11478,"NA":11480},{"trials":11467,"activeCount":100},[],{"trials":11469,"activeCount":100},[],{"trials":11471,"activeCount":100},[11472],{"nctId":11391,"briefTitle":11392,"status":123,"phases":11473,"primaryCompletion":11394,"completion":11394,"start":11395,"enrollment":11396,"conditions":11474,"interventions":11475},[88,89],[24,18,21,1600],[11382,11399,11400,11401,11402,11403],{"trials":11477,"activeCount":100},[],{"trials":11479,"activeCount":100},[],{"trials":11481,"activeCount":100},[],{"intervention":11403,"totalTrials":139,"cells":11483},{"EARLY_PHASE1":11484,"PHASE1":11486,"PHASE2":11488,"PHASE3":11494,"PHASE4":11496,"NA":11498},{"trials":11485,"activeCount":100},[],{"trials":11487,"activeCount":100},[],{"trials":11489,"activeCount":100},[11490],{"nctId":11391,"briefTitle":11392,"status":123,"phases":11491,"primaryCompletion":11394,"completion":11394,"start":11395,"enrollment":11396,"conditions":11492,"interventions":11493},[88,89],[24,18,21,1600],[11382,11399,11400,11401,11402,11403],{"trials":11495,"activeCount":100},[],{"trials":11497,"activeCount":100},[],{"trials":11499,"activeCount":100},[],{"intervention":3246,"totalTrials":139,"cells":11501},{"EARLY_PHASE1":11502,"PHASE1":11504,"PHASE2":11506,"PHASE3":11512,"PHASE4":11514,"NA":11516},{"trials":11503,"activeCount":100},[],{"trials":11505,"activeCount":100},[],{"trials":11507,"activeCount":100},[11508],{"nctId":3239,"briefTitle":3240,"status":123,"phases":11509,"primaryCompletion":367,"completion":3242,"start":1287,"enrollment":3243,"conditions":11510,"interventions":11511},[89],[3177,3176,373,3178],[3159,3246],{"trials":11513,"activeCount":100},[],{"trials":11515,"activeCount":100},[],{"trials":11517,"activeCount":100},[],{"intervention":11519,"totalTrials":139,"cells":11520},"Clostridium difficile toxoids A and B",{"EARLY_PHASE1":11521,"PHASE1":11523,"PHASE2":11525,"PHASE3":11534,"PHASE4":11536,"NA":11538},{"trials":11522,"activeCount":100},[],{"trials":11524,"activeCount":100},[],{"trials":11526,"activeCount":100},[11527],{"nctId":11528,"briefTitle":11529,"status":123,"phases":11530,"primaryCompletion":2123,"completion":1596,"start":2225,"enrollment":11531,"conditions":11532,"interventions":11533},"NCT01230957","Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults",[89],650,[8401,9149],[11519,11519,11519,11519,11519,11519],{"trials":11535,"activeCount":100},[],{"trials":11537,"activeCount":100},[],{"trials":11539,"activeCount":100},[],{"intervention":11541,"totalTrials":96,"cells":11542},"Quadrivalent RIV with H3 strain 1",{"EARLY_PHASE1":11543,"PHASE1":11545,"PHASE2":11571,"PHASE3":11573,"PHASE4":11575,"NA":11577},{"trials":11544,"activeCount":100},[],{"trials":11546,"activeCount":100},[11547,11558],{"nctId":11548,"briefTitle":11549,"status":123,"phases":11550,"primaryCompletion":11551,"completion":11551,"start":3204,"enrollment":6649,"conditions":11552,"interventions":11553},"NCT04144179","Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age",[88],"2020-02-24",[15],[11541,11554,11555,11556,11557],"Quadrivalent RIV with H3 strain 2","Quadrivalent RIV with H3 strain 3","Quadrivalent RIV with H3 strain 4","Quadrivalent RIV with 2018-2019 NH H3 strain",{"nctId":11559,"briefTitle":11560,"status":123,"phases":11561,"primaryCompletion":11562,"completion":11562,"start":11563,"enrollment":11564,"conditions":11565,"interventions":11567},"NCT04451954","Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects",[88],"2021-09-20","2020-07-02",210,[11566,33],"Influenza Immunisation",[11541,11568,11554,11569,11557,11570],"Quadrivalent RIV with H3 strain 1 and adjuvant","Quadrivalent RIV with H3 strain 2 and adjuvant","Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant",{"trials":11572,"activeCount":100},[],{"trials":11574,"activeCount":100},[],{"trials":11576,"activeCount":100},[],{"trials":11578,"activeCount":100},[],{"intervention":11554,"totalTrials":96,"cells":11580},{"EARLY_PHASE1":11581,"PHASE1":11583,"PHASE2":11593,"PHASE3":11595,"PHASE4":11597,"NA":11599},{"trials":11582,"activeCount":100},[],{"trials":11584,"activeCount":100},[11585,11589],{"nctId":11548,"briefTitle":11549,"status":123,"phases":11586,"primaryCompletion":11551,"completion":11551,"start":3204,"enrollment":6649,"conditions":11587,"interventions":11588},[88],[15],[11541,11554,11555,11556,11557],{"nctId":11559,"briefTitle":11560,"status":123,"phases":11590,"primaryCompletion":11562,"completion":11562,"start":11563,"enrollment":11564,"conditions":11591,"interventions":11592},[88],[11566,33],[11541,11568,11554,11569,11557,11570],{"trials":11594,"activeCount":100},[],{"trials":11596,"activeCount":100},[],{"trials":11598,"activeCount":100},[],{"trials":11600,"activeCount":100},[],{"intervention":11557,"totalTrials":96,"cells":11602},{"EARLY_PHASE1":11603,"PHASE1":11605,"PHASE2":11615,"PHASE3":11617,"PHASE4":11619,"NA":11621},{"trials":11604,"activeCount":100},[],{"trials":11606,"activeCount":100},[11607,11611],{"nctId":11548,"briefTitle":11549,"status":123,"phases":11608,"primaryCompletion":11551,"completion":11551,"start":3204,"enrollment":6649,"conditions":11609,"interventions":11610},[88],[15],[11541,11554,11555,11556,11557],{"nctId":11559,"briefTitle":11560,"status":123,"phases":11612,"primaryCompletion":11562,"completion":11562,"start":11563,"enrollment":11564,"conditions":11613,"interventions":11614},[88],[11566,33],[11541,11568,11554,11569,11557,11570],{"trials":11616,"activeCount":100},[],{"trials":11618,"activeCount":100},[],{"trials":11620,"activeCount":100},[],{"trials":11622,"activeCount":100},[],{"intervention":11624,"totalTrials":139,"cells":11625},"ORG101 - Experimental 1",{"EARLY_PHASE1":11626,"PHASE1":11628,"PHASE2":11641,"PHASE3":11643,"PHASE4":11645,"NA":11647},{"trials":11627,"activeCount":100},[],{"trials":11629,"activeCount":100},[11630],{"nctId":11631,"briefTitle":11632,"status":123,"phases":11633,"primaryCompletion":11634,"completion":11634,"start":11635,"enrollment":11636,"conditions":11637,"interventions":11639},"NCT05131373","Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris",[88],"2023-11-27","2021-09-28",38,[11638,412],"Acne Vulgaris",[11624,11640],"ORG101PL - Placebo 1",{"trials":11642,"activeCount":100},[],{"trials":11644,"activeCount":100},[],{"trials":11646,"activeCount":100},[],{"trials":11648,"activeCount":100},[],{"intervention":11640,"totalTrials":139,"cells":11650},{"EARLY_PHASE1":11651,"PHASE1":11653,"PHASE2":11659,"PHASE3":11661,"PHASE4":11663,"NA":11665},{"trials":11652,"activeCount":100},[],{"trials":11654,"activeCount":100},[11655],{"nctId":11631,"briefTitle":11632,"status":123,"phases":11656,"primaryCompletion":11634,"completion":11634,"start":11635,"enrollment":11636,"conditions":11657,"interventions":11658},[88],[11638,412],[11624,11640],{"trials":11660,"activeCount":100},[],{"trials":11662,"activeCount":100},[],{"trials":11664,"activeCount":100},[],{"trials":11666,"activeCount":100},[],{"intervention":11668,"totalTrials":139,"cells":11669},"RSV\u002FhMPV vaccine dose A1",{"EARLY_PHASE1":11670,"PHASE1":11672,"PHASE2":11697,"PHASE3":11699,"PHASE4":11701,"NA":11703},{"trials":11671,"activeCount":100},[],{"trials":11673,"activeCount":100},[11674],{"nctId":11675,"briefTitle":11676,"status":123,"phases":11677,"primaryCompletion":11678,"completion":11678,"start":11679,"enrollment":11680,"conditions":11681,"interventions":11684},"NCT06583031","Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years",[88],"2025-10-09","2024-10-09",385,[11682,11683],"RSV Infection","hMPV",[11668,11685,11686,11687,11688,11689,11690,11691,11692,11693,11694,11695,11696],"RSV\u002FhMPV vaccine dose A2","RSV\u002FhMPV vaccine dose A3","RSV\u002FhMPV vaccine dose B1","RSV\u002FhMPV vaccine dose B2","RSV\u002FhMPV vaccine dose B3","RSV\u002FhMPV vaccine dose C1","RSV\u002FhMPV vaccine dose C2","RSV\u002FhMPV vaccine dose C3","RSV\u002FhMPV vaccine dose 1","RSV\u002FhMPV vaccine dose 2","RSV\u002FhMPV vaccine dose 3","Monovalent RSV Vaccine",{"trials":11698,"activeCount":100},[],{"trials":11700,"activeCount":100},[],{"trials":11702,"activeCount":100},[],{"trials":11704,"activeCount":100},[],{"intervention":11685,"totalTrials":139,"cells":11706},{"EARLY_PHASE1":11707,"PHASE1":11709,"PHASE2":11715,"PHASE3":11717,"PHASE4":11719,"NA":11721},{"trials":11708,"activeCount":100},[],{"trials":11710,"activeCount":100},[11711],{"nctId":11675,"briefTitle":11676,"status":123,"phases":11712,"primaryCompletion":11678,"completion":11678,"start":11679,"enrollment":11680,"conditions":11713,"interventions":11714},[88],[11682,11683],[11668,11685,11686,11687,11688,11689,11690,11691,11692,11693,11694,11695,11696],{"trials":11716,"activeCount":100},[],{"trials":11718,"activeCount":100},[],{"trials":11720,"activeCount":100},[],{"trials":11722,"activeCount":100},[],{"intervention":11686,"totalTrials":139,"cells":11724},{"EARLY_PHASE1":11725,"PHASE1":11727,"PHASE2":11733,"PHASE3":11735,"PHASE4":11737,"NA":11739},{"trials":11726,"activeCount":100},[],{"trials":11728,"activeCount":100},[11729],{"nctId":11675,"briefTitle":11676,"status":123,"phases":11730,"primaryCompletion":11678,"completion":11678,"start":11679,"enrollment":11680,"conditions":11731,"interventions":11732},[88],[11682,11683],[11668,11685,11686,11687,11688,11689,11690,11691,11692,11693,11694,11695,11696],{"trials":11734,"activeCount":100},[],{"trials":11736,"activeCount":100},[],{"trials":11738,"activeCount":100},[],{"trials":11740,"activeCount":100},[],{"intervention":11687,"totalTrials":139,"cells":11742},{"EARLY_PHASE1":11743,"PHASE1":11745,"PHASE2":11751,"PHASE3":11753,"PHASE4":11755,"NA":11757},{"trials":11744,"activeCount":100},[],{"trials":11746,"activeCount":100},[11747],{"nctId":11675,"briefTitle":11676,"status":123,"phases":11748,"primaryCompletion":11678,"completion":11678,"start":11679,"enrollment":11680,"conditions":11749,"interventions":11750},[88],[11682,11683],[11668,11685,11686,11687,11688,11689,11690,11691,11692,11693,11694,11695,11696],{"trials":11752,"activeCount":100},[],{"trials":11754,"activeCount":100},[],{"trials":11756,"activeCount":100},[],{"trials":11758,"activeCount":100},[],{"intervention":11688,"totalTrials":139,"cells":11760},{"EARLY_PHASE1":11761,"PHASE1":11763,"PHASE2":11769,"PHASE3":11771,"PHASE4":11773,"NA":11775},{"trials":11762,"activeCount":100},[],{"trials":11764,"activeCount":100},[11765],{"nctId":11675,"briefTitle":11676,"status":123,"phases":11766,"primaryCompletion":11678,"completion":11678,"start":11679,"enrollment":11680,"conditions":11767,"interventions":11768},[88],[11682,11683],[11668,11685,11686,11687,11688,11689,11690,11691,11692,11693,11694,11695,11696],{"trials":11770,"activeCount":100},[],{"trials":11772,"activeCount":100},[],{"trials":11774,"activeCount":100},[],{"trials":11776,"activeCount":100},[],{"intervention":11689,"totalTrials":139,"cells":11778},{"EARLY_PHASE1":11779,"PHASE1":11781,"PHASE2":11787,"PHASE3":11789,"PHASE4":11791,"NA":11793},{"trials":11780,"activeCount":100},[],{"trials":11782,"activeCount":100},[11783],{"nctId":11675,"briefTitle":11676,"status":123,"phases":11784,"primaryCompletion":11678,"completion":11678,"start":11679,"enrollment":11680,"conditions":11785,"interventions":11786},[88],[11682,11683],[11668,11685,11686,11687,11688,11689,11690,11691,11692,11693,11694,11695,11696],{"trials":11788,"activeCount":100},[],{"trials":11790,"activeCount":100},[],{"trials":11792,"activeCount":100},[],{"trials":11794,"activeCount":100},[],{"intervention":11690,"totalTrials":139,"cells":11796},{"EARLY_PHASE1":11797,"PHASE1":11799,"PHASE2":11805,"PHASE3":11807,"PHASE4":11809,"NA":11811},{"trials":11798,"activeCount":100},[],{"trials":11800,"activeCount":100},[11801],{"nctId":11675,"briefTitle":11676,"status":123,"phases":11802,"primaryCompletion":11678,"completion":11678,"start":11679,"enrollment":11680,"conditions":11803,"interventions":11804},[88],[11682,11683],[11668,11685,11686,11687,11688,11689,11690,11691,11692,11693,11694,11695,11696],{"trials":11806,"activeCount":100},[],{"trials":11808,"activeCount":100},[],{"trials":11810,"activeCount":100},[],{"trials":11812,"activeCount":100},[],{"intervention":11691,"totalTrials":139,"cells":11814},{"EARLY_PHASE1":11815,"PHASE1":11817,"PHASE2":11823,"PHASE3":11825,"PHASE4":11827,"NA":11829},{"trials":11816,"activeCount":100},[],{"trials":11818,"activeCount":100},[11819],{"nctId":11675,"briefTitle":11676,"status":123,"phases":11820,"primaryCompletion":11678,"completion":11678,"start":11679,"enrollment":11680,"conditions":11821,"interventions":11822},[88],[11682,11683],[11668,11685,11686,11687,11688,11689,11690,11691,11692,11693,11694,11695,11696],{"trials":11824,"activeCount":100},[],{"trials":11826,"activeCount":100},[],{"trials":11828,"activeCount":100},[],{"trials":11830,"activeCount":100},[],{"intervention":11692,"totalTrials":139,"cells":11832},{"EARLY_PHASE1":11833,"PHASE1":11835,"PHASE2":11841,"PHASE3":11843,"PHASE4":11845,"NA":11847},{"trials":11834,"activeCount":100},[],{"trials":11836,"activeCount":100},[11837],{"nctId":11675,"briefTitle":11676,"status":123,"phases":11838,"primaryCompletion":11678,"completion":11678,"start":11679,"enrollment":11680,"conditions":11839,"interventions":11840},[88],[11682,11683],[11668,11685,11686,11687,11688,11689,11690,11691,11692,11693,11694,11695,11696],{"trials":11842,"activeCount":100},[],{"trials":11844,"activeCount":100},[],{"trials":11846,"activeCount":100},[],{"trials":11848,"activeCount":100},[],{"intervention":11693,"totalTrials":139,"cells":11850},{"EARLY_PHASE1":11851,"PHASE1":11853,"PHASE2":11859,"PHASE3":11861,"PHASE4":11863,"NA":11865},{"trials":11852,"activeCount":100},[],{"trials":11854,"activeCount":100},[11855],{"nctId":11675,"briefTitle":11676,"status":123,"phases":11856,"primaryCompletion":11678,"completion":11678,"start":11679,"enrollment":11680,"conditions":11857,"interventions":11858},[88],[11682,11683],[11668,11685,11686,11687,11688,11689,11690,11691,11692,11693,11694,11695,11696],{"trials":11860,"activeCount":100},[],{"trials":11862,"activeCount":100},[],{"trials":11864,"activeCount":100},[],{"trials":11866,"activeCount":100},[],{"intervention":11694,"totalTrials":139,"cells":11868},{"EARLY_PHASE1":11869,"PHASE1":11871,"PHASE2":11877,"PHASE3":11879,"PHASE4":11881,"NA":11883},{"trials":11870,"activeCount":100},[],{"trials":11872,"activeCount":100},[11873],{"nctId":11675,"briefTitle":11676,"status":123,"phases":11874,"primaryCompletion":11678,"completion":11678,"start":11679,"enrollment":11680,"conditions":11875,"interventions":11876},[88],[11682,11683],[11668,11685,11686,11687,11688,11689,11690,11691,11692,11693,11694,11695,11696],{"trials":11878,"activeCount":100},[],{"trials":11880,"activeCount":100},[],{"trials":11882,"activeCount":100},[],{"trials":11884,"activeCount":100},[],{"intervention":11695,"totalTrials":139,"cells":11886},{"EARLY_PHASE1":11887,"PHASE1":11889,"PHASE2":11895,"PHASE3":11897,"PHASE4":11899,"NA":11901},{"trials":11888,"activeCount":100},[],{"trials":11890,"activeCount":100},[11891],{"nctId":11675,"briefTitle":11676,"status":123,"phases":11892,"primaryCompletion":11678,"completion":11678,"start":11679,"enrollment":11680,"conditions":11893,"interventions":11894},[88],[11682,11683],[11668,11685,11686,11687,11688,11689,11690,11691,11692,11693,11694,11695,11696],{"trials":11896,"activeCount":100},[],{"trials":11898,"activeCount":100},[],{"trials":11900,"activeCount":100},[],{"trials":11902,"activeCount":100},[],{"intervention":11696,"totalTrials":139,"cells":11904},{"EARLY_PHASE1":11905,"PHASE1":11907,"PHASE2":11913,"PHASE3":11915,"PHASE4":11917,"NA":11919},{"trials":11906,"activeCount":100},[],{"trials":11908,"activeCount":100},[11909],{"nctId":11675,"briefTitle":11676,"status":123,"phases":11910,"primaryCompletion":11678,"completion":11678,"start":11679,"enrollment":11680,"conditions":11911,"interventions":11912},[88],[11682,11683],[11668,11685,11686,11687,11688,11689,11690,11691,11692,11693,11694,11695,11696],{"trials":11914,"activeCount":100},[],{"trials":11916,"activeCount":100},[],{"trials":11918,"activeCount":100},[],{"trials":11920,"activeCount":100},[],{"intervention":11922,"totalTrials":139,"cells":11923},"Pneumococcal Conjugate Vaccine",{"EARLY_PHASE1":11924,"PHASE1":11926,"PHASE2":11936,"PHASE3":11938,"PHASE4":11940,"NA":11942},{"trials":11925,"activeCount":100},[],{"trials":11927,"activeCount":100},[11928],{"nctId":11929,"briefTitle":11930,"status":123,"phases":11931,"primaryCompletion":2824,"completion":2824,"start":11932,"enrollment":9739,"conditions":11933,"interventions":11934},"NCT06698198","Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)",[88],"2018-12-03",[113],[11922,11935],"Prevnar 13®",{"trials":11937,"activeCount":100},[],{"trials":11939,"activeCount":100},[],{"trials":11941,"activeCount":100},[],{"trials":11943,"activeCount":100},[],{"intervention":11935,"totalTrials":139,"cells":11945},{"EARLY_PHASE1":11946,"PHASE1":11948,"PHASE2":11954,"PHASE3":11956,"PHASE4":11958,"NA":11960},{"trials":11947,"activeCount":100},[],{"trials":11949,"activeCount":100},[11950],{"nctId":11929,"briefTitle":11930,"status":123,"phases":11951,"primaryCompletion":2824,"completion":2824,"start":11932,"enrollment":9739,"conditions":11952,"interventions":11953},[88],[113],[11922,11935],{"trials":11955,"activeCount":100},[],{"trials":11957,"activeCount":100},[],{"trials":11959,"activeCount":100},[],{"trials":11961,"activeCount":100},[],{"intervention":11555,"totalTrials":139,"cells":11963},{"EARLY_PHASE1":11964,"PHASE1":11966,"PHASE2":11972,"PHASE3":11974,"PHASE4":11976,"NA":11978},{"trials":11965,"activeCount":100},[],{"trials":11967,"activeCount":100},[11968],{"nctId":11548,"briefTitle":11549,"status":123,"phases":11969,"primaryCompletion":11551,"completion":11551,"start":3204,"enrollment":6649,"conditions":11970,"interventions":11971},[88],[15],[11541,11554,11555,11556,11557],{"trials":11973,"activeCount":100},[],{"trials":11975,"activeCount":100},[],{"trials":11977,"activeCount":100},[],{"trials":11979,"activeCount":100},[],{"intervention":11556,"totalTrials":139,"cells":11981},{"EARLY_PHASE1":11982,"PHASE1":11984,"PHASE2":11990,"PHASE3":11992,"PHASE4":11994,"NA":11996},{"trials":11983,"activeCount":100},[],{"trials":11985,"activeCount":100},[11986],{"nctId":11548,"briefTitle":11549,"status":123,"phases":11987,"primaryCompletion":11551,"completion":11551,"start":3204,"enrollment":6649,"conditions":11988,"interventions":11989},[88],[15],[11541,11554,11555,11556,11557],{"trials":11991,"activeCount":100},[],{"trials":11993,"activeCount":100},[],{"trials":11995,"activeCount":100},[],{"trials":11997,"activeCount":100},[],{"intervention":11999,"totalTrials":139,"cells":12000},"ACAM3000 MVA Vaccine",{"EARLY_PHASE1":12001,"PHASE1":12003,"PHASE2":12011,"PHASE3":12013,"PHASE4":12015,"NA":12017},{"trials":12002,"activeCount":100},[],{"trials":12004,"activeCount":100},[12005],{"nctId":12006,"briefTitle":12007,"status":123,"phases":12008,"primaryCompletion":1229,"completion":1229,"start":1298,"enrollment":1926,"conditions":12009,"interventions":12010},"NCT00079820","Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults",[88],[9089],[11999],{"trials":12012,"activeCount":100},[],{"trials":12014,"activeCount":100},[],{"trials":12016,"activeCount":100},[],{"trials":12018,"activeCount":100},[],{"intervention":341,"totalTrials":139,"cells":12020},{"EARLY_PHASE1":12021,"PHASE1":12023,"PHASE2":12029,"PHASE3":12031,"PHASE4":12033,"NA":12035},{"trials":12022,"activeCount":100},[],{"trials":12024,"activeCount":100},[12025],{"nctId":332,"briefTitle":333,"status":123,"phases":12026,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":12027,"interventions":12028},[88],[339],[341,342,343,42],{"trials":12030,"activeCount":100},[],{"trials":12032,"activeCount":100},[],{"trials":12034,"activeCount":100},[],{"trials":12036,"activeCount":100},[],{"intervention":342,"totalTrials":139,"cells":12038},{"EARLY_PHASE1":12039,"PHASE1":12041,"PHASE2":12047,"PHASE3":12049,"PHASE4":12051,"NA":12053},{"trials":12040,"activeCount":100},[],{"trials":12042,"activeCount":100},[12043],{"nctId":332,"briefTitle":333,"status":123,"phases":12044,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":12045,"interventions":12046},[88],[339],[341,342,343,42],{"trials":12048,"activeCount":100},[],{"trials":12050,"activeCount":100},[],{"trials":12052,"activeCount":100},[],{"trials":12054,"activeCount":100},[],{"intervention":343,"totalTrials":139,"cells":12056},{"EARLY_PHASE1":12057,"PHASE1":12059,"PHASE2":12065,"PHASE3":12067,"PHASE4":12069,"NA":12071},{"trials":12058,"activeCount":100},[],{"trials":12060,"activeCount":100},[12061],{"nctId":332,"briefTitle":333,"status":123,"phases":12062,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":12063,"interventions":12064},[88],[339],[341,342,343,42],{"trials":12066,"activeCount":100},[],{"trials":12068,"activeCount":100},[],{"trials":12070,"activeCount":100},[],{"trials":12072,"activeCount":100},[],{"intervention":12074,"totalTrials":139,"cells":12075},"Investigational Tdap vaccine Formulation B",{"EARLY_PHASE1":12076,"PHASE1":12078,"PHASE2":12095,"PHASE3":12097,"PHASE4":12099,"NA":12101},{"trials":12077,"activeCount":100},[],{"trials":12079,"activeCount":100},[12080],{"nctId":12081,"briefTitle":12082,"status":123,"phases":12083,"primaryCompletion":12084,"completion":12084,"start":12085,"enrollment":532,"conditions":12086,"interventions":12090},"NCT03958799","A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada",[88],"2021-04-06","2019-06-26",[12087,12088,12089],"Tetanus Immunisation (Healthy Volunteers)","Diphtheria Immunisation (Healthy Volunteers)","Pertussis Immunisation (Healthy Volunteers)",[12074,12091,12092,12093,12094],"Investigational Tdap vaccine Formulation C","Investigational Tdap vaccine Formulation A","Investigational Tdap vaccine Formulation D","Licensed Tdap vaccine",{"trials":12096,"activeCount":100},[],{"trials":12098,"activeCount":100},[],{"trials":12100,"activeCount":100},[],{"trials":12102,"activeCount":100},[],{"intervention":12091,"totalTrials":139,"cells":12104},{"EARLY_PHASE1":12105,"PHASE1":12107,"PHASE2":12113,"PHASE3":12115,"PHASE4":12117,"NA":12119},{"trials":12106,"activeCount":100},[],{"trials":12108,"activeCount":100},[12109],{"nctId":12081,"briefTitle":12082,"status":123,"phases":12110,"primaryCompletion":12084,"completion":12084,"start":12085,"enrollment":532,"conditions":12111,"interventions":12112},[88],[12087,12088,12089],[12074,12091,12092,12093,12094],{"trials":12114,"activeCount":100},[],{"trials":12116,"activeCount":100},[],{"trials":12118,"activeCount":100},[],{"trials":12120,"activeCount":100},[],{"intervention":12092,"totalTrials":139,"cells":12122},{"EARLY_PHASE1":12123,"PHASE1":12125,"PHASE2":12131,"PHASE3":12133,"PHASE4":12135,"NA":12137},{"trials":12124,"activeCount":100},[],{"trials":12126,"activeCount":100},[12127],{"nctId":12081,"briefTitle":12082,"status":123,"phases":12128,"primaryCompletion":12084,"completion":12084,"start":12085,"enrollment":532,"conditions":12129,"interventions":12130},[88],[12087,12088,12089],[12074,12091,12092,12093,12094],{"trials":12132,"activeCount":100},[],{"trials":12134,"activeCount":100},[],{"trials":12136,"activeCount":100},[],{"trials":12138,"activeCount":100},[],{"intervention":12093,"totalTrials":139,"cells":12140},{"EARLY_PHASE1":12141,"PHASE1":12143,"PHASE2":12149,"PHASE3":12151,"PHASE4":12153,"NA":12155},{"trials":12142,"activeCount":100},[],{"trials":12144,"activeCount":100},[12145],{"nctId":12081,"briefTitle":12082,"status":123,"phases":12146,"primaryCompletion":12084,"completion":12084,"start":12085,"enrollment":532,"conditions":12147,"interventions":12148},[88],[12087,12088,12089],[12074,12091,12092,12093,12094],{"trials":12150,"activeCount":100},[],{"trials":12152,"activeCount":100},[],{"trials":12154,"activeCount":100},[],{"trials":12156,"activeCount":100},[],{"intervention":12094,"totalTrials":139,"cells":12158},{"EARLY_PHASE1":12159,"PHASE1":12161,"PHASE2":12167,"PHASE3":12169,"PHASE4":12171,"NA":12173},{"trials":12160,"activeCount":100},[],{"trials":12162,"activeCount":100},[12163],{"nctId":12081,"briefTitle":12082,"status":123,"phases":12164,"primaryCompletion":12084,"completion":12084,"start":12085,"enrollment":532,"conditions":12165,"interventions":12166},[88],[12087,12088,12089],[12074,12091,12092,12093,12094],{"trials":12168,"activeCount":100},[],{"trials":12170,"activeCount":100},[],{"trials":12172,"activeCount":100},[],{"trials":12174,"activeCount":100},[],{"intervention":12176,"totalTrials":139,"cells":12177},"MVA",{"EARLY_PHASE1":12178,"PHASE1":12180,"PHASE2":12191,"PHASE3":12193,"PHASE4":12195,"NA":12197},{"trials":12179,"activeCount":100},[],{"trials":12181,"activeCount":100},[12182],{"nctId":12183,"briefTitle":12184,"status":12185,"phases":12186,"primaryCompletion":12187,"completion":12187,"start":1229,"enrollment":100,"conditions":12188,"interventions":12190},"NCT00389103","Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)","WITHDRAWN",[88],"2007-01",[9089,12189],"Atopic Dermatitis",[12176],{"trials":12192,"activeCount":100},[],{"trials":12194,"activeCount":100},[],{"trials":12196,"activeCount":100},[],{"trials":12198,"activeCount":100},[],{"intervention":12200,"totalTrials":139,"cells":12201},"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).",{"EARLY_PHASE1":12202,"PHASE1":12204,"PHASE2":12216,"PHASE3":12218,"PHASE4":12220,"NA":12222},{"trials":12203,"activeCount":100},[],{"trials":12205,"activeCount":100},[12206],{"nctId":12207,"briefTitle":12208,"status":123,"phases":12209,"primaryCompletion":12210,"completion":12210,"start":12211,"enrollment":12212,"conditions":12213,"interventions":12214},"NCT06165276","A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study",[88],"2008-08-27","2006-07-25",285,[441],[12200,12215],"Meningococcal Group C-CRM197 Conjugate Vaccine",{"trials":12217,"activeCount":100},[],{"trials":12219,"activeCount":100},[],{"trials":12221,"activeCount":100},[],{"trials":12223,"activeCount":100},[],{"intervention":12215,"totalTrials":139,"cells":12225},{"EARLY_PHASE1":12226,"PHASE1":12228,"PHASE2":12234,"PHASE3":12236,"PHASE4":12238,"NA":12240},{"trials":12227,"activeCount":100},[],{"trials":12229,"activeCount":100},[12230],{"nctId":12207,"briefTitle":12208,"status":123,"phases":12231,"primaryCompletion":12210,"completion":12210,"start":12211,"enrollment":12212,"conditions":12232,"interventions":12233},[88],[441],[12200,12215],{"trials":12235,"activeCount":100},[],{"trials":12237,"activeCount":100},[],{"trials":12239,"activeCount":100},[],{"trials":12241,"activeCount":100},[],{"intervention":3424,"totalTrials":139,"cells":12243},{"EARLY_PHASE1":12244,"PHASE1":12246,"PHASE2":12252,"PHASE3":12254,"PHASE4":12256,"NA":12258},{"trials":12245,"activeCount":100},[],{"trials":12247,"activeCount":100},[12248],{"nctId":3416,"briefTitle":3417,"status":123,"phases":12249,"primaryCompletion":3419,"completion":3419,"start":3420,"enrollment":3421,"conditions":12250,"interventions":12251},[88],[759],[3424,3425],{"trials":12253,"activeCount":100},[],{"trials":12255,"activeCount":100},[],{"trials":12257,"activeCount":100},[],{"trials":12259,"activeCount":100},[],{"intervention":12261,"totalTrials":139,"cells":12262},"Pneumococcal Vaccine High Dose",{"EARLY_PHASE1":12263,"PHASE1":12265,"PHASE2":12279,"PHASE3":12281,"PHASE4":12283,"NA":12285},{"trials":12264,"activeCount":100},[],{"trials":12266,"activeCount":100},[12267],{"nctId":12268,"briefTitle":12269,"status":123,"phases":12270,"primaryCompletion":1596,"completion":1586,"start":1430,"enrollment":12271,"conditions":12272,"interventions":12275},"NCT01446926","Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants",[88],280,[12273,299,12274],"Pneumonia","Streptococcus Pneumoniae Infections",[12261,12276,12261,12276,12277,12276,12278,12278,12276,12261,12276],"Tris buffered saline","Pneumococcal Vaccine Low Dose","Pneumococcal Vaccine Middle Dose",{"trials":12280,"activeCount":100},[],{"trials":12282,"activeCount":100},[],{"trials":12284,"activeCount":100},[],{"trials":12286,"activeCount":100},[],{"intervention":12276,"totalTrials":139,"cells":12288},{"EARLY_PHASE1":12289,"PHASE1":12291,"PHASE2":12297,"PHASE3":12299,"PHASE4":12301,"NA":12303},{"trials":12290,"activeCount":100},[],{"trials":12292,"activeCount":100},[12293],{"nctId":12268,"briefTitle":12269,"status":123,"phases":12294,"primaryCompletion":1596,"completion":1586,"start":1430,"enrollment":12271,"conditions":12295,"interventions":12296},[88],[12273,299,12274],[12261,12276,12261,12276,12277,12276,12278,12278,12276,12261,12276],{"trials":12298,"activeCount":100},[],{"trials":12300,"activeCount":100},[],{"trials":12302,"activeCount":100},[],{"trials":12304,"activeCount":100},[],{"intervention":12277,"totalTrials":139,"cells":12306},{"EARLY_PHASE1":12307,"PHASE1":12309,"PHASE2":12315,"PHASE3":12317,"PHASE4":12319,"NA":12321},{"trials":12308,"activeCount":100},[],{"trials":12310,"activeCount":100},[12311],{"nctId":12268,"briefTitle":12269,"status":123,"phases":12312,"primaryCompletion":1596,"completion":1586,"start":1430,"enrollment":12271,"conditions":12313,"interventions":12314},[88],[12273,299,12274],[12261,12276,12261,12276,12277,12276,12278,12278,12276,12261,12276],{"trials":12316,"activeCount":100},[],{"trials":12318,"activeCount":100},[],{"trials":12320,"activeCount":100},[],{"trials":12322,"activeCount":100},[],{"intervention":12278,"totalTrials":139,"cells":12324},{"EARLY_PHASE1":12325,"PHASE1":12327,"PHASE2":12333,"PHASE3":12335,"PHASE4":12337,"NA":12339},{"trials":12326,"activeCount":100},[],{"trials":12328,"activeCount":100},[12329],{"nctId":12268,"briefTitle":12269,"status":123,"phases":12330,"primaryCompletion":1596,"completion":1586,"start":1430,"enrollment":12271,"conditions":12331,"interventions":12332},[88],[12273,299,12274],[12261,12276,12261,12276,12277,12276,12278,12278,12276,12261,12276],{"trials":12334,"activeCount":100},[],{"trials":12336,"activeCount":100},[],{"trials":12338,"activeCount":100},[],{"trials":12340,"activeCount":100},[],{"intervention":11568,"totalTrials":139,"cells":12342},{"EARLY_PHASE1":12343,"PHASE1":12345,"PHASE2":12351,"PHASE3":12353,"PHASE4":12355,"NA":12357},{"trials":12344,"activeCount":100},[],{"trials":12346,"activeCount":100},[12347],{"nctId":11559,"briefTitle":11560,"status":123,"phases":12348,"primaryCompletion":11562,"completion":11562,"start":11563,"enrollment":11564,"conditions":12349,"interventions":12350},[88],[11566,33],[11541,11568,11554,11569,11557,11570],{"trials":12352,"activeCount":100},[],{"trials":12354,"activeCount":100},[],{"trials":12356,"activeCount":100},[],{"trials":12358,"activeCount":100},[],{"intervention":11569,"totalTrials":139,"cells":12360},{"EARLY_PHASE1":12361,"PHASE1":12363,"PHASE2":12369,"PHASE3":12371,"PHASE4":12373,"NA":12375},{"trials":12362,"activeCount":100},[],{"trials":12364,"activeCount":100},[12365],{"nctId":11559,"briefTitle":11560,"status":123,"phases":12366,"primaryCompletion":11562,"completion":11562,"start":11563,"enrollment":11564,"conditions":12367,"interventions":12368},[88],[11566,33],[11541,11568,11554,11569,11557,11570],{"trials":12370,"activeCount":100},[],{"trials":12372,"activeCount":100},[],{"trials":12374,"activeCount":100},[],{"trials":12376,"activeCount":100},[],{"intervention":11570,"totalTrials":139,"cells":12378},{"EARLY_PHASE1":12379,"PHASE1":12381,"PHASE2":12387,"PHASE3":12389,"PHASE4":12391,"NA":12393},{"trials":12380,"activeCount":100},[],{"trials":12382,"activeCount":100},[12383],{"nctId":11559,"briefTitle":11560,"status":123,"phases":12384,"primaryCompletion":11562,"completion":11562,"start":11563,"enrollment":11564,"conditions":12385,"interventions":12386},[88],[11566,33],[11541,11568,11554,11569,11557,11570],{"trials":12388,"activeCount":100},[],{"trials":12390,"activeCount":100},[],{"trials":12392,"activeCount":100},[],{"trials":12394,"activeCount":100},[],{"intervention":3435,"totalTrials":139,"cells":12396},{"EARLY_PHASE1":12397,"PHASE1":12399,"PHASE2":12405,"PHASE3":12407,"PHASE4":12409,"NA":12411},{"trials":12398,"activeCount":100},[],{"trials":12400,"activeCount":100},[12401],{"nctId":3427,"briefTitle":3428,"status":123,"phases":12402,"primaryCompletion":3430,"completion":3430,"start":3431,"enrollment":3432,"conditions":12403,"interventions":12404},[88],[15,759],[3435,762],{"trials":12406,"activeCount":100},[],{"trials":12408,"activeCount":100},[],{"trials":12410,"activeCount":100},[],{"trials":12412,"activeCount":100},[],{"intervention":12414,"totalTrials":139,"cells":12415},"RSV\u002FhMPV mRNA LNP 1",{"EARLY_PHASE1":12416,"PHASE1":12418,"PHASE2":12432,"PHASE3":12434,"PHASE4":12436,"NA":12438},{"trials":12417,"activeCount":100},[],{"trials":12419,"activeCount":100},[12420],{"nctId":12421,"briefTitle":12422,"status":123,"phases":12423,"primaryCompletion":12424,"completion":12424,"start":12425,"enrollment":6588,"conditions":12426,"interventions":12428},"NCT06237296","Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and\u002For Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older",[88],"2025-02-11","2024-01-23",[3668,33,12427],"Metapneumovirus Infection",[12414,12429,12430,12431],"RSV\u002FhMPV mRNA LNP 2","RSV mRNA LNP 1","hMPV mRNA LNP 1",{"trials":12433,"activeCount":100},[],{"trials":12435,"activeCount":100},[],{"trials":12437,"activeCount":100},[],{"trials":12439,"activeCount":100},[],{"intervention":12429,"totalTrials":139,"cells":12441},{"EARLY_PHASE1":12442,"PHASE1":12444,"PHASE2":12450,"PHASE3":12452,"PHASE4":12454,"NA":12456},{"trials":12443,"activeCount":100},[],{"trials":12445,"activeCount":100},[12446],{"nctId":12421,"briefTitle":12422,"status":123,"phases":12447,"primaryCompletion":12424,"completion":12424,"start":12425,"enrollment":6588,"conditions":12448,"interventions":12449},[88],[3668,33,12427],[12414,12429,12430,12431],{"trials":12451,"activeCount":100},[],{"trials":12453,"activeCount":100},[],{"trials":12455,"activeCount":100},[],{"trials":12457,"activeCount":100},[],{"intervention":12430,"totalTrials":139,"cells":12459},{"EARLY_PHASE1":12460,"PHASE1":12462,"PHASE2":12468,"PHASE3":12470,"PHASE4":12472,"NA":12474},{"trials":12461,"activeCount":100},[],{"trials":12463,"activeCount":100},[12464],{"nctId":12421,"briefTitle":12422,"status":123,"phases":12465,"primaryCompletion":12424,"completion":12424,"start":12425,"enrollment":6588,"conditions":12466,"interventions":12467},[88],[3668,33,12427],[12414,12429,12430,12431],{"trials":12469,"activeCount":100},[],{"trials":12471,"activeCount":100},[],{"trials":12473,"activeCount":100},[],{"trials":12475,"activeCount":100},[],{"intervention":12431,"totalTrials":139,"cells":12477},{"EARLY_PHASE1":12478,"PHASE1":12480,"PHASE2":12486,"PHASE3":12488,"PHASE4":12490,"NA":12492},{"trials":12479,"activeCount":100},[],{"trials":12481,"activeCount":100},[12482],{"nctId":12421,"briefTitle":12422,"status":123,"phases":12483,"primaryCompletion":12424,"completion":12424,"start":12425,"enrollment":6588,"conditions":12484,"interventions":12485},[88],[3668,33,12427],[12414,12429,12430,12431],{"trials":12487,"activeCount":100},[],{"trials":12489,"activeCount":100},[],{"trials":12491,"activeCount":100},[],{"trials":12493,"activeCount":100},[],{"intervention":12495,"totalTrials":139,"cells":12496},"Meningococcal Polysaccharide Tetanus Protein Conjugate",{"EARLY_PHASE1":12497,"PHASE1":12499,"PHASE2":12508,"PHASE3":12510,"PHASE4":12512,"NA":12514},{"trials":12498,"activeCount":100},[],{"trials":12500,"activeCount":100},[12501],{"nctId":12502,"briefTitle":12503,"status":123,"phases":12504,"primaryCompletion":1287,"completion":3363,"start":1236,"enrollment":12505,"conditions":12506,"interventions":12507},"NCT00631995","Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers",[88],360,[27,162],[12495,12495,12495,12495,12495],{"trials":12509,"activeCount":100},[],{"trials":12511,"activeCount":100},[],{"trials":12513,"activeCount":100},[],{"trials":12515,"activeCount":100},[],{"intervention":696,"totalTrials":139,"cells":12517},{"EARLY_PHASE1":12518,"PHASE1":12520,"PHASE2":12526,"PHASE3":12528,"PHASE4":12530,"NA":12532},{"trials":12519,"activeCount":100},[],{"trials":12521,"activeCount":100},[12522],{"nctId":688,"briefTitle":689,"status":646,"phases":12523,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":12524,"interventions":12525},[88],[170,33],[696,697,698,699],{"trials":12527,"activeCount":100},[],{"trials":12529,"activeCount":100},[],{"trials":12531,"activeCount":100},[],{"trials":12533,"activeCount":100},[],{"intervention":697,"totalTrials":139,"cells":12535},{"EARLY_PHASE1":12536,"PHASE1":12538,"PHASE2":12544,"PHASE3":12546,"PHASE4":12548,"NA":12550},{"trials":12537,"activeCount":100},[],{"trials":12539,"activeCount":100},[12540],{"nctId":688,"briefTitle":689,"status":646,"phases":12541,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":12542,"interventions":12543},[88],[170,33],[696,697,698,699],{"trials":12545,"activeCount":100},[],{"trials":12547,"activeCount":100},[],{"trials":12549,"activeCount":100},[],{"trials":12551,"activeCount":100},[],{"intervention":12553,"totalTrials":139,"cells":12554},"mRNA NA vaccine",{"EARLY_PHASE1":12555,"PHASE1":12557,"PHASE2":12569,"PHASE3":12571,"PHASE4":12573,"NA":12575},{"trials":12556,"activeCount":100},[],{"trials":12558,"activeCount":100},[12559],{"nctId":12560,"briefTitle":12561,"status":123,"phases":12562,"primaryCompletion":12563,"completion":12563,"start":12564,"enrollment":12565,"conditions":12566,"interventions":12567},"NCT05426174","Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older",[88],"2024-01-03","2022-06-09",233,[759,33],[12553,12568],"High Dose Quadrivalent Influenza Vaccine",{"trials":12570,"activeCount":100},[],{"trials":12572,"activeCount":100},[],{"trials":12574,"activeCount":100},[],{"trials":12576,"activeCount":100},[],{"intervention":12568,"totalTrials":139,"cells":12578},{"EARLY_PHASE1":12579,"PHASE1":12581,"PHASE2":12587,"PHASE3":12589,"PHASE4":12591,"NA":12593},{"trials":12580,"activeCount":100},[],{"trials":12582,"activeCount":100},[12583],{"nctId":12560,"briefTitle":12561,"status":123,"phases":12584,"primaryCompletion":12563,"completion":12563,"start":12564,"enrollment":12565,"conditions":12585,"interventions":12586},[88],[759,33],[12553,12568],{"trials":12588,"activeCount":100},[],{"trials":12590,"activeCount":100},[],{"trials":12592,"activeCount":100},[],{"trials":12594,"activeCount":100},[],{"intervention":12596,"totalTrials":139,"cells":12597},"Pneumococcal vaccine Formulation 1",{"EARLY_PHASE1":12598,"PHASE1":12600,"PHASE2":12611,"PHASE3":12613,"PHASE4":12615,"NA":12617},{"trials":12599,"activeCount":100},[],{"trials":12601,"activeCount":100},[12602],{"nctId":12603,"briefTitle":12604,"status":123,"phases":12605,"primaryCompletion":1453,"completion":1453,"start":1182,"enrollment":5257,"conditions":12606,"interventions":12608},"NCT01444352","Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults",[88],[299,12274,12607],"Pneumococcal Pneumonia",[12596,12609,12610],"Pneumococcal vaccine Formulation 2","Pneumococcal vaccine Formulation 3",{"trials":12612,"activeCount":100},[],{"trials":12614,"activeCount":100},[],{"trials":12616,"activeCount":100},[],{"trials":12618,"activeCount":100},[],{"intervention":12609,"totalTrials":139,"cells":12620},{"EARLY_PHASE1":12621,"PHASE1":12623,"PHASE2":12629,"PHASE3":12631,"PHASE4":12633,"NA":12635},{"trials":12622,"activeCount":100},[],{"trials":12624,"activeCount":100},[12625],{"nctId":12603,"briefTitle":12604,"status":123,"phases":12626,"primaryCompletion":1453,"completion":1453,"start":1182,"enrollment":5257,"conditions":12627,"interventions":12628},[88],[299,12274,12607],[12596,12609,12610],{"trials":12630,"activeCount":100},[],{"trials":12632,"activeCount":100},[],{"trials":12634,"activeCount":100},[],{"trials":12636,"activeCount":100},[],{"intervention":12610,"totalTrials":139,"cells":12638},{"EARLY_PHASE1":12639,"PHASE1":12641,"PHASE2":12647,"PHASE3":12649,"PHASE4":12651,"NA":12653},{"trials":12640,"activeCount":100},[],{"trials":12642,"activeCount":100},[12643],{"nctId":12603,"briefTitle":12604,"status":123,"phases":12644,"primaryCompletion":1453,"completion":1453,"start":1182,"enrollment":5257,"conditions":12645,"interventions":12646},[88],[299,12274,12607],[12596,12609,12610],{"trials":12648,"activeCount":100},[],{"trials":12650,"activeCount":100},[],{"trials":12652,"activeCount":100},[],{"trials":12654,"activeCount":100},[],{"intervention":12656,"totalTrials":139,"cells":12657},"Trivalent-Darwin influenza vaccine",{"EARLY_PHASE1":12658,"PHASE1":12660,"PHASE2":12673,"PHASE3":12675,"PHASE4":12677,"NA":12679},{"trials":12659,"activeCount":100},[],{"trials":12661,"activeCount":100},[12662],{"nctId":12663,"briefTitle":12664,"status":123,"phases":12665,"primaryCompletion":12666,"completion":12666,"start":12667,"enrollment":6971,"conditions":12668,"interventions":12669},"NCT06507553","Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older",[88],"2025-03-04","2024-08-12",[15,33],[12656,12670,12671,12672],"Augment-Tasmania influenza vaccine","TIV-2X Darwin influenza vaccine","Trivalent-Tasmania influenza vaccine",{"trials":12674,"activeCount":100},[],{"trials":12676,"activeCount":100},[],{"trials":12678,"activeCount":100},[],{"trials":12680,"activeCount":100},[],{"intervention":12670,"totalTrials":139,"cells":12682},{"EARLY_PHASE1":12683,"PHASE1":12685,"PHASE2":12691,"PHASE3":12693,"PHASE4":12695,"NA":12697},{"trials":12684,"activeCount":100},[],{"trials":12686,"activeCount":100},[12687],{"nctId":12663,"briefTitle":12664,"status":123,"phases":12688,"primaryCompletion":12666,"completion":12666,"start":12667,"enrollment":6971,"conditions":12689,"interventions":12690},[88],[15,33],[12656,12670,12671,12672],{"trials":12692,"activeCount":100},[],{"trials":12694,"activeCount":100},[],{"trials":12696,"activeCount":100},[],{"trials":12698,"activeCount":100},[],{"intervention":12671,"totalTrials":139,"cells":12700},{"EARLY_PHASE1":12701,"PHASE1":12703,"PHASE2":12709,"PHASE3":12711,"PHASE4":12713,"NA":12715},{"trials":12702,"activeCount":100},[],{"trials":12704,"activeCount":100},[12705],{"nctId":12663,"briefTitle":12664,"status":123,"phases":12706,"primaryCompletion":12666,"completion":12666,"start":12667,"enrollment":6971,"conditions":12707,"interventions":12708},[88],[15,33],[12656,12670,12671,12672],{"trials":12710,"activeCount":100},[],{"trials":12712,"activeCount":100},[],{"trials":12714,"activeCount":100},[],{"trials":12716,"activeCount":100},[],{"intervention":12672,"totalTrials":139,"cells":12718},{"EARLY_PHASE1":12719,"PHASE1":12721,"PHASE2":12727,"PHASE3":12729,"PHASE4":12731,"NA":12733},{"trials":12720,"activeCount":100},[],{"trials":12722,"activeCount":100},[12723],{"nctId":12663,"briefTitle":12664,"status":123,"phases":12724,"primaryCompletion":12666,"completion":12666,"start":12667,"enrollment":6971,"conditions":12725,"interventions":12726},[88],[15,33],[12656,12670,12671,12672],{"trials":12728,"activeCount":100},[],{"trials":12730,"activeCount":100},[],{"trials":12732,"activeCount":100},[],{"trials":12734,"activeCount":100},[],{"intervention":12736,"totalTrials":139,"cells":12737},"parainfluenza virus type 3 vaccine",{"EARLY_PHASE1":12738,"PHASE1":12740,"PHASE2":12754,"PHASE3":12756,"PHASE4":12758,"NA":12760},{"trials":12739,"activeCount":100},[],{"trials":12741,"activeCount":100},[12742],{"nctId":12743,"briefTitle":12744,"status":123,"phases":12745,"primaryCompletion":10644,"completion":10644,"start":12746,"enrollment":10062,"conditions":12747,"interventions":12749},"NCT06604767","Study of a Respiratory Syncytial Virus\u002FHuman Metapneumovirus\u002FParainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older",[88],"2024-09-17",[3668,12427,12748],"Parainfluenzae Virus Infection",[12736,12750,12751,12752,12753],"RSV\u002FhMPV\u002FPIV3 vaccine","RSV\u002FhMPV vaccine","RSV vaccine 1","RSV vaccine 2",{"trials":12755,"activeCount":100},[],{"trials":12757,"activeCount":100},[],{"trials":12759,"activeCount":100},[],{"trials":12761,"activeCount":100},[],{"intervention":12750,"totalTrials":139,"cells":12763},{"EARLY_PHASE1":12764,"PHASE1":12766,"PHASE2":12772,"PHASE3":12774,"PHASE4":12776,"NA":12778},{"trials":12765,"activeCount":100},[],{"trials":12767,"activeCount":100},[12768],{"nctId":12743,"briefTitle":12744,"status":123,"phases":12769,"primaryCompletion":10644,"completion":10644,"start":12746,"enrollment":10062,"conditions":12770,"interventions":12771},[88],[3668,12427,12748],[12736,12750,12751,12752,12753],{"trials":12773,"activeCount":100},[],{"trials":12775,"activeCount":100},[],{"trials":12777,"activeCount":100},[],{"trials":12779,"activeCount":100},[],{"intervention":12751,"totalTrials":139,"cells":12781},{"EARLY_PHASE1":12782,"PHASE1":12784,"PHASE2":12790,"PHASE3":12792,"PHASE4":12794,"NA":12796},{"trials":12783,"activeCount":100},[],{"trials":12785,"activeCount":100},[12786],{"nctId":12743,"briefTitle":12744,"status":123,"phases":12787,"primaryCompletion":10644,"completion":10644,"start":12746,"enrollment":10062,"conditions":12788,"interventions":12789},[88],[3668,12427,12748],[12736,12750,12751,12752,12753],{"trials":12791,"activeCount":100},[],{"trials":12793,"activeCount":100},[],{"trials":12795,"activeCount":100},[],{"trials":12797,"activeCount":100},[],{"intervention":12752,"totalTrials":139,"cells":12799},{"EARLY_PHASE1":12800,"PHASE1":12802,"PHASE2":12808,"PHASE3":12810,"PHASE4":12812,"NA":12814},{"trials":12801,"activeCount":100},[],{"trials":12803,"activeCount":100},[12804],{"nctId":12743,"briefTitle":12744,"status":123,"phases":12805,"primaryCompletion":10644,"completion":10644,"start":12746,"enrollment":10062,"conditions":12806,"interventions":12807},[88],[3668,12427,12748],[12736,12750,12751,12752,12753],{"trials":12809,"activeCount":100},[],{"trials":12811,"activeCount":100},[],{"trials":12813,"activeCount":100},[],{"trials":12815,"activeCount":100},[],{"intervention":12753,"totalTrials":139,"cells":12817},{"EARLY_PHASE1":12818,"PHASE1":12820,"PHASE2":12826,"PHASE3":12828,"PHASE4":12830,"NA":12832},{"trials":12819,"activeCount":100},[],{"trials":12821,"activeCount":100},[12822],{"nctId":12743,"briefTitle":12744,"status":123,"phases":12823,"primaryCompletion":10644,"completion":10644,"start":12746,"enrollment":10062,"conditions":12824,"interventions":12825},[88],[3668,12427,12748],[12736,12750,12751,12752,12753],{"trials":12827,"activeCount":100},[],{"trials":12829,"activeCount":100},[],{"trials":12831,"activeCount":100},[],{"trials":12833,"activeCount":100},[],{"intervention":12835,"totalTrials":139,"cells":12836},"HSV 2 Formulation 1",{"EARLY_PHASE1":12837,"PHASE1":12839,"PHASE2":12857,"PHASE3":12859,"PHASE4":12861,"NA":12863},{"trials":12838,"activeCount":100},[],{"trials":12840,"activeCount":100},[12841],{"nctId":12842,"briefTitle":12843,"status":646,"phases":12844,"primaryCompletion":12845,"completion":12845,"start":12846,"enrollment":12847,"conditions":12848,"interventions":12850},"NCT04222985","Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2",[88],"2021-05-19","2020-02-18",24,[12849],"Genital Herpes",[12835,12851,12852,12853,12854,12855,12856],"HSV 2 Formulation 2","HSV 2 Formulation 3","HSV 2 Formulation 4","HSV 2 Formulation 5","HSV 2 Formulation 6","Sodium Chloride 0.9%",{"trials":12858,"activeCount":100},[],{"trials":12860,"activeCount":100},[],{"trials":12862,"activeCount":100},[],{"trials":12864,"activeCount":100},[],{"intervention":12851,"totalTrials":139,"cells":12866},{"EARLY_PHASE1":12867,"PHASE1":12869,"PHASE2":12875,"PHASE3":12877,"PHASE4":12879,"NA":12881},{"trials":12868,"activeCount":100},[],{"trials":12870,"activeCount":100},[12871],{"nctId":12842,"briefTitle":12843,"status":646,"phases":12872,"primaryCompletion":12845,"completion":12845,"start":12846,"enrollment":12847,"conditions":12873,"interventions":12874},[88],[12849],[12835,12851,12852,12853,12854,12855,12856],{"trials":12876,"activeCount":100},[],{"trials":12878,"activeCount":100},[],{"trials":12880,"activeCount":100},[],{"trials":12882,"activeCount":100},[],{"intervention":12852,"totalTrials":139,"cells":12884},{"EARLY_PHASE1":12885,"PHASE1":12887,"PHASE2":12893,"PHASE3":12895,"PHASE4":12897,"NA":12899},{"trials":12886,"activeCount":100},[],{"trials":12888,"activeCount":100},[12889],{"nctId":12842,"briefTitle":12843,"status":646,"phases":12890,"primaryCompletion":12845,"completion":12845,"start":12846,"enrollment":12847,"conditions":12891,"interventions":12892},[88],[12849],[12835,12851,12852,12853,12854,12855,12856],{"trials":12894,"activeCount":100},[],{"trials":12896,"activeCount":100},[],{"trials":12898,"activeCount":100},[],{"trials":12900,"activeCount":100},[],{"intervention":12853,"totalTrials":139,"cells":12902},{"EARLY_PHASE1":12903,"PHASE1":12905,"PHASE2":12911,"PHASE3":12913,"PHASE4":12915,"NA":12917},{"trials":12904,"activeCount":100},[],{"trials":12906,"activeCount":100},[12907],{"nctId":12842,"briefTitle":12843,"status":646,"phases":12908,"primaryCompletion":12845,"completion":12845,"start":12846,"enrollment":12847,"conditions":12909,"interventions":12910},[88],[12849],[12835,12851,12852,12853,12854,12855,12856],{"trials":12912,"activeCount":100},[],{"trials":12914,"activeCount":100},[],{"trials":12916,"activeCount":100},[],{"trials":12918,"activeCount":100},[],{"intervention":12854,"totalTrials":139,"cells":12920},{"EARLY_PHASE1":12921,"PHASE1":12923,"PHASE2":12929,"PHASE3":12931,"PHASE4":12933,"NA":12935},{"trials":12922,"activeCount":100},[],{"trials":12924,"activeCount":100},[12925],{"nctId":12842,"briefTitle":12843,"status":646,"phases":12926,"primaryCompletion":12845,"completion":12845,"start":12846,"enrollment":12847,"conditions":12927,"interventions":12928},[88],[12849],[12835,12851,12852,12853,12854,12855,12856],{"trials":12930,"activeCount":100},[],{"trials":12932,"activeCount":100},[],{"trials":12934,"activeCount":100},[],{"trials":12936,"activeCount":100},[],{"intervention":12855,"totalTrials":139,"cells":12938},{"EARLY_PHASE1":12939,"PHASE1":12941,"PHASE2":12947,"PHASE3":12949,"PHASE4":12951,"NA":12953},{"trials":12940,"activeCount":100},[],{"trials":12942,"activeCount":100},[12943],{"nctId":12842,"briefTitle":12843,"status":646,"phases":12944,"primaryCompletion":12845,"completion":12845,"start":12846,"enrollment":12847,"conditions":12945,"interventions":12946},[88],[12849],[12835,12851,12852,12853,12854,12855,12856],{"trials":12948,"activeCount":100},[],{"trials":12950,"activeCount":100},[],{"trials":12952,"activeCount":100},[],{"trials":12954,"activeCount":100},[],{"intervention":12856,"totalTrials":139,"cells":12956},{"EARLY_PHASE1":12957,"PHASE1":12959,"PHASE2":12965,"PHASE3":12967,"PHASE4":12969,"NA":12971},{"trials":12958,"activeCount":100},[],{"trials":12960,"activeCount":100},[12961],{"nctId":12842,"briefTitle":12843,"status":646,"phases":12962,"primaryCompletion":12845,"completion":12845,"start":12846,"enrollment":12847,"conditions":12963,"interventions":12964},[88],[12849],[12835,12851,12852,12853,12854,12855,12856],{"trials":12966,"activeCount":100},[],{"trials":12968,"activeCount":100},[],{"trials":12970,"activeCount":100},[],{"trials":12972,"activeCount":100},[],{"intervention":12974,"totalTrials":139,"cells":12975},"A\u002FH5N1 inactivated, split-virion influenza vaccine+Adjuvant",{"EARLY_PHASE1":12976,"PHASE1":12978,"PHASE2":12987,"PHASE3":12989,"PHASE4":12991,"NA":12993},{"trials":12977,"activeCount":100},[],{"trials":12979,"activeCount":100},[12980],{"nctId":12981,"briefTitle":12982,"status":123,"phases":12983,"primaryCompletion":5524,"completion":5255,"start":12187,"enrollment":3216,"conditions":12984,"interventions":12985},"NCT00457509","Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults",[88],[5259,8984,2354],[12974,12974,12974,12974,12986],"A\u002FH5N1 inactivated, split-virion influenza vaccine",{"trials":12988,"activeCount":100},[],{"trials":12990,"activeCount":100},[],{"trials":12992,"activeCount":100},[],{"trials":12994,"activeCount":100},[],{"intervention":12986,"totalTrials":139,"cells":12996},{"EARLY_PHASE1":12997,"PHASE1":12999,"PHASE2":13005,"PHASE3":13007,"PHASE4":13009,"NA":13011},{"trials":12998,"activeCount":100},[],{"trials":13000,"activeCount":100},[13001],{"nctId":12981,"briefTitle":12982,"status":123,"phases":13002,"primaryCompletion":5524,"completion":5255,"start":12187,"enrollment":3216,"conditions":13003,"interventions":13004},[88],[5259,8984,2354],[12974,12974,12974,12974,12986],{"trials":13006,"activeCount":100},[],{"trials":13008,"activeCount":100},[],{"trials":13010,"activeCount":100},[],{"trials":13012,"activeCount":100},[],{"intervention":13014,"totalTrials":139,"cells":13015},"Shz QIV 0.25 mL, 2 doses",{"EARLY_PHASE1":13016,"PHASE1":13018,"PHASE2":13030,"PHASE3":13032,"PHASE4":13034,"NA":13036},{"trials":13017,"activeCount":100},[],{"trials":13019,"activeCount":100},[13020],{"nctId":13021,"briefTitle":13022,"status":123,"phases":13023,"primaryCompletion":13024,"completion":13024,"start":7397,"enrollment":13025,"conditions":13026,"interventions":13027},"NCT03430089","Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine",[88],"2019-06-06",101,[15,2892],[13014,13028,13029],"Shz QIV 0.5 mL, 2 doses","Shz QIV 0.5 mL, single dose",{"trials":13031,"activeCount":100},[],{"trials":13033,"activeCount":100},[],{"trials":13035,"activeCount":100},[],{"trials":13037,"activeCount":100},[],{"intervention":13028,"totalTrials":139,"cells":13039},{"EARLY_PHASE1":13040,"PHASE1":13042,"PHASE2":13048,"PHASE3":13050,"PHASE4":13052,"NA":13054},{"trials":13041,"activeCount":100},[],{"trials":13043,"activeCount":100},[13044],{"nctId":13021,"briefTitle":13022,"status":123,"phases":13045,"primaryCompletion":13024,"completion":13024,"start":7397,"enrollment":13025,"conditions":13046,"interventions":13047},[88],[15,2892],[13014,13028,13029],{"trials":13049,"activeCount":100},[],{"trials":13051,"activeCount":100},[],{"trials":13053,"activeCount":100},[],{"trials":13055,"activeCount":100},[],{"intervention":13029,"totalTrials":139,"cells":13057},{"EARLY_PHASE1":13058,"PHASE1":13060,"PHASE2":13066,"PHASE3":13068,"PHASE4":13070,"NA":13072},{"trials":13059,"activeCount":100},[],{"trials":13061,"activeCount":100},[13062],{"nctId":13021,"briefTitle":13022,"status":123,"phases":13063,"primaryCompletion":13024,"completion":13024,"start":7397,"enrollment":13025,"conditions":13064,"interventions":13065},[88],[15,2892],[13014,13028,13029],{"trials":13067,"activeCount":100},[],{"trials":13069,"activeCount":100},[],{"trials":13071,"activeCount":100},[],{"trials":13073,"activeCount":100},[],{"intervention":6059,"totalTrials":1157,"cells":13075},{"EARLY_PHASE1":13076,"PHASE1":13078,"PHASE2":13080,"PHASE3":13082,"PHASE4":13115,"NA":13117},{"trials":13077,"activeCount":100},[],{"trials":13079,"activeCount":100},[],{"trials":13081,"activeCount":100},[],{"trials":13083,"activeCount":100},[13084,13093,13097,13101,13105,13111],{"nctId":13085,"briefTitle":13086,"status":123,"phases":13087,"primaryCompletion":13088,"completion":13088,"start":13089,"enrollment":13090,"conditions":13091,"interventions":13092},"NCT03765437","Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam",[90],"2019-03-17","2019-01-15",230,[15],[6059],{"nctId":6052,"briefTitle":6053,"status":123,"phases":13094,"primaryCompletion":6055,"completion":1317,"start":3186,"enrollment":6056,"conditions":13095,"interventions":13096},[90],[15],[6059,6059,6059,6041],{"nctId":6278,"briefTitle":6279,"status":646,"phases":13098,"primaryCompletion":6281,"completion":6281,"start":6282,"enrollment":6283,"conditions":13099,"interventions":13100},[90],[3460],[6059,6267],{"nctId":7189,"briefTitle":7190,"status":123,"phases":13102,"primaryCompletion":7192,"completion":7192,"start":5281,"enrollment":7193,"conditions":13103,"interventions":13104},[90],[15],[6059,7178,7196],{"nctId":13106,"briefTitle":13107,"status":123,"phases":13108,"primaryCompletion":3851,"completion":125,"start":6587,"enrollment":5257,"conditions":13109,"interventions":13110},"NCT01967784","Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan",[90],[15],[6059],{"nctId":7830,"briefTitle":7831,"status":646,"phases":13112,"primaryCompletion":7833,"completion":7833,"start":7834,"enrollment":7835,"conditions":13113,"interventions":13114},[90],[759],[7819,7838],{"trials":13116,"activeCount":100},[],{"trials":13118,"activeCount":100},[13119,13128,13138],{"nctId":13120,"briefTitle":13121,"status":123,"phases":13122,"primaryCompletion":13123,"completion":13123,"start":13124,"enrollment":13125,"conditions":13126,"interventions":13127},"NCT05568979","Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022\u002F23",[],"2022-11-29","2022-10-06",1001,[3460],[6059,7576],{"nctId":13129,"briefTitle":13130,"status":123,"phases":13131,"primaryCompletion":13132,"completion":13132,"start":13133,"enrollment":13134,"conditions":13135,"interventions":13137},"NCT01945424","Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry",[],"2019-09-15","2013-08-16",244,[13136,15],"Pregnancy",[6059],{"nctId":13139,"briefTitle":13140,"status":123,"phases":13141,"primaryCompletion":13142,"completion":13142,"start":13143,"enrollment":13144,"conditions":13145,"interventions":13146},"NCT05078060","Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021\u002F22",[],"2021-12-02","2021-10-12",1804,[3460],[6059,7576],{"intervention":668,"totalTrials":743,"cells":13148},{"EARLY_PHASE1":13149,"PHASE1":13151,"PHASE2":13153,"PHASE3":13155,"PHASE4":13165,"NA":13176},{"trials":13150,"activeCount":100},[],{"trials":13152,"activeCount":100},[],{"trials":13154,"activeCount":100},[],{"trials":13156,"activeCount":100},[13157,13161],{"nctId":660,"briefTitle":661,"status":123,"phases":13158,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":13159,"interventions":13160},[90],[170,33],[582,668,669,670,671,672,673,486,446,674,675,676,676,671,486],{"nctId":1104,"briefTitle":1105,"status":123,"phases":13162,"primaryCompletion":1107,"completion":1107,"start":1108,"enrollment":1109,"conditions":13163,"interventions":13164},[90],[27,1046,468],[582,668],{"trials":13166,"activeCount":100},[13167],{"nctId":13168,"briefTitle":13169,"status":123,"phases":13170,"primaryCompletion":13171,"completion":13171,"start":13172,"enrollment":13173,"conditions":13174,"interventions":13175},"NCT02864927","Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea",[91],"2019-06-12","2016-07-21",1311,[27,1046,468],[668,668],{"trials":13177,"activeCount":100},[13178],{"nctId":13179,"briefTitle":13180,"status":123,"phases":13181,"primaryCompletion":13182,"completion":13182,"start":1924,"enrollment":5257,"conditions":13183,"interventions":13184},"NCT02699840","Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation",[],"2016-07-25",[27,1046,468],[668,668,668],{"intervention":5412,"totalTrials":743,"cells":13186},{"EARLY_PHASE1":13187,"PHASE1":13189,"PHASE2":13191,"PHASE3":13193,"PHASE4":13206,"NA":13215},{"trials":13188,"activeCount":100},[],{"trials":13190,"activeCount":100},[],{"trials":13192,"activeCount":100},[],{"trials":13194,"activeCount":100},[13195,13199],{"nctId":5406,"briefTitle":5407,"status":123,"phases":13196,"primaryCompletion":2351,"completion":3363,"start":4575,"enrollment":5409,"conditions":13197,"interventions":13198},[90],[1046,1330,1331,1332,512],[5412,5395,5413,5414],{"nctId":13200,"briefTitle":13201,"status":123,"phases":13202,"primaryCompletion":1326,"completion":1287,"start":1191,"enrollment":13203,"conditions":13204,"interventions":13205},"NCT00539032","Immunology and Safety of Menactra® in Children in Saudi Arabia",[90],238,[27,1280],[5412,5412],{"trials":13207,"activeCount":100},[13208],{"nctId":13209,"briefTitle":13210,"status":123,"phases":13211,"primaryCompletion":1767,"completion":125,"start":2016,"enrollment":13212,"conditions":13213,"interventions":13214},"NCT01270503","Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines",[91],538,[27,1588],[5412,5412,5412],{"trials":13216,"activeCount":100},[13217],{"nctId":13218,"briefTitle":13219,"status":123,"phases":13220,"primaryCompletion":1564,"completion":6833,"start":2800,"enrollment":1238,"conditions":13221,"interventions":13222},"NCT01689155","Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children",[],[27,162],[5412],{"intervention":7576,"totalTrials":743,"cells":13224},{"EARLY_PHASE1":13225,"PHASE1":13227,"PHASE2":13229,"PHASE3":13235,"PHASE4":13241,"NA":13243},{"trials":13226,"activeCount":100},[],{"trials":13228,"activeCount":100},[],{"trials":13230,"activeCount":100},[13231],{"nctId":10014,"briefTitle":10015,"status":123,"phases":13232,"primaryCompletion":10017,"completion":10017,"start":10018,"enrollment":10019,"conditions":13233,"interventions":13234},[89],[15],[7576,7576,7576,10005,10022],{"trials":13236,"activeCount":100},[13237],{"nctId":7568,"briefTitle":7569,"status":123,"phases":13238,"primaryCompletion":7571,"completion":7571,"start":7572,"enrollment":7573,"conditions":13239,"interventions":13240},[90],[3460],[7576,7557],{"trials":13242,"activeCount":100},[],{"trials":13244,"activeCount":100},[13245,13249],{"nctId":13120,"briefTitle":13121,"status":123,"phases":13246,"primaryCompletion":13123,"completion":13123,"start":13124,"enrollment":13125,"conditions":13247,"interventions":13248},[],[3460],[6059,7576],{"nctId":13139,"briefTitle":13140,"status":123,"phases":13250,"primaryCompletion":13142,"completion":13142,"start":13143,"enrollment":13144,"conditions":13251,"interventions":13252},[],[3460],[6059,7576],{"intervention":13254,"totalTrials":96,"cells":13255},"DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines",{"EARLY_PHASE1":13256,"PHASE1":13258,"PHASE2":13260,"PHASE3":13262,"PHASE4":13272,"NA":13274},{"trials":13257,"activeCount":100},[],{"trials":13259,"activeCount":100},[],{"trials":13261,"activeCount":100},[],{"trials":13263,"activeCount":100},[13264],{"nctId":13265,"briefTitle":13266,"status":123,"phases":13267,"primaryCompletion":3808,"completion":1326,"start":1229,"enrollment":13268,"conditions":13269,"interventions":13270},"NCT00401531","Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants",[90],412,[36,1666,18,21,3821],[13254,13271],"DTaP-HB-IPV and Pneumococcal polysaccharide vaccines",{"trials":13273,"activeCount":100},[],{"trials":13275,"activeCount":100},[13276],{"nctId":13277,"briefTitle":13278,"status":123,"phases":13279,"primaryCompletion":1555,"completion":1925,"start":2799,"enrollment":2546,"conditions":13280,"interventions":13281},"NCT02610348","Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age",[92],[36],[13254,13271],{"intervention":13271,"totalTrials":96,"cells":13283},{"EARLY_PHASE1":13284,"PHASE1":13286,"PHASE2":13288,"PHASE3":13290,"PHASE4":13296,"NA":13298},{"trials":13285,"activeCount":100},[],{"trials":13287,"activeCount":100},[],{"trials":13289,"activeCount":100},[],{"trials":13291,"activeCount":100},[13292],{"nctId":13265,"briefTitle":13266,"status":123,"phases":13293,"primaryCompletion":3808,"completion":1326,"start":1229,"enrollment":13268,"conditions":13294,"interventions":13295},[90],[36,1666,18,21,3821],[13254,13271],{"trials":13297,"activeCount":100},[],{"trials":13299,"activeCount":100},[13300],{"nctId":13277,"briefTitle":13278,"status":123,"phases":13301,"primaryCompletion":1555,"completion":1925,"start":2799,"enrollment":2546,"conditions":13302,"interventions":13303},[92],[36],[13254,13271],{"intervention":13305,"totalTrials":96,"cells":13306},"DTaP-IPV\u002FHib",{"EARLY_PHASE1":13307,"PHASE1":13309,"PHASE2":13311,"PHASE3":13313,"PHASE4":13315,"NA":13317},{"trials":13308,"activeCount":100},[],{"trials":13310,"activeCount":100},[],{"trials":13312,"activeCount":100},[],{"trials":13314,"activeCount":100},[],{"trials":13316,"activeCount":100},[],{"trials":13318,"activeCount":100},[13319,13326],{"nctId":13320,"briefTitle":13321,"status":123,"phases":13322,"primaryCompletion":1563,"completion":1563,"start":1287,"enrollment":13323,"conditions":13324,"interventions":13325},"NCT00855855","Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease",[],20830,[3811,18,24,1666,21],[13305],{"nctId":13327,"briefTitle":13328,"status":123,"phases":13329,"primaryCompletion":1565,"completion":13330,"start":1237,"enrollment":13331,"conditions":13332,"interventions":13334},"NCT00804284","Database Surveillance Safety Study of PENTACEL® Vaccine",[],"2015-01",62538,[18,24,21,13333],"Haemophilus Influenzae",[13305,13335],"Other DTap Vaccines",{"intervention":13337,"totalTrials":96,"cells":13338},"None administered in this study",{"EARLY_PHASE1":13339,"PHASE1":13341,"PHASE2":13343,"PHASE3":13345,"PHASE4":13347,"NA":13349},{"trials":13340,"activeCount":100},[],{"trials":13342,"activeCount":100},[],{"trials":13344,"activeCount":100},[],{"trials":13346,"activeCount":100},[],{"trials":13348,"activeCount":100},[],{"trials":13350,"activeCount":100},[13351,13358],{"nctId":13352,"briefTitle":13353,"status":123,"phases":13354,"primaryCompletion":1428,"completion":1428,"start":2979,"enrollment":13355,"conditions":13356,"interventions":13357},"NCT00728260","36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds",[],1421,[27,1588],[13337],{"nctId":13359,"briefTitle":13360,"status":123,"phases":13361,"primaryCompletion":1428,"completion":1428,"start":2979,"enrollment":13362,"conditions":13363,"interventions":13364},"NCT00254995","Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine",[],62626,[27,1588],[13337],{"intervention":13366,"totalTrials":139,"cells":13367},"Flublok Quadrivalent influenza vaccine RIV4",{"EARLY_PHASE1":13368,"PHASE1":13370,"PHASE2":13372,"PHASE3":13374,"PHASE4":13376,"NA":13378},{"trials":13369,"activeCount":100},[],{"trials":13371,"activeCount":100},[],{"trials":13373,"activeCount":100},[],{"trials":13375,"activeCount":100},[],{"trials":13377,"activeCount":100},[],{"trials":13379,"activeCount":100},[13380],{"nctId":13381,"briefTitle":13382,"status":123,"phases":13383,"primaryCompletion":13384,"completion":13384,"start":593,"enrollment":13385,"conditions":13386,"interventions":13387},"NCT04460781","Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring",[],"2022-02-28",96175,[15],[13366,13388],"Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4",{"intervention":13388,"totalTrials":139,"cells":13390},{"EARLY_PHASE1":13391,"PHASE1":13393,"PHASE2":13395,"PHASE3":13397,"PHASE4":13399,"NA":13401},{"trials":13392,"activeCount":100},[],{"trials":13394,"activeCount":100},[],{"trials":13396,"activeCount":100},[],{"trials":13398,"activeCount":100},[],{"trials":13400,"activeCount":100},[],{"trials":13402,"activeCount":100},[13403],{"nctId":13381,"briefTitle":13382,"status":123,"phases":13404,"primaryCompletion":13384,"completion":13384,"start":593,"enrollment":13385,"conditions":13405,"interventions":13406},[],[15],[13366,13388],{"intervention":13408,"totalTrials":139,"cells":13409},"Tetanus Toxoid, acellular pertussis, diphtheria toxoid",{"EARLY_PHASE1":13410,"PHASE1":13412,"PHASE2":13414,"PHASE3":13416,"PHASE4":13418,"NA":13420},{"trials":13411,"activeCount":100},[],{"trials":13413,"activeCount":100},[],{"trials":13415,"activeCount":100},[],{"trials":13417,"activeCount":100},[],{"trials":13419,"activeCount":100},[],{"trials":13421,"activeCount":100},[13422],{"nctId":13423,"briefTitle":13424,"status":123,"phases":13425,"primaryCompletion":4532,"completion":1317,"start":1190,"enrollment":13426,"conditions":13427,"interventions":13428},"NCT00258882","Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine",[],327293,[21],[13408],{"intervention":13430,"totalTrials":139,"cells":13431},"CYD-TDV Dengue Vaccine",{"EARLY_PHASE1":13432,"PHASE1":13434,"PHASE2":13436,"PHASE3":13438,"PHASE4":13440,"NA":13442},{"trials":13433,"activeCount":100},[],{"trials":13435,"activeCount":100},[],{"trials":13437,"activeCount":100},[],{"trials":13439,"activeCount":100},[],{"trials":13441,"activeCount":100},[],{"trials":13443,"activeCount":100},[13444],{"nctId":13445,"briefTitle":13446,"status":123,"phases":13447,"primaryCompletion":664,"completion":664,"start":13448,"enrollment":13449,"conditions":13450,"interventions":13451},"NCT04023708","Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During Pregnancy",[],"2022-03-11",104,[1153],[13430],{"intervention":13453,"totalTrials":139,"cells":13454},"Stamaril®",{"EARLY_PHASE1":13455,"PHASE1":13457,"PHASE2":13459,"PHASE3":13461,"PHASE4":13463,"NA":13465},{"trials":13456,"activeCount":100},[],{"trials":13458,"activeCount":100},[],{"trials":13460,"activeCount":100},[],{"trials":13462,"activeCount":100},[],{"trials":13464,"activeCount":100},[],{"trials":13466,"activeCount":100},[13467],{"nctId":13468,"briefTitle":13469,"status":123,"phases":13470,"primaryCompletion":13471,"completion":13471,"start":13472,"enrollment":3981,"conditions":13473,"interventions":13474},"NCT03541694","Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea",[],"2018-05-30","2018-04-11",[352],[13453],{"intervention":13476,"totalTrials":139,"cells":13477},"Pentacel®",{"EARLY_PHASE1":13478,"PHASE1":13480,"PHASE2":13482,"PHASE3":13484,"PHASE4":13486,"NA":13488},{"trials":13479,"activeCount":100},[],{"trials":13481,"activeCount":100},[],{"trials":13483,"activeCount":100},[],{"trials":13485,"activeCount":100},[],{"trials":13487,"activeCount":100},[],{"trials":13489,"activeCount":100},[13490],{"nctId":13491,"briefTitle":13492,"status":123,"phases":13493,"primaryCompletion":13494,"completion":13494,"start":13495,"enrollment":13496,"conditions":13497,"interventions":13498},"NCT01129362","Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines",[],"2014-12-30","2010-02-08",1195,[21],[13476,13499],"Other Pertussis Vaccines",{"intervention":13499,"totalTrials":139,"cells":13501},{"EARLY_PHASE1":13502,"PHASE1":13504,"PHASE2":13506,"PHASE3":13508,"PHASE4":13510,"NA":13512},{"trials":13503,"activeCount":100},[],{"trials":13505,"activeCount":100},[],{"trials":13507,"activeCount":100},[],{"trials":13509,"activeCount":100},[],{"trials":13511,"activeCount":100},[],{"trials":13513,"activeCount":100},[13514],{"nctId":13491,"briefTitle":13492,"status":123,"phases":13515,"primaryCompletion":13494,"completion":13494,"start":13495,"enrollment":13496,"conditions":13516,"interventions":13517},[],[21],[13476,13499],{"intervention":13519,"totalTrials":139,"cells":13520},"DTaP-IPV-Hep B-PRP-T combined vaccine",{"EARLY_PHASE1":13521,"PHASE1":13523,"PHASE2":13525,"PHASE3":13527,"PHASE4":13529,"NA":13531},{"trials":13522,"activeCount":100},[],{"trials":13524,"activeCount":100},[],{"trials":13526,"activeCount":100},[],{"trials":13528,"activeCount":100},[],{"trials":13530,"activeCount":100},[],{"trials":13532,"activeCount":100},[13533],{"nctId":13534,"briefTitle":13535,"status":123,"phases":13536,"primaryCompletion":13537,"completion":13537,"start":13538,"enrollment":13539,"conditions":13540,"interventions":13541},"NCT06793826","Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea",[],"2026-01-15","2025-01-17",713,[36,1378],[13519],{"intervention":13543,"totalTrials":139,"cells":13544},"Quadrivalent Intradermal Influenza Vaccine",{"EARLY_PHASE1":13545,"PHASE1":13547,"PHASE2":13549,"PHASE3":13551,"PHASE4":13553,"NA":13555},{"trials":13546,"activeCount":100},[],{"trials":13548,"activeCount":100},[],{"trials":13550,"activeCount":100},[],{"trials":13552,"activeCount":100},[],{"trials":13554,"activeCount":100},[],{"trials":13556,"activeCount":100},[13557],{"nctId":13558,"briefTitle":13559,"status":123,"phases":13560,"primaryCompletion":13561,"completion":13561,"start":13562,"enrollment":13563,"conditions":13564,"interventions":13565},"NCT02554409","Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry",[],"2019-04-30","2015-10-13",87,[13136,15],[13543],{"intervention":13567,"totalTrials":139,"cells":13568},"Tetanus and diphtheria toxoids and acellular pertussis",{"EARLY_PHASE1":13569,"PHASE1":13571,"PHASE2":13573,"PHASE3":13575,"PHASE4":13577,"NA":13579},{"trials":13570,"activeCount":100},[],{"trials":13572,"activeCount":100},[],{"trials":13574,"activeCount":100},[],{"trials":13576,"activeCount":100},[],{"trials":13578,"activeCount":100},[],{"trials":13580,"activeCount":100},[13581],{"nctId":13582,"briefTitle":13583,"status":123,"phases":13584,"primaryCompletion":1854,"completion":1902,"start":3153,"enrollment":13585,"conditions":13586,"interventions":13587},"NCT00524732","Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age",[],7156,[21,18],[13567],{"intervention":13589,"totalTrials":139,"cells":13590},"Menactra®",{"EARLY_PHASE1":13591,"PHASE1":13593,"PHASE2":13595,"PHASE3":13597,"PHASE4":13599,"NA":13601},{"trials":13592,"activeCount":100},[],{"trials":13594,"activeCount":100},[],{"trials":13596,"activeCount":100},[],{"trials":13598,"activeCount":100},[],{"trials":13600,"activeCount":100},[],{"trials":13602,"activeCount":100},[13603],{"nctId":13604,"briefTitle":13605,"status":123,"phases":13606,"primaryCompletion":1288,"completion":1971,"start":3614,"enrollment":13607,"conditions":13608,"interventions":13609},"NCT00862277","Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine",[],763,[468,27],[13589,13610],"Menomune®",{"intervention":13610,"totalTrials":139,"cells":13612},{"EARLY_PHASE1":13613,"PHASE1":13615,"PHASE2":13617,"PHASE3":13619,"PHASE4":13621,"NA":13623},{"trials":13614,"activeCount":100},[],{"trials":13616,"activeCount":100},[],{"trials":13618,"activeCount":100},[],{"trials":13620,"activeCount":100},[],{"trials":13622,"activeCount":100},[],{"trials":13624,"activeCount":100},[13625],{"nctId":13604,"briefTitle":13605,"status":123,"phases":13626,"primaryCompletion":1288,"completion":1971,"start":3614,"enrollment":13607,"conditions":13627,"interventions":13628},[],[468,27],[13589,13610],{"intervention":13335,"totalTrials":139,"cells":13630},{"EARLY_PHASE1":13631,"PHASE1":13633,"PHASE2":13635,"PHASE3":13637,"PHASE4":13639,"NA":13641},{"trials":13632,"activeCount":100},[],{"trials":13634,"activeCount":100},[],{"trials":13636,"activeCount":100},[],{"trials":13638,"activeCount":100},[],{"trials":13640,"activeCount":100},[],{"trials":13642,"activeCount":100},[13643],{"nctId":13327,"briefTitle":13328,"status":123,"phases":13644,"primaryCompletion":1565,"completion":13330,"start":1237,"enrollment":13331,"conditions":13645,"interventions":13646},[],[18,24,21,13333],[13305,13335]]